

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028641 A2(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US02/31059

(22) International Filing Date:
30 September 2002 (30.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/326,463 1 October 2001 (01.10.2001) US
60/326,758 2 October 2001 (02.10.2001) US(71) Applicant (for all designated States except US): **TAISHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo 171-8633 (JP).

(72) Inventors; and



(75) Inventors/Applicants (for US only): **SEKIGUCHI, Yoshinori** [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo 171-8633 (JP). **KANUMA, Kosuke** [JP/JP]; 24-1,Takata 3-chome, Toshima-ku, Tokyo 171-8633 (JP). **OMODERA, Katsunori** [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo 171-8633 (JP). **TRAN, Thuy-Anh** [US/US]; 4833 Fairport way, San Diego, CA 92130 (US). **KRAMER, Bryan, Aubrey** [US/US]; 5645 Friars Road #358, San Diego, CA 92110 (US). **BEELEY, Nigel, Robert, Arnold** [GB/US]; 227 Loma Corta Drive, Solana Beach, CA 92705 (US).(74) Agents: **CORUZZI, Laura, A.** et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: MCH RECEPTOR ANTAGONISTS



(57) Abstract: The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

MCH RECEPTOR ANTAGONISTS

Field of the Invention

The present invention relates to compounds which act as antagonists for MCH receptors and to the use of these compounds in pharmaceutical compositions.

Background of the Invention

Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., *Biochem. Biophys. Res. Commun.* 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/neuromodulator to alter a number of behavioral responses such as feeding habits. For example, injection of MCH into rats has been reported to increase their consumption of food. Reports indicate that genetically engineered mice which lack MCH show lower body weight and increased metabolism. See Saito et al., *TEM*, vol. 11, 299 (2000). As such, the literature suggests that discovery of MCH antagonists that interact with SCL-1 expressing cells will be useful in developing obesity treatments. See Shimomura et al., *Biochem. Biophys. Res. Commun.* 261, 622-26 (1999).

G protein-coupled receptors (GPCRs) share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane. The fourth and fifth transmembrane helices are joined on the extracellular side of the membrane by a strand of amino acids that forms a relatively large loop. Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The carboxy terminus of the receptor lies intracellularly, and the amino terminus lies in the extracellular space. It is thought that the loop joining helices five and six,

as well as the carboxy terminus, interact with the G protein. Currently, Gq, Gs, Gi, and Go are G proteins that have been identified as possible proteins that interact with the receptor.

Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different states or conformations: an “inactive” state and an “active” state. A receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway and produces a biological response.

A receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand. Recent discoveries, including but not exclusively limited to, modifications to the amino acid sequence of the receptor, provide alternative mechanisms other than ligands to stabilize the active state conformation. These approaches effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent approaches is termed “constitutive receptor activation.” In contrast, antagonists can competitively bind to the receptor at the same site as agonists, but do not activate the intracellular response initiated by the active form of the receptor, and therefore inhibit the intracellular responses by agonists.

Certain 2-aminoquinazoline derivatives have been reported to be NPY antagonists which are said to be effective in the treatment of disorders and diseases associated with the NPY receptor subtype Y5. See PCT Patent Application 97/20823. Quinazoline derivatives have also been found to be useful by enhancing antitumor activity. See PCT Patent Application 92/07844.

Recently, our current knowledge of human obesity has advanced dramatically. Previously, obesity was viewed as an oppugnant behavior of inappropriate eating in the setting of appealing foods. Studies of animal models of obesity, biochemical alterations in both humans and animals, and the complex interactions of psychosocial and cultural factors that create receptiveness to human obesity indicate that this disease in humans is multifaceted and deeply entrenched in biologic systems. Thus, it is almost certain that obesity has multiple causes and that there are different types of obesity. Not only does MCHR1 antagonist have potent and durable anti-obesity effects in rodents, it has surprising antidepressant and anxiolytic properties as well (Borowsky et al., Nature Medicine, 8, 825-830, 2002). MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models such as social interaction, forced swimming test and ultrasonic

vocalization. These findings indicate that MCHR1 antagonists could be useful for treatment of obesity patients with multiple causes. Moreover, MCHR1 antagonists could be used to treat subjects not only with obesity, but also those with depression and anxiety. These advantages make it different from NPY receptor antagonists, with which anxiogenic-like activity may be expected, as NPY itself has anxiolytic-like effect.

Obesity is also regarded as a chronic disease and the possibility of long-term treatment is a concept that is receiving more attention. In this context, it is noteworthy that the depletion of MCH leads to hypophagia as well as leanness (Shimada et al., *Nature*, 396, 670-674, 1998). By contrast, NPY (Erickson et al., *Nature*, 381, 415-418, 1996), as well as the Y1 (Pedrazzini et al., *Nature Medicine*, 4, 722-726, 1998) and Y5 receptors (Marsh et al., *Nature Medicine*, 4, 718-721, 1998), disrupted mice maintained a stable body weight or rather became obese. Considering the above reports, MCHR1 antagonists may be more attractive than Y1 or Y5 receptor antagonists in terms of long-term treatment of obese patients.

An increasing number of children and adolescents are overweight. Although not all overweight children will necessarily become overweight adults, the growing occurrence of obesity in childhood is likely to be reflected in increasing obesity in adult years. The high prevalence of obesity in our adult population and the likelihood that the nation of the future will be even more obese demands a re-examination of the health implications of this disease. See, *Health Implications of Obesity*. NIH Consens. Statement Online 1985 Feb 11-13; 5(9):1-7.

"Clinical obesity" is a measurement of the excess body fat relative to lean body mass and is defined as a body weight more than 20% above the ideal body weight. Recent estimates suggest that 1 in 2 adults in the United States is clinically obese, an increase of more than 25% over the past decades. Flegal M.D. et al., 22 *Int. J. Obes. Relat. Metab. Disor.* 39 (1998). Both overweight conditions and clinical obesity are a major health concerns worldwide, in particular because clinical obesity is often accompanied by numerous complications, *i.e.*, hypertension and Type II diabetes, which in turn can cause coronary artery disease, stroke, late-stage complications of diabetes and premature death. (See, *e.g.*, Nishina P.M. et al., 43 *Metab.* 554 (1994)).


Although the etiologic mechanisms underlying obesity require further clarification, the net effect of such mechanisms leads to an imbalance between energy intake and

expenditure. Both genetic and environmental factors are likely to be involved in the pathogenesis of obesity. These include excess caloric intake, decreased physical activity, and metabolic and endocrine abnormalities.


Treatment of overweight conditions and clinical obesity via pharmaceutical agents are not only of importance with respect to the conditions themselves, but also with respect to the possibility of preventing other diseases that are associated with, *e.g.*, clinical obesity, as well as enhancement of the positive feeling of "self" that often accompanies those who are overweight or clinically obese and who encounter a significant reduction in body weight. Given the foregoing discussion, it is apparent that compounds which help in the treatment of such disorders would be useful and would provide an advance in both research and clinical medicine. The present invention is directed to these, as well as other, important ends.

Summary of the Invention

The present invention, in one aspect, relates to compounds represented by Formula I:




or a pharmaceutically acceptable salt or prodrug thereof, wherein Q is



II

or



III

R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

- halogen,
- hydroxy,
- oxo,

- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by C₁-C₃ alkoxy,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by C₁-C₃ alkyl,
 - substituted heterocyclyl-ethylideneaminoxy,
- C₁-C₃ alkoxycarbonyl,
- C₁-C₃ alkoxycarbonyl substituted by carbocyclic aryl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylamino,
- mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from
 - cyano,
 - carbocyclic aryl,
 - heterocyclyl,

- mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkylcarbonylamino,
 - C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - C₁-C₄ alkoxy carbonylamino,
 - heterocyclyl carbonylamino,
 - carbocyclic arylsulfonylamino,
 - carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylaminocarbonyl,
 - halogenated mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - carbocyclic arylsulfonyl,

- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - C₃-C₆ cycloalkenyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,

- nitro,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- halogenated C₁-C₃ alkoxy,
- C₁-C₄ alkoxy,
- C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkylcarbonyloxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - mercapto,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,

- C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
C₂-C₈ alkenyl substituted by substituent(s) independently selected from
- halogen,
 - oxo,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
- C₁-C₃ alkyl,

- C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl,
- (v) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,
carbocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - nitro,
- (vii) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - carbocyclic aryloxy,
 - mono- or di-C₁-C₃ alkylamino-N-oxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - carbocyclylimino,

- carbocyclylimino substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₁-C₉ alkoxy,
 - C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - hydroxy,
 - halogen,
 - carboxy,
 - mono- or di-C₁-C₃ alkylamino,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₂-C₃ alkenyloxy,
 - C₁-C₃ alkylcarbonyloxy,

- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - halogenated C₁-C₄ alkyl,
 - C₁-C₃ alkoxy,
- heterocyclyloxy,
- heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- (carbocyclic aryl)S(O)₂O,
- carboxy,
- C₁-C₃ alkoxycarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
- amino,
- mono- or di-C₁-C₄ alkylamino,
- mono- or di-C₁-C₄ alkylamino substituted by cyano,
- mono- or di-carbocyclic arylamino,
- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- carbocyclic aryl diazo,
- carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,

- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - cyano,
 - C₁-C₃ alkyl,
 - heterocyclylthio,
 - C₁-C₃ alkylsulfonyl,
 - mono- or di-C₁-C₃ alkylaminosulfonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - (viii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic arylcarbonylamino,

- halogenated carbocyclic arylcarbonylamino,
- C₁-C₃ alkoxy carbonyl,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by carbocyclic aryl,
- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₄ alkylcarbonylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkenylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkoxy carbonyl,
- heterocyclylthio,
- heterocyclylthio substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,

- carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
- C₁-C₃ alkoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxycarbonyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - SO₂NH₂,

•heterocyclyl,


C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

•halogen,

•C₁-C₃ alkyl,

•C₁-C₃ alkoxy,

or a group of Formula IV;












wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

















•carbocyclic aryl,

•halogenated carbocyclic aryl,

•carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;





wherein R_4 is H or C_1 - C_3 alkyl;

R_5 is H, C_1 - C_3 alkyl, or C_1 - C_3 alkyl substituted by a substituted carbocyclic aryl;

Y is $-S(O)_2-$, $-C(O)-$, or $-(CH_2)_m$;

m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-

dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl;

halogen is fluoro, chloro, bromo, or iodo.

Preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•halogen,

•oxo,

•C₁-C₃ alkoxy,

•C₁-C₃ alkoxy substituted by carbocyclic aryl,

•C₁-C₃ alkylcarbonyloxy,

•carbocyclyloxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

- halogen,
- nitro,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
- oxo,
- carbocyclic arylcarbonylamino,
- halogenated carbocyclic arylcarbonylamino,
- heterocycloxy,
- heterocycloxy substituted by C₁-C₃ alkyl,
- substituted heterocyclyl-ethylideneaminooxy,
- C₁-C₃ alkoxycarbonyl,
- C₁-C₃ alkoxycarbonyl substituted by carbocyclic aryl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylamino substituted by hydroxy,
- C₁-C₃ alkylcarbonylamino,
- C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
- C₁-C₃ alkylcarbonylamino,
- carbocyclic arylcarbonylamino,
- heterocyclyl,
- C₁-C₄ alkoxycarbonylamino,
- heterocyclyl carbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
- nitro,
- C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by substituent(s) independently selected from
- mono- or di-carbocyclic arylaminocarbonyl,
- halogenated mono- or di-carbocyclic arylaminocarbonyl,
- carbocyclic aryl,

- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - C₃-C₆ cycloalkenyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,

- carbocyclic aryl,
- heterocyclyl,
- C₁-C₄ alkoxy,
- C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkylcarbonyloxy,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - mercapto,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₆ alkenyl,
C₂-C₆ alkenyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- (iii) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl,
- (iv) carbocyclyl,
carbocyclyl substituted by nitro,
- (v) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,

- cyano,
- nitro,
- C₁-C₉ alkyl,
- C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryloxy,
 - carbocyclylimino,
 - carbocyclylimino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by C₁-C₃ alkoxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
 - amino,
 - mono- or di-C₁-C₃ alkylamino,

- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by cyano,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (vi) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by carbocyclic aryl,

- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- C₁-C₃ alkoxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,

- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - SO₂NH₂,
- heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,

or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;

wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-

benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, cinnolyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Other preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyoxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminoxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,

- heterocyclylthio substituted by methyl,
- C₅-C₆ cycloalkyl,
- C₅-C₆ cycloalkenyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - halogenated C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,

- halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₇ alkoxy,
 - halogenated C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,
 - amino,
 - di-methylamino,

- propargynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino substituted by methyl,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
- halogenated methylthio,
- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,

- carbocyclic aryl substituted by nitro,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein R₄ and R₅ are independently selected from H or C₁-C₃ alkyl;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluorenylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, azetidyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,

- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,
 - C₅-C₆ cycloalkenyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - halogenated C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,




- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- C₁-C₂ alkyl,
- C₁-C₂ substituted by carbocyclic aryl,
- methoxy,
- methoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
- methyl substituted by oxo,
- methyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- hydroxy,
- cyano,
- nitro,
- C₁-C₉ alkyl,
- C₁-C₉ alkyl substituted by substituent(s) independently selected from
- halogen,
- oxo,
- carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryloxy,
- C₁-C₇ alkoxy,
- halogenated C₁-C₇ alkoxy,
- C₁-C₇ alkoxy substituted by carbocyclic aryl,

- methylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by methoxy,
- amino,
- di-methylamino,
- propargynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino substituted by methyl,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
- halogenated methylthio,
- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,

- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryl substituted by nitro,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;



Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren-9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 4-oxo-benzopyranyl, azetidiny, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9*H*-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Further other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₅ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminooxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,
 - cyclohexenyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,

- carbocyclic aryl,
- heterocyclyl,
- C₁-C₂ alkoxy,
- halogenated C₁-C₂ alkoxy,
- C₁-C₂ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- halogenated mono-carbocyclic arylaminocarbonyl,
- carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₂ alkyl substituted by substituent(s) independently selected from

- halogen,
- oxo,
- carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryloxy,
- C₁-C₂ alkoxy,
- halogenated C₁-C₂ alkoxy,
- C₁-C₂ alkoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by methoxy,
- amino,
- di-methylamino,
- propargynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino substituted by methyl,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
- halogenated methylthio,
- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,

- heterocyclyl,
- methoxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by methyl,
- C₁-C₃ alkylthio,
- propenylthio,
- carbocyclic arylthio,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by methyl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryl substituted by nitro,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -C(O)-;













wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;













carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;













heterocyclyl is 1*H*-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl, thienyl, 1,2,3-triazolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;













halogen is fluoro, chloro, bromo, or iodo.













The following compounds are specially preferred;
























































































,




,




,




,




,




,




,




,




,















,



























,



























,


























,




,




,




,




,




,




,




,




,















,
















,



























,


































,




,




,




,




,




,




,




,




,







,



,



,



; or, in case of, a salt thereof.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•C₅-C₆ cycloalkyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) C₃-C₆ cycloalkyl,

(iii) carbocyclic aryl,

(iv) or heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

heterocyclyl is 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.

Further other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₄ alkyl,

C₁-C₄ alkyl substituted by substituent(s) independently selected from

•cyclopentyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) carbocyclic aryl,

(iii) or heterocyclyl;

R_2 is methylamino or dimethylamino;

L is selected from Formula XX - XXII;


Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;


heterocyclyl is 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, thienyl, 1*H*-indolyl, quinoxalyl, quinolyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.


The following compounds are specially preferred;




,




,




,




,




,




,




,




,




,




,
















,



,







; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•halogen,

•hydroxy,

•oxo,

•C₁-C₃ alkoxy,

•C₁-C₃ alkoxy substituted by substituent(s) independently selected from

••carbocyclic aryl,

••heterocyclyl,

••heterocyclyl substituted by C₁-C₃ alkyl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

••halogen,

••nitro,

••carbocyclic aryl,

••carbocyclic aryl substituted by C₁-C₃ alkoxy,

••C₁-C₄ alkyl,

••C₁-C₄ alkyl substituted by substituent(s) independently selected from

•••mono- or di-C₁-C₃ alkylamino,

•••mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,

•••mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,

•mono- or di-C₁-C₃ alkylamino,

•mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from

••cyano,

••carbocyclic aryl,

••heterocyclyl,

•mono- or di-carbocyclic arylamino,

•mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkyl,

•C₁-C₃ alkylcarbonylamino,

- C₁-C₄ alkoxycarbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - heterocyclylthio,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- hydroxy,
- nitro,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,

- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by nitro,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (v) C₃-C₆ cycloalkenyl,
C₃-C₆ cycloalkenyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,

carbocyclyl substituted by substituent(s) independently selected from

- hydroxy,

- nitro,

(vii) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,

- hydroxy,

- cyano,

- nitro,

- C₁-C₉ alkyl,

- C₁-C₉ alkyl substituted by substituent(s) independently selected from

- halogen,

- hydroxy,

- oxo,

- C₁-C₃ alkoxy,

- carbocyclic aryloxy,

- mono- or di-C₁-C₃ alkylamino-N-oxy,

- mono- or di-C₁-C₃ alkylamino,

- mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,

- mono- or di-carbocyclic arylamino,

- mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,

- carbocyclic aryl,

- halogenated carbocyclic aryl,

- heterocyclyl,

- heterocyclyl substituted by C₁-C₃ alkyl,

- C₂-C₃ alkenyl,

- C₂-C₃ alkenyl substituted by carbocyclic aryl,

- C₁-C₉ alkoxy,

- C₁-C₉ alkoxy substituted by substituent(s) independently selected from

- hydroxy,

- halogen,

- carboxy,

- mono- or di-C₁-C₃ alkylamino,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₂-C₃ alkenyloxy,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
- halogen,
- C₁-C₄ alkyl,
- halogenated C₁-C₄ alkyl,
- C₁-C₃ alkoxy,
- heterocyclyloxy,
- heterocyclyloxy substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- (carbocyclic aryl)S(O)₂O,
- carboxy,
- C₁-C₃ alkoxy carbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- amino,
- mono- or di-C₁-C₄ alkylamino,
- mono- or di-C₁-C₄ alkylamino substituted by cyano,
- mono- or di-carbocyclic arylamino,

- C₁-C₃ alkylcarbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkyl,
- heterocyclylthio,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (viii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,

- hydroxy,
- oxo,
- C₁-C₃ alkylcarbonyloxy,
- C₁-C₃ alkoxycarbonyl,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by carbocyclic aryl,
- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₄ alkylcarbonylamino,
 - C₁-C₃ alkylthio,
 - carbocyclic arylthio,
 - halogenated carbocyclic arylthio,
 - carbocyclic arylthio substituted by C₁-C₃ alkoxycarbonyl,
 - heterocyclylthio,
 - heterocyclylthio substituted by C₁-C₃ alkyl,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - C₁-C₃ alkoxycarbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,

- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- halogenated C₁-C₃ alkoxy,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxycarbonyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- SO₂NH₂,
- heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,

or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;

wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -(CH₂)_m, m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl;

carbocyclyl is 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 2,2',5',2''-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl;

halogen is fluoro, chloro, bromo, or iodo.

Other preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- methoxy,
- methoxy substituted by carbocyclic aryl,

- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- mono-C₁-C₂ alkylamino substituted by cyano,
- mono- or di-C₁-C₂ alkylamino substituted by carbocyclic aryl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by methyl,
- carbocyclic arylsulfonylamino substituted by methyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - C₁-C₂ alkoxy,
 - halogenated C₁-C₂ alkoxy,
 - heterocyclyl substituted by carbocyclic aryl,
- (ii) C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
- (iii) C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) cyclohexyl substituted by carbocyclic arylmethyl,
- (v) carbocyclyl,
- (vi) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - amino,
 - C₁-C₉ alkyl,
 - halogenated C₁-C₉ alkyl,

- C₁-C₉ alkoxy,
- C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - halogenated carbocyclic aryl,
- propenyloxy,
- methylamino,
- di-C₁-C₂ alkylamino,
- di-C₁-C₂ alkylamino substituted by cyano,
- methylthio,
- halogenated methylthio,
- (vii) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - methoxy,
 - C₁-C₂ alkoxycarbonyl,
 - carbocyclic arylthio substituted by methoxycarbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - halogenated methyl,
 - heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein R₄ and R₅ are independently selected from H or C₁-C₃ alkyl;

Y is -(CH₂)_m, m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl;

carbocyclyl is 9H-fluorenyl, acenaphthyl, or anthraquinonyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxolanyl, 1H-indolyl, 1H-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-

dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2*H*-benzopyranyl, 4*H*-benzo[1,3]dioxinyl, azetidiny, imidazo[2,1-*b*]thiazolyl, morpholinyl, or 2,3-dihydro-benzofuryl;

halogen is fluoro, chloro, bromo, or iodo.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₇ alkyl substituted by substituent(s) independently selected from

- methoxy,
- methoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- mono-ethylamino substituted by cyano,
- di-methylamino substituted by carbocyclic aryl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by methyl,
- carbocyclic arylsulfonylamino substituted by methyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - methoxy,
 - halogenated methoxy,
 - heterocyclyl substituted by carbocyclic aryl,

(ii) C₂-C₇ alkenyl substituted by substituent(s) independently selected from

- methoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by methoxy,

(iii) butynyl substituted by carbocyclic aryl,

(iv) cyclohexyl substituted by carbocyclic arylmethyl,

(v) carbocyclyl,

(vi) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- hydroxy,
- cyano,
- amino,
- C₁-C₂ alkyl,
- halogenated methyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - halogenated carbocyclic aryl,
- propenyloxy,
- di-C₁-C₂ alkylamino,
- di-C₁-C₂ alkylamino substituted by cyano,
- methylthio,
- halogenated methylthio,

(vii) heterocyclyl,

or heterocyclyl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkyl substituted by hydroxy,
- C₁-C₃ alkyl substituted by carbocyclic aryl,
- methoxy,
- ethoxycarbonyl,

- carbocyclic arylthio substituted by methoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - halogenated methyl,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -(CH₂)_m, m is 0 or 1;













wherein carbocyclic aryl is phenyl, **naphthyl**, or biphenyl;













carbocyclyl is acenaphthyl;


heterocyclyl is 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 9*H*-carbazolyl, benzo[1,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidiny, imidazo[2,1-*b*]thiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[*b*]thienyl;;


halogen is fluoro, chloro, bromo, or iodo.













The following compounds are specially preferred;


























































,




,




,




,




,




,




,




,




,




,





















,










,














; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;

R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

•halogen,

•carbocyclyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

••halogen,

••nitro,

••C₁-C₃ alkyl,

••halogenated C₁-C₃ alkyl,

(ii) C₂-C₃ alkenyl,

C₂-C₃ alkenyl substituted by carbocyclic aryl,

(iii) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

•halogen,

•cyano,

•nitro,

•C₁-C₅ alkyl,

•C₁-C₅ alkyl substituted by substituent(s) independently selected from

••halogen,

••oxo,

•C₂-C₃ alkenyl,

•C₁-C₄ alkoxy,

•C₁-C₄ alkoxy substituted by substituent(s) independently selected from

••halogen,

••heterocyclyl,

••halogenated heterocyclyl,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

- halogen,
- nitro,
- heterocyclyloxy,
- heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₄ alkylamino,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic aryl diazo,
 - carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic aryl,
- (iv) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylsulfonyl,
 - C₁-C₃ alkoxycarbonyl,

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from









- hydroxy,
 - C₁-C₃ alkoxy,
 - amino,
 - NHBoc,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - SO₂NH₂,
 - heterocyclyl,
 - C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from


- carbocyclic aryl,

- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;
 - L is selected from Formula V - XIX;
 - wherein R₄ is H or C₁-C₃ alkyl;
 - R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;
 - Y is -S(O)₂;
 - wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;
 - carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl;
 - heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1*H*-pyrrolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl;
 - halogen is fluoro, chloro, bromo, or iodo.

The following compounds are specially preferred;



and



; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
R₁ is selected from H, -CO₂tBu, or -CO₂Bn (Bn is a benzyl group);
R₂ is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is a single bond;
or a salt thereof.

Also provided in accordance with the present invention are methods of modulating G-protein receptor SLC-1 comprising contacting the SLC-1 receptor with a compound of the invention.

The present invention further provides pharmaceutical compositions containing MCH receptor antagonists of the invention.

Brief Description of the Figures

Figure 1 provides an illustration of IP₃ production from several non-endogenous, constitutively activated version of MCH receptor as compared with the endogenous version of this receptor.

Detailed Description


The present invention relates to MCH receptor antagonist compounds, and methods of modulating MCH receptors by contacting the receptors with one or more compounds of the invention.

The term "antagonist" is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist. As used herein, the term "agonist" is intended to mean moieties that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes. In the context of the present invention, a pharmaceutical composition comprising a MCH receptor antagonist of the invention can be utilized for modulating the activity of the MCH receptor,


decreasing body weight and/or affecting metabolism such that the recipient loses weight and/or maintains weight. Such pharmaceutical compositions can be used in the context of disorders and/or diseases where weight gain is a component of the disease and/or disorder such as, for example, obesity.

As used herein, the term "contact" or "contacting" shall mean bringing the indicated moieties together, whether in an in vitro system or an in vivo system. Thus, "contacting" an MCH receptor with a compound of the invention includes the administration of a compound of the invention to an animal having an MCH receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation containing an MCH receptor.


Compounds of the invention include those having Formula I, shown below:



wherein Q can be either Formula II or III:



or



R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

•halogen,

•hydroxy,

•oxo,

•C₁-C₃ alkoxy,

•C₁-C₃ alkoxy substituted by substituent(s) independently selected from

••carbocyclic aryl,

- heterocyclyl,
- heterocyclyl substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
- halogen,
- nitro,
- carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
- oxo,
- mono- or di-C₁-C₃ alkylamino,
- mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
- mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,
- carbocyclic arylcarbonylamino,
- halogenated carbocyclic arylcarbonylamino,
- heterocyclyloxy,
- heterocyclyloxy substituted by C₁-C₃ alkyl,
- substituted heterocyclyl-ethylideneaminooxy,
- C₁-C₃ alkoxy carbonyl,
- C₁-C₃ alkoxy carbonyl substituted by carbocyclic aryl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylamino,
- mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from
- cyano,
- carbocyclic aryl,
- heterocyclyl,
- mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkyl,
- C₁-C₃ alkylcarbonylamino,
- C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
- C₁-C₃ alkylcarbonylamino,
- carbocyclic arylcarbonylamino,
- heterocyclyl,
- C₁-C₄ alkoxy carbonylamino,
- heterocyclyl carbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
- nitro,
- C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by substituent(s) independently selected from
- mono- or di-carbocyclic arylaminocarbonyl,
- halogenated mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylamino,
- halogenated mono- or di-carbocyclic arylamino,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkoxy,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from

- nitro,
- C₁-C₃ alkyl,
- C₃-C₆ cycloalkyl,
- C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
- C₃-C₆ cycloalkenyl,
- carbocyclyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,

- halogenated C₁-C₃ alkoxy,
- C₁-C₄ alkoxy,
- C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkylcarbonyloxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - mercapto,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,

- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,

- carbocyclic aryl,
- mono- or di-C₁-C₃ alkylamino,
- mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
- carbocyclic arylcarbonylamino,
- carbocyclic aryl,
- (v) C₃-C₆ cycloalkenyl,
- C₃-C₆ cycloalkenyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - nitro,
- (vii) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - carbocyclic aryloxy,
 - mono- or di-C₁-C₃ alkylamino-N-oxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - carbocyclylimino,
 - carbocyclylimino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,

- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- heterocyclyl,
- heterocyclyl substituted by C₁-C₃ alkyl,
- C₂-C₃ alkenyl,
- C₂-C₃ alkenyl substituted by carbocyclic aryl,
- C₁-C₉ alkoxy,
- C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - hydroxy,
 - halogen,
 - carboxy,
 - mono- or di-C₁-C₃ alkylamino,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- C₂-C₃ alkenyloxy,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,

- nitro,
- C₁-C₄ alkyl,
- halogenated C₁-C₄ alkyl,
- C₁-C₃ alkoxy,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- (carbocyclic aryl)S(O)₂O,
- carboxy,
- C₁-C₃ alkoxycarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
- amino,
- mono- or di-C₁-C₄ alkylamino,
- mono- or di-C₁-C₄ alkylamino substituted by cyano,
- mono- or di-carbocyclic arylamino,
- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- carbocyclic aryl diazo,
- carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,

- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - cyano,
 - C₁-C₃ alkyl,
- heterocyclylthio,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (viii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkylthio,

- C₁-C₃ alkylthio substituted by carbocyclic aryl,
- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₄ alkylcarbonylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkenylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkoxycarbonyl,
- heterocyclylthio,
- heterocyclylthio substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
- C₁-C₃ alkoxycarbonyl,
- carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

••halogen,

••nitro,

••C₁-C₃ alkyl,

••halogenated C₁-C₃ alkyl,

••C₁-C₃ alkoxy,

••halogenated C₁-C₃ alkoxy,

•heterocyclyl,

•heterocyclyl substituted by substituent(s) independently selected from

••halogen,

••C₁-C₃ alkyl,

••halogenated C₁-C₃ alkyl,

••C₁-C₃ alkoxy,

••C₁-C₃ alkoxycarbonyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

•hydroxy,

•C₁-C₃ alkoxy,

•amino,

•-NHBoc,

•C₃-C₆ cycloalkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

••halogen,

••C₁-C₃ alkyl,


••C₁-C₃ alkoxy,

••-SO₂NH₂,

•heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from













- halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- or a group of Formula IV;




wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;





wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -S(O)₂-, -C(O)-, or -(CH₂)_m;

m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl,

1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,2',5',2''-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl;

halogen is fluoro, chloro, bromo, or iodo.

Preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- halogen,
- oxo,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from

- oxo,
- carbocyclic arylcarbonylamino,
- halogenated carbocyclic arylcarbonylamino,
- heterocycloxy,
- heterocycloxy substituted by C₁-C₃ alkyl,
- substituted heterocyclyl-ethylideneaminoxy,
- C₁-C₃ alkoxy carbonyl,
- C₁-C₃ alkoxy carbonyl substituted by carbocyclic aryl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylamino substituted by hydroxy,
- C₁-C₃ alkylcarbonylamino,
- C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
- C₁-C₃ alkylcarbonylamino,
- carbocyclic arylcarbonylamino,
- heterocyclyl,
- C₁-C₄ alkoxy carbonylamino,
- heterocyclyl carbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
- nitro,
- C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by substituent(s) independently selected from
- mono- or di-carbocyclic arylaminocarbonyl,
- halogenated mono- or di-carbocyclic arylaminocarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkoxy,
- carbocyclic arylthio,

- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - C₃-C₆ cycloalkenyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by substituent(s) independently selected from

- halogen,
- carbocyclic aryl,
- carbocyclic aryloxy,
- C₁-C₃ alkylcarbonyloxy,
- mono- or di-carbocyclic arylamino,
- halogenated mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - mercapto,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₆ alkenyl,
 - C₂-C₆ alkenyl substituted by substituent(s) independently selected from

- oxo,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- (iii) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl,
- (iv) carbocyclyl,
carbocyclyl substituted by nitro,
- (v) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from

- halogen,
- oxo,
- carbocyclic aryloxy,
- carbocyclylimino,
- carbocyclylimino substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
- C₁-C₇ alkoxy,
- C₁-C₇ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by C₁-C₃ alkoxy,
- C₁-C₃ alkoxy carbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
- amino,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,

- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by cyano,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (vi) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by carbocyclic aryl,
 - C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,

- C₁-C₃ alkoxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

•halogen,

•C₁-C₃ alkyl,

•C₁-C₃ alkoxy,

•-SO₂NH₂,

•heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s)

independently selected from

•halogen,

•C₁-C₃ alkyl,

•C₁-C₃ alkoxy,

or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

•carbocyclic aryl,

•halogenated carbocyclic aryl,

•carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;

wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, *C*-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, cinnolyl,

furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Other preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminooxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,
- C₅-C₆ cycloalkyl,
- C₅-C₆ cycloalkenyl,
- carbocyclyl substituted by substituent(s) independently selected from

- halogen,
- methyl,
- methoxy,
- ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - halogenated C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,

- carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
(v) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₇ alkoxy,
 - halogenated C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,
 - amino,
 - di-methylamino,
 - propargynylcarbonylamino substituted by carbocyclic aryl,
 - carbocyclic arylsulfonylamino substituted by methyl,
 - (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
 - halogenated methylthio,

- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryl substituted by nitro,
 - heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein R₄ and R₅ are independently selected from H or C₁-C₃ alkyl;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren-9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isindolyl, 2,3-dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocycloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminoxy,
- tert*-butoxycarbonylamino,

- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
- carbocyclic arylthio,
- heterocyclylthio substituted by nitro,
- heterocyclylthio substituted by methyl,
- C₅-C₆ cycloalkenyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - halogenated C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,




- C₁-C₂ substituted by carbocyclic aryl,
- methoxy,
- methoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₇ alkoxy,
 - halogenated C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,

- amino,
- di-methylamino,
- propargynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino substituted by methyl,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
- halogenated methylthio,
- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,

- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryl substituted by nitro,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;



Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren-9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 4-oxo-benzopyranyl, azetidiny, benzo[*b*]thienyl, furyl, isoxazolyl, morpholinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9*H*-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

Further other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₅ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,

- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminoxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,
 - cyclohexenyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₂ alkoxy,

- halogenated C₁-C₂ alkoxy,
- C₁-C₂ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- halogenated mono-carbocyclic arylaminocarbonyl,
- carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₂ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,

- carbocyclic aryl substituted by methyl,
- carbocyclic aryloxy,
- C₁-C₂ alkoxy,
- halogenated C₁-C₂ alkoxy,
- C₁-C₂ alkoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by methoxy,
- amino,
- di-methylamino,
- propargynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino substituted by methyl,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
- halogenated methylthio,
- carbocyclic arylthio substituted by cyano,
- di-propylamino sulfonyl,
- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,

- carbocyclic aryloxy substituted by methyl,
- C₁-C₃ alkylthio,
- propenylthio,
- carbocyclic arylthio,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by methyl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by methyl,
- carbocyclic aryl substituted by nitro,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -C(O)-;


wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;













carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;













heterocyclyl is 1*H*-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl, thienyl, 1,2,3-triazolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;













halogen is fluoro, chloro, bromo, or iodo.













The following compounds are specially preferred;








































































,




,




,




,




,




,




,




,




,















,















,
















,
























































































































































; or, in case of, a salt thereof.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•C₅-C₆ cycloalkyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) C₃-C₆ cycloalkyl,

(iii) carbocyclic aryl,

(iv) or heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

heterocyclyl is 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; halogen is fluoro, chloro, bromo, or iodo.

Further other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₄ alkyl,

C₁-C₄ alkyl substituted by substituent(s) independently selected from

•cyclopentyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) carbocyclic aryl,

(iii) or heterocyclyl;

R_2 is methylamino or dimethylamino;

L is selected from Formula XX - XXII;













Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;


heterocyclyl is 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, thienyl, 1*H*-indolyl, quinoxalyl, quinolyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo.

The following compounds are specially preferred;







; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;

R₁ represents

- (i) C₁-C₁₀ alkyl,
C₁-C₁₀ alkyl substituted by substituent(s) independently selected from
- halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by C₁-C₃ alkoxy,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from
 - cyano,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkyl,
 - C₁-C₃ alkylcarbonylamino,

- C₁-C₄ alkoxycarbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - heterocyclylthio,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- hydroxy,
- nitro,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,

- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by nitro,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (v) C₃-C₆ cycloalkenyl,
C₃-C₆ cycloalkenyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,

carbocyclyl substituted by substituent(s) independently selected from

- hydroxy,

- nitro,

(vii) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,

- hydroxy,

- cyano,

- nitro,

- C₁-C₉ alkyl,

- C₁-C₉ alkyl substituted by substituent(s) independently selected from

- halogen,

- hydroxy,

- oxo,

- C₁-C₃ alkoxy,

- carbocyclic aryloxy,

- mono- or di-C₁-C₃ alkylamino-N-oxy,

- mono- or di-C₁-C₃ alkylamino,

- mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,

- mono- or di-carbocyclic arylamino,

- mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,

- carbocyclic aryl,

- halogenated carbocyclic aryl,

- heterocyclyl,

- heterocyclyl substituted by C₁-C₃ alkyl,

- C₂-C₃ alkenyl,

- C₂-C₃ alkenyl substituted by carbocyclic aryl,

- C₁-C₉ alkoxy,

- C₁-C₉ alkoxy substituted by substituent(s) independently selected from

- hydroxy,

- halogen,

- carboxy,

- mono- or di-C₁-C₃ alkylamino,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- C₂-C₃ alkenyloxy,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₄ alkyl,
 - halogenated C₁-C₄ alkyl,
 - C₁-C₃ alkoxy,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- (carbocyclic aryl)S(O)₂O,
- carboxy,
- C₁-C₃ alkoxycarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- amino,
- mono- or di-C₁-C₄ alkylamino,
- mono- or di-C₁-C₄ alkylamino substituted by cyano,
- mono- or di-carbocyclic arylamino,

- C₁-C₃ alkylcarbonylamino,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkyl,
- heterocyclylthio,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (viii) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,

- hydroxy,
- oxo,
- C₁-C₃ alkylcarbonyloxy,
- C₁-C₃ alkoxycarbonyl,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by carbocyclic aryl,
- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₄ alkylcarbonylamino,
- C₁-C₃ alkylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkoxycarbonyl,
- heterocyclylthio,
- heterocyclylthio substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
- C₁-C₃ alkoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,

- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- halogenated C₁-C₃ alkoxy,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxycarbonyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- SO₂NH₂,
- heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,

or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;

wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -(CH₂)_m, m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl;

carbocyclyl is 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl;

halogen is fluoro, chloro, bromo, or iodo.

Other preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- methoxy,
- methoxy substituted by carbocyclic aryl,

- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- mono-C₁-C₂ alkylamino substituted by cyano,
- mono- or di-C₁-C₂ alkylamino substituted by carbocyclic aryl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by methyl,
- carbocyclic arylsulfonylamino substituted by methyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - C₁-C₂ alkoxy,
 - halogenated C₁-C₂ alkoxy,
 - heterocyclyl substituted by carbocyclic aryl,
- (ii) C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
- (iii) C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) cyclohexyl substituted by carbocyclic arylmethyl,
- (v) carbocyclyl,
- (vi) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - amino,
 - C₁-C₉ alkyl,
 - halogenated C₁-C₉ alkyl,

- C₁-C₉ alkoxy,
- C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - halogenated carbocyclic aryl,
- propenyloxy,
- methylamino,
- di-C₁-C₂ alkylamino,
- di-C₁-C₂ alkylamino substituted by cyano,
- methylthio,
- halogenated methylthio,
- (vii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - methoxy,
 - C₁-C₂ alkoxycarbonyl,
 - carbocyclic arylthio substituted by methoxycarbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - halogenated methyl,
 - heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein R₄ and R₅ are independently selected from H or C₁-C₃ alkyl;

Y is -(CH₂)_m, m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, phenanthryl, or biphenyl;

carbocyclyl is 9H-fluorenyl, acenaphthyl, or anthraquinonyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxolanyl, 1H-indolyl, 1H-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-

dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2*H*-benzopyranyl, 4*H*-benzo[1,3]dioxinyl, azetidiny, imidazo[2,1-*b*]thiazolyl, morpholinyl, or 2,3-dihydro-benzofuryl;

halogen is fluoro, chloro, bromo, or iodo.

Other more preferred compounds of this invention are those compounds of Formula I wherein,

Q is Formula II;

R₁ represents

(i) C₁-C₇ alkyl substituted by substituent(s) independently selected from

- methoxy,
- methoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- mono-ethylamino substituted by cyano,
- di-methylamino substituted by carbocyclic aryl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by methyl,
- carbocyclic arylsulfonylamino substituted by methyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - methoxy,
 - halogenated methoxy,
 - heterocyclyl substituted by carbocyclic aryl,

(ii) C₂-C₇ alkenyl substituted by substituent(s) independently selected from

- methoxy substituted by carbocyclic aryl,

- carbocyclic aryl,

- carbocyclic aryl substituted by methoxy,

(iii) butynyl substituted by carbocyclic aryl,

(iv) cyclohexyl substituted by carbocyclic arylmethyl,

(v) carbocyclyl,

(vi) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,

- hydroxy,

- cyano,

- amino,

- C₁-C₂ alkyl,

- halogenated methyl,

- C₁-C₃ alkoxy,

- C₁-C₃ alkoxy substituted by substituent(s) independently selected from

- halogen,

- halogenated carbocyclic aryl,

- propenyloxy,

- di-C₁-C₂ alkylamino,

- di-C₁-C₂ alkylamino substituted by cyano,

- methylthio,

- halogenated methylthio,

(vii) heterocyclyl,

or heterocyclyl substituted by substituent(s) independently selected from

- halogen,

- C₁-C₃ alkyl,

- C₁-C₃ alkyl substituted by hydroxy,

- C₁-C₃ alkyl substituted by carbocyclic aryl,

- methoxy,

- ethoxycarbonyl,

- carbocyclic arylthio substituted by methoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - halogenated methyl,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula XX - XXII;

Y is -(CH₂)_m, m is 0 or 1;


wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;













carbocyclyl is acenaphthyl;













heterocyclyl is 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 9*H*-carbazolyl, benzo[1,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidiny, imidazo[2,1-*b*]thiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[*b*]thienyl;;













halogen is fluoro, chloro, bromo, or iodo.













The following compounds are specially preferred;















































































































,




,




,




,




,




,




,




,




,




,



,



,



; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;

R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

- halogen,
- carbocyclyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,

(ii) C₂-C₃ alkenyl,

C₂-C₃ alkenyl substituted by carbocyclic aryl,

(iii) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- cyano,
- nitro,
- C₁-C₅ alkyl,
- C₁-C₅ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₂-C₃ alkenyl,
 - C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - heterocyclyl,
 - halogenated heterocyclyl,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by substituent(s) independently selected from

- halogen,
- nitro,
- heterocycloxy,
- heterocycloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₄ alkylamino,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic aryl diazo,
 - carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic aryl,
- (iv) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylsulfonyl,
 - C₁-C₃ alkoxycarbonyl,

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}); morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;

R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- SO₂NH₂,
- heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,

or a group of Formula IV;

wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl substituted by substituent(s) independently selected from

- carbocyclic aryl,

- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;

wherein R₄ is H or C₁-C₃ alkyl;

R₅ is H, C₁-C₃ alkyl, or C₁-C₃ alkyl substituted by a substituted carbocyclic aryl;

Y is -S(O)₂-;






wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1*H*-pyrrolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl;

halogen is fluoro, chloro, bromo, or iodo.

The following compounds are specially preferred;



; or, in case of, a salt thereof.

Preferred compounds of this invention are those compounds of Formula I wherein,
Q is Formula II;
R₁ is selected from H, -CO₂^tBu, or -CO₂Bn (Bn is a benzyl group);
R₂ is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is a single bond;
or a salt thereof.

One embodiment of the invention includes any compound of the invention which selectively binds an MCH receptor, such selective binding is preferably demonstrated by a K_i for one or more other GPCR(s), preferably NPY, being at least 10-fold greater than the K_i for any particular MCH receptor, preferable MCHR1.

As used herein, the term "alkyl" is intended to denote hydrocarbon compounds including straight chain and branched chain, including for example but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, and the like.

The term "alkoxy" is intended to denote substituents of the formula
-O-alkyl.

At various places in the present specification substituents of compounds of the invention are disclosed in groups. It is specifically intended that the invention include each and every individual subcombination of the members of such groups.

G-protein coupled receptors (GPCRs) represent a major class of cell surface receptors with which many neurotransmitters interact to mediate their effects. GPCRs are predicted to have seven membrane-spanning domains and are coupled to their effectors via G-proteins linking receptor activation with intracellular biochemical sequelae such as stimulation of adenylyl cyclase. Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/modulator/regulator to alter a number of behavioral responses.

Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human, exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH

has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders. For reviews, see 1. Baker, *Int. Rev. Cytol.* 126:1-47 (1991); 2. Baker, *TEM* 5:120-126 (1994); 3. Nahon, *Critical Rev. in Neurobiol* 221:221-262, (1994); 4. Knigge et al., *Peptides* 18(7):1095-1097, (1996). The role of MCH in feeding or body weight regulation is supported by Qu et al., *Nature* 380:243-247, (1996), demonstrating that MCH is over expressed in the hypothalamus of ob/ob mice compared with ob/+mice, and that fasting further increased MCH mRNA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles as reported by Rossi et al., *Endocrinology* 138:351-355, (1997). MCH also has been reported to functionally antagonize the behavioral effects of α -MSH; see: Miller et al., *Peptides* 14:1-10, (1993); Gonzalez et al., *Peptides* 17:171-177, (1996); and Sanchez et al., *Peptides* 18:3933-396, (1997). In addition, stress has been shown to increase POMC mRNA levels while decreasing the MCH precursor preproMCH (ppMCH) mRNA levels; Presse et al., *Endocrinology* 131:1241-1250, (1992). Thus MCH may serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity; Baker, *Int. Rev. Cytol.* 126:1-47, (1991); Knigge et al., *Peptides* 17:1063-1073, (1996).

The localization and biological activities of MCH peptide suggest that the modulation of MCH receptor activity may be useful in a number of therapeutic applications. MCH is expressed in the lateral hypothalamus, a brain area implicated in the regulation of thirst and hunger: Grillon et al., *Neuropeptides* 31:131-136, (1997); recently orexins A and B, which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus; Sakurai et al., *Cell* 92:573-585 (1998). MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation; Herve and Fellmann, *Neuropeptides* 31:237-242 (1997); after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA; Bahjaoui-Bouhaddi et al., *Neuropeptides* 24:251-258, (1994). Consistent with the ability of MCH to stimulate feeding in rats; Rossi et al., *Endocrinology* 138:351-355, (1997); is the observation that MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice; Qu et al., *Nature* 380:243-247, (1996); and decreased in the hypothalami of rats treated with leptin,

whose food intake and body weight gains are also decreased; Sahu, *Endocrinology* 139:795-798, (1998). MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis); Ludwig et al., *Am. J. Physiol. Endocrinol. Metab.* 274:E627-E633, (1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.

Accordingly, a MCH receptor antagonist is desirable for the prophylaxis or treatment of obesity or obesity related disorders. An obesity related disorder is a disorder that has been directly or indirectly associated to obesity, such as, type II diabetes, syndrome X, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis, insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders.

In species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers; Bittencourt et al., *J. Comp. Neurol.* 319:218-245, (1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it may be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntington's Chorea in which extrapyramidal circuits are known to be involved.

Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5q12-13) (Pedutour et al., 1994). Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar ataxia type II (SCA2) has been mapped; Auburger et al., *Cytogenet. Cell. Genet.* 61:252-256,

(1992); Twells et al., *Cytogenet. Cell. Genet.* 61:262-265, (1992). This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24; Craddock et al., *Hum. Mol. Genet.* 2:1941-1943, (1993). Darier's disease is characterized by abnormalities in keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical patterns of the MCH neural system in the rat and human brains, the MCH gene may represent a good candidate for SCA2 or Darier's disease. Interestingly, diseases with high social impact have been mapped to this locus. Indeed, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5q12-13 using genetic linkage analysis; Melki et al., *Nature (London)* 344:767-768, (1990); Westbrook et al., *Cytogenet. Cell. Genet.* 61:225-231, (1992). Furthermore, independent lines of evidence support the assignment of a major schizophrenia locus to chromosome 5q11.2-13.3; Sherrington et al., *Nature (London)* 336:164-167, (1988); Bassett et al., *Lancet* 1:799-801, (1988); Gilliam et al., *Genomics* 5:940-944, (1989). The above studies suggest that MCH may play a role in neurodegenerative diseases and disorders of emotion.

Additional therapeutic applications for MCH-related compounds are suggested by the observed effects of MCH in other biological systems. For example, MCH may regulate reproductive functions in male and female rats. MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes; Hervieu et al., *Biology of Reproduction* 54:1161-1172, (1996). MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats; Gonzalez et al., *Peptides* 17:171-177, (1996). In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti-MCH antiserum inhibited LH release; Gonzalez et al., *Neuroendocrinology* 66:254-262, (1997). The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge; MacKenzie et al., *Neuroendocrinology* 39:289-295, (1984). MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. MCH analogues may also be useful in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that MCH-containing neurons may participate in the neural circuitry underlying PTZ-induced seizure; Knigge and Wagner,

Peptides 18:1095-1097, (1997). MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats; McBride et al., Peptides 15:757-759, (1994); raising the possibility that MCH receptor antagonists may be beneficial for memory storage and/or retention. A possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH may participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume; Parkes, J. Neuroendocrinol. 8:57-63, (1996). Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH may be an important peptide involved in the central control of fluid homeostasis in mammals.

In a recent citation MCHR1 antagonists surprisingly demonstrated their use as an anti-depressants and/or anti-anxiety agents. MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models, such as, social interaction, forced swimming test and ultrasonic vocalization. Therefore, MCHR1 antagonists could be useful to independently treat subjects with depression and/or anxiety. Also, MCHR1 antagonists could be useful to treat subjects that suffer from depression and/or anxiety and obesity.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian MCH1 receptor which comprises administering to the subject an amount of a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality. In separate embodiments, the abnormality is a regulation of a steroid or pituitary hormone disorder, an epinephrine release disorder, an anxiety disorder, a gastrointestinal disorder, a cardiovascular disorder, an electrolyte balance disorder, hypertension, diabetes, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, a stress-related disorder, a fluid-balance disorder, a seizure disorder,

pain, psychotic behavior, morphine tolerance, opiate addiction or migraine.

Compositions of the invention may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in *Remington's Pharmaceutical Sciences* (Mack Pub. Co., Easton, PA, 1980).

The compounds of the invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients which could facilitate the therapeutic effect of the compound.

Compounds of the present invention or a solvate or physiologically functional derivative thereof can be used as active ingredients in pharmaceutical compositions, specifically as a MCH receptor antagonists. By the term "active ingredient" is defined in the context of a "pharmaceutical composition" and shall mean a component of a pharmaceutical composition that provides the primary pharmaceutical benefit, as opposed to an "inactive ingredient" which would generally be recognized as providing no pharmaceutical benefit. The term "pharmaceutical composition" shall mean a composition comprising at one active ingredient and at least one ingredient that is not an active ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to use for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).

Pharmaceutical compositions, including, but not limited to, pharmaceutical compositions, comprising at least one compound of the present invention and/or an acceptable salt or solvate thereof (*e.g.*, a pharmaceutically acceptable salt or solvate) as an active ingredient combined with at least one carrier or excipient (*e.g.*, pharmaceutical carrier or excipient) may be used in the treatment of clinical conditions for which a MCH receptor antagonist is indicated. At least one compound of the present invention may be combined with the carrier in either solid or liquid form in a unit dose formulation. The pharmaceutical carrier must be compatible with the other ingredients in the composition and must be tolerated by the individual recipient. Other physiologically active ingredients may be incorporated into the pharmaceutical composition of the invention if desired, and if such ingredients are compatible with the other ingredients in the composition. Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if

necessary, forming the resulting mixture into a desired shape.

Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tableting lubricants, and disintegrants may be used in tablets and capsules for oral administration. Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants may be added to the liquid preparations. Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.

It is noted that when the MCH receptor antagonists are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of MCH receptor antagonists for the treatment of obesity in domestic animals (*e.g.*, cats and dogs), and MCH receptor antagonists in other domestic animals where no disease or disorder is evident (*e.g.*, food-oriented animals such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.

Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water, in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, dioxane, or acetonitrile are preferred. For instance, when the compound (I) possesses an acidic functional group, it can form an inorganic salt such as an alkali metal salt (*e.g.*, sodium salt, potassium salt, etc.), an alkaline earth metal salt (*e.g.* calcium salt, magnesium salt, barium salt, etc.), and an ammonium salt. When the compound (I) possesses a basic functional group, it can form an inorganic salt (*e.g.*, hydrochloride, sulfate, phosphate, hydrobromate, etc.) or an organic salt (*e.g.*, acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate, tartrate, etc.).

When a compound of the invention contains optical isomers, stereoisomers, regio isomers, rotational isomers, a single substance and a mixture of them are included as a

compound of the invention. For example, when a chemical formula is represented as showing no stereochemical designation(s), such as Formula IX, then all possible stereoisomer, optical isomers and mixtures thereof are considered within the scope of that formula. Accordingly, Formula XXII, specifically designates the cis relationship between the two amino groups on the cyclohexyl ring and therefore this formula is also fully embraced by Formula IX.

The novel substituted quinazolines of the present invention can be readily prepared according to a variety of synthetic manipulations, all of which would be familiar to one skilled in the art. Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme 1-31.

The common intermediate (E) of the novel substituted quinazolines can be prepared as shown in Scheme 1. Commercially available 1*H*,3*H*-quinazoline-2,4-dione (A) is converted to 2,4-dihalo-quinazoline (B) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably *N,N*-diisopropylethylamine, etc.) or an aromatic amine (preferably *N,N*-dimethylaniline, etc.). Reaction temperature ranges from about 100°C to 200°C, preferably about 140°C to 180°C. The halogen of 4-position of 2,4-dihalo-quinazoline (B) is selectively substituted by a primary or secondary amine (HNR_{2a}R_{2b}, wherein R_{2a} and R_{2b} are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (C). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably *N,N*-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0°C to 200°C, preferably about 10°C to 150°C.

In turn, this is substituted by the mono-protected diamine (R₄HN-A-NR₅P, wherein R₄HN-A-NR₅P is as defined below, R₄ and R₅ are as defined above, and P is a protective group) with or without a base in an inert solvent to provide 2,4-disubstitued amino quinazoline (D). The base includes an alkali metal carbonate (preferably sodium carbonate

or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably *N,N*-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50°C to 200°C, preferably about 80°C to 150°C. Also this reaction can be carried out under microwave conditions. Representative protecting groups suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, *Protective Groups in Organic Synthesis*, second edition, John Wiley & Sons, New York, 1991, the disclosure of which is incorporated herein by reference in its entirety. The deprotection of the protective group leads to the common intermediate (E) of the novel substituted quinazolines.

The conversion of the common intermediate (E) to the novel substituted quinazolines (F-H) of the present invention is outlined in Scheme 2.

The amine (E) is reacted with a sulfonyl chloride (R_1SO_2Cl) and a base in an inert solvent to provide the novel sulfonamide (F) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), alcohol solvents (preferably 2-propanol, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about $-20^{\circ}C$ to $50^{\circ}C$, preferably about $0^{\circ}C$ to $40^{\circ}C$.

The amine (E) is reacted with a carboxylic acid (R_1CO_2H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (G) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC \cdot HCl), bromo-tris-pyrrolidino-phosmium hexafluorophosphate (PyBroP), *O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably *N,N*-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably *N,N*-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBt), HOBt-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about $-20^{\circ}C$ to $50^{\circ}C$, preferably about $0^{\circ}C$ to $40^{\circ}C$.


Alternatively, the novel amide (G) of the present invention can be obtained by amidation reaction using an acid chloride (R_1COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or

potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably *N,N*-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about -20°C to 50°C, preferably about 0°C to 40°C.

The novel amide (G) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (H) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-*tert*-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about -78°C to 200°C, preferably about 50°C to 120°C.


Alternatively, the novel amine (H) of the present invention can be obtained by reductive amination reaction using aldehyde (R_1CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about -20°C to 120°C, preferably about 0°C to 100°C. Also this reaction can be carried out under microwave conditions.

Scheme 2




Compounds of Formula (I) can be prepared as shown in Scheme 3. The amine of commercially available *trans*-4-aminomethyl-cyclohexanecarboxylic acid is protected as *tert*-butyl carbamate. The carboxylic acid is reduced to the alcohol by sodium borohydride via the mixed acid anhydride. Tosylation of the alcohol with tosylchloride followed by azidation give the azide, which is converted to the amine by lithium aluminum hydride reduction. The coupling of the amine with the quinazoline core (C), which is synthesized in Scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Boc-group is achieved by an acid to give compounds of Formula (I).

Scheme 3




Compounds of Formula (K) can be prepared as shown in Scheme 4. Known *cis*-(4-aminomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (J), synthesis of which is described in WO 01/72710, can be led to compounds of Formula (K) according to the method of scheme 3.

Scheme 4




Compounds of Formula (L) can be prepared as shown in Scheme 5. The amine of *cis*-[4-(2-amino-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester is protected as benzyl carbamate. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (L).

Scheme 5




Compounds of Formula (N) can be prepared as shown in Scheme 6. The amine of commercially available *trans*-4-aminomethyl-cyclohexanecarboxylic acid is protected as *tert*-butyl carbamate. The carboxylic acid is transformed to benzyl carbamate (M) by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the amine. The amine is converted to compounds of Formula (N) according to the method of scheme 3.

Scheme 6




Compounds of Formula (O) can be prepared from the compound of Formula (M), which is described in Scheme 6, as shown in Scheme 7. The compound of Formula (M) can be led to compounds of Formula (O) according to the method of scheme 5.

Scheme 7




Compounds of Formula (Q) can be prepared as shown in Scheme 8. [4-(Benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (P), synthesis of which is described in WO 01/72710, can be led to compounds of Formula (Q) according to the method of scheme 5.

Scheme 8




Alternatively compounds of Formula (Q) can be prepared as shown in Scheme 9. The amine of commercially available *cis*-4-amino-cyclohexanecarboxylic acid is protected as *tert*-butyl carbamate. The carboxylic acid (R) is converted to the amide (S) by aqueous ammonia via the mixed acid anhydride. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The amide is reduced to compounds of Formula (Q).

Scheme 9




Compounds of Formula (T) can be prepared from the compound of Formula (P), which is described in Scheme 8, as shown in Scheme 10. The compound of Formula (P) can be led to compounds of Formula (T) according to the method of scheme 6.

Scheme 10




Alternatively compounds of Formula (T) can be prepared as shown in Scheme 11. The amide (S), which is described in Scheme 9, is reduced to the amine. The amine can be led to compounds of Formula (T) according to the method of scheme 3.

Scheme 11




Compounds of Formula (V) can be prepared as shown in Scheme 12. The mono-protection of commercially available *trans*-cyclohexane-1,4-diamine can be achieved by the method described in *Synthetic communications*, 20, 2559-2564 (1990). The conversion to compounds of Formula (V) can be accomplished according to the method of scheme 3.

Scheme 12




Compounds of Formula (X) can be prepared as shown in Scheme 13. The dicarboxylic acid of commercially available *cis*-cyclohexane-1,4-dicarboxylic acid is transformed to dibenzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the diamine. The mono-protection of the diamine can be achieved according to the method of scheme 12 to give the compound (W). The conversion to compounds of Formula (X) can be accomplished according to the method of scheme 3.

Scheme 13




Alternatively the compound of Formula (W) can be prepared as shown in Scheme 14. The carboxylic acid (R), which is described in Scheme 9, is transformed to benzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the compound of Formula (W).

Scheme 14




Compounds of Formula (Y) can be prepared according to the method described in Scheme 12 by using commercially available 4-aminomethyl-benzylamine as a starting material (Scheme 15).

Scheme 15




Compounds of Formula (A') can be prepared as shown in Scheme 16. The mono-protection of commercially available 4-aminomethyl-phenylamine can be achieved by using an equimolecular amount of (Boc)₂O to give mono-*tert*-butyl carbamate (Z). The amine can be led to compounds of Formula (A') according to the method of scheme 3.

Scheme 16




Compounds of Formula (B') can be prepared from the compound of Formula (Z), which is described in Scheme 16, as shown in Scheme 17. The compound of Formula (Z) can be led to compounds of Formula (B') according to the method of scheme 5.

Scheme 17




Compounds of Formula (C') can be prepared according to the method described in Scheme 3 by using commercially available (4-amino-phenyl)-carbamic acid *tert*-butyl ester as a starting material (Scheme 18).

Scheme 18




Compounds of Formula (E') can be prepared as shown in Scheme 19. The selective protection of the secondary amine in the presence of the primary amine of commercially available 4-(aminomethyl)piperidin is achieved by the method described in *Synthetic communications*, 22, 2357-2360 (1992) to give the amine (D'). The amine is converted to compounds of Formula (E') according to the method of scheme 3.

Scheme 19




Compounds of Formula (F') can be prepared from the compound of Formula (D'), which is described in Scheme 19, as shown in Scheme 20. The compound of Formula (D') can be led to compounds of Formula (F') according to the method of Scheme 5.

Scheme 20




Compounds of Formula (G') can be prepared according to the method described in Scheme 5 by using commercially available 1-benzyl-piperidin-4-ylamine as a starting material (Scheme 21).

Scheme 21




Compounds of Formula (H') can be prepared as shown in Scheme 22. The amine of commercially available 1-benzyl-piperidin-4-ylamine is protected as *tert*-butyl carbamate. The deprotection of benzyl group is achieved by hydrogen reduction to give the amine. The amine can be led to compounds of Formula (H') according to the method of scheme 3.

Scheme 22




Compounds of Formula (I') can be prepared according to the method described in Scheme 3 by using commercially available pyrrolidin-3-yl-carbamic acid *tert*-butyl ester as a starting material (Scheme 23).

Scheme 23



Alternatively, the novel sulfonamide (F), the novel amide (G), and the novel amine (H) of the present invention are directly synthesized from the quinazoline core (C), which is synthesized in Scheme 1, as shown in Scheme 24. This coupling is performed with or without a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably *N,N*-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50°C to 200°C, preferably about 80°C to 180°C. Also this reaction can be carried out under microwave conditions.


Scheme 24



Compounds of Formula (K') can be prepared as shown in Scheme 25.


Commercially available *trans*-4-aminomethyl-cyclohexanecarboxylic acid is reacted with sulfonyl chloride (R_1SO_2Cl) to give the sulfonamide. The carboxylic acid is converted to the amide via the mixed acid anhydride. The amide is reduced to the amine (J') by borane reduction. The coupling of the amine with the quinazoline core (C), which is synthesized in Scheme 1, gives the novel sulfonamide (K') of the present invention.

Scheme 25




Compounds of Formula (L') can be prepared from the compound of Formula (U), which is described in Scheme 12, as shown in Scheme 26. The amine (U) is reacted with sulfonyl chloride (R_1SO_2Cl) to give the sulfonamide. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel sulfonamide (L') of the present invention.

Scheme 26




Compounds of Formula (M') can be prepared according to the method described in Scheme 26 by using the compound of Formula (D'), which is described in Scheme 19, as a starting material (Scheme 27).

Scheme 27




Compounds of Formula (N') can be prepared according to the method described in Scheme 26 by using commercially available pyrrolidin-3-yl-carbamic acid *tert*-butyl ester as a starting material (Scheme 28).

Scheme 28




Compounds of Formula (O) can be prepared from the compound of Formula (Z), which is described in Scheme 16, as shown in Scheme 29. The aniline (Z) is reacted with carboxylic acid (R_1CO_2H) to give the amide. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel sulfonamide (O') of the present invention.

Scheme 29




Compounds of Formula (P') can be prepared as shown in Scheme 30. The amine (W), which is synthesized in Scheme 13, is subjected to reductive amination by aldehyde (R_1CHO). The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives the novel amine (P') of the present invention.

Scheme 30



Scheme 31 shows the preparation of compounds (Q') of the invention where Q of Formula I has Formula III. The compound (J'), which is synthesized in Scheme 25, is reacted with (1-*tert*-butoxycarbonylamino-1-trifluoromethanesulfonylimino-methyl)-carbamic acid *tert*-butyl ester. The deprotection of Boc-group is achieved by an acid to give the novel guanidine (Q') of the present invention.

Scheme 31



Examples

The compounds of the invention and their synthesis are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the particulars of these examples. "Ambient temperature" as referred to in the following example is meant to indicate a temperature falling between 0 °C and 40 °C.

Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows :

¹H NMR : proton nuclear magnetic resonance spectrum

AcOH : acetic acid

APCI : atmospheric pressure chemical ionization

(Boc)₂O : di-tertiary-butyl dicarbonate

BuLi : butyl lithium

BuOH : butanol

CaCl₂ : calcium chloride

CDCl₃ : deuterated chloroform

CF₃CO₂H : trifluoroacetic acid

CH₂Cl₂ : dichloromethane

CHCl₃ : chloroform

CI : chemical ionization

CuCl : copper (I) chloride

D₂O : deuterium oxide

DMAP : 4-dimethylaminopyridine

DMF : *N,N*-dimethylformamide

DMSO : dimethyl sulfoxide

EDC : 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

ESI : electrospray ionization

Et₂O : diethyl ether

EtOAc : acetic acid ethyl ester

EtOH : ethanol

FAB : fast atom bombardment

H₂SO₄ : sulfuric acid

HATU : *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium-

hexafluorophosphate

HCHO : formaldehyde

HCl : hydrogen chloride

HOAt : 1-hydroxy-7-azabenzotriazole

HOBt : 1-hydroxybenzotriazole

HPLC : high performance liquid chromatography

K₂CO₃ : potassium carbonate

KHSO₄ : potassium bisulfate

Me₂NH : dimethylamine

MeNH₂ : methylamine

MeOH : methanol

MgSO₄ : magnesium sulfate

Na₂CO₃ : sodium carbonate

Na₂SO₄ · 10H₂O : sodium sulfate decahydrate

NaBH(OAc)₃ : sodium triacetoxymborohydride

NaBH₃CN : sodium cyanoborohydride

NaBH₄ : sodium borohydride

NaHCO₃ : sodium hydrogencarbonate

NaN₃ : sodium azide

NaNO₂ : sodium nitrate

Pd(OH)₂ : palladium hydroxide

Pd/C : palladium carbon

POCl₃ : phosphoryl chloride

PVP : poly(4-vinylpyridine)

PyBroP : bromo-tris-pyrrolidino phosphonium hexafluoro phosphate

SOCl₂ : thionyl chloride

t-BuOH : tertiary butanol

TFA : trifluoroacetic acid

THF : tetrahydrofuran

WSC : water solubule carbodiimide

ZCl : benzyloxycarbonyl chloride

s : singlet

d : doublet

t : triplet

q : quartet

dd : doublet doublet

dt : doublet triplet

ddd : doublet doublet doublet

brs : broad singlet

m : multiplet

J : coupling constant

Hz : Hertz


The analytical condition of high performance liquid chromatography is as follows:

Solvent A: 0.050% TFA in water

Solvent B: 0.035% TFA in acetonitrile

5 - 100% B over 5 min, flow rate 3.5 ml/min

Example 1



***trans*-4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide**

Step A: Synthesis of 2,4-dichloro-quinazoline.

To a suspension of 1*H*-quinazoline-2,4-dione (150 g, 925 mmol) in POCl₃ (549 mL, 5.89 mol) was added dimethyl-phenyl-amine (123 mL, 962 mmol). The mixture was stirred at reflux for 7 hr and concentrated. The solution was poured into ice water, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel,

50% CHCl₃ in hexane to 10% EtOAc in CHCl₃) to give 2,4-dichloro-quinazoline (159g, 86%) as a pale yellow solid.

CI MS m/e 199, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.27 (dt, *J* = 8.3, 1.1 Hz, 1 H), 7.95-8.04 (m, 2 H), 7.71-7.81 (m, 1 H).

Step B: Synthesis of (2-chloro-quinazolin-4-yl)-dimethyl-amine.

A solution of 2,4-dichloro-quinazoline (102 g, 530 mmol) in THF (1.2 L) was cooled to 4 °C and 50% aqueous Me₂NH (139 mL, 1.33 mol) was added. The mixture was stirred at ambient temperature for 80 min. The solution was alkalized with saturated aqueous NaHCO₃ (pH = 9), and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 50% Et₂O in hexane (250 mL) and stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with 50% Et₂O in hexane, and dried at 80 °C to give (2-chloro-quinazolin-4-yl)-dimethyl-amine (104 g, 94%) as a pale yellow solid.

ESI MS m/e 207, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.00 (d, *J* = 8.4 Hz, 1 H), 7.73-7.78 (m, 2 H), 7.68 (ddd, *J* = 8.4, 6.9, 1.4 Hz, 1 H), 3.41 (s, 6 H).

Step C: Synthesis of *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid.

To a solution of *trans*-4-aminomethyl-cyclohexanecarboxylic acid (150 g, 954 mmol) in 1.32 M aqueous sodium hydroxide (750 mL) were added *t*-BuOH (1680 mL) and (Boc)₂O (215 g, 985 mmol). The reaction mixture was stirred at ambient temperature for 18 hr. To the reaction mixture was added H₂O (2.8 L), and cooled at 5 °C. The aqueous layer was acidified with saturated aqueous KHSO₄ (pH = 3), extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous NaHCO₃ and brine, dried over MgSO₄, filtered, concentrated and dried under reduced pressure to give *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid (165 g, 67%) as a white solid.

ESI MS m/e 280, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.60 (brs, 1 H), 2.98 (t, *J* = 6.3 Hz, 2 H), 2.19-2.33 (m, 1 H), 1.99-2.11 (m, 2 H), 1.77-1.90 (m, 2 H), 1.44 (s, 9 H), 1.34-1.52 (m, 3 H), 0.86-1.05 (m, 2 H).

Step D: Synthesis of *trans*-(4-hydroxymethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.

A suspension of *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexane-carboxylic acid (155 g, 603 mmol) in CH₂Cl₂ (1.35 L) was cooled at -65 °C and triethylamine (126 mL, 904 mmol) and a solution of ethyl chloroformate (58 mL, 751 mmol) in CH₂Cl₂ (200 mL) were added below -60 °C. The reaction mixture was stirred at 0 °C for 50 min. The mixture was acidified with saturated aqueous KHSO₄ (pH = 3), and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was washed with saturated aqueous Na₂CO₃ and brine, dried over MgSO₄, filtered, and concentrated to give a colorless oil. A solution of the above oil in THF (1.5 L) was cooled at -65 °C and NaBH₄ (26.6 g, 703 mmol) and MeOH (45 mL) were added. The mixture was stirred at -40 °C for 25 min, and stirred at 4 °C for 3 hr. The mixture was acidified with saturated aqueous KHSO₄ (pH = 3), and the aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous Na₂CO₃ and brine, dried over MgSO₄, filtered, and concentrated, and purified by flash chromatography (silica gel, 17% MeOH in CHCl₃) to give *trans*-(4-hydroxymethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (123 g, 84%) as a white solid.

ESI MS *m/e* 266, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.59 (brs, 1 H), 3.46 (d, *J* = 6.4 Hz, 2 H), 2.98 (t, *J* = 6.3 Hz, 2 H), 1.75-1.94 (m, 4 H), 1.45 (s, 9 H), 1.24-1.70 (m, 3 H), 0.81-1.12 (m, 4 H).

Step E: Synthesis of *trans*-(4-azidomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.

A solution of *trans*-(4-hydroxymethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (123 g, 505 mmol) in pyridine (1 L) was cooled at 4 °C and a solution of *p*-toluenesulfonyl chloride (125 g, 657 mmol) in pyridine (200 ml) was added below 10 °C. The mixture was stirred at ambient temperature for 15 hr and concentrated. After dissolution with EtOAc and H₂O, the organic layer was separated. The aqueous layer was extracted with EtOAc (three times), the combined organic layer was washed with H₂O, dried over MgSO₄, filtered, and concentrated to give a pale yellow oil. To a solution of the above oil in DMF (1.6 L) was added NaN₃ (98.8 g, 1.52 mol). The reaction mixture was stirred at ambient temperature for 14 hr and concentrated. After dissolution with CHCl₃ and saturated aqueous NaHCO₃, the organic layer was separated. The aqueous layer was

extracted with CHCl_3 (three times), the combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 17% EtOAc in hexane) to give *trans*-(4-azidomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (124 g, 91%) as a colorless oil.

ESI MS m/e 291, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 4.59 (brs, 1 H), 3.13 (d, $J = 6.5$ Hz, 2 H), 2.98 (t, $J = 6.4$ Hz, 2 H), 1.70-1.90 (m, 4 H), 1.44 (s, 9 H), 1.25-1.65 (m, 2 H), 0.87-1.07 (m, 4 H).

Step F: Synthesis of *trans*-(4-aminomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.

A suspension of lithium aluminum hydride (2.76 g, 72.6 mmol) in THF (225 mL) was cooled at 0 °C and a solution of *trans*-(4-azidomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (15.0 g, 55.9 mmol) in THF (75 mL) was added over 1 hr. The reaction mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with $\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$, filtered through a pad of celite, and concentrated. The residue was purified by flash chromatography (silica gel, 50% MeOH in CHCl_3) to give *trans*-(4-aminomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (12.3 g, 91%) as a pale yellow oil.

ESI MS m/e 243, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 4.60 (brs, 1 H), 2.97 (t, $J = 6.3$ Hz, 2 H), 2.53 (d, $J = 6.4$ Hz, 2 H), 1.70-1.92 (m, 4 H), 1.44 (s, 9 H), 1.08-1.54 (m, 4 H), 0.81-1.02 (m, 4 H).

Step G: Synthesis of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid *tert*-butyl ester.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine (15.2 g, 73.3 mmol) and *trans*-(4-aminomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (14.8 g, 61.0 mmol) in 2-propanol (80 mL) was stirred at reflux for 4 days, poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid *tert*-butyl ester (20.4 g, 81%) as a pale yellow solid.


ESI MS m/e 414, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.81 (d, $J = 8.2$ Hz, 1 H), 7.40-7.52 (m, 2 H), 6.98-7.06 (m, 1 H), 4.93 (brs, 1 H), 4.59 (brs, 1 H), 3.35 (t, $J = 6.2$ Hz, 2 H), 3.26 (s, 6 H), 2.97 (t, $J = 6.2$ Hz, 2H), 1.72-1.95 (m, 4H), 1.44 (s, 9H), 1.30-1.62 (m, 2H), 0.84-1.12 (m, 4H).

Step H: Synthesis of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride.

To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]cyclohexylmethyl}-carbamic acid *tert*-butyl ester (3.84 g, 9.28 mmol) in EtOAc (50 mL) was added 4 M hydrogen chloride in EtOAc (38 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH_2Cl_2 (50 mL) was added diisopropylethylamine (6.46 mL, 37.1 mmol). The mixture was cooled at 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (3.31 g, 9.75 mmol) in CH_2Cl_2 (10 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide (3.45 g, 60%) as a pale yellow solid.

ESI MS m/e 616, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.89 (d, $J = 8.9$ Hz, 1 H), 7.81 (d, $J = 7.6$ Hz, 1 H), 7.35-7.61 (m, 4 H), 7.02 (t, $J = 6.8$ Hz, 1 H), 4.96 (brs, 1 H), 3.35 (t, $J = 6.1$ Hz, 2 H), 3.26 (s, 6 H), 2.79 (d, $J = 6.7$ Hz, 2 H), 1.32-1.98 (m, 6 H), 0.72-1.12 (m, 4 H).

Example 2




***trans*-4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-**

cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride**Step A: Synthesis of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride.**

A solution of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide obtained step H of example 1 (3.45 g, 5.61 mmol) in EtOAc (100 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (1.66 mL) was added. The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. The solid was recrystallized from 16% EtOH in Et₂O, and dried under reduced pressure to give *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride (2.76g, 75%) as a white solid.

ESI MS *m/e* 616, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.50 (brs, 1H), 8.42 (t, *J* = 6.0 Hz, 1 H), 7.86-7.94 (m, 2 H), 7.51-7.68 (m, 4H), 7.21-7.28 (m, 1 H), 4.83 (d, *J* = 6.4 Hz, 1 H), 3.51 (s, 6 H), 3.35 (t, *J* = 6.0 Hz, 2H), 2.78 (t, *J* = 6.4 Hz, 2H), 1.73-1.95 (m, 4H), 1.35-1.65 (m, 2H), 0.81-1.12 (m, 4H).

Example 3***trans*-4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester.**

To a suspension of *trans*-4-aminomethyl-cyclohexanecarboxylic acid (15.0 g, 95.4 mmol) in CHCl₃ (150 mL) were added 1 M aqueous sodium hydroxide (150 mL) and (Boc)₂O (21.9 g, 100 mmol) successively. The reaction mixture was stirred at ambient

temperature for 15 hr, and partitioned between CHCl_3 and water. The aqueous layer was acidified with saturated aqueous KHSO_4 ($\text{pH} = 3$), extracted with CHCl_3 (three times). The combined organic layer was washed with brine, dried over MgSO_4 , filtered, and concentrated to give a white solid. To a suspension of the above solid in benzene (75 mL) were added phosphorazidic acid diphenyl ester (16.2 g, 58.9 mmol) and triethylamine (5.94 g, 58.7 mmol). The reaction mixture was stirred at reflux for 3 hr (**Caution! Vigorous exothermic reaction**). Benzyl alcohol (6.65 g, 61.5 mmol) was added, the reaction mixture was stirred at reflux for 24 hr, concentrated. After dissolution with EtOAc and H_2O , the organic layer was separated. The aqueous layer was extracted with EtOAc (twice), the combined organic layer was washed with 1 M aqueous KHSO_4 , saturated aqueous NaHCO_3 , and brine, dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. A suspension of the above solid in Et_2O was stirred at ambient temperature for 30 min and filtered. The filtrate was washed with Et_2O and dried under reduced pressure to give *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (17.4 g, 50%) as a white solid.

ESI MS m/e 385, $\text{M} + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.22-7.41 (m, 5 H), 5.09 (s, 2 H), 4.20-4.68 (m, 2 H), 3.23-3.60 (m, 1 H), 2.96 (t, 2 H, $J = 6.4$ Hz), 1.62-2.18 (m, 4 H), 1.44 (s, 9 H), 1.30-1.60 (m, 1 H), 0.90-1.23 (m, 4 H).

Step B: Synthesis of *trans*-(4-aminomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride.

To a suspension of *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (4.00 g, 11.0 mmol) in EtOAc (40 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). To the reaction mixture was added CHCl_3 (10 mL) and the mixture was stirred at ambient temperature for 3 hr. To the reaction mixture was 4 M hydrogen chloride in EtOAc (20 mL) and the mixture was stirred at ambient temperature for 1.5 hr, filtered, washed with EtOAc, and dried under reduced pressure to give *trans*-(4-aminomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride (2.96 g, 90%) as a white solid.

ESI MS m/e 263, $\text{M} (\text{free}) + \text{H}^+$; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.12 (brs, 3 H), 7.25-7.40 (m, 5 H), 7.21 (d, 1 H, $J = 7.8$ Hz), 5.00 (s, 2 H), 3.17-3.30 (m, 1 H), 2.62 (d, 2 H, $J = 7.0$ Hz), 1.64-1.88 (m, 4 H), 1.42-1.60 (m, 1 H), 0.90-1.21 (m, 4 H).

Step C: Synthesis of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid benzyl ester .

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine (1.50 g, 7.22 mmol) and *trans*-(4-aminomethyl-cyclohexyl)-carbamic acid benzyl ester hydrochloride (2.59 g, 8.67 mmol) in 2-propanol (15 mL) was stirred at reflux for 8 days and dissolved in CHCl_3 and MeOH. The mixture was poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid benzyl ester (1.20 g, 38%) as a pale yellow solid.

ESI MS m/e 434, $M + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.76-7.82 (m, 1 H), 7.40-7.50 (m, 2 H), 7.25-7.40 (m, 5 H), 6.95-7.04 (m, 1 H), 5.08 (s, 2 H), 4.82-5.05 (m, 1 H), 4.40-4.70 (m, 1 H), 3.40-3.60 (m, 1 H), 3.35 (t, 2 H, $J = 6.3$ Hz), 3.26 (s, 6 H), 1.96-2.18 (m, 2 H), 1.80-1.96 (m, 2 H), 1.45-1.61 (m, 1 H), 1.00-1.20 (m, 4 H).


Step D: Synthesis of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide.

To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid benzyl ester (500 mg, 1.15 mmol) in MeOH (5 mL) was added 5% Pd/C (50 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 2 hr, at 50 °C for 8 hr, and at ambient temperature for 10.5 hr, filtered, and concentrated to give a colorless oil. To a solution of the above oil in CH_2Cl_2 (5 mL) was added diisopropylethylamine (420 μL , 2.41 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (431 mg, 1.27 mmol) in CH_2Cl_2 (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide (560 mg, 81%) as a pale yellow solid.

ESI MS m/e 602, $M + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.90 (d, 1 H, $J = 8.9$ Hz), 7.80

(dd, 1 H, $J = 8.4, 0.9$ Hz), 7.38-7.58 (m, 4 H), 7.01 (ddd, 1 H, $J = 8.4, 6.7, 1.6$ Hz), 4.85-5.04 (m, 1 H), 3.31 (t, 2 H, $J = 6.3$ Hz), 3.24 (s, 6 H), 3.07-3.20 (m, 1 H), 1.70-1.90 (m, 4 H), 1.42-1.58 (m, 1 H), 0.90-1.28 (m, 4 H).

Example 4



*N*²-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine

Step A: Synthesis of *N*²-(1-benzyl-piperidin-4-yl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 362, $M + H^+$; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, $J = 7.6$ Hz, 1 H), 7.20-7.52 (m, 7 H), 6.97-7.05 (m, 1 H), 4.74-4.90 (m, 1 H), 3.90-4.05 (m, 1 H), 3.53 (s, 2 H), 3.26 (s, 6 H), 2.78-2.90 (m, 2 H), 2.02-2.24 (m, 4 H), 1.48-1.62 (m, 2 H).


Step B: Synthesis of *N*²-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

To a solution of *N*²-(1-benzyl-piperidin-4-yl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (500 mg, 1.38 mmol) in MeOH (5 mL) was added 20% Pd(OH)₂ (100 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 hr, at 50 °C for 8 hr, at ambient temperature for 16.5 hr, filtered through a pad of celite, and concentrated. To a solution of the residue in CH₂Cl₂ (5 mL) was added diisopropylethylamine (510 μ L, 2.93 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (493 mg, 1.45 mmol) in CH₂Cl₂ (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄,

filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *N*²-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (339 mg, 43%) as a pale yellow solid.

ESI MS *m/e* 596, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.87 (d, *J* = 8.2 Hz, 1 H), 7.81 (dd, *J* = 8.3, 1.0 Hz, 1 H), 7.36-7.61 (m, 4 H), 7.04 (ddd, *J* = 8.3, 6.8, 1.4 Hz, 1 H), 4.77 (d, *J* = 7.8 Hz, 1 H), 3.97-4.14 (m, 1 H), 3.68-3.86 (m, 2 H), 3.25 (s, 6 H), 2.87-3.01 (m, 2 H), 2.10-2.23 (m, 2 H), 1.51-1.70 (m, 2 H).

Example 5



trans-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of *trans*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester.

To a solution of *trans*-cyclohexane-1,4-diamine (15.0 g, 131 mmol) in 1,4-dioxane (85 mL) was added (Boc)₂O (3.61 g, 16.5 mmol) dropwise over 4 hr. The mixture was stirred at ambient temperature for 19 hr and concentrated. To the residue was added H₂O and the insoluble material was removed by filtration. The filtrate was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated to give *trans*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.15 g, 11% based on diamine, 89% based on (Boc)₂O) as a white solid.

ESI MS *m/e* 215, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.43 (brs, 1 H), 3.36 (brs, 1 H), 2.57-2.70 (m, 1 H), 1.78-2.04 (m, 4 H), 1.44 (s, 9 H), 1.05-1.38 (m, 4 H).

Step B: Synthesis of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.


Using the procedure for the step G of example 1, the title compound was obtained. ESI MS *m/e* 408, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 8.2 Hz, 1 H), 7.39-

7.52 (m, 2 H), 7.02 (ddd, 1 H, $J = 8.3, 6.3, 1.9$ Hz, 1 H), 4.68-4.78 (m, 1 H), 4.43 (brs, 1 H), 3.89 (brs, 1 H), 3.46 (brs, 1 H), 3.25 (s, 6 H), 2.15-2.24 (m, 2 H), 1.97-2.10 (m, 2 H), 1.45 (s, 9 H), 1.21-1.35 (m, 4 H).

Step C: Synthesis of *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.

To a solution of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (500 mg, 1.30 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH₂Cl₂ (7 mL) was added diisopropylethylamine (905 μ L, 5.20 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (462 mg, 1.36 mmol) in CH₂Cl₂ (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. To the reaction mixture was added a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (88 mg, 0.26 mmol) in CH₂Cl₂ (0.5 mL) and the mixture was stirred at 4 °C for 1 hr. To the reaction mixture was added diisopropylethylamine (230 μ L, 1.32 mmol) and the mixture was stirred at 4 °C for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamid (339 mg, 44%) as a white solid.

ESI MS m/e 588, $M + H^+$; ¹H NMR (300 MHz, CDCl₃) δ 7.92 (d, $J = 8.9$ Hz, 1 H), 7.80 (dd, $J = 8.3, 0.7$ Hz, 1 H), 7.37-7.59 (m, 4 H), 6.99-7.06 (m, 1 H), 4.64-4.75 (m, 1 H), 3.78-3.94 (m, 1 H), 3.17-3.30 (m, 7 H), 2.09-2.20 (m, 2 H), 1.85-1.97 (m, 2 H), 1.12-1.47 (m, 4 H).

Example 6***trans*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of *trans*-(4-amino-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.**

To a suspension of *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (4.00 g, 11.0 mmol) in MeOH (40 mL) was added 5% Pd/C (400 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 hr, filtered through a pad of celite, and concentrated to give a white solid. A suspension of the above solid in hexane (15 mL) was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, dried under reduced pressure to give *trans*-(4-amino-cyclohexylmethyl)-carbamic acid *tert*-butyl ester (2.52 g, 100%) as a white solid.

ESI MS m/e 229, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 4.56-4.88 (m, 1 H), 3.00 (t, $J = 6.5$ Hz, 2 H), 2.54-2.65 (m, 1 H), 1.70-1.94 (m, 4 H), 1.44 (s, 9 H), 1.18-1.50 (m, 1 H), 0.92-1.15 (m, 4 H).

Step B: Synthesis of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester.


Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 422, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) 7.81 (d, $J = 7.9$ Hz, 1 H), 7.38-7.52 (m, 2 H), 6.96-7.07 (m, 1 H), 4.55-4.84 (m, 2 H), 3.75-3.97 (m, 1 H), 3.26 (s, 6 H), 3.01 (t, $J = 6.4$ Hz, 2 H), 2.15-2.30 (m, 2 H), 1.75-1.88 (m, 2 H), 1.45 (s, 9 H), 1.35-1.54 (m, 1 H), 1.00-1.30 (m, 4 H).

Step C: Synthesis of *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide.

To a suspension of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester (500 mg, 1.25 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH₂Cl₂ (7 mL) was added diisopropylethylamine (905 µL, 5.20 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (446 mg, 1.31 mmol) in CH₂Cl₂ (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 1.5 hr. To the reaction mixture was added a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (85mg, 0.25 mmol) in CH₂Cl₂ (0.5 mL) and the mixture was stirred at 4 °C for 1 hr. To the reaction mixture was added diisopropylethylamine (220 µL, 1.26 mmol) and the mixture was stirred at 4 °C for 1 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide (624 mg, 83%) as a pale yellow solid.

ESI MS *m/e* 602, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, *J* = 8.9 Hz, 1 H), 7.80 (d, *J* = 8.5 Hz, 1 H), 7.39-7.60 (m, 4 H), 7.04 (ddd, *J* = 8.2, 6.8, 1.6 Hz, 1 H), 3.71-3.92 (m, 1 H), 3.30 (s, 6 H), 2.85 (d, *J* = 6.5 Hz, 2 H), 2.10-2.22 (m, 2 H), 1.70-1.86 (m, 2 H), 1.37-1.53 (m, 1 H), 0.98-1.32 (m, 4 H).

Example 7



*N*²-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-ylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine

Step A: Synthesis of 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester.

To a solution of C-piperidin-4-yl-methylamine (15.0 g, 131 mmol) in toluene (165 mL) was added benzaldehyde (13.9 g, 131 mmol) and the mixture was stirred at reflux with a Dean-Stark trap under N₂ atmosphere for 3 hr, and cooled on an ice-bath. To the reaction mixture was added (Boc)₂O (31.5 g, 144 mmol) dropwise over 15 min. The mixture was stirred at ambient temperature for 2.5 days, and concentrated. To the residue was added 1 M aqueous KHSO₄ and the mixture was stirred at ambient temperature for 7 hr, the aqueous layer was washed with Et₂O (twice), alkalized with sodium hydroxide, and extracted with CHCl₃ (five times). The combined organic layer was dried over MgSO₄, filtered, concentrated. The precipitate was suspended in hexane (10 mL) and the suspension was stirred at ambient temperature for 10 min. The solid was collected by filtration and dried under reduced pressure to give 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (25.8 g, 92%) as a white solid.

ESI MS *m/e* 215, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.85-4.22 (m, 2 H), 2.90 (d, *J* = 6.8 Hz, 2 H), 2.50-2.80 (m, 2 H), 1.70-2.02 (m, 3 H), 1.45 (s, 9 H), 1.10-1.28 (m, 2 H).

Step B: Synthesis of 4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS *m/e* 386, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 8.4 Hz, 1 H), 7.41-7.53 (m, 2 H), 6.99-7.06 (m, 1 H), 5.16 (brs, 1 H), 4.00-4.20 (m, 2 H), 3.41 (t, *J* = 6.1 Hz, 2 H), 3.26 (s, 6 H), 2.60-2.77 (m, 2 H), 1.67-1.84 (m, 3 H), 1.45 (s, 9 H), 1.11-1.28 (m, 2 H).


Step C: Synthesis of *N*²-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-ylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

To a suspension of 4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (500 mg, 1.30 mmol) in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated to give a white solid. To a suspension of the above solid in CH₂Cl₂ (5 mL) was added diisopropylethylamine (480 μL, 2.76 mmol). The mixture was cooled to 4 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (462 mg, 1.36 mmol) in CH₂Cl₂ (2 mL) was added below 5 °C. The reaction

mixture was stirred at 4 °C for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 14% to 20% EtOAc in hexane) to give *N*²-[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-ylmethyl]-*N*¹,*N*¹-dimethyl-quinazoline-2,4-diamine (420 mg, 55%) as a yellow solid.

ESI MS *m/e* 588, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.85 (d, *J* = 8.9 Hz, 1 H), 7.81 (dd, *J* = 8.7, 0.9 Hz, 1 H), 7.40-7.56 (m, 4 H), 7.04 (ddd, *J* = 8.2, 6.7, 1.6 Hz, 1 H), 5.10-5.46 (brs, 1 H), 3.85 (d, *J* = 12.4 Hz, 2 H), 3.40 (t, *J* = 6.4 Hz, 2 H), 3.27 (s, 6 H), 2.56-2.67 (m, 2 H), 1.64-1.91 (m, 3 H), 1.23-1.43 (m, 2 H).

Example 8



4-Bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of 4-(benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester.

To a solution of 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (7.00 g, 32.7 mmol) in CHCl₃ (70 mL) was added triethylamine (3.64 g, 36.0 mmol). The resulting solution was cooled to 4 °C and ZCl (6.13 g, 35.9 mmol) was added below 8 °C over 15 min. The reaction mixture was stirred at ambient temperature for 18 hr, and poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times), dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 33% to 50% EtOAc in hexane) to give 4-(benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester (10.7 g, 94%) as a colorless oil.

ESI MS *m/e* 371, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.26-7.37 (m, 5 H), 5.09 (s, 2 H), 4.84-5.01 (m, 1 H), 3.95-4.22 (m, 2 H), 2.98-3.16 (m, 2 H), 2.66 (t, *J* = 12.4 Hz, 2 H),

1.58-1.72 (m, 3 H), 1.45 (s, 9 H), 0.98-1.18 (m, 2 H).

Step B: Synthesis of piperidin-4-ylmethyl-carbamic acid benzyl ester hydrochloride.

A solution of 4-(benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid *tert*-butyl ester (10.2 g, 29.3 mmol) in EtOAc (100 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (100 mL) was added. The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in hexane (30 mL) and the mixture was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, and dried under reduced pressure to give piperidin-4-ylmethyl-carbamic acid benzyl ester hydrochloride (7.24 g, 87%) as a white solid.


ESI MS *m/e* 271, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.10 (brs, 2 H), 7.20-7.50 (m, 6 H), 5.02 (s, 2 H), 3.15-3.28 (m, 2 H), 2.68-3.02 (m, 4 H), 1.56-1.82 (m, 3 H), 1.20-1.52 (m, 2 H).

Step C: Synthesis of [1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-carbamic acid benzyl ester.

Using the procedure for the step C of example 3, the title compound was obtained. ESI MS *m/e* 420, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.78 (d, *J* = 8.2 Hz, 1 H), 7.21-7.49 (m, 7 H), 6.95-7.04 (m, 1 H), 5.06-5.17 (m, 2 H), 4.83-4.98 (m, 3 H), 3.24 (s, 6 H), 3.00-3.16 (m, 2 H), 2.77-2.91 (m, 2 H), 1.58-1.97 (m, 3 H), 1.12-1.33 (m, 2 H).

Step D: Synthesis of 4-bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step D of example 3, the title compound was obtained. ESI MS *m/e* 588, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.87 (d, *J* = 8.7 Hz, 1 H), 7.78 (d, *J* = 8.2 Hz, 1 H), 7.44-7.59 (m, 4 H), 6.97-7.06 (m, 1 H), 4.94-5.04 (m, 1 H), 4.89 (d, *J* = 13.2 Hz, 2 H), 3.25 (s, 6 H), 2.75-2.88 (m, 4 H), 1.64-1.82 (m, 3 H), 1.05-1.28 (m, 2 H).

Example 9***cis*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of *cis*-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.**

To a suspension of *cis*-cyclohexane-1,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr (**Caution! Vigorous exothermic reaction**). Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give *cis*-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.

ESI MS *m/e* 405, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.40 (m, 10 H), 5.07 (s, 4 H), 4.70-5.00 (m, 2 H), 3.52-3.80 (m, 2 H), 1.60-1.80 (m, 4 H), 1.45-1.60 (m, 4 H).

Step B: Synthesis of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester.

To a solution of *cis*-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtered through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)₂O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr. The reaction mixture was stirred at

ambient temperature for 1.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in MeOH (660 mL) was added a solution of (Boc)₂O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 10 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)₂O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 3.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (5.01 g, 10% based on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)₂O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 13 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.53 g, 7% based on the starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (11.1 g) as a colorless oil.

ESI MS *m/e* 215, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.30-4.82 (m, 1 H), 3.50-3.80 (m, 1 H), 2.78-2.95 (m, 1 H), 1.44 (s, 9H), 1.20-1.80 (m, 8 H).

Step C: Synthesis of *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (3.00 g, 14.4 mmol) and *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.72 g, 17.4 mmol) in 2-propanol (10 mL) was stirred at reflux for 5.5 days, poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester including solvent (5.44 g) as a colorless oil. To a solution of the above material (5.44 g) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (50 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous NaHCO₃, and the precipitate was collected by filtration to give *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (2.26 g, 55%) as a white solid. The aqueous layer was extracted CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (687 mg, 17%) as a white solid.

ESI MS *m/e* 285, M⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.86 (d, *J* = 7.5 Hz, 1 H), 7.47 (t, *J* = 8.3 Hz, 1 H), 7.29 (d, *J* = 8.3 Hz, 1 H), 7.01 (t, *J* = 7.6 Hz, 1 H), 6.56 (d, *J* = 7.5 Hz, 1 H), 3.83-4.06 (m, 1 H), 3.38-3.52 (m, 1 H), 3.20 (s, 6 H), 1.22-1.82 (m, 8 H).


Step D: Synthesis of *cis*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.

To a suspension of *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (680 mg, 2.38 mmol) in CH₂Cl₂ (7 mL) was added diisopropylethylamine (620 μL, 3.56 mmol). The mixture was cooled on an ice-bath and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (849 mg, 2.50 mmol) in CH₂Cl₂ (3 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 6.5 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *cis*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-

trifluoromethoxy-benzenesulfonamide (782 mg, 56%) as a pale yellow solid.

ESI MS m/e 588, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.92 (d, $J = 8.9$ Hz, 1 H), 7.81 (dd, $J = 8.3, 1.2$ Hz, 1 H), 7.41-7.58 (m, 4 H), 7.04 (ddd, $J = 8.3, 6.6, 1.6$ Hz, 1 H), 4.00-4.12 (m, 1 H), 3.36-3.45 (m, 1 H), 3.31 (s, 6 H), 1.54-1.84 (m, 8 H).

Example 10




trans-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-methanesulfonamide

Step A: Synthesis of *trans-N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-methane sulfonamide.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 392, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.81 (d, $J = 7.8$ Hz, 1 H), 7.38-7.53 (m, 2 H), 7.02 (ddd, $J = 8.3, 6.6, 1.6$ Hz, 1 H), 5.07 (brs, 1 H), 4.61 (brs, 1 H), 3.36 (t, $J = 6.2$ Hz, 2 H), 3.27 (s, 6 H), 2.94 (s, 3 H), 2.91-3.01 (m, 2 H), 1.76-1.98 (m, 4 H), 1.37-1.64 (m, 2 H), 0.85-1.12 (m, 4 H).

Example 11




trans-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide

Step A: Synthesis of *trans-N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-

cyclohexylmethyl}-2-trifluoromethoxy-benzamide.

To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]cyclohexylmethyl}-carbamic acid *tert*-butyl ester obtained in step G of example 1 (800 mg, 1.93 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 60 min and concentrated to give a white solid. To a suspension of the solid in CH₂Cl₂ (10 mL) was added diisopropylethylamine (706 μ L, 4.05 mmol). The mixture was cooled at 4 °C and a solution of 2-(trifluoromethoxy)benzoyl chloride (455 mg, 2.03 mmol) in CH₂Cl₂ (4 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 90 min. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *trans*-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide (772 mg, 80%) as a pale yellow solid.


ESI MS *m/e* 502, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.90 (dd, *J* = 7.4, 1.6, Hz, 1 H), 7.81 (d, *J* = 8.1 Hz, 1 H), 7.33-7.55 (m, 4 H), 7.29 (d, *J* = 8.8, Hz, 1 H), 6.96-7.08 (m, 1 H), 6.55 (brs, 1 H), 4.97 (brs, 1 H), 3.28-3.43 (m, 4 H), 3.26 (s, 6 H), 1.76-2.10 (m, 4 H), 1.44-1.72 (m, 2 H), 0.90-1.21 (m, 4 H).

Example 12***trans*-Butane-1-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide****Step A: Synthesis of *trans*-butane-1-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide.**

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS *m/e* 434, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 8.2 Hz, 1 H), 7.35-

7.54 (m, 2 H), 6.97-7.07 (m, 1 H), 4.41 (t, $J = 6.1$ Hz, 1 H), 3.36 (t, $J = 6.1$ Hz, 2 H), 3.27 (s, 6 H), 2.89-3.05 (m, 4 H), 1.71-1.97 (m, 6 H), 1.37-1.65 (m, 4 H), 0.82-1.12 (m, 7 H).

Example 13



***trans*-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide**

Step A: Synthesis of 4-bromo-2-trifluoromethoxy-benzaldehyde.

A solution of 4-bromo-1-iodo-2-trifluoromethoxy-benzene (1.00 g, 2.72 mmol) in THF (15 mL) was cooled to -78 °C, and 2.66 M BuLi in hexane (2.05 mL, 5.44 mmol) was added dropwise. The reaction mixture was stirred at -78 °C for 1.5 h, and *N*-formylmorpholine (0.57 mL, 5.63 mmol) was added. The reaction mixture was stirred at -78 °C for 15 min and at ambient temperature for 80 min. The reaction was quenched with 0.25 M aqueous citric acid (10 mL), and the resulting mixture was extracted with EtOAc (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 2% to 5% EtOAc in hexane) to give 4-bromo-2-trifluoromethoxy-benzaldehyde (560 mg, 77%) as a pale brown solid.

CI MS m/e 269, $M + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 10.33 (s, 1 H), 7.85 (d, $J = 8.1$ Hz, 1 H), 7.50-7.67 (m, 2 H).

Step B: Synthesis of 4-bromo-2-trifluoromethoxy-benzoic acid.

A solution of 4-bromo-2-trifluoromethoxy-benzaldehyde (550 mg, 2.04 mmol) in 1,4-dioxane (27 mL) and H_2O (9 mL) was cooled at 4 °C. To the solution were added amidosulfuric acid (296 mg, 3.05 mmol) and sodium dihydrogen phosphate dihydrate (1.4 g, 8.98 mmol). The mixture was stirred at 4 °C for 15 min. To the reaction mixture was added a solution of sodium chlorite (238 mg, 2.63 mmol) in H_2O (1.5 mL) and stirred at 4 °C for 15 min. To the reaction mixture was added Na_2CO_3 (304 mg, 2.41 mmol) and stirred


at 4 °C for 15 min. The mixture was acidified with conc-HCl (pH = 1), and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 1% MeOH in CHCl₃) to give 4-bromo-2-trifluoromethoxy-benzoic acid (471 mg, 81%) as a white solid.

ESI MS m/e 284, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.98 (d, *J* = 8.4 Hz, 1 H), 7.53-7.62 (m, 2 H).

Step C: Synthesis of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide.

To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid (454 mg, 1.59 mmol) in CH₂Cl₂ (6 mL) were added DMF (1.5 μL, 0.02 mmol) and SOCl₂ (158 μL, 2.17 mmol). The mixture was stirred at reflux for 1 hr and concentrated to give acid chloride as a pale yellow oil. To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]cyclohexylmethyl}-carbamic acid *tert*-butyl ester obtained in step G of example 1 (624 mg, 1.51 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (8 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH₂Cl₂ (6 mL) was added diisopropylethylamine (552 μL, 3.17 mmol). The mixture was cooled at 4 °C and a solution of acid chloride in CH₂Cl₂ (6 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2.5 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzamide (309 mg, 35%) as a pale yellow solid.

ESI MS m/e 580, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.89 (d, *J* = 8.4 Hz, 1 H), 7.81 (d, *J* = 8.2 Hz, 1 H), 7.39-7.67 (m, 4 H), 7.02 (ddd, *J* = 8.2, 6.4, 1.9 Hz, 1 H), 6.53 (brs, 1 H), 4.99 (brs, 1 H), 3.37 (t, *J* = 6.5 Hz, 2 H), 3.32 (t, *J* = 6.3 Hz, 2 H), 3.27 (s, 6 H), 1.76-2.02 (m, 4 H), 1.48-1.67 (m, 2 H), 0.94-1.16 (m, 4 H).

Example 14


***trans*-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide.**

Step A: Synthesis of *trans*-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide.

To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]cyclohexylmethyl}-carbamic acid *tert*-butyl ester obtained in step G of example 1 (500 mg, 1.21 mmol) in EtOAc (8 mL) was added 4 M hydrogen chloride in EtOAc (7 mL). The mixture was stirred at ambient temperature for 40 min and concentrated to give a white solid. To a suspension of the solid in CH₂Cl₂ (7 mL) was added pyridine (215 μ L, 2.66 mmol). The mixture was cooled at 4 °C and a solution of 2-trifluoromethoxy-benzenesulfonyl chloride (331 mg, 1.27 mmol) in CH₂Cl₂ (2 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 2 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give *trans*-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide (231 mg, 36%) as a pale yellow solid.

ESI MS *m/e* 538, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.03 (dd, *J* = 8.0, 1.6 Hz, 1 H), 7.81 (d, *J* = 8.2 Hz, 1 H), 7.57-7.66 (m, 1 H), 7.36-7.52 (m, 4 H), 7.02 (ddd, *J* = 8.3, 6.5, 1.7 Hz, 1 H), 4.94 (brs, 1 H), 4.66 (brs, 1 H), 3.34 (t, *J* = 6.4 Hz, 2 H), 3.26 (s, 6 H), 2.78 (t, *J* = 6.2 Hz, 2 H), 1.68-2.01 (m, 4 H), 1.29-1.60 (m, 2 H), 0.79-1.07 (m, 4 H).

Example 15



trans-*N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-*N*['],*N*[']-dimethyl-quinazoline-2,4-diamine

Step A: Synthesis of *trans*-*N*²-(4-aminomethyl-cyclohexylmethyl)-*N*['],*N*[']-dimethyl-quinazoline-2,4-diamine.

To a suspension of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid *tert*-butyl ester (20.1 g, 48.6 mmol) in EtOAc (200 mL) was added 4 M hydrogen chloride in EtOAc (200 mL). The mixture was stirred at ambient temperature for 90 min and concentrated to give a solid. The solid was alkalized with saturated aqueous NaHCO₃ (pH = 9), concentrated, and purified by flash chromatography (NH silica gel, 33% MeOH in CHCl₃) to give *trans*-*N*²-(4-aminomethyl-cyclohexylmethyl)-*N*['],*N*[']-dimethyl-quinazoline-2,4-diamine (14.7 g, 97%) as a white solid. ESI MS *m/e* 314, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 8.2 Hz, 1 H), 7.42-7.52 (m, 2 H), 7.01 (ddd, *J* = 8.2, 6.2, 0.9 Hz, 1 H), 4.95 (brs, 1 H), 3.36 (t, *J* = 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.52 (d, *J* = 6.4 Hz, 2 H), 1.75-1.96 (m, 5 H), 1.48-1.66 (m, 1 H), 0.82-1.40 (m, 6 H).


Step B: Synthesis of *trans*-*N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-*N*['],*N*[']-dimethyl-quinazoline-2,4-diamine.

To a solution of *trans*-*N*²-(4-aminomethyl-cyclohexylmethyl)-*N*['],*N*[']-dimethyl-quinazoline-2,4-diamine (500 mg, 1.59 mmol) in CH₂Cl₂ (5 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step A of example 13 (428 mg, 1.59 mmol), acetic acid (95 mg, 1.59 mmol), and NaBH(OAc)₃ (505 mg, 2.38 mmol). The reaction mixture was stirred at ambient temperature for 4 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by

flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give *trans*-*N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-*N*¹,*N*⁴-dimethyl-quinazoline-2,4-diamine (783 mg, 89%) as a pale yellow solid.

ESI MS *m/e* 566, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 8.2 Hz, 1 H), 7.34-7.52 (m, 5 H), 7.01 (ddd, *J* = 8.3, 6.2, 2.0 Hz, 1 H), 5.00 (brs, 1 H), 3.77 (s, 2 H), 3.36 (t, *J* = 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.43 (d, *J* = 6.7 Hz, 2 H), 1.76-1.95 (m, 4 H), 1.34-1.65 (m, 2 H), 0.83-1.12 (m, 4 H).

Example 16



***trans*-4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-*N*-methyl-2-trifluoromethoxy-benzenesulfonamide**


Step A: Synthesis of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-*N*-methyl-2-trifluoromethoxy-benzenesulfonamide.

To a solution of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide obtained in step H of example 1 (380 mg, 0.61 mmol) in DMF (2 mL) was added 60% sodium hydride in oil (24.6 mg, 0.61 mmol). The reaction mixture was stirred at ambient temperature for 80 min. The reaction mixture was cooled at 0 °C and iodomethane (38.3 μL, 0.61 mmol) was added and stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane, and silica gel, 5% MeOH in CHCl₃) to give *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-*N*-methyl-2-trifluoromethoxy-benzenesulfonamide (268 mg, 69%) as a pale yellow solid.

ESI MS *m/e* 630, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.88 (d, *J* = 9.2 Hz, 1 H), 7.81 (d,

$J = 8.4$ Hz, 1 H), 7.41-7.57 (m, 4 H), 7.03 (ddd, $J = 8.4, 6.3, 1.8$ Hz, 1 H), 3.37 (t, $J = 6.2$ Hz, 2 H), 3.27 (s, 6 H), 2.97 (d, $J = 7.5$ Hz, 2H), 2.81 (s, 3H), 1.73-1.97 (m, 4H), 1.46-1.66 (m, 2H), 0.83-1.12 (m, 4H).

Example 17




trans- N^2 -(4-([(4-Bromo-2-trifluoromethoxy-benzyl)-methyl-amino]-methyl)-cyclohexylmethyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine

Step A: Synthesis of *trans*- N^2 -(4-([(4-bromo-2-trifluoromethoxy-benzyl)-methyl-amino]-methyl)-cyclohexylmethyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine.

To a solution of *trans*- N^2 -{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}- N^4,N^4 -dimethyl-quinazoline-2,4-diamine obtained in step B of example 15 (290 mg, 0.52 mmol) in CH_2Cl_2 (3 mL) were added 37% aqueous formaldehyde (42 mg, 0.52 mmol), acetic acid (31 mg, 0.52 mmol), and $\text{NaBH}(\text{OAc})_3$ (165 mg, 0.78 mmol). The reaction mixture was stirred at ambient temperature for 19 hr. The reaction was quenched with saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane) to give *trans*- N^2 -(4-([(4-bromo-2-trifluoromethoxy-benzyl)-methyl-amino]-methyl)-cyclohexylmethyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine (153 mg, 51%) as a pale yellow solid.

ESI MS m/e 580, $M + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.81 (d, $J = 7.6$ Hz, 1 H), 7.34-7.53 (m, 5 H), 7.02 (ddd, $J = 8.3, 6.2, 2.0$ Hz, 1 H), 3.44 (s, 2 H), 3.36 (t, $J = 6.3$ Hz, 2 H), 3.27 (s, 6 H), 2.14 (s, 3H), 2.11-2.18 (m, 2 H), 1.81-1.96 (m, 4H), 1.36-1.66 (m, 2 H), 0.73-1.13 (m, 4 H).


Example 18

***trans*- 3-Trifluoromethoxy-biphenyl-4-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide**

Step A: Synthesis of *trans*- 3-trifluoromethoxy-biphenyl-4-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide.

To a solution of *trans*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide obtained in step H of example 1 (122 mg, 0.198 mmol) in toluene (2.7 mL) were added MeOH (0.9 mL), 2 M aqueous K₂CO₃ (0.9 mL), phenylboronic acid (29.0 mg, 0.237 mmol), and tetrakis(triphenylphosphine)palladium (23.0 mg, 0.02 mmol). The reaction mixture was stirred at 130 °C for 10 hr. The mixture was poured into water, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane and silica gel, 9% MeOH in CHCl₃) to give *trans*-3-trifluoromethoxy-biphenyl-4-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide (77 mg, 0.125 mmol) as a white solid.


ESI MS *m/e* 614, *M* + *H*⁺; ¹H NMR (200 MHz, CDCl₃) δ 8.07 (d, *J* = 8.4 Hz, 1 H), 7.82 (d, *J* = 8.8 Hz, 1 H), 7.38-7.67 (m, 9 H), 7.03 (ddd, *J* = 8.4, 6.2, 2.2 Hz, 1 H), 5.11 (brs, 1 H), 4.71 (brs, 1 H), 3.35 (t, *J* = 6.2 Hz, 2 H), 3.27 (s, 6 H), 2.73-2.90 (m, 2 H), 1.67-2.03 (m, 4 H), 1.30-1.64 (m, 2 H), 0.75-1.16 (m, 4 H).

Example 19

***trans*-Octane-1-sulfonic acid{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide**

Step A: Synthesis of *trans*-octane-1-sulfonic acid{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 490, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.81 (d, $J = 7.8$ Hz, 1 H), 7.38-7.54 (m, 2 H), 7.02 (ddd, $J = 8.3, 6.6, 1.7$ Hz, 1 H), 5.01 (brs, 1 H), 4.45 (t, $J = 6.2$ Hz, 1 H), 3.36 (t, $J = 6.2$ Hz, 2 H), 3.26 (s, 6 H), 2.86-3.04 (m, 4 H), 1.70-1.96 (m, 6 H), 1.12-1.65 (m, 11 H), 0.76-1.11 (m, 8 H).

Example 20

***trans*-Propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide**


Step A: Synthesis of *trans*-propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide.

To a suspension of *trans*- N^2 -(4-aminomethyl-cyclohexylmethyl)- N^1,N^1 -dimethyl-quinazoline-2,4-diamine obtained in step A of example 15 (227 mg, 0.72 mmol) in CH_2Cl_2 (4 mL) was added diisopropylethylamine (263 μ L, 1.51 mmol). The mixture was cooled at 4 $^\circ$ C and a solution of 2-propanesulfonyl chloride (108 mg, 0.76 mmol) in CH_2Cl_2 (1 mL)

was added below 5 °C. The reaction mixture was stirred at ambient temperature for 12 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 66% EtOAc in hexane) to give *trans*-propane-2-sulfonic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-amide (135 mg, 45%) as a pale yellow solid.

ESI MS *m/e* 420, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 7.8 Hz, 1 H), 7.39-7.52 (m, 2 H), 7.02 (ddd, *J* = 8.3, 6.5, 1.7 Hz, 1 H), 5.02 (brs, 1 H), 4.22 (t, *J* = 6.2 Hz, 1 H), 3.36 (t, *J* = 6.2 Hz, 2 H), 3.27 (s, 6 H), 3.09-3.21 (m, 1 H), 2.97 (t, *J* = 6.5 Hz, 2 H), 1.75-1.97 (m, 4 H), 1.39-1.64 (m, 2 H), 1.37 (d, *J* = 6.8 Hz, 6 H), 0.85-1.12 (m, 4 H).

Example 21



***N*²-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3-yl]-*N*²,*N*²-dimethyl-quinazoline-2,4-diamine**

Step A: Synthesis of 1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3-ylamine hydrochloride.

To a solution of pyrrolidin-3-yl-carbamic acid *tert*-butyl ester (1.00 g, 5.37 mmol) in CH₂Cl₂ (10 mL) was added diisopropylethylamine (1.96 mL, 5.92 mmol). The mixture was cooled at 0 °C and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (2.01 g, 5.92 mmol) in CH₂Cl₂ (10 mL) was added below 10 °C. The reaction mixture was stirred at 4 °C for 15 min, dissolved in CHCl₃ and saturated aqueous NaHCO₃. The two phases were separated, the aqueous layer was extracted with CHCl₃ (twice). The combined organic layer was dried over MgSO₄, filtered, concentrated, and dried under reduced pressure to give a pale brown solid. To a solution of the above solid in CHCl₃ (50 mL) was added 4 M hydrogen chloride in EtOAc (50 mL). The mixture was stirred at ambient temperature for 1 hr, filtered, washed with EtOAc, and dried under reduced pressure to

give 1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3-ylamine hydrochloride (1.83 g, 80%) as a white solid.


ESI MS m/e 388, M^+ ; 1H NMR (300 MHz, DMSO- d_6) δ 8.44 (brs, 3 H), 7.82-7.94 (m, 3 H), 3.76-3.84 (m, 1 H), 3.42-3.58 (m, 2 H), 3.23-3.40 (m, 2 H), 2.10-2.23 (m, 1 H), 1.88-2.02 (m, 1 H).

Step B: Synthesis of N^2 -[1-(4-bromo-2-trifluoromethoxy-benzenesulfonyl)-pyrrolidin-3-yl]- N^4,N^4 -dimethyl-quinazoline-2,4-diamine

Using the procedure for the step C of example 3, the title compound was obtained.

ESI MS m/e 560, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.82-7.89 (m, 2 H), 7.40-7.75 (m, 4 H), 7.08 (ddd, $J = 8.3, 6.8, 1.5$ Hz, 1 H), 4.83 (brs, 1 H), 4.53-4.64 (m, 1 H), 3.75 (dd, $J = 10.3, 5.8$ Hz, 1 H), 3.48-3.64 (m, 2 H), 3.44 (dd, $J = 10.3, 4.4$ Hz, 1 H), 3.27 (s, 6 H), 2.21-2.36 (m, 1 H), 1.86-2.00 (m, 1 H).

Example 22



***cis*-4-Bromo- N -{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide**

Step A: Synthesis of *cis*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester.

To MeOH (220 mL) cooled at 0 °C was added thionyl chloride (52 mL) below 10 °C over 2.5 hr and the solution was stirred at 0 °C for 1 hr. To the reaction mixture was added *cis*-cyclohexane-1,4-dicarboxylic acid (30.0 g, 174 mmol) and the mixture was stirred at ambient temperature for 14 hr and concentrated. The residue was dissolved in $CHCl_3$, poured into saturated aqueous $NaHCO_3$, and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated. A suspension of lithium aluminum hydride (13.2 g, 348 mmol) in THF (400 mL) was cooled at -20 °C. A solution of the above residue in THF (200 mL) was added

dropwise, and the mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with $\text{Na}_2\text{SO}_4 \cdot 10\text{H}_2\text{O}$, filtered through a pad of celite, and concentrated. To a solution of the above residue in toluene (500 mL) was added triphenylphosphine (37.2 g, 142 mmol). To the mixture cooled at 4 °C were added phthalimide (20.9 g, 142 mmol) and 40% diethyl azodicarboxylate (DEAD) in toluene (61.7 mL, 136 mmol) over 25 min. The reaction mixture was stirred at ambient temperature for 12 hr, poured into H_2O . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated. The precipitate was suspended in Et_2O , filtered, washed with MeOH and Et_2O , and dried under reduced pressure to give a white solid (16.5 g). To a suspension of the above solid (16.5 g, 41.0 mmol) in EtOH (735 mL) was added hydrazine hydrate (20.5 g, 410 mmol). The mixture was stirred at reflux for 2.5 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (120 mL) and 1, 4-dioxane (160 mL). To the mixture cooled on an ice-bath was added $(\text{Boc})_2\text{O}$ (30.4 g, 139 mmol) and the mixture was stirred at ambient temperature for 2.5 hr, and poured into H_2O . The aqueous layer was extracted with CHCl_3 (ten times). The combined organic layer was dried over MgSO_4 , filtered and concentrated. The precipitate was suspended in hexane, filtered, washed with hexane, and dried under reduced pressure to give *cis*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester (5.10 g, 9%) as a white solid.

ESI MS m/e 365, $\text{M} + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 4.49-4.59 (m, 2 H), 3.05 (t, $J = 6.6$ Hz, 4 H), 1.29-1.69 (m, 28 H).

Step C: Synthesis of *cis*-(4-aminomethyl-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.

To a solution of *cis*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester (2.55 g, 7.45 mmol) in CH_2Cl_2 (40 mL) was added 4 M hydrogen chloride in EtOAc (4 mL). The reaction mixture was stirred at ambient temperature for 5 hr and concentrated. The residue was dissolved in 1,4-dioxane (20 mL) and 10% aqueous sodium hydroxide (40 mL) and the resulting solution was cooled on an ice-bath. $(\text{Boc})_2\text{O}$ (829 mg, 3.80 mmol) was added dropwise and the mixture was stirred at ambient temperature for 3 h. The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered and concentrated, and purified by flash chromatography (silica gel, 9% MeOH in CHCl_3) to give *cis*-(4-aminomethyl-

cyclohexylmethyl)-carbamic acid *tert*-butyl ester (255 mg, 14%) as a pale yellow oil.

ESI MS *m/e* 243, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 4.58 (brs, 1 H), 3.06 (t, $J = 6.7$ Hz, 2 H), 2.60 (d, $J = 5.9$ Hz, 2 H), 1.28-1.70 (m, 19 H).


Step D: Synthesis of *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-carbamic acid *tert*-butyl ester.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS *m/e* 414, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.81 (d, $J = 7.8$ Hz, 1 H), 7.42-7.52 (m, 2 H), 7.02 (ddd, $J = 8.3, 6.3, 1.9$ Hz, 1 H), 4.52 (brs, 1 H), 3.45 (t, $J = 6.6$ Hz, 2 H), 3.27 (s, 6 H), 3.08 (t, $J = 6.5$ Hz, 2 H), 1.34-1.86 (m, 19 H).

Step E: Synthesis of *cis*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS *m/e* 616, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.90 (d, $J = 8.9$ Hz, 1 H), 7.81 (d, $J = 7.8$ Hz, 1 H), 7.41-7.58 (m, 4 H), 7.03 (ddd, $J = 8.2, 6.6, 1.5$ Hz, 1 H), 3.41 (t, $J = 6.5$ Hz, 2 H), 3.50 (s, 6 H), 2.90 (d, $J = 7.3$ Hz, 2 H), 1.32-1.86 (m, 10 H).

Example 23



***cis*-4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamide**

Step A: Synthesis of *cis*-(4-hydroxymethyl-cyclohexyl)-carbamic acid *tert*-butyl ester..

A suspension of *cis*-4-amino-cyclohexanecarboxylic acid (244 g, 1.70 mol) in MeOH (2.45 L) was cooled to $-8^{\circ}C$. Thionyl chloride (45.0 mL, 617 mmol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in $CHCl_3$ (3.00 L)

were added triethylamine (261 mL, 1.87 mol) and (Boc)₂O (409 g, 1.87 mol) successively. The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, CHCl₃ only to 10% MeOH in CHCl₃) to give a colorless oil (531 g). To a suspension cooled at -4 °C of lithium aluminum hydride (78.3 g, 2.06 mol) in Et₂O (7.9 L) was added a solution of above oil (530.9 g) in Et₂O (5.3 L) below 0 °C. The resulting suspension was stirred at ambient temperature for 2 hr. The reaction mixture was cooled on an ice-bath, quenched with cold water, filtered through a pad of celite. The filtrate was dried over MgSO₄, filtered, and concentrated. The precipitate was suspended in hexane (300 mL), filtered, washed with hexane, and dried under reduced pressure to give *cis*-(4-hydroxymethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (301 g, 77%) as a white solid. ESI MS *m/e* 252, M + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.30-4.82 (m, 1 H), 3.75 (brs, 1 H), 3.51 (d, *J* = 6.2 Hz, 1 H), 1.52-1.77 (m, 7 H), 1.45 (s, 9 H), 1.16-1.36 (m, 2 H).

Step B: Synthesis of *cis*-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of *cis*-(4-hydroxymethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added triphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% diethyl azodicarboxylate (DEAD) in toluene was added over 1 hr. The reaction mixture was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of above solid (27.5 g) in EtOH (275 mL) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered and concentrated. To a solution of the above residue in CHCl₃ (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0 °C and ZCl (14.4 g, 84.4 mmol) was added below 5 °C. The reaction mixture was stirred at ambient temperature for 16 hr, and poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 2%

MeOH in CHCl_3) to give *cis*-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (25.3 g, 91%) as a colorless oil.

ESI MS m/e 385, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.27-7.38 (m, 5 H), 5.09 (s, 2 H), 4.76-4.92 (m, 1 H), 4.42-4.76 (m, 1 H), 3.72 (brs, 1 H), 3.10 (t, $J = 6.4$ Hz, 2 H), 1.48-1.75 (m, 7 H), 1.44 (s, 9 H), 1.13-1.31 (m, 2 H).


Step C: Synthesis of *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester.

A mixture of *cis*-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.00 g, 11.0 mmol) and 5% Pd/C (400 mg) in MeOH (40 mL) was stirred under hydrogen atmosphere at ambient temperature for 8.5 hr and at 50 °C for 12 hr, filtered through a pad of celite, and concentrated. The precipitate was suspended in hexane and the suspension was stirred at ambient temperature for 30 min. The solid was collected by filtration, washed with hexane, and dried (3.03 g). A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (1.00 g, 4.82 mmol) and the above solid (1.65 g, 7.23 mmol) in 2-propanol (10 mL) was stirred at reflux for 5 days, poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (629 mg, 43%) as a pale yellow solid.

ESI MS m/e 400, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.81 (d, $J = 8.2$ Hz, 1 H), 7.42-7.56 (m, 2 H), 6.98-7.06 (m, 1 H), 4.64-4.75 (m, 1 H), 3.67-3.82 (m, 1 H), 3.29-3.44 (m, 2 H), 3.28 (s, 6 H), 1.50-1.78 (m, 7 H), 1.45 (s, 9 H), 1.21-1.42 (m, 2 H).

Step D: Synthesis of *cis*-4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-2-trifluoromethoxy-benzenesulfonamid.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 602, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.91 (d, $J = 8.9$ Hz, 1 H), 7.82 (dd, $J = 8.0, 1.0$ Hz, 1 H), 7.42-7.56 (m, 4 H), 7.04 (ddd, $J = 8.3, 6.6, 1.6$ Hz, 1 H), 3.44-3.50 (m, 1 H), 3.40 (t, $J = 6.0$ Hz, 2 H), 3.28 (s, 6 H), 1.22-1.78 (m, 9 H).

Example 24***cis*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of *cis*-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.**

To a solution of *cis*-[4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester obtained in step C of example 23 (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtered, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (five times), dried over MgSO₄, filtered and concentrated, and dried under reduced pressure to give *cis*-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

ESI MS *m/e* 263, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.36 (s, 5 H), 5.12 (brs, 3 H), 2.96-3.32 (m, 3 H), 1.36-1.98 (m, 9 H).

Step B: Synthesis of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.


Using the procedure for the step G of example 1, the title compound was obtained. ESI MS *m/e* 434, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 9.0 Hz, 1 H), 7.26-7.52 (m, 7 H), 7.01 (ddd, *J* = 8.2, 6.5, 1.7 Hz, 1 H), 5.10 (s, 2 H), 4.93-5.06 (m, 1 H), 4.82-4.93 (m, 1 H), 4.18-4.28 (m, 1 H), 3.26 (s, 6 H), 3.11 (t, *J* = 6.3 Hz, 2 H), 1.80-1.93 (m, 2 H), 1.52-1.73 (m, 5 H), 1.23-1.40 (m, 2 H).

Step C: Synthesis of *cis*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step D of example 3, the title compound was obtained.

ESI MS m/e 602, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.90 (d, $J = 8.9$ Hz, 1 H), 7.81 (dd, $J = 8.3, 1.3$ Hz, 1 H), 7.38-7.59 (m, 4 H), 7.02 (ddd, $J = 8.2, 6.8, 1.2$ Hz, 1 H), 4.75-5.24 (m, 1 H), 4.16-4.27 (m, 1 H), 3.27 (s, 6 H), 2.86 (d, $J = 6.4$ Hz, 2 H), 1.78-1.91 (m, 2 H), 1.51-1.70 (m, 5 H), 1.21-1.38 (m, 2 H).

Example 25




4-Bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3-yl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of [1-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3-yl]-carbamic acid *tert*-butyl ester.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 358, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.81 (d, $J = 8.2$ Hz, 1 H), 7.45-7.54 (m, 2 H), 6.98-7.05 (m, 1 H), 4.67-4.80 (m, 1 H), 4.25-4.40 (m, 1 H), 3.85-3.94 (m, 1 H), 3.68-3.79 (m, 2 H), 3.52-3.62 (m, 1 H), 3.27 (s, 6 H), 2.16-2.28 (m, 1 H), 1.86-2.01 (m, 1 H), 1.45 (s, 9 H).

Step B: Synthesis of 4-bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-pyrrolidin-3-yl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 560, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.94 (d, $J = 8.4$ Hz, 1 H), 7.81 (d, $J = 8.1$ Hz, 1 H), 7.44-7.58 (m, 4 H), 7.03 (ddd, $J = 8.4, 5.7, 2.6$ Hz, 1 H), 4.76-5.04 (m, 1 H), 3.96-4.11 (m, 1 H), 3.70-3.82 (m, 2 H), 3.58-3.68 (m, 1 H), 3.45-3.54 (m, 1 H), 3.25 (s, 6 H), 2.11-2.24 (m, 1 H), 1.86-1.99 (m, 1 H).

Example 26**4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-benzyl]-2-trifluoromethoxy-benzene sulfonamide****Step A: Synthesis of (4-amino-benzyl)-carbamic acid *tert*-butyl ester.**

To a solution of 4-aminomethyl-phenylamine (1.00 g, 8.19 mmol) in CHCl_3 (10 mL) was added triethylamine (870 mg, 8.60 mmol). After cooling on an ice-bath, $(\text{Boc})_2\text{O}$ (1.88 g, 8.61 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 55 min and poured into saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 9% MeOH in CHCl_3) to give (4-amino-benzyl)-carbamic acid *tert*-butyl ester (1.79 g, 99%) as a yellow solid.

ESI MS m/e 245, $\text{M} + \text{Na}^+$; ^1H NMR (200 MHz, CDCl_3) δ 7.07 (d, $J = 8.4$ Hz, 2 H), 6.63 (d, $J = 8.4$ Hz, 2 H), 4.76 (brs, 1 H), 4.18 (d, $J = 5.3$ Hz, 2 H), 3.65 (brs, 2 H), 1.45 (s, 9 H).


Step B: Synthesis of 4-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-benzyl]-2-trifluoromethoxy-benzenesulfonamide.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (1.00 g, 4.82 mmol) and (4-amino-benzyl)-carbamic acid *tert*-butyl ester (1.28 g, 5.76 mmol) in 2-propanol (10 mL) was stirred at reflux for 3 hr, cooled, poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow solid (2.32 g). To a solution of the above solid (750 mg, 1.91 mmol) in EtOAc (7 mL) was added 4 M hydrogen chloride in EtOAc (7 mL). The mixture was stirred at ambient

temperature for 2 hr, concentrated to give a white solid. To a suspension of the above solid in CH_2Cl_2 (5 mL) was added diisopropylethylamine (730 μL , 4.19 mmol). The mixture was cooled on an ice-bath and a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (777 mg, 2.29 mmol) in CH_2Cl_2 (2 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 9 hr, poured into saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-benzyl]-2-trifluoromethoxy-benzenesulfonamide (519 mg, 56%) as a pale yellow solid.

ESI MS m/e 618, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.88 (t, $J = 9.0$ Hz, 2 H), 7.64 (d, $J = 8.6$ Hz, 2 H), 7.48-7.61 (m, 4 H), 6.98-7.20 (m, 4 H), 4.96 (brs, 1 H), 4.13 (s, 2 H), 3.34 (s, 6 H).

Example 27



4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of (4-aminomethyl-benzyl)-carbamic acid *tert*-butyl ester.

To a solution of 4-aminomethyl-benzylamine (15.0 g, 110 mmol) in CHCl_3 (85 mL) was added a solution of $(\text{Boc})_2\text{O}$ (3.03 g, 13.9 mmol) in CHCl_3 (45 mL) dropwise over 3.5 hr. The reaction mixture was stirred at ambient temperature for 13 hr, and concentrated. After dissolution with H_2O , the aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with H_2O (three times), dried over MgSO_4 , filtered, and concentrated to give (4-aminomethyl-benzyl)-carbamic acid *tert*-butyl ester (3.20 g, 12%) as a white solid.

ESI MS m/e 237, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.21-7.30 (m, 4 H), 4.86-5.02 (m, 1 H), 4.29 (d, $J = 5.8$ Hz, 2 H), 3.84 (s, 2 H), 1.46 (s, 9 H).


Step B: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-carbamic acid *tert*-butyl ester.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 408, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.85 (d, $J = 8.2$ Hz, 1 H), 7.47-7.55 (m, 2 H), 7.37 (d, $J = 8.0$ Hz, 2 H), 7.24 (d, $J = 8.0$ Hz, 2 H), 7.05-7.10 (m, 1 H), 5.35-5.45 (m, 1 H), 4.90-5.04 (m, 1 H), 4.72 (d, $J = 5.8$ Hz, 2 H), 4.31 (d, $J = 5.8$ Hz, 2 H), 3.27 (s, 6 H), 1.49 (s, 9 H).

Step C: Synthesis of 4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step H of example 1, the title compound was obtained. ESI MS m/e 610, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.83 (d, $J = 8.4$ Hz, 2 H), 7.44-7.54 (m, 4 H), 7.29 (d, $J = 7.9$ Hz, 2 H), 7.11 (d, $J = 8.1$ Hz, 2 H), 7.06 (ddd, $J = 8.3, 6.3, 2.0$ Hz, 1 H), 4.67 (d, $J = 5.9$ Hz, 2 H), 4.15 (s, 2 H), 3.26 (s, 6 H).

Example 28



cis- N^2 -[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^4,N^4 -dimethyl-quinazoline-2,4-diamine


Step A: Synthesis of *cis*- N^2 -[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^4,N^4 -dimethyl-quinazoline-2,4-diamine.

Using the procedure for the step B of example 15, the title compound was obtained.

ESI MS m/e 560, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.80 (dd, $J = 7.9, 0.9$ Hz, 1 H),

7.36-7.51 (m, 5 H), 7.01 (ddd, $J = 8.3, 6.4, 1.9$ Hz, 1 H), 4.95-5.18 (m, 1 H), 4.08-4.22 (m, 1 H), 3.81 (s, 2 H), 3.25 (s, 6 H), 2.55-2.70 (m, 1 H), 1.65-1.90 (m, 6 H), 1.29-1.65 (m, 2 H).

Example 29




cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of *cis-N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step A of example 20, the title compound was obtained. ESI MS m/e 532, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 8.06 (dd, $J = 8.1, 1.9$ Hz, 1 H), 7.81 (dd, $J = 8.4, 1.4$ Hz, 1 H), 7.36-7.66 (m, 5 H), 7.03 (ddd, $J = 8.3, 6.7, 1.5$ Hz, 1 H), 4.72-5.07 (m, 2 H), 3.95-4.10 (m, 1 H), 3.32-3.48 (m, 1 H), 3.25 (s, 6 H), 1.37-2.17 (m, 8 H).

Example 30



N^2 -[1-(4-Bromo-2-trifluoromethoxy-benzyl)-piperidin-4-yl]- N^4,N^4 -dimethyl-quinazoline-2,4-diamine

Step A: Synthesis of N^2 -(1-benzyl-piperidin-4-yl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 362, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.80 (d, $J = 7.6$ Hz, 1 H), 7.20-7.52 (m, 7 H), 6.97-7.05 (m, 1 H), 4.74-4.90 (m, 1 H), 3.90-4.05 (m, 1 H), 3.53 (s, 2 H), 3.26 (s, 6 H), 2.78-2.90 (m, 2 H), 2.02-2.24 (m, 4 H), 1.48-1.62 (m, 2 H).

Step B: Synthesis of N^4, N^4 -dimethyl- N^2 -piperidin-4-yl-quinazoline-2,4-diamine.

To a solution of N^2 -(1-benzyl-piperidin-4-yl)- N^4, N^4 -dimethyl-quinazoline-2,4-diamine (1.80 g, 4.98 mmol) in MeOH (18 mL) was added 20% $Pd(OH)_2$ (360 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered through a pad of celite, and concentrated to give N^4, N^4 -dimethyl- N^2 -piperidin-4-yl-quinazoline-2,4-diamine (1.33 g, 99%) as a pale yellow solid.


ESI MS m/e 272, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.86 (d, $J = 8.6$ Hz, 1 H), 7.43-7.62 (m, 2 H), 7.15 (t, $J = 8.2$ Hz, 1 H), 4.12-4.29 (m, 1 H), 3.29-3.47 (m, 2 H), 3.37 (s, 6 H), 2.96-3.12 (m, 2 H), 2.20-2.34 (m, 2 H), 1.79-1.97 (m, 2 H).

Step C: Synthesis of N^2 -[1-(4-bromo-2-trifluoromethoxy-benzyl)-piperidin-4-yl]- N^4, N^4 -dimethyl-quinazoline-2,4-diamine.

Using the procedure for the step B of example 15, the title compound was obtained.

ESI MS m/e 546, $M + Na^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.80 (dd, $J = 8.7, 0.9$ Hz, 1 H), 7.34-7.54 (m, 5 H), 7.01 (ddd, $J = 8.3, 6.6, 1.6$ Hz, 1 H), 4.76-4.95 (m, 1 H), 3.87-4.06 (m, 1 H), 3.52 (s, 2 H), 3.25 (s, 6 H), 2.71-2.86 (m, 2 H), 2.17-2.33 (m, 2 H), 1.97-2.12 (m, 2 H), 1.44-1.61 (m, 2 H).

Example 31




N^4, N^4 -Dimethyl- N^2 -[1-(2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-quinazoline-2,4-diamine

Step A: Synthesis of *N',N'*-dimethyl-*N*²-[1-(2-trifluoromethoxy-benzenesulfonyl)-piperidin-4-yl]-quinazoline-2,4-diamine.

Using the procedure for the step A of example 20, the title compound was obtained. ESI MS *m/e* 518, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.02 (dd, *J* = 7.9, 1.9 Hz, 1 H), 7.81 (dd, *J* = 8.4, 0.7 Hz, 1 H), 7.34-7.67 (m, 5 H), 7.04 (ddd, *J* = 8.3, 6.7, 1.5 Hz, 1 H), 4.81 (brs, 1 H), 3.95-4.12 (m, 1 H), 3.78 (d, *J* = 12.8 Hz, 2 H), 3.25 (s, 6 H), 2.85-3.05 (m, 2 H), 2.05-2.28 (m, 2 H), 1.50-1.71 (m, 2 H).

Example 32



4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-carbamic acid *tert*-butyl ester.

Using the procedure for the step G of example 1, the title compound was obtained. ESI MS *m/e* 402, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 10.05 (brs, 1 H), 7.94 (d, *J* = 8.4 Hz, 1 H), 7.50-7.66 (m, 4 H), 7.23-7.38 (m, 3 H), 6.57-6.64 (m, 1 H), 3.48 (s, 6 H), 1.53 (s, 9 H).


Step B: Synthesis of 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy-benzenesulfonamide

To a suspension of [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-carbamic acid *tert*-butyl ester (380 mg, 1.00 mmol) in EtOAc (4 mL) and CH₂Cl₂ (4 mL) was added 4 M hydrogen chloride in EtOAc (4 mL). The mixture was stirred at ambient temperature for 4 hr and concentrated to give a white solid. The solid was alkalized with saturated aqueous NaHCO₃, filtered, washed with H₂O and hexane, and dried at 50 °C under reduced

pressure. To a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (680 mg, 2.00 mmol) in CH_2Cl_2 (30 mL) was added PVP (8 mL). To the resulting suspension was added a solution of the above solid in CH_2Cl_2 (5 mL). The mixture was stirred at ambient temperature for 10.5 hr and filtered. The filtrate was washed with saturated aqueous NaHCO_3 , dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, EtOAc) to give a solid. The solid was washed with Et_2O and dried at 50 °C under reduced pressure to give 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy-benzenesulfonamide (202 mg, 35%) as a pale yellow solid.

ESI MS m/e 582, $M + H^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.88 (d, $J = 8.4$ Hz, 1 H), 7.73 (d, $J = 8.4$ Hz, 1 H), 7.64 (d, $J = 8.9$ Hz, 2 H), 7.51-7.58 (m, 3 H), 7.44 (dd, $J = 8.4$, 1.7 Hz, 1 H), 7.07-7.24 (m, 1 H), 7.02 (d, $J = 8.9$ Hz, 2 H), 3.32 (s, 6 H).

Example 33



4-Bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of [4-(*tert*-butoxycarbonylamino-methyl)-phenyl]-carbamic acid benzyl ester.

To a solution of 4-aminomethyl-phenylamine (3.00 g, 24.6 mmol) in CHCl_3 (30 mL) was added triethylamine (2.61 g, 25.8 mmol). After cooling on an ice-bath, $(\text{Boc})_2\text{O}$ (5.63 g, 25.8 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 55 min and poured into saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times) and the combined organic layer was dried over MgSO_4 , filtered, and concentrated to give a pale yellow oil. To a solution of the above oil in CHCl_3 (30 mL) was added diisopropylethylamine (3.33 g, 25.8 mmol). The resulting solution was cooled to 4 °C and ZnCl_2 (4.40 g, 25.8 mmol) was added below 10 °C over 5 min. The reaction mixture was stirred at ambient temperature for 12 hr, and poured into

saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCl_3) to give [4-(*tert*-butoxycarbonylamino-methyl)-phenyl]-carbamic acid benzyl ester (2.64 g, 30%) as a white solid.

ESI MS m/e 379, $M + \text{Na}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.11-7.44 (m, 9 H), 6.76 (brs, 1 H), 5.19 (s, 2 H), 4.81 (brs, 1 H), 4.25 (d, $J = 5.1$ Hz, 2 H), 1.45 (s, 9 H).

Step B: Synthesis of (4-aminomethyl-phenyl)-carbamic acid benzyl ester hydrochloride.

A solution of [4-(*tert*-butoxycarbonylamino-methyl)-phenyl]-carbamic acid benzyl ester (1.25 g, 3.51 mmol) in EtOAc (20 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (20 mL) was added. The mixture was stirred at ambient temperature for 20 min. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give (4-aminomethyl-phenyl)-carbamic acid benzyl ester hydrochloride (957 mg, 93%) as a white solid.

ESI MS m/e 279, $M + \text{Na}^+$; ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 9.90 (s, 1 H), 8.37 (brs, 3 H), 7.29-7.55 (m, 9 H), 5.15 (s, 2 H), 3.85-4.01 (m, 2 H).

Step C: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-carbamic acid benzyl ester.

Using the procedure for the step C of example 3, the title compound was obtained. ESI MS m/e 428, $M + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 7.82 (d, $J = 7.5$ Hz, 1 H), 7.25-7.52 (m, 11 H), 6.98-7.07 (m, 1 H), 6.74 (brs, 1 H), 5.28 (brs, 1 H), 5.19 (s, 2 H), 4.65 (d, $J = 5.9$ Hz, 2 H), 3.25 (s, 6 H).


Step D: Synthesis of 4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-2-trifluoromethoxy-benzenesulfonamide.

To a solution of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-carbamic acid benzyl ester (318 mg, 0.744 mmol) in MeOH (3 mL) was added 5% Pd/C (30 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 41.5 hr, filtered through a pad of celite, and concentrated. To a solution of 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (505 mg, 1.49 mmol) in CH_2Cl_2 (12 mL) was added PVP (6 mL).

To the resulting suspension was added a solution of the above residue in CH₂Cl₂ (10 mL). The mixture was stirred at ambient temperature for 1.5 days, filtered, poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane) to give 4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-2-trifluoromethoxy-benzenesulfonamide (330 mg, 74%) as a pale brown solid.

ESI MS *m/e* 596, *M* + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.83 (d, *J* = 8.4 Hz, 1 H), 7.77 (d, *J* = 8.4 Hz, 1 H), 7.41-7.60 (m, 4 H), 7.22 (d, *J* = 8.6 Hz, 2 H), 7.08-7.18 (m, 1 H), 6.99 (d, *J* = 8.6 Hz, 2 H), 4.56 (d, *J* = 5.6 Hz, 2 H), 3.34 (s, 6 H).

Example 34




trans-*N,N'*-Dimethyl-*N''*-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-quinazoline-2,4-diamine

Step A: Synthesis of *trans*-*N,N'*-dimethyl-*N''*-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-quinazoline-2,4-diamine.

Using the procedure for the step B of example 15, the title compound was obtained.

ESI MS *m/e* 510, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 8.2 Hz, 1 H), 7.39-7.57 (m, 3 H), 7.15-7.35 (m, 3 H), 7.02 (ddd, *J* = 8.3, 6.0, 2.2 Hz, 1 H), 3.83 (s, 2 H), 3.35 (t, *J* = 6.3 Hz, 2 H), 3.27 (s, 6 H), 2.45 (d, *J* = 6.5 Hz, 2 H), 1.69-2.04 (m, 4 H), 1.37-1.69 (m, 2 H), 0.84-1.12 (m, 4 H).


Example 35

***N',N'*-Dimethyl-*N*²-[1-(2-trifluoromethoxy-benzyl)-piperidin-4-yl]-quinazoline-2,4-diamine**

Step A: Synthesis of *N',N'*-dimethyl-*N*²-[1-(2-trifluoromethoxy-benzyl)-piperidin-4-yl]-quinazoline-2,4-diamine.

Using the procedure for the step B of example 15, the title compound was obtained.

ESI MS *m/e* 468, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 7.8 Hz, 1 H), 7.37-7.63 (m, 3 H), 7.17-7.35 (m, 3 H), 7.02 (ddd, *J* = 8.3, 6.4, 1.9 Hz, 1 H), 5.12 (brs, 1 H), 3.86-4.07 (m, 1 H), 3.60 (s, 2 H), 3.26 (s, 6 H), 2.74-2.94 (m, 2 H), 2.18-2.37 (m, 2 H), 1.98-2.15 (m, 2 H), 1.45-1.69 (m, 2 H).

Example 36

***trans*-*N',N'*-Dimethyl-*N*²-(4-[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-methyl)-cyclohexylmethyl)-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *trans*-*N',N'*-dimethyl-*N*²-(4-[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-methyl)-cyclohexylmethyl)-quinazoline-2,4-diamine-dihydrochloride.

To a solution of *trans*-*N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexylmethyl}-*N',N'*-dimethyl-quinazoline-2,4-diamine obtained in step B of example

reaction mixture was added 4-bromo-2-trifluoromethoxy-benzaldehyde (4 g, 14.9 mmol) in Et₂O (18 mL). The mixture was stirred at ambient temperature for 4 hr, filtrated, and concentrated. To the above residue was added 10% H₂SO₄ in AcOH (40 mL). The mixture was stirred at ambient temperature for 90 min. The solution was poured into H₂O, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was washed with saturated aqueous NaHCO₃, washed with brine, dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 9% EtOAc in hexane) to give (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde (1.25 g, 30 %) as a pale brown oil.

ESI MS m/e 284, M + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 9.74 (t, *J* = 1.5 Hz, 1 H), 7.41-7.51 (m, 2 H), 7.16 (d, *J* = 8.4 Hz, 1 H), 3.75 (d, *J* = 1.5 Hz, 2 H).

Step B: Synthesis of *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.


To a suspension of *cis*-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine obtained in step C of example 9 (300 mg, 1.05 mmol) in CH₂Cl₂ (3 mL) were added (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde (357 mg, 1.26 mmol), AcOH (76 mg, 1.26 mmol), and NaBH(OAc)₃ (334 mg, 1.57 mmol). The reaction mixture was stirred at ambient temperature for 4.5 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of above solid in EtOAc (0.8 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 30 min and concentrated. A solution of the residue in Et₂O (2 mL) was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride (161 mg, 25%) as a white solid.

ESI MS m/e 552, M (free)⁺; ¹H NMR (200 MHz, CDCl₃) δ 12.66 (brs, 1 H), 9.91 (brs, 2 H), 8.71 (brs, 1 H), 7.93 (d, *J* = 6.6 Hz, 1 H), 7.19-7.77 (m, 6 H), 4.31 (brs, 1 H), 3.54 (s, 6 H), 3.09-3.78 (m, 5 H), 2.00-2.48 (m, 6 H), 1.62-1.96 (m, 2 H).

15 (300 mg, 0.529 mol) in toluene (6.6 mL) were added MeOH (2.2 mL), 2 M aqueous K_2CO_3 (2.2 mL), phenylboronic acid (77 mg, 0.635 mmol), and tetrakis (triphenylphosphine) palladium (61 mg, 0.053 mmol). The reaction mixture was stirred at 130 °C for 12 hr. The mixture was poured into water, and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated and, purified by flash chromatography (NH-silica gel, 33% $CHCl_3$ in hexane and silica gel, 9% MeOH in $CHCl_3$) to give pale yellow oil. To a solution of above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (0.1 mL). The mixture was stirred at ambient temperature for 20 min and concentrated. A solution of the residue in Et_2O (2 mL) was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with Et_2O , and dried under reduced pressure to give *trans*- N^4, N^4 -dimethyl- N^2 -(4-[[3-(trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-methyl]-cyclohexylmethyl)-quinazoline-2,4-diamine dihydrochloride (70 mg, 21%) as a white solid.

ESI MS m/e 564, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.27 (s, 1 H), 9.96 (brs, 2 H), 8.17-8.32 (m, 2 H), 7.89 (d, $J = 7.9$ Hz, 1 H), 7.34-7.64 (m, 9 H), 7.20 (t, $J = 7.7$ Hz, 1 H), 4.29 (brs, 2 H), 3.50 (s, 6 H), 3.28 (t, $J = 6.1$ Hz, 2 H), 2.69 (brs, 2 H), 1.79-2.11 (m, 4 H), 1.44-1.68 (m, 2 H), 0.91-1.16 (m, 4 H).


Example 37



cis- N^2 -{4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}- N^4, N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde.

To a suspension of (methoxymethyl) triphenylphosphonium chloride (5.29 g, 14.9 mol) in Et_2O (50 mL) was added 1.8 M phenyl lithium in 30% Et_2O in cyclohexane (8.58 mL, 15.5 mmol). The mixture was stirred at ambient temperature for 10 min. To the

Example 38


2HCl

***cis*-N',N'-Dimethyl-N²-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyl]-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N',N'-dimethyl-N²-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyl]-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 460, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.68 (d, *J* = 7.6 Hz, 1 H), 8.19-8.33 (m, 1 H), 7.95 (d, *J* = 8.2 Hz, 1 H), 7.66 (t, *J* = 7.7 Hz, 1 H), 7.47 (d, *J* = 8.1 Hz, 1 H), 7.18-7.44 (m, 4 H), 4.35 (s, 2 H), 4.15-4.47 (m, 1 H), 3.53 (s, 6 H), 3.02-3.31 (m, 1 H), 1.95-2.37 (m, 6 H), 1.51-1.85 (m, 2 H).

Example 39

2HCl

***cis*-N²-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N',N'-dimethyl-quinazoline-2,4-diamine dihydrochloride**


Step A: Synthesis of *cis*-N²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N',N'-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 2, the title compound was obtained.

ESI MS *m/e* 538, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.77 (d, *J* = 7.5 Hz, 1 H), 8.11 (d, *J* = 8.4 Hz, 1 H), 7.92 (d, *J* = 8.6 Hz, 1 H), 7.67 (t, *J* = 7.7 Hz, 1 H), 7.41-7.53 (m,

2 H), 7.37 (s, 1 H), 7.28 (t, $J = 7.8$ Hz, 1 H), 4.19-4.40 (m, 1 H), 4.26 (s, 2 H), 3.52 (s, 7 H), 3.07-3.25 (m, 1 H), 2.00-2.39 (m, 6 H), 1.61-1.88 (m, 2 H).

Example 40



***cis*-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide hydrochloride**


Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide hydrochloride.

To a solution of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (4.57 g, 10.5 mmol) in MeOH (46 mL) was added 5% Pd/C (460 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered, and concentrated to give a white solid (3.79 g). To a solution of the above solid (500 mg, 1.67 mmol) in CH₂Cl₂ (5 mL) was added diisopropylethylamine (440 µL, 2.53 mmol). The mixture was cooled on an ice-bath and a solution of 2-trifluoromethoxy-benzenesulfonyl chloride (457 mg, 1.75 mmol) in CH₂Cl₂ (2 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 10 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzenesulfonamide hydrochloride (262 mg, 34%) as a white solid.

ESI MS m/e 524, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.18 (s, 1 H), 8.75 (d, $J =$

7.6 Hz, 1 H), 8.03 (dd, $J = 8.0, 1.7$ Hz, 1 H), 7.89 (d, $J = 8.2$ Hz, 1 H), 7.56-7.71 (m, 2 H), 7.34-7.55 (m, 3 H), 7.24 (t, $J = 7.5$ Hz, 1 H), 4.99 (t, $J = 6.5$ Hz, 1 H), 4.20-4.33 (m, 1 H), 3.50 (s, 6 H), 2.88 (t, $J = 6.3$ Hz, 2 H), 1.78-1.99 (m, 2 H), 1.38-1.77 (m, 7 H).

Example 41



*cis-N*²-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride


Step A: Synthesis of *cis-N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

To a solution of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (4.57 g, 10.5 mmol) in MeOH (46 mL) was added 5% Pd/C (460 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered, and concentrated to give a colorless solid (3.79 g). To a solution of the above solid (500 mg, 1.67 mmol) in CH₂Cl₂ (5 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step A of example 13 (449 mg, 1.67 mmol), AcOH (100 mg, 1.67 mmol), and NaBH(OAc)₃ (531 g, 2.51 mmol). The reaction mixture was stirred at ambient temperature with CaCl₂ tube for 9 hr, poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis-N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride (147 mg, 34%) as a white solid.

ESI MS m/e 552, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.62 (s, 1 H), 10.07 (brs,

2 H), 8.66 (d, $J = 7.6$ Hz, 1 H), 8.22 (d, $J = 8.4$ Hz, 1 H), 7.90 (d, $J = 8.4$ Hz, 1 H), 7.65 (t, $J = 7.6$ Hz, 1 H), 7.52 (dd, $J = 8.3, 1.8$ Hz, 1 H), 7.33-7.48 (m, 2 H), 7.26 (t, $J = 7.5$ Hz, 1 H), 4.11-4.36 (m, 3 H), 3.51 (s, 6 H), 2.76-2.97 (m, 2 H), 1.51-2.27 (m, 9 H).

Example 42




***cis*-*N'*,*N'*-Dimethyl-*N*²-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-*N'*,*N'*-dimethyl-*N*²-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 41, the title compound was obtained. ESI MS m/e 474, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.81 (s, 1 H), 9.97 (brs, 1 H), 8.69 (d, $J = 7.5$ Hz, 1 H), 8.16-8.28 (m, 1 H), 7.90 (d, $J = 8.4$ Hz, 1 H), 7.63 (t, $J = 7.6$ Hz, 1 H), 7.18-7.51 (m, 4 H), 4.31 (brs, 2 H), 4.15-4.30 (m, 1 H), 3.50 (s, 6 H), 2.70-2.94 (m, 2 H), 1.41-2.28 (m, 10 H).

Example 43




***cis*-3-Trifluoromethoxy-biphenyl-4-sulfonic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride**

Step A: Synthesis of *cis*-3-trifluoromethoxy-biphenyl-4-sulfonic acid [4-(4-

dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 36, the title compound was obtained. ESI MS m/e 586, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.20 (brs, 1 H), 8.82 (d, J = 8.1 Hz, 1 H), 8.09 (d, J = 8.6 Hz, 1 H), 7.88 (d, J = 7.8 Hz, 1 H), 7.40-7.73 (m, 8 H), 7.25 (t, J = 8.4 Hz, 1 H), 5.41 (d, J = 8.6 Hz, 1 H), 4.07-4.22 (m, 1 H), 3.49 (s, 6 H), 3.37-3.62 (m, 1 H), 1.57-2.01 (m, 8 H).


Example 44

***cis*- N^2 -{4-[Bis-(4-bromo-2-trifluoromethoxy-benzyl)-amino]-cyclohexyl}- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*- N^2 -{4-[bis-(4-bromo-2-trifluoromethoxy-benzyl)-amino]-cyclohexyl}- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.


ESI MS m/e 790, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.50-12.82 (m, 2 H), 9.50-9.69 (m, 1 H), 8.39 (d, J = 8.1 Hz, 2 H), 7.91 (d, J = 8.1 Hz, 1 H), 7.66 (t, J = 7.8 Hz, 1 H), 7.48 (t, J = 8.7 Hz, 2 H), 7.07-7.43 (m, 4 H), 4.06-4.67 (m, 5 H), 3.51 (s, 6 H), 2.97-3.27 (m, 1 H), 2.21-2.59 (m, 4 H), 1.89-2.17 (m, 2 H), 1.36-1.82 (m, 2 H)

Example 45

cis-N',N'-Dimethyl-N²-{4-[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *cis-N',N'-dimethyl-N²-{4-[(3-trifluoromethoxy-biphenyl-4-ylmethyl)-amino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.*

Using the procedure for the step A of example 43, the title compound was obtained. ESI MS *m/e* 536, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.63 (brs, 1 H), 10.07 (brs, 2 H), 8.68 (d, *J* = 7.3 Hz, 1 H), 8.33 (d, *J* = 8.1 Hz, 1 H), 7.90 (d, *J* = 8.4 Hz, 1 H), 7.17-7.68 (m, 10 H), 4.40 (s, 2 H), 4.19-4.33 (m, 1 H), 3.50 (s, 6 H), 3.16-3.37 (m, 1 H), 2.03-2.48 (m, 6 H), 1.64-1.88 (m, 2 H).

Example 46

trans-N²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N',N'-dimethyl-quinazoline-2,4-diamine dihydrochloride


Step A: Synthesis of *trans-N²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N',N'-dimethyl-quinazoline-2,4-diamine dihydrochloride.*

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 537, M (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.00 (brs, 1 H), 10.08 (brs, 2 H), 8.40 (d, *J* = 7.2 Hz, 1 H), 8.05 (d, *J* = 8.2 Hz, 1 H), 7.91 (d, *J* = 8.4 Hz, 1 H), 7.65 (t,

$J = 7.7$ Hz, 1 H), 7.38-7.57 (m, 3 H), 7.26 (t, $J = 7.6$ Hz, 1 H), 4.17 (s, 2 H), 3.83-4.06 (m, 1 H), 3.53 (s, 6 H), 2.76-2.99 (m, 1 H), 2.09-2.46 (m, 4 H), 1.74-2.00 (m, 2 H), 1.28-1.58 (m, 2 H).

Example 47



1-(4-Bromo-2-trifluoromethoxy-phenyl)-1-[4-(4-dimethylamino-quinazolin-2-ylamino)-piperidin-1-yl]-methanone hydrochloride


Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-[4-(4-dimethylamino-quinazolin-2-ylamino)-piperidin-1-yl]-methanone hydrochloride.

To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid obtained in step B of example 13 (440 mg, 1.47 mmol) in CH_2Cl_2 (5 mL) were added DMF (1.1 μL , 15 μmol) and SOCl_2 (175 μL , 2.09 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a solution of N,N' -dimethyl- N^2 -piperidin-4-yl-quinazoline-2,4-diamine obtained in step B of example 30 (400 mg, 1.47 mmol) in CH_2Cl_2 (4 mL) was added diisopropylethylamine (538 μL , 3.08 mmol). The mixture was cooled at 4 °C and a solution of above acid chloride in CH_2Cl_2 (3 mL) was added below 5 °C. The reaction mixture was stirred at 4 °C for 3 hr. The reaction was quenched with saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% EtOAc in hexane) to give a pale yellow oil. To a solution of above oil in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (0.26 mL). The mixture was stirred at ambient temperature for 50 min and concentrated. A solution of the residue in Et_2O (5 mL) was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with Et_2O , and dried under reduced pressure to give (4-bromo-2-trifluoromethoxy-phenyl)-[4-(4-dimethylamino-quinazolin-2-ylamino)-piperidin-1-yl]-methanone hydrochloride (126

mg, 16%) as a white solid.

ESI MS m/e 538, M (free) + H^+ ; 1H NMR (200 MHz, $CDCl_3$) δ 13.35 (brs, 1 H), 9.06 (d, J = 7.5 Hz, 1 H), 7.93 (d, J = 8.4 Hz, 1 H), 7.67 (dt, J = 7.7, 0.9 Hz, 1 H), 7.43-7.61 (m, 3 H), 7.18-7.41 (m, 2 H), 4.00-4.44 (m, 2 H), 3.54 (s, 6 H), 3.03-3.78 (m, 3 H), 1.52-2.24 (m, 4 H).

Example 48




***cis*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide dihydrochloride**

Step A: Synthesis of 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide dihydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 551, M (free) $^+$; 1H NMR (200 MHz, $CDCl_3$) δ 13.24 (brs, 1 H), 8.95 (d, J = 7.9 Hz, 1 H), 7.92 (d, J = 8.4 Hz, 1 H), 7.71 (d, J = 8.4 Hz, 1 H), 7.60-7.67 (m, 1 H), 7.44-7.58 (m, 3 H), 7.20-7.34 (m, 1 H), 6.57 (d, J = 8.4 Hz, 1 H), 4.00-4.41 (m, 2 H), 3.53 (s, 6 H), 1.66-2.04 (m, 8 H).

Example 49




***cis*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride**

Step A: Synthesis of 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 565, M (free)⁺; ¹H NMR (200 MHz, CDCl₃) δ 13.20 (brs, 1 H), 8.93 (d, J = 7.9 Hz, 1 H), 7.90 (d, J = 8.4 Hz, 1 H), 7.84 (d, J = 8.4 Hz, 1 H), 7.42-7.70 (m, 4 H), 7.18-7.34 (m, 1 H), 6.87 (t, J = 5.5 Hz, 1 H), 4.34 (brs, 1 H), 3.51 (s, 6 H), 3.43 (t, J = 5.7 Hz, 2 H), 1.52-2.17 (m, 9 H).

Example 50



***cis*-*N*²-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-*N*⁴-methyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of (2-chloro-quinazolin-4-yl)-methyl-amine.

A solution of 2,4-dichloro-quinazoline obtained in step A of example 1 (125 g, 628 mmol) in THF (1 L) was cooled to 4 °C and 40% aqueous MeNH₂ (136 mL, 1.57 mol) was added. The mixture was stirred at ambient temperature for 80 min. The solution was alkalized with saturated aqueous NaHCO₃ (pH = 9) and concentrated. The precipitate was collected by filtration, washed with H₂O and hexane, and dried at 80 °C to give (2-chloro-quinazolin-4-yl)-methyl-amine (114 g, 94%) as a white solid.

ESI MS m/e 193, M^+ ; ¹H NMR (300 MHz, CDCl₃) δ 7.68-7.78 (m, 3 H), 7.39-7.48 (m, 1 H), 6.34 (brs, 1 H), 3.22 (d, J = 4.8 Hz, 3 H).

Step B: Synthesis of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.


Using the procedure for the step G of example 1, the title compound was obtained. ESI MS m/e 372, $M + H^+$; ¹H NMR (300 MHz, CDCl₃) δ 7.36-7.56 (m, 3 H), 7.06 (ddd, J = 8.2, 6.8, 1.3 Hz, 1 H), 5.71 (brs, 1 H), 5.10 (brs, 1 H), 4.45-4.72 (m, 1 H), 4.00-4.26 (m,

1 H), 3.49-3.76 (m, 1 H), 3.12 (d, $J = 4.8$ Hz, 3 H), 1.50-1.93 (m, 8 H), 1.46 (s, 9 H).

Step C: Synthesis of *cis*- N^2 -[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^4 -methyl-quinazoline-2,4-diamine dihydrochloride.

To a suspension of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (1.75 g, 4.71 mmol) in EtOAc (5 mL) and CHCl_3 (10 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous NaHCO_3 and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated (2.15 g). To a suspension of the above residue (300 mg, 1.11 mmol) in CH_2Cl_2 (3 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in Step A of Example 13 (297 mg, 1.10 mmol), AcOH (66 mg, 1.10 mmol), and $\text{NaBH}(\text{OAc})_3$ (351 mg, 1.66 mmol). The reaction mixture was stirred at ambient temperature with CaCl_2 tube for 4 hr, poured into saturated aqueous NaHCO_3 , and the aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane), and concentrated to give a pale yellow oil (91 mg). To a solution of the residue (71 mg) in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et_2O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*- N^2 -[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^4 -methyl-quinazoline-2,4-diamine dihydrochloride (62 mg, 20%) as a white solid.

ESI MS m/e 524, M (free) + H^+ ; ^1H NMR (300 MHz, CDCl_3) δ 7.34-7.57 (m, 6 H), 7.05 (ddd, $J = 8.2, 6.8, 1.4$ Hz, 1 H), 5.52 (brs, 1 H), 4.09-4.27 (m, 1 H), 3.82 (s, 2 H), 3.12 (d, $J = 4.8$ Hz, 3 H), 2.57-2.72 (m, 1 H), 1.41-1.94 (m, 8 H).

Example 51


2HCl

***cis*-N²-{4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step C of example 50, the title compound was obtained.

ESI MS *m/e* 538, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.18 (brs, 1 H), 9.93 (brs, 3 H), 8.74 (d, *J* = 6.2 Hz, 1 H), 7.71-7.94 (m, 1 H), 7.60 (t, 1 H, *J* = 7.7 Hz, 1 H), 7.21-7.45 (m, 5 H), 3.94-4.26 (m, 1 H), 3.35-3.58 (m, 2 H), 3.08-3.33 (m, 3 H), 2.94 (brs, 3 H), 1.64-2.42 (m, 8 H).

Example 52

2HCl


***cis*-N⁴-Methyl-N²-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyl]-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N⁴-methyl-N²-[4-(2-trifluoromethoxy-benzylamino)-cyclohexyl]-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step C of example 50, the title compound was obtained.

ESI MS m/e 446, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.36-7.56 (m, 4 H), 7.17-7.33 (m, 3 H), 7.04 (ddd, 1 H, J = 8.2, 6.8, 1.4 Hz, 1 H), 5.66 (brs, 1 H), 5.18 (brs, 1 H), 4.11-4.27 (m, 1 H), 3.87 (s, 2 H), 3.10 (d, J = 4.8 Hz, 3 H), 2.60-2.74 (m, 1 H), 1.45-1.95 (m, 8 H).

Example 53



***cis*-4-Bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride**


Step A: Synthesis of *cis*-4-bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride.

To a suspension of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester obtained in step B of example 50 (1.75 g, 4.71 mmol) in EtOAc (5 mL) and $CHCl_3$ (10 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalized with saturated aqueous $NaHCO_3$ and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated. To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid obtained in step B of example 13 (331 mg, 1.16 mmol) in CH_2Cl_2 (5 mL) were added DMF (1 μ L, 0.01 mmol) and $SOCl_2$ (120 μ L, 1.65 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a suspension of *cis*-*N*-(4-amino-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine (300 mg, 1.11 mmol) in CH_2Cl_2 (3 mL) was added diisopropylethylamine (410 μ L, 2.35 mmol). The mixture was cooled on an ice-bath and a solution of the above residue in CH_2Cl_2 (3 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 3.5 hr. The reaction was quenched with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by

flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of the residue (116 mg) in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give 4-bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide (102 mg, 16%) as a white solid.

ESI MS *m/e* 538, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.72 (s, 1 H), 8.66 (d, *J* = 7.1 Hz, 1 H), 8.35 (brs, 1 H), 8.16 (d, *J* = 7.7 Hz, 1 H), 7.74 (d, *J* = 8.4 Hz, 1 H), 7.48-7.60 (m, 2 H), 7.40-7.43 (m, 1 H), 7.30 (d, *J* = 8.4 Hz, 1 H), 7.19 (t, *J* = 7.8 Hz, 1 H), 6.57 (d, *J* = 8.1 Hz, 1 H), 4.34 (brs, 1 H), 4.15 (brs, 1 H), 3.22 (d, *J* = 3.9 Hz, 3 H), 1.90 (m, 8 H).

Example 54



cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride


Step A: Synthesis of *cis-N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.

To a solution of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (4.57 g, 10.5 mmol) in MeOH (46 mL) was added 5% Pd/C (460 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 3 days, filtered, and concentrated to give a white solid (3.79 g). To a solution of the above solid (300 mg, 1.00 mmol) in CH₂Cl₂ (3 mL) was added triethylamine (280 μL, 2.01 mmol). The mixture was cooled on an ice-bath and a solution of 2-trifluoromethoxy-benzoyl chloride (236 mg, 1.05 mmol) in CH₂Cl₂ (2 mL) was added dropwise. The reaction mixture was stirred on an ice-bath for 5 hr. The reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered,

concentrated, purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane and silica gel, 10% MeOH in CHCl₃), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride (134 mg, 31%) as a white solid.

ESI MS *m/e* 510, *M* (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.29 (s, 1 H), 8.89 (d, *J* = 7.9 Hz, 1 H), 7.93 (dd, *J* = 7.7, 1.8 Hz, 1 H), 7.89 (d, *J* = 8.4 Hz, 1 H), 7.63 (t, *J* = 7.3 Hz, 1 H), 7.52 (d, *J* = 7.9 Hz, 1 H), 7.47 (dd, *J* = 8.1, 1.9 Hz, 1 H), 7.39 (t, *J* = 7.6 Hz, 1 H), 7.29 (d, *J* = 9.0 Hz, 1 H), 7.23 (d, *J* = 7.3 Hz, 1 H), 6.77 (t, *J* = 5.6 Hz, 1 H), 4.18-4.36 (m, 1 H), 3.51 (s, 6 H), 3.42 (t, *J* = 6.3 Hz, 2 H), 1.35-2.02 (m, 9 H).

Example 55




cis-*N*-[4-(4-Methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride

Step A: Synthesis of *cis*-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 54, the title compound was obtained. ESI MS *m/e* 460, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.61 (s, 1 H), 8.70 (d, *J* = 4.4 Hz, 1 H), 8.57 (d, *J* = 7.6 Hz, 1 H), 8.26 (d, *J* = 8.1 Hz, 1 H), 7.82 (dd, *J* = 7.7, 1.8 Hz, 1 H), 7.08-7.57 (m, 6 H), 6.60 (d, *J* = 8.1 Hz, 1 H), 4.25-4.45 (m, 1 H), 4.01-4.25 (m, 1 H), 3.20 (d, *J* = 4.5 Hz, 3 H), 1.53-2.18 (m, 8 H).

Example 56




***cis-N*-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride**

Step A: Synthesis of *cis-N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride.

To a suspension of polymer supported DMAP (2.45 g, 7.35 mmol) in CH₂Cl₂ (6 mL) were added 2-trifluoromethoxy-benzoyl chloride (472 mg, 2.10 mmol) and *cis-N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine obtained in step C of example 9 (300 mg, 1.05 mmol). The mixture was stirred at ambient temperature for 24 h, filtered, poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The reaction mixture was stirred at ambient temperature for 1 hr, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis-N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzamide hydrochloride (145 mg, 27%) as a white solid.

ESI MS *m/e* 474, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.22 (s, 1 H), 8.88 (d, *J* = 7.5 Hz, 1 H), 7.90 (d, *J* = 8.2 Hz, 1 H), 7.79 (dd, *J* = 7.6, 1.9 Hz, 1 H), 7.64 (t, *J* = 7.5 Hz, 1 H), 7.52 (d, *J* = 8.7 Hz, 1 H), 7.47 (dd, *J* = 8.1, 1.9 Hz, 1 H), 7.37 (dt, *J* = 7.5, 1.2 Hz, 1 H), 7.20-7.33 (m, 2 H), 6.66 (d, *J* = 8.4 Hz, 1 H), 4.06-4.36 (m, 2 H), 3.52 (s, 6 H), 1.55-2.21 (m, 8 H).

Example 57




***cis*-*N*²-[4-(4-Bromo-2-trifluoromethoxy-phenylamino)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-*N*²-[4-(4-bromo-2-trifluoromethoxy-phenylamino)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

To a glass flask were added 18-crown-6 (647 mg, 2.45 mmol), 4-Bromo-1-iodo-2-trifluoromethoxy-benzene (770 mg, 2.10 mmol), *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine obtained in step C of example 9 (500 mg, 1.75 mmol), sodium *tert*-butoxide (235 mg, 2.45 mmol), tris(dibenzylideneacetone)dipalladium (160 mg, 0.175 mmol), (R)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (160 mg, 0.175 mmol) and THF (3.5 mL). The reaction mixture was stirred at reflux 18 hr. The mixture was filtered through a pad of celite, concentrated, and purified by flash chromatography (NH-silica gel, 33% EtOAc in hexane) to give a pale yellow oil. To a solution of above oil in Et₂O (2 mL) was added 4 M hydrogen chloride in EtOAc (0.3 mL). The mixture was stirred at ambient temperature for 30 min and concentrated. A solution of the residue in Et₂O (2 mL) was stirred at ambient temperature for 15 min. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *cis*-*N*²-[4-(4-bromo-2-trifluoromethoxy-phenylamino)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride (189 mg, 18%) as a white solid.

ESI MS *m/e* 524, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.04 (s, 1 H), 8.85 (d, *J* = 7.9 Hz, 1 H), 7.90 (d, *J* = 8.1 Hz, 1 H), 7.61-7.70 (m, 1 H), 7.53 (d, *J* = 7.6 Hz, 1 H), 7.22-7.31 (m, 1 H), 6.94 (s, 1 H), 6.79 (s, 1 H), 6.65 (s, 1 H), 4.28 (brs, 1H), 3.52 (s, 6 H), 3.30-3.45 (m, 2 H), 1.64-2.08 (m, 8 H).

Example 58



***cis*-N-[4-(4-Methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamid hydrochloride**

Step A: Synthesis of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

Using the procedure for the step G of Example 1, the title compound was obtained. ESI MS m/e 420, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.20-7.59 (m, 8 H), 7.04 (ddd, J = 8.2, 6.8, 1.3 Hz, 1 H), 5.54-5.76 (m, 1 H), 5.10 (s, 2 H), 4.78-5.24 (m, 2 H), 4.18-4.36 (m, 1 H), 3.11 (d, J = 4.8 Hz, 3 H), 2.92-3.16 (m, 2 H), 1.06-1.94 (m, 9 H).


Step B: Synthesis of *cis*-N-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamid hydrochloride.

To a solution of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (2.73 g, 6.50 mmol) in MeOH (27 mL) was added 10% Pd/C (273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concentrated to give a colorless solid (1.95 g). To a suspension of polymer supported DMAP (2.45 g, 7.35 mmol) in CH_2Cl_2 (10 mL) were added 2-trifluoromethoxy-benzoyl chloride (472 mg, 2.10 mmol) and the above solid (300 mg, 1.05 mmol). The mixture was stirred at ambient temperature for 2.5 days, filtered, poured into saturated aqueous $NaHCO_3$. The aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) and flash chromatography (silica gel, 20% MeOH in $CHCl_3$), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et_2O (5 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-N-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride (20 mg, 4%) as a white solid.

ESI MS m/e 474, M + H^+ ; 1H NMR (500 MHz, $CDCl_3$) δ 12.82 (s, 1 H), 8.63 (d, J = 7.3

Hz, 1 H), 7.97-8.12 (m, 2 H), 7.91 (dd, $J = 7.6, 1.5$ Hz, 1 H), 7.54 (t, $J = 7.6$ Hz, 1 H), 7.48 (dt, $J = 7.9, 1.8$ Hz, 1 H), 7.38 (t, $J = 7.0$ Hz, 1 H), 7.26-7.35 (m, 2 H), 7.19 (t, $J = 7.6$ Hz, 1 H), 6.77 (t, $J = 5.8$ Hz, 1 H), 4.30-4.41 (m, 1 H), 3.41 (t, $J = 6.4$ Hz, 2 H), 3.20 (d, $J = 3.7$ Hz, 3 H), 1.48-2.01 (m, 9 H).

Example 59




***cis*-N⁴-Methyl-N²-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N⁴-methyl-N²-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.

To a solution of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step A of example 58 (2.73 g, 6.50 mmol) in MeOH (27 mL) was added 10% Pd/C (273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concentrated to give a colorless solid (1.95 g). To a solution of the above solid (300 mg, 1.05 mmol) in MeOH (3 mL) were added 2-trifluoromethoxy-benzaldehyde (200 mg, 1.05 mmol), AcOH (63 mg, 1.05 mmol), and NaBH₃CN (99 mg, 1.58 mmol). The reaction mixture was stirred at ambient temperature with CaCl₂ tube for 4 hr, poured into 1 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) and flash chromatography (silica gel, 10% MeOH in CHCl₃), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-N⁴-methyl-N²-{4-[(2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride (175 mg, 33%) as a white solid.

ESI MS m/e 460, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 11.49 (brs, 1 H), 9.74 (brs, 1 H), 9.57 (d, $J = 4.4$ Hz, 1 H), 8.43 (d, $J = 8.4$ Hz, 1 H), 8.27 (d, $J = 8.4$ Hz, 1 H), 8.13 (dd, $J = 7.5, 1.8$ Hz, 1 H), 7.24-7.51 (m, 4 H), 6.95-7.16 (m, 2 H), 4.28 (s, 2 H), 4.13-4.38 (m, 1 H), 2.99 (d, $J = 4.5$ Hz, 3 H), 2.92 (d, $J = 4.8$ Hz, 2 H), 1.41-2.19 (m, 9 H).

Example 60




*cis-N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-*N*^d-methyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *cis-N*²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-*N*^d-methyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of Example 59, the title compound was obtained.

ESI MS m/e 538, M (free) + H^+ ; 1H NMR (500 MHz, $CDCl_3$) δ 11.23 (brs, 1 H), 9.75 (brs, 2 H), 9.46 (brs, 1 H), 8.43 (d, $J = 7.9$ Hz, 1 H), 8.29 (d, $J = 8.5$ Hz, 1 H), 8.08 (d, $J = 8.5$ Hz, 1 H), 7.55 (dd, $J = 8.6, 1.8$ Hz, 1 H), 7.44-7.52 (m, 2 H), 7.14 (t, $J = 7.3$ Hz, 1 H), 7.07 (d, $J = 7.9$ Hz, 1 H), 4.24 (s, 2 H), 4.19-4.30 (m, 1 H), 2.88-3.05 (m, 5 H), 1.38-1.84 (m, 9 H).

Example 61



***cis*-4-Bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride**


Step A: Synthesis of *cis*-4-bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.

To a solution of *cis*-[4-(4-Methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step A of example 58 (2.73 g, 6.50 mmol) in MeOH (27 mL) was added 10% Pd/C (273 mg). The mixture was stirred at 50 °C under hydrogen atmosphere for 14 hr, filtered, and concentrated to give *cis*-*N*²-(4-Aminomethyl-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine (1.95 g) as a white solid. To a solution of 4-bromo-2-trifluoromethoxy-benzoic acid obtained in step B of example 13 (599 mg, 2.10 mmol) in CH₂Cl₂ (6 mL) was added DMF (1 μL, 14.7 μmol) and SOCl₂ (190 μL, 2.60 mmol). The mixture was stirred at reflux for 30 min and concentrated to give acid chloride as a pale yellow oil. To a suspension of polymer supported DMAP (2.45 g, 7.35 mmol) in CH₂Cl₂ (6 mL) were added above acid chloride and *cis*-*N*²-(4-aminomethyl-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine (300 mg). The mixture was stirred at ambient temperature for 24 hr, filtered, poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane), and concentrated. To a solution of the residue in EtOAc (1 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The reaction mixture was stirred at ambient temperature for 1 hr, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-4-bromo-*N*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride (47 mg, 8%) as a white solid.

ESI MS *m/e* 551, *M* (free)⁺; ¹H NMR (500 MHz, CDCl₃) δ 12.61 (s, 1 H), 8.56 (d, *J* = 7.3 Hz, 1 H), 8.40 (brs, 1 H), 8.15 (d, *J* = 8.5 Hz, 1 H), 7.78 (d, *J* = 8.5 Hz, 1 H), 7.47-7.55 (m, 2 H), 7.42 (t, *J* = 1.5 Hz, 1 H), 7.26 (d, *J* = 8.5 Hz, 1 H), 7.17 (t, *J* = 7.6 Hz, 1 H), 6.88 (t, *J*

= 5.8 Hz, 1 H), 4.32-4.44 (m, 1 H), 3.40 (t, J = 6.1 Hz, 2 H), 3.20 (d, J = 4.3 Hz, 3 H), 1.49-2.00 (m, 8 H).

Example 62



*cis-N*²-{4-[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyl}-*N,N'*-dimethyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of (E)-3-(4-bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester.

To a solution of (ethoxy-methoxymethyl-phosphinoyl)-acetic acid ethyl ester (3.45 g, 15.4 mmol) in THF (230 mL) was added 60% sodium hydride in oil (370 mg, 15.4 mmol). The mixture was stirred at ambient temperature for 50 min and cooled at 4 °C. To the reaction mixture was added 4-bromo-2-trifluoromethoxy-benzaldehyde (3 g, 11.2 mmol) in THF (100 mL). The mixture was stirred at ambient temperature for 15 hr. The solution was poured into H₂O, and the aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 5% EtOAc in hexane) to give (E)-3-(4-Bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester (2.98 g, 79 %) as a colorless oil.

CI MS m/e 339, $M + H^+$; ¹H NMR (300 MHz, CDCl₃) δ 7.85 (d, J = 15.8 Hz, 1 H), 7.42-7.58 (m, 3 H), 6.48 (d, J = 15.8 Hz, 1 H), 4.29 (q, J = 7.0 Hz, 2 H), 1.35 (t, J = 7.0 Hz, 3 H).

Step B: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-1-ol.

A suspension of lithium aluminum hydride (834 mg, 22.0 mmol) in Et₂O (20 mL) was cooled at 4 °C. A solution of (E)-3-(4-bromo-2-trifluoromethoxy-phenyl)-acrylic acid ethyl ester (2.98 g, 8.79 mmol) in Et₂O (9 mL) was added dropwise, and the mixture was

stirred at ambient temperature for 90 min. The reaction was quenched with EtOAc (6 mL) and saturated aqueous NH_4Cl was added dropwise. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was washed with 1 M aqueous HCl, dried over MgSO_4 , filtered, concentrated, and purified by flash chromatography (silica gel, 25% EtOAc in hexane) to give 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-1-ol (1.14 g, 43 %) as a colorless oil.

EI MS m/e 298, M^+ ; ^1H NMR (300 MHz, CDCl_3) δ 7.10-7.43 (m, 3 H), 3.68 (t, $J = 6.4$ Hz, 2 H), 2.67-2.80 (m, 2 H), 1.75-1.94 (m, 2 H).

Step C: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionaldehyde.

A solution of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-1-ol (1.03 g, 3.44 mmol) in CH_2Cl_2 (47 mL) was cooled at 4 °C and added celite (1.4 g) and pyridinium chlorochromate (1.11 g, 5.16 mmol). The reaction mixture was stirred at ambient temperature for 6 hr and filtered through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 16% EtOAc in hexane) to give 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionaldehyde (659 mg, 64%) as a colorless oil.


CI MS m/e 297, $\text{M} + \text{H}^+$; ^1H NMR (300 MHz, CDCl_3) δ 9.80 (t, $J = 1.1$ Hz, 1 H), 7.32-7.42 (m, 2 H), 7.17 (d, $J = 8.4$ Hz, 1 H), 2.96 (t, $J = 7.4$ Hz, 2 H), 2.72-2.81 (m, 2 H).

Step D: Synthesis of *cis*- N^2 -{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyl}- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 566, M (free) + H^+ ; ^1H NMR (300 MHz, CDCl_3) δ 8.81 (d, $J = 7.2$ Hz, 1 H), 7.91 (d, $J = 7.9$ Hz, 1 H), 7.60-7.70 (m, 1 H), 7.49 (d, $J = 8.4$ Hz, 1 H), 7.12-7.42 (m, 5 H), 4.31 (brs, 1 H), 3.52 (s, 6 H), 3.23 (brs, 1 H), 3.02-3.14 (m, 2 H), 2.78 (t, $J = 7.8$ Hz, 2 H), 1.97-2.36 (m, 8 H), 1.59-1.85 (m, 2 H).

Example 63



***cis*-*N*²-{4-[4-(4-bromo-2-trifluoromethoxy-phenyl)-butylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of (E)-4-(4-bromo-2-trifluoromethoxy-phenyl)-but-2-enoic acid ethyl ester.

Using the procedure for the step A of example 62, the title compound was obtained. ESI MS *m/e* 352, *M*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.33-7.53 (m, 3 H), 6.64 (d, *J* = 16.2 Hz, 1 H), 6.37 (dt, *J* = 16.0, 7.1 Hz, 1 H), 4.18 (q, *J* = 7.2 Hz, 2 H), 3.28 (dd, *J* = 7.1, 1.5 Hz, 2 H), 1.29 (t, *J* = 7.2 Hz, 3 H).

Step B: Synthesis of 4-(4-bromo-2-trifluoromethoxy-phenyl)-butan-1-ol.

Using the procedure for the step B of example 62, the title compound was obtained.

EI MS *m/e* 312, *M*⁺; ¹H NMR (200 MHz, CDCl₃) δ 7.10-7.42 (m, 3 H), 3.68 (t, *J* = 5.1 Hz, 2 H), 2.60-2.82 (m, 2 H), 1.50-1.79 (m, 4 H), 1.10-1.50 (brs, 1 H).

Step C: Synthesis of 4-(4-bromo-2-trifluoromethoxy-phenyl)-butyraldehyde.

Using the procedure for the step C of example 62, the title compound was obtained.

ESI MS *m/e* 311, *M* + *H*⁺; ¹H NMR (200 MHz, CDCl₃) δ 9.79 (s, 1 H), 7.02-7.22 (m, 3 H), 2.60-2.84 (m, 2 H), 2.49 (t, *J* = 5.9 Hz, 2 H), 1.80-2.03 (m, 2 H).


Step D: Synthesis of *cis*-*N*²-{4-[4-(4-bromo-2-trifluoromethoxy-phenyl)-butylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

To a suspension of *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine obtained in step C of example 9 (240 mg, 0.84 mmol) in MeOH (3 mL) were added 4-(4-bromo-2-trifluoromethoxy-phenyl)-butyraldehyde (262 mg, 0.84 mmol), acetic acid (79 mg, 1.26 mmol), and NaBH₃CN (79 mg, 1.26 mmol). The reaction mixture was

stirred at ambient temperature for 8 hr. The reaction was quenched with saturated aqueous NaHCO_3 . The aqueous layer was extracted with CHCl_3 (three times). The combined organic layer was dried over MgSO_4 , filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a pale yellow solid. To a solution of above solid in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et_2O (20 mL) was stirred at ambient temperature for 1 hr. The solid was collected by filtration, washed with Et_2O , and dried under reduced pressure to give *cis*- N^2 -{4-[4-(4-bromo-2-trifluoromethoxy-phenyl)-butylamino]-cyclohexyl}- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride (220 mg, 40%) as a white solid.

ESI MS m/e 580, M (free) + H^+ ; ^1H NMR (200 MHz, CDCl_3) δ 12.73 (brs, 1 H), 9.55 (brs, 2 H), 8.66-8.88 (m, 1 H), 7.92 (d, $J = 7.9$ Hz, 1 H), 7.66 (t, $J = 7.3$ Hz, 1 H), 7.48 (d, $J = 7.7$ Hz, 1 H), 7.12-7.40 (m, 3 H), 4.20-4.42 (m, 1 H), 3.52 (s, 6 H), 2.92-3.42 (m, 3 H), 2.60-2.78 (m, 2 H), 1.58-2.59 (m, 12 H).

Example 64



2HCl

cis- N^2 -(4-{[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of N^2 -(4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine.

To a solution of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester obtained in step B of example 24 (12.1 g, 27.9 mmol) in MeOH (120 mL) was added 10% Pd/C (1.21 g). The mixture was stirred at 50 °C under hydrogen atmosphere for 19 hr, filtered, concentrated, and purified by flash

chromatography (NH-silica gel, 66% EtOAc in hexane to 15% MeOH in chloroform) to give *N*²-(4-aminomethyl-cyclohexyl)-*N*¹,*N*¹-dimethyl-quinazoline-2,4-diamine (6.9 g, 83%) as a yellow solid.


CI MS *m/e* 300, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.81 (d, *J* = 8.4 Hz, 1 H), 7.40-7.51 (m, 2 H), 6.98-7.04 (m, 1 H), 5.04 (d, *J* = 7.3 Hz, 1 H), 4.24-4.30 (m, 1 H), 3.27 (s, 6 H), 2.60 (d, *J* = 6.4 Hz, 2 H), 1.81-1.96 (m, 2 H), 1.57-1.76 (m, 4 H), 0.90-1.51 (m, 5 H).

Step B: Synthesis of *cis-N*²-(4-{[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-*N*¹,*N*¹-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 566, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.45 (s, 1 H), 9.74 (brs, 2 H), 8.70 (d, *J* = 7.6 Hz, 1 H), 7.90 (d, *J* = 8.4 Hz, 1 H), 7.66 (t, *J* = 7.6 Hz, 1 H), 7.17-7.52 (m, 4 H), 4.30 (brs, 1 H), 3.52 (s, 6 H), 3.32-3.50 (m, 2 H), 3.17 (brs, 2 H), 3.01 (brs, 2 H), 1.56-2.10 (m, 9 H).

Example 65




***cis-N*²-(4-{[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-*N*¹-methyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis-N*²-(4-{[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-*N*¹-methyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 59, the title compound was obtained.

ESI MS *m/e* 552 *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 11.66 (s, 1 H), 9.62 (brs, 1 H), 9.40 (brs, 1 H), 8.05-8.50 (m, 2 H), 7.21-7.58 (m, 4 H), 6.96-7.21 (m, 2 H), 4.26 (brs, 1 H), 3.41 (brs, 2 H), 2.75-3.31 (m, 7H), 1.30-2.24 (m, 9 H).

Example 66




***cis*-N^d,N^d-Dimethyl-N²-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N^d,N^d-dimethyl-N²-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.

To a solution of *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N^d,N^d-dimethyl-quinazoline-2,4-diamine dihydrochloride obtained in step B of example 37 (250 mg, 0.4 mmol) in EtOH (5 mL) was added 10% Pd/C (75 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 17 hr, filtered, poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended with Et₂O (15 mL) and stirred at ambient temperature for 1 hr. The solid was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *cis*-N^d,N^d-dimethyl-N²-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride (104 mg, 48%) as a white solid.

ESI MS *m/e* 474, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.62 (s, 1 H), 9.78 (brs, 2 H), 8.71 (brs, 1 H), 7.93 (d, *J* = 8.4 Hz, 1 H), 7.39-7.77 (m, 3 H), 7.14-7.37 (m, 4 H), 4.33 (brs, 1 H), 3.15-3.71 (m, 11 H), 1.93-2.53 (m, 6 H), 1.62-1.89 (m, 2 H).

Example 67



***cis*-2-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride**

Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-acetic acid.


Using the procedure for the step B of example 13, the title compound was obtained.

ESI MS m/e 298, M^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.39-7.47 (m, 2 H), 7.22 (d, $J = 8.1$ Hz, 1 H), 3.70 (s, 2 H).

Step B: Synthesis of *cis*-2-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 566, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.15 (s, 1 H), 8.91 (d, $J = 7.7$ Hz, 1 H), 7.89 (d, $J = 8.4$ Hz, 1 H), 7.61-7.70 (m, 1 H), 7.48-7.56 (m, 1 H), 7.39-7.45 (m, 1 H), 7.21-7.33 (m, 2 H), 6.02 (d, $J = 8.8$ Hz, 1 H), 4.19-4.33 (m, 1 H), 3.82-4.03 (m, 1 H), 3.53 (s, 2 H), 3.51 (s, 6 H), 1.64-1.97 (m, 8 H).

Example 68




***cis*-2-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide hydrochloride**

Step A: Synthesis of *cis*-2-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained.

ESI MS m/e 580, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.85 (brs, 1 H), 9.08 (d, J = 8.4 Hz, 1 H), 7.90 (d, J = 8.8 Hz, 1 H), 7.58-7.72 (m, 1 H), 7.19-7.54 (m, 5 H), 6.81-6.98 (m, 1 H), 4.28-4.51 (m, 1 H), 3.83 (s, 2 H), 3.51 (s, 6 H), 3.29-3.34 (m, 2 H), 1.42-2.03 (m, 9 H).

Example 69



cis-3-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)cyclohexyl]-propionamide hydrochloride


Step A: Synthesis of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionic acid.

To a solution of 3-(4-bromo-2-trifluoromethoxy-phenyl)-propan-1-ol obtained in step B of example 62 (1 g, 3.34 mmol) in acetone (15 mL) was added Jones reagent (4 mL) at 4 °C. The mixture was stirred at ambient temperature for 2 hr. The solution was poured into water (50 mL), and the aqueous layer was extracted with Et_2O (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by flash chromatography (silica gel, 25% $EtOAc$ in hexane) to give 3-(4-Bromo-2-trifluoromethoxy-phenyl)-propionic acid (930 mg, 89%) as a colorless oil.

ESI MS m/e 313, M^+ ; 1H NMR (200 MHz, $CDCl_3$) δ 7.31-7.50 (m, 2 H), 7.10-7.29 (m, 1 H), 2.97 (t, J = 7.7 Hz, 2 H), 2.65 (t, J = 7.7 Hz, 2 H).

Step B: Synthesis of *cis*-3-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)cyclohexyl]-propionamide hydrochloride.


Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 580, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.12 (brs, 1 H), 8.92 (d, J = 7.9 Hz, 1 H), 7.90 (d, J = 8.3 Hz, 1 H), 7.47-7.73 (m, 2 H), 7.15-7.44 (m, 3 H), 5.92 (d, J = 8.4 Hz, 1 H), 4.18-4.38 (m, 1 H), 3.76-4.03 (m, 1 H), 3.51 (s, 6 H), 2.98 (t, J = 7.7 Hz, 2 H), 2.44 (t, J = 7.7 Hz, 2 H), 1.55-1.96 (m, 9 H).

Example 70

cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-(2-trifluoromethoxy-phenyl)-acetamide hydrochloride

Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-(2-trifluoromethoxy-phenyl)-acetamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 488, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.20 (s, 1H), 8.84 (d, *J* = 7.6 Hz, 1H), 7.89 (d, *J* = 8.7 Hz, 1H), 7.60-7.70 (m, 1H), 7.49-7.56 (m, 1H), 7.20-7.43 (m, 5H), 5.98 (d, *J* = 7.6 Hz, 1H), 4.23 (brs, 1H), 3.84-4.03 (m, 1H), 3.59 (s, 2H), 3.50 (s, 6H), 1.62-1.98 (m, 8H).

Example 71

cis-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide hydrochloride

Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 502, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.99 (s, 1H), 8.99 (d, *J* = 8.5 Hz, 1H), 7.90 (d, *J* = 8.2 Hz, 1H), 7.63 (t, *J* = 7.62 Hz, 1H), 7.38-7.54 (m, 2H), 7.16-

7.34 (m, 4 H), 6.55 (brs, 1 H), 4.28-4.43 (m, 1 H), 3.81 (s, 2 H), 3.51 (s, 6 H), 3.27 (s, 2 H), 1.46-1.99 (m, 9 H).

Example 72




***cis-N',N'*-Dimethyl-*N*²-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride**

Step A: *cis-N',N'*-dimethyl-*N*²-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride

To a solution of *cis-N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide (free) obtained in step A of example 71 (246 mg, 0.5 mmol) in THF (3.5 mL) was added 1 M borane-THF complex (2.45 mL, 2.45 mmol). The mixture was stirred at reflux for 2.5 h, and concentrated. To a solution of above residue in THF (3.5 mL) was added 1 M hydrochloric acid (4.41 mL, 4.41 mmol). The mixture was stirred at reflux for 1 hr, and cooled to ambient temperature. To the reaction mixture was added 2 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et₂O (15 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *cis-N',N'*-dimethyl-*N*²-(4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride (81 mg, 30%) as a white solid.


FAB MS *m/e* 488, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.56 (s, 1 H), 9.72 (brs, 1 H), 8.72 (d, *J* = 7.7 Hz, 1 H), 7.90 (d, *J* = 8.2 Hz, 1 H), 7.66 (t, *J* = 7.7 Hz, 1 H), 7.42-7.54 (m, 2 H), 7.15-7.32 (m, 4 H), 4.22-4.35 (m, 1 H), 3.51 (s, 6 H), 3.38-3.59 (m, 2 H), 3.11-3.30 (m, 2 H), 2.92-3.07 (m, 2 H), 2.21 (brs, 1 H), 1.50-2.01 (m, 8 H).

Example 73

***cis-N⁴*-Methyl-*N*²-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis-N⁴*-methyl-*N*²-(4-{[2-(2-trifluoromethoxy-phenyl)-ethylamino]-methyl}-cyclohexyl)-quinazoline-2,4-diamine dihydrochloride.


Using the procedure for the step A of example 66, the title compound was obtained. ESI MS *m/e* 474, M (free) + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 11.72 (s, 1 H), 9.23-9.94 (m, 3 H), 8.00-8.66 (m, 2 H), 6.64-7.66 (m, 7 H), 4.26 (brs, 1 H), 2.73-3.65 (m, 9 H), 1.27-2.44 (m, 9 H).

Example 74

***cis-N⁴*-Methyl-*N*²-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis-N⁴*-methyl-*N*²-{4-[2-(2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-quinazoline-2,4-diamine dihydrochloride.


Using the procedure for the step A of example 66, the title compound was obtained. ESI MS *m/e* 460, M (free) + H⁺; ¹H NMR (200 MHz, CDCl₃) δ 12.20 (brs, 1 H), 9.84 (brs, 3 H), 8.59-8.79 (m, 1 H), 7.79-8.02 (m, 1 H), 7.10-7.70 (m, 7 H), 3.95-4.26 (m, 1 H), 3.09-3.54 (m, 5 H), 2.82-3.03 (m, 3 H), 1.57-2.43 (m, 8 H).

Example 75

cis-3-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-propionamide hydrochloride

Step A: Synthesis of *cis*-3-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-propionamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 594, *M* (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.72 (s, 1 H), 9.01 (d, *J* = 8.7 Hz, 1 H), 7.90 (d, *J* = 8.2 Hz, 1 H), 7.65 (t, *J* = 7.6 Hz, 1 H), 7.47 (d, *J* = 7.6 Hz, 1 H), 7.21-7.41 (m, 3 H), 6.96 (brs, 1 H), 4.31-4.44 (m, 1 H), 3.51 (s, 6 H), 3.23-3.35 (m, 2 H), 3.03 (t, *J* = 7.6 Hz, 2 H), 2.76 (t, *J* = 7.6 Hz, 2 H), 1.38-1.98 (m, 9 H).

Example 76


cis-*N*²-(4-{[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyl}-cyclohexyl)-*N*²,*N*²-dimethyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *cis*-*N*²-(4-{[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyl}-cyclohexyl)-*N*²,*N*²-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained.

ESI MS m/e 580, M (free) + H^+ ; 1H NMR (200 MHz, $CDCl_3$) δ 12.56 (s, 1 H), 9.40-9.71 (m, 2 H), 8.56-8.76 (m, 1 H), 7.91 (d, $J = 8.4$ Hz, 1 H), 7.66 (t, $J = 7.6$ Hz, 1 H), 7.13-7.47 (m, 5 H), 4.17-4.39 (m, 1 H), 3.51 (s, 6 H), 2.83-3.16 (m, 4 H), 2.67-2.82 (m, 2 H), 1.38-2.53 (m, 11 H).

Example 77



***cis*-N²-[4-(4-Amino-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine trihydrochloride**


Step A: Synthesis of *cis*-N²-[4-(4-amino-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine trihydrochloride.

To a solution of *cis*-N²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine obtained in step A of example 28 (1.5 g, 2.79 mmol) in EtOH (25 mL) were added copper powder (443 mg, 6.93 mmol), CuCl (690 mg, 2.79 mmol), and 28% aqueous NH_3 (25 mL). The reaction mixture was stirred at reflux for 3.5 hr. The mixture was poured into water, and the aqueous layer was extracted with $CHCl_3$ (three times). The combined organic layer was dried over $MgSO_4$, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of above oil in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.25 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et_2O (15 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et_2O , and dried under reduced pressure to give *cis*-N²-[4-(4-amino-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine trihydrochloride (104 mg, 6%) as a white solid.

ESI MS m/e 475, M (free) + H^+ ; 1H NMR (300 MHz, $DMSO-d_6$) δ 13.08 (brs, 1 H), 9.15 (brs, 2 H), 8.32-8.48 (m, 1 H), 8.19 (d, $J = 8.1$ Hz, 1 H), 7.73-7.85 (m, 1 H), 7.46 (d, $J =$

8.4 Hz, 1 H), 7.37 (t, $J = 7.4$ Hz, 2 H), 6.56-6.71 (m, 2 H), 3.94-4.26 (m, 3 H), 3.49 (s, 6 H), 3.02-3.24 (m, 1 H), 1.59-2.09 (m, 8 H).

Example 78



*cis-N*²-(4-{[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyl}-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *N*²-(4-aminomethyl-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine


Using the procedure for the step A of example 64, the title compound was obtained. ESI MS m/e 286, $M + H^+$; ¹H NMR (300 MHz, CDCl₃) δ 7.35-7.59 (m, 3 H), 6.97-7.11 (m, 1 H), 5.59 (brs, 1 H), 5.00-5.18 (m, 1 H), 4.21-4.39 (m, 1 H), 3.13 (d, $J = 4.8$ Hz, 3 H), 2.61 (d, $J = 6.2$ Hz, 2 H), 1.57-1.99 (m, 5 H), 1.04-1.52 (m, 4 H).

Step B: Synthesis of *cis-N*²-(4-{[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]-methyl}-cyclohexyl)-*N*⁴-methyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step D of example 63, the title compound was obtained.

ESI MS m/e 566, M (free) + H^+ ; ¹H NMR (300 MHz, CDCl₃) δ 11.63 (s, 1 H), 9.45 (brs, 3 H), 8.41 (d, $J = 8.5$ Hz, 1 H), 8.32 (d, $J = 7.9$ Hz, 1 H), 7.46 (t, $J = 7.54$ Hz, 1 H), 7.24-7.39 (m, 3 H), 6.99-7.17 (m, 2 H), 4.13-4.35 (m, 1 H), 2.85-3.12 (m, 7 H), 2.75 (t, $J = 7.6$ Hz, 2 H), 2.27-2.47 (m, 2 H), 1.97-2.18 (m, 1 H), 1.37-1.91 (m, 8 H).

Example 79




cis-*N*²-{4-[3-(4-Bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyl}-*N'*-methyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *cis*-*N*²-{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyl}-*N'*-methyl-quinazoline-2,4-diamine dihydrochloride

To a suspension of *cis*-[4-(4-methylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester obtained in step B of example 50 (8.68 g, 23.4 mmol) in CHCl₃ (87mL) was added 4 M hydrogen chloride in EtOAc (100 mL). The reaction mixture was stirred at ambient temperature for 2 hr, and concentrated. The residue was alkalinized with saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated (10.57 g). To a suspension of the above residue (594 mg) in MeOH (6 mL) were added 3-(4-bromo-2-trifluoromethoxy-phenyl)-propionaldehyde obtained in step C of example 62 (650 mg, 2.19 mmol), AcOH (132 mg, 2.19 mmol), and NaBH₃CN (207 mg, 3.29 mmol). The reaction mixture was stirred at ambient temperature for 16 hr, poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane and silica gel, 16% MeOH in CHCl₃) to give a yellow oil. To a solution of the residue in EtOAc (6 mL) was added 4 M hydrogen chloride in EtOAc (0.14 mL). The reaction mixture was stirred at ambient temperature for 30 min, and concentrated. A solution of the residue in Et₂O (10 mL) was stirred at ambient temperature for 1 hr and the precipitate was collected by filtration to give *cis*-*N*²-{4-[3-(4-bromo-2-trifluoromethoxy-phenyl)-propylamino]-cyclohexyl}-*N'*-methyl-quinazoline-2,4-diamine dihydrochloride (59 mg, 7%) as a white solid.

ESI MS *m/e* 552, *M* (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.37 (s, 1 H), 9.78 (brs, 1 H), 9.59 (brs, 2 H), 8.68 (d, *J* = 8.2 Hz, 1 H), 7.55-7.67 (m, 2 H), 7.27-7.43 (m, 5 H), 3.78-3.96 (m, 1 H), 2.94-3.24 (m, 3 H), 2.50-2.89 (m, 5 H), 2.09-2.50 (m, 6 H), 1.60-1.98 (m, 4 H).


Example 80

***cis*-N²-[4-(4-Chloro-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N²-[4-(4-chloro-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

A mixture of conc. HCl (420 μ L) and NaNO₂ (44 mg, 0.64 mmol) were stirred at 70 °C for 10 min. To the reaction mixture was added a solution of *cis*-N²-[4-(4-amino-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (free) obtained in step A of example 77 in AcOH (15 mL), and stirred at ambient temperature for 10 min. To the reaction mixture was added a solution of CuCl (146 mg, 1.47 mmol) in conc. HCl (1 mL), and stirred at 80 °C for 6 hr. The reaction mixture was alkalized with saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) to give a yellow oil. To a solution of above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A solution of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give *cis*-N²-[4-(4-chloro-2-trifluoromethoxy-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride (70 mg, 29%) as a white solid.

ESI MS *m/e* 494, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 12.66 (s, 1 H), 9.82-10.28 (m, 2 H), 8.78 (d, *J* = 7.6 Hz, 1 H), 8.24 (d, *J* = 8.3 Hz, 1 H), 7.92 (d, *J* = 8.2 Hz, 1 H), 7.67 (t, *J* = 7.6 Hz, 1 H), 7.47 (d, *J* = 8.1 Hz, 1 H), 7.18-7.41 (m, 3 H), 4.20-4.44 (m, 3 H), 3.52 (s, 6 H), 3.23 (brs, 1 H), 2.02-2.65 (m, 6 H), 1.75 (t, *J* = 12.8 Hz, 2 H).

Example 81

***trans*-N²-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**


Step A: Synthesis of N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine

To a suspension of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid *tert*-butyl ester obtained in step B of example 6 (400 mg, 1.00 mmol) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 80 min. The reaction mixture was alkalinized with 2 M aqueous sodium hydroxide, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane to 3% MeOH in CHCl₃) to give N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (250 mg, 83%) as a pale yellow oil.

ESI MS *m/e* 300, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 9.3 Hz, 1 H), 7.38-7.53 (m, 2 H), 6.97-7.05 (m, 1 H), 4.77 (d, *J* = 9.3 Hz, 1 H), 3.73-4.02 (m, 1 H), 3.26 (s, 6 H), 2.57 (d, *J* = 6.2 Hz, 2 H), 2.13-2.31 (m, 2 H), 1.75-1.96 (m, 2 H), 0.92-1.45 (m, 7 H).

Step B: Synthesis of *trans*-N²-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained. ESI MS *m/e* 552, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.72 (s, 1 H), 10.19 (brs, 2 H), 8.18 (d, *J* = 8.9 Hz, 1 H), 8.06 (d, *J* = 7.9 Hz, 1 H), 7.91 (d, *J* = 8.3 Hz, 1 H), 7.42-7.65 (m, 3 H), 7.35 (d, *J* = 8.3 Hz, 1 H), 7.23 (t, *J* = 7.5 Hz, 1 H), 4.18-4.29 (m, 2 H), 3.69-3.89 (m, 1 H), 3.52 (s, 6 H), 2.64-2.81 (m, 2 H), 1.90-2.24 (m, 5 H), 1.02-1.56 (m, 4 H).

Example 82

***trans*-*N*²-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *trans*-*N*²-(4-amino-cyclohexylmethyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.


To a solution of *trans*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid benzyl ester obtained in step C of example 3 (330 mg, 0.76 mmol) in MeOH (3.3 mL) was added 10% Pd/C (33 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 25 hr, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give *trans*-*N*²-(4-amino-cyclohexylmethyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (250 mg, 98%) as a pale yellow oil.

ESI MS *m/e* 300, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 8.1 Hz, 1 H), 7.40-7.55 (m, 2 H), 6.95-7.07 (m, 1 H), 4.86-5.02 (m, 1 H), 3.36 (t, *J* = 6.3 Hz, 2 H), 3.26 (s, 6 H), 2.53-2.70 (m, 1 H), 1.77-1.98 (m, 4 H), 0.93-1.64 (m, 7 H).

Step B: Synthesis of *trans*-*N*²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 552, *M* (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.21 (s, 1 H), 10.03 (brs, 2 H), 8.34-8.47 (m, 1 H), 8.07 (d, *J* = 8.4 Hz, 1 H), 7.91 (d, *J* = 8.4 Hz, 1 H), 7.38-7.71 (m, 4 H), 7.20-7.34 (m, 1 H), 4.03-4.20 (m, 2 H), 3.51 (s, 6 H), 3.28-3.42 (m, 2 H), 2.65-2.92 (m, 1 H), 2.16-2.35 (m, 2 H), 1.86-2.05 (m, 2 H), 1.56-1.83 (m, 3 H), 0.89-1.16 (m, 2 H).

Example 83


2HCl

***cis*-N²-[4-(2,2-Diphenyl-ethylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N²-[4-(2,2-diphenyl-ethylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 466, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 12.60 (brs, 1 H), 8.76-9.28 (m, 3 H), 7.91 (d, *J* = 8.3 Hz, 1 H), 7.59-7.71 (m, 2 H), 7.14-7.51 (m, 10 H), 5.00 (t, *J* = 7.7 Hz, 1 H), 4.30-4.40 (m, 1 H), 3.72 (d, *J* = 7.4 Hz, 2 H), 3.51 (s, 6 H), 3.19-3.43 (m, 1 H), 1.85-2.31 (m, 6 H), 1.52-1.76 (s, 2 H).

Example 84

2HCl

{2-[3-(4-Bromo-2-trifluoromethoxy-benzylamino)-pyrrolidin-1-yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride

Step A: Synthesis of [2-(3-amino-pyrrolidin-1-yl)-quinazolin-4-yl]-dimethyl-amine.

Using the procedure for the step A of example 81, the title compound was obtained.


ESI MS *m/e* 258, M + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 7.80 (d, *J* = 8.2 Hz, 1 H), 7.41-7.57 (m, 2 H), 6.93-7.06 (m, 1 H), 3.61-4.02 (m, 4 H), 3.40 (dd, *J* = 11.0, 4.97 Hz, 1 H), 3.26 (s, 6 H), 2.09-2.30 (m, 1 H), 1.68-1.87 (m, 1 H), 1.22-1.63 (m, 2 H).

Step B: Synthesis of {2-[3-(4-bromo-2-trifluoromethoxy-benzylamino)-pyrrolidin-1-yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 510, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 8.05-8.61 (m, 2 H), 7.61-7.96 (m, 2 H), 7.33-7.57 (m, 2 H), 7.17-7.31 (m, 1 H), 4.42-4.64 (m, 2 H), 4.34 (s, 2 H), 3.58-4.24 (m, 3 H), 3.46 (s, 6 H), 2.81 (brs, 1 H), 2.31-2.60 (m, 1 H).

Example 85



2HCl


(2-{3-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-pyrrolidin-1-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride

Step A: Synthesis of (2-{3-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-pyrrolidin-1-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 524, M (free) H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 8.15-8.53 (m, 1 H), 7.70-7.93 (m, 1 H), 7.62 (t, $J = 7.6$ Hz, 1 H), 7.11-7.46 (m, 4 H), 3.60-4.70 (m, 5 H), 3.45 (s, 6 H), 3.04-3.59 (m, 4 H), 2.29-2.98 (m, 2 H).

Example 86




2HCl

***N*²-[1-(2,2-Diphenyl-ethyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-[1-(2,2-diphenyl-ethyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained. ESI MS *m/e* 452, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.54 (brs, 1 H), 12.42 (s, 1 H), 9.82 (d, *J* = 8.4 Hz, 1 H), 7.92 (d, *J* = 8.1 Hz, 1 H), 7.66-7.74 (m, 1 H), 7.40-7.54 (m, 5 H), 7.27-7.39 (m, 5 H), 7.14-7.26 (m, 2 H), 5.17 (t, *J* = 6.3 Hz, 1 H), 4.39-4.56 (m, 1 H), 3.70-3.87 (m, 2 H), 3.34-3.60 (m, 7 H), 3.07-3.25 (m, 2 H), 2.55-2.87 (m, 2 H), 1.61-1.94 (m, 4 H).

Example 87




1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-piperidin-1-yl]-3,3-diphenyl-propan-1-one hydrochloride

Step A: Synthesis of 1-[4-(4-dimethylamino-quinazolin-2-ylamino)-piperidin-1-yl]-3,3-diphenyl-propan-1-one hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 502, *M* + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.45 (brs, 1 H), 8.73 (d, *J* = 6.9 Hz, 1 H), 7.89 (d, *J* = 8.2 Hz, 1 H), 7.61-7.70 (m, 1 H), 7.56 (d, *J* = 7.6 Hz, 1 H), 7.25-7.39 (m, 11 H), 4.67 (t, *J* = 7.5 Hz, 1 H), 3.97-4.14 (m, 2 H), 3.70-3.89 (m, 1 H), 3.50 (s, 6 H), 3.13-3.30 (m, 2 H), 2.99-3.12 (m, 2 H), 1.31-1.99 (m, 4 H).

Example 88




***cis*-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,3-diphenyl-propionamide hydrochloride**

Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,3-diphenyl-propionamide hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 494, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.20 (s, 1 H), 8.77 (d, $J = 8.2$ Hz, 1 H), 7.88 (d, $J = 7.7$ Hz, 1 H), 7.60-7.69 (m, 1 H), 7.53 (d, $J = 17.1$ Hz, 1 H), 7.12-7.33 (m, 11 H), 5.72 (d, $J = 9.2$ Hz, 1 H), 4.57 (t, $J = 8.0$ Hz, 1 H), 4.11-4.23 (m, 1 H), 3.72-3.87 (m, 1 H), 3.49 (s, 6 H), 2.88 (d, $J = 7.9$ Hz, 2 H), 1.47-1.85 (m, 8 H).

Example 89



(2-{4-[(4-Bromo-2-trifluoromethoxy-benzylamino)-methyl]-piperidin-1-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride

Step A: Synthesis of [2-(4-aminomethyl-piperidin-1-yl)-quinazolin-4-yl]-dimethyl-amine.


Using the procedure for the step A of example 64, the title compound was obtained. ESI MS m/e 286, M + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 7.79 (d, $J = 8.3$ Hz, 1 H), 7.42-7.52 (m, 1 H), 7.23-7.36 (m, 1 H), 6.94-7.07 (m, 1 H), 4.94 (d, $J = 12.7$ Hz, 2 H), 3.26 (s, 6 H), 2.74-3.01 (m, 2 H), 2.61 (d, $J = 6.6$ Hz, 2 H), 1.46-1.99 (m, 4 H), 1.01-1.39 (m, 3 H).

Step B: Synthesis of (2-{4-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-piperidin-1-yl}-quinazolin-4-yl)-dimethyl-amine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 538, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.66 (s, 1 H), 8.50 (d, J = 8.1 Hz, 1 H), 8.23 (d, J = 8.6 Hz, 1 H), 7.88 (d, J = 8.4 Hz, 1 H), 7.66 (t, J = 7.9 Hz, 1 H), 7.50 (dd, J = 8.4, 1.9 Hz, 1 H), 7.36-7.41 (m, 1 H), 7.24-7.34 (m, 1 H), 5.01 (brs, 2 H), 4.27 (s, 2 H), 3.49 (s, 6 H), 3.05-3.37 (m, 2 H), 2.44-2.92 (m, 3 H), 1.82-2.37 (m, 2 H), 1.14-1.62 (m, 2 H).

Example 90




[2-(4-{2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino}-methyl)-piperidin-1-yl]-quinazolin-4-yl)-dimethyl-amine dihydrochloride

Step A: Synthesis of [2-(4-{2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino}-methyl)-piperidin-1-yl]-quinazolin-4-yl)-dimethyl-amine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 552, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.63 (s, 1 H), 8.48 (d, J = 8.2 Hz, 1 H), 7.79-7.97 (d, J = 7.5 Hz, 1 H), 7.58-7.73 (m, 1 H), 7.19-7.48 (m, 4 H), 5.02 (brs, 2 H), 3.49 (s, 6 H), 2.82-3.69 (m, 6 H), 1.98-2.79 (m, 5 H), 1.52 (brs, 2 H).

Example 91




***N*²-{1-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin-4-yl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-{1-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin-4-yl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 538, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 12.61 (brs, 1 H), 12.43 (s, 1 H), 9.97 (d, *J* = 8.1 Hz, 1 H), 7.94 (d, *J* = 7.9 Hz, 1 H), 7.65-7.76 (m, 1 H), 7.28-7.52 (m, 5 H), 4.48-4.62 (m, 1 H), 3.12-3.73 (m, 14 H), 2.68-2.92 (m, 2 H), 1.96-2.13 (m, 2 H).

Example 92




***N*²-[1-(3,3-Diphenyl-propyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-[1-(3,3-diphenyl-propyl)-piperidin-4-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 466, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 12.42 (s, 1 H), 12.26 (brs, 1 H), 9.87 (d, *J* = 8.2 Hz, 1 H), 7.93 (d, *J* = 8.2 Hz, 1 H), 7.65-7.74 (m, 1 H), 7.47 (d, *J* = 8.2 Hz, 1 H), 7.13-7.37 (m, 11 H), 4.44-4.60 (m, 1 H), 3.98 (t, *J* = 7.9 Hz, 1 H), 3.28-3.65 (m, 10 H), 2.93-3.09 (m, 2 H), 2.63-2.88 (m, 4 H), 1.84-2.02 (m, 2 H).

Example 93




***cis*-*N*²-[4-(3,3-Diphenyl-propylamino)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-*N*²-[4-(3,3-diphenyl-propylamino)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 480, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.58 (s, 1 H), 9.53 (s, 2 H), 8.58 (d, *J* = 7.9 Hz, 1 H), 7.91 (d, *J* = 8.1 Hz, 1 H), 7.64 (t, *J* = 7.7 Hz, 1 H), 7.48 (d, *J* = 7.9 Hz, 1 H), 7.08-7.33 (m, 11 H), 4.18-4.33 (m, 1 H), 4.11 (t, *J* = 7.7 Hz, 1 H), 3.50 (s, 6 H), 3.16 (brs, 1 H), 2.96 (brs, 2 H), 2.64-2.84 (m, 2 H), 1.87-2.25 (m, 6 H), 1.53-1.75 (m, 2 H).

Example 94



***cis*-*N*²-{4-[(2,2-Diphenyl-ethylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**


Step A: Synthesis of *cis*-*N*²-{4-[(2,2-diphenyl-ethylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 480, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.78 (s, 1 H), 8.94 (brs, 2 H), 8.80 (d, *J* = 8.4 Hz, 1 H), 7.89 (d, *J* = 8.1 Hz, 1 H), 7.60-7.69 (m, 1 H), 7.44-7.58 (m, 2 H), 7.18-7.42 (m, 9 H), 4.91 (t, *J* = 8.0 Hz, 1 H), 4.19-4.34 (m, 1 H), 3.61-3.76 (m, 2 H),

3.50 (s, 6 H), 2.81-2.97 (m, 2 H), 2.04-2.19 (m, 1 H), 1.74-1.91 (m, 2 H), 1.45-1.69 (m, 6 H).

Example 95



***N*²-[1-(4-Bromo-2-trifluoromethoxy-benzyl)-piperidin-4-ylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*⁴,*N*⁴-dimethyl-*N*²-piperidin-4-ylmethyl-quinazoline-2,4-diamine.


Using the procedure for the step A of example 81, the title compound was obtained. ESI MS *m/e* 408, *M* + *Na*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (d, *J* = 8.3 Hz, 1 H), 7.39-7.59 (m, 2 H), 6.96-7.12 (m, 1 H), 4.79-5.11 (m, 1 H), 3.94-4.31 (m, 2 H), 3.42 (t, *J* = 5.9 Hz, 2 H), 3.27 (s, 6 H), 2.70 (t, *J* = 12.1 Hz, 2 H), 1.63-1.92 (m, 3 H), 1.46 (s, 9 H), 0.99-1.37 (m, 2 H).

Step B: Synthesis of *N*²-[1-(4-bromo-2-trifluoromethoxy-benzyl)-piperidin-4-ylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 538, *M* (free) + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.13 (s, 1 H), 12.69 (brs, 1 H), 8.73 (t, *J* = 6.3 Hz, 1 H), 8.19 (d, *J* = 8.2 Hz, 1 H), 7.90 (d, *J* = 7.6 Hz, 1 H), 7.45-7.73 (m, 4 H), 7.22-7.33 (m, 1 H), 4.10-4.24 (m, 2 H), 3.36-3.67 (m, 10 H), 2.61-2.86 (m, 2 H), 1.80-2.33 (m, 5 H).

Example 96




***N*²-{1-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-{1-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 552, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.16 (brs, 1 H), 8.74 (m, 1 H), 7.92 (d, *J* = 8.2 Hz, 1 H), 7.67 (t, *J* = 7.5 Hz, 1 H), 7.53 (d, *J* = 7.6 Hz, 1 H), 7.22-7.46 (m, 5 H), 3.44-3.71 (m, 10 H), 3.26-3.39 (m, 2 H), 3.01-3.15 (m, 2 H), 2.63-2.86 (m, 2 H), 1.87-2.33 (m, 5 H).

Example 97



***N*²-[1-(4-Bromo-2-trifluoromethoxy-benzyl)-pyrrolidin-3-yl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-(1-benzyl-pyrrolidin-3-yl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (5.1 g, 28.9 mmol) and 1-Benzyl-pyrrolidin-3-ylamine (5.1 g, 28.9 mmol) in BuOH (8 mL) was stirred at reflux for 26 hr, poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 10% to 16% EtOAc in hexane) to give *N*²-(1-benzyl-pyrrolidin-3-yl)-*N*⁴,*N*⁴-dimethyl-

quinazoline-2,4-diamine (3.37 g, 50%) as a pale yellow solid.

ESI MS m/e 348, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.80 (d, $J = 9.0$ Hz, 1 H), 7.46 (m, 2 H), 7.18-7.38 (m, 5 H), 7.02 (ddd, $J = 8.3, 6.3, 1.9$ Hz, 1 H), 5.30 (brs, 1 H), 4.59-4.75 (m, 1 H), 3.63 (d, $J = 2.5$ Hz, 2 H), 3.25 (s, 6 H), 2.88 (dd, $J = 9.6, 6.6$ Hz, 1 H), 2.70-2.81 (m, 1 H), 2.28-2.60 (m, 3 H), 1.64-1.78 (m, 1 H).

Step B: Synthesis of N^{\prime},N^{\prime} -dimethyl- N^2 -pyrrolidin-3-yl-quinazoline-2,4-diamine.

To a solution of N^2 -(1-benzyl-pyrrolidin-3-yl)- N^{\prime},N^{\prime} -dimethyl-quinazoline-2,4-diamine (3.3 g, 9.5 mmol) in MeOH (33 mL) was added $Pd(OH)_2$ (660 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 13 hr, and stirred at 50 °C for 6 hr. The mixture was filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 3% MeOH in $CHCl_3$) to give N^{\prime},N^{\prime} -dimethyl- N^2 -pyrrolidin-3-yl-quinazoline-2,4-diamine (2.3 g, 93%) as a yellow oil.


ESI MS m/e 258, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.82 (d, $J = 7.8$ Hz, 1 H), 7.42-7.54 (m, 2 H), 7.03 (ddd, $J = 8.3, 6.4, 1.8$ Hz, 1 H), 5.03 (brs, 1 H), 4.52 (brs, 1 H), 3.26 (s, 6 H), 2.83-3.24 (m, 4 H), 1.97-2.30 (m, 2 H), 1.57-1.77 (m, 1 H).

Step C: Synthesis of N^2 -[1-(4-bromo-2-trifluoromethoxy-benzyl)-pyrrolidin-3-yl]- N^{\prime},N^{\prime} -dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 510, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 13.22 (brs, 1 H), 12.87 (s, 1 H), 9.68 (d, $J = 7.4$ Hz, 1 H), 8.11 (d, $J = 8.4$ Hz, 1 H), 7.95 (d, $J = 8.4$ Hz, 1 H), 7.71 (t, $J = 8.3$ Hz, 1 H), 7.43-7.63 (m, 3 H), 7.28-7.38 (m, 1 H), 4.94-5.15 (m, 1 H), 4.41 (s, 2 H), 4.00-4.17 (m, 1 H), 3.26-3.82 (m, 8 H), 3.00-3.16 (m, 1 H), 2.59-2.82 (m, 1 H), 2.18-2.37 (m, 1 H).

Example 98




***N*²-{1-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethyl]-pyrrolidin-3-yl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *N*²-{1-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethyl]-pyrrolidin-3-yl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS *m/e* 524, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 9.61-9.78 (m, 1 H), 7.96 (d, *J* = 8.4 Hz, 1 H), 7.71 (t, *J* = 7.7 Hz, 1 H), 7.55 (d, *J* = 8.2 Hz, 1 H), 7.29-7.47 (m, 4 H), 4.89-5.12 (m, 1 H), 4.07-4.28 (m, 1 H), 2.99-3.97 (m, 13 H), 2.55-2.79 (m, 1 H), 2.22-2.42 (m, 1 H).

Example 99




1-(4-Bromo-2-trifluoromethoxy-phenyl)-1-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidin-1-yl}-methanone hydrochloride

Step A: Synthesis of 1-(4-bromo-2-trifluoromethoxy-phenyl)-1-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidin-1-yl}-methanone hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 552, M (free) + H⁺ ; ¹H NMR (300 MHz, CDCl₃) δ 13.44 (brs, 1 H), 8.53-8.77 (m, 1 H), 7.90 (d, *J* = 8.5 Hz, 1 H), 7.66 (t, *J* = 7.7 Hz, 1 H), 7.43-7.61 (m, 3 H), 7.19-7.37 (m, 1 H), 4.69-4.85 (m, 1 H), 3.20-3.63 (m, 10 H), 2.61-3.13 (m, 2 H), 1.76-2.14 (m, 3 H), 1.08-1.48 (m, 2 H).

Example 100




HCl

***cis*-3-(3,4-Difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-propionamide hydrochloride**

Step A: Synthesis of *cis*-3-(3,4-difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-propionamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 454, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.05 (s, 1 H), 8.87 (d, *J* = 8.1 Hz, 1 H), 7.89 (d, *J* = 8.2 Hz, 1 H), 7.65 (t, *J* = 7.7 Hz, 1 H), 7.51 (d, *J* = 7.3 Hz, 1 H), 7.20-7.27 (m, 1 H), 6.88-7.09 (m, 3 H), 5.97 (d, *J* = 8.5 Hz, 1 H), 4.26 (brs, 1 H), 3.91 (brs, 1 H), 3.51 (s, 6 H), 2.92 (t, *J* = 7.6 Hz, 2 H), 2.44 (t, *J* = 7.6 Hz, 2 H), 1.61-1.93 (brs, 8 H).

Example 101



2HCl


***cis*-*N*²-{4-[3-(3,4-Difluoro-phenyl)-propylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-*N*²-{4-[3-(3,4-difluoro-phenyl)-propylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 440, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.62 (s, 1 H), 9.54 (s, 2 H), 8.72 (d, *J* = 7.6 Hz, 1 H), 7.91 (d, *J* = 8.4 Hz, 1 H), 7.62-7.70 (m, 1 H), 7.48 (d, *J* = 7.6 Hz, 1 H), 7.24-7.33 (m, 1 H), 6.90-7.06 (m, 3 H), 4.29 (brs, 1 H), 3.52 (s, 6 H), 3.00-3.42

(m, 3 H), 2.67-2.81 (m, 2 H), 1.93-2.43 (m, 8 H), 1.60-1.80 (m, 2 H).

Example 102



HCl

***trans*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride**


Step A: Synthesis of *N*²-(4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine.

Using the procedure for the step A of example 81, the title compound was obtained. ESI MS *m/e* 300, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4 Hz, 1 H), 7.45 (m, 2 H), 7.00 (ddd, *J* = 8.4, 6.3, 1.9 Hz, 1 H), 4.80 (d, *J* = 8.2 Hz, 1 H), 3.82-3.94 (m, 1 H), 3.24 (s, 6 H), 2.56 (d, *J* = 6.2 Hz, 2 H), 2.14-2.28 (m, 2 H), 1.78-1.92 (m, 2 H), 0.95-1.42 (m, 7 H).

Step B: Synthesis of *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 566, *M* + *H*⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.48 (s, 1 H), 8.34 (d, *J* = 7.5 Hz, 1 H), 7.83-7.94 (m, 2 H), 7.43-7.69 (m, 4 H), 7.20-7.29 (m, 1 H), 6.49-6.62 (m, 1 H), 3.72-3.93 (m, 1 H), 3.50 (s, 6 H), 3.39 (t, *J* = 6.3 Hz, 2 H), 2.09-2.22 (m, 2 H), 1.85-1.98 (m, 2 H), 1.37-1.69 (m, 3 H), 1.08-1.28 (m, 2 H).

Example 103




HCl

4-Bromo-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-trifluoromethoxy-benzamide hydrochloride

Step A: Synthesis of 4-bromo-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 552, M (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.50 (s, 1 H), 8.73 (d, J = 8.5 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.81 (d, J = 8.4 Hz, 1 H), 7.62-7.71 (m, 1 H), 7.53 (dd, J = 8.4, 1.87 Hz, 1 H), 7.45 (s, 1 H), 7.23-7.32 (m, 1 H), 6.77-6.87 (m, 1 H), 3.30-3.55 (m, 10 H), 2.96-3.27 (m, 2 H), 1.89-2.15 (m, 3 H), 1.28-1.57 (m, 2 H).

Example 104




***cis*-2-(3,4-Difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide hydrochloride**

Step A: Synthesis of *cis*-2-(3,4-difluoro-phenyl)-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 454, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.66 (s, 1 H), 9.08 (d, J = 8.9 Hz, 1 H), 7.90 (d, J = 8.1 Hz, 1 H), 7.66 (ddd, J = 8.4, 7.2, 1.2 Hz, 1 H), 7.48 (dd, J = 8.4, 0.9 Hz, 1 H), 7.32-7.41 (m, 1 H), 7.12-7.31 (m, 3 H), 6.97-7.08 (m, 1 H), 4.35-4.48 (m, 1 H), 3.78 (s, 2 H), 3.52 (s, 6 H), 3.28-3.36 (m, 2 H), 1.42-2.05 (m, 9 H).

Example 105




***cis*-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride**

Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 440, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.89 (s, 1 H), 9.11 (d, *J* = 8.2 Hz, 1 H), 7.88 (m, 3 H), 7.64 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1 H), 7.49 (dd, *J* = 8.4, 0.9 Hz, 1 H), 7.18-7.29 (m, 2 H), 6.96-7.07 (m, 1 H), 4.29-4.44 (m, 1 H), 3.51 (s, 8 H), 1.55-2.02 (m, 9 H).

Example 106




2HCl

***cis*-N²-(4-([2-(3,4-Difluoro-phenyl)-ethylamino]-methyl)-cyclohexyl)-N⁸,N⁸-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N²-(4-([2-(3,4-difluoro-phenyl)-ethylamino]-methyl)-cyclohexyl)-N⁸,N⁸-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 440, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.43 (s, 1 H), 9.64 (brs, 2 H), 8.66 (d, *J* = 8.3 Hz, 1 H), 7.91 (d, *J* = 8.3 Hz, 1 H), 7.67 (t, *J* = 7.8 Hz, 1 H), 7.46 (d, *J* = 8.3 Hz, 1 H), 7.28 (t, *J* = 7.8 Hz, 1 H), 6.97-7.17 (m, 3 H), 4.24-4.37 (m, 1 H), 3.52 (s, 6 H), 3.30-3.44 (m, 2 H), 2.94-3.25 (m, 4 H), 1.57-2.28 (m, 9 H).

Example 107




***cis*-N²-{4-[(3,4-Difluoro-benzylamino)-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-N²-{4-[(3,4-difluoro-benzylamino)-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 426, M (free) + H⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.39 (s, 2 H), 8.44 (m, 1 H), 8.17 (d, *J* = 8.4 Hz, 1 H), 7.72-7.88 (m, 2 H), 7.27-7.61 (m, 4 H), 4.11-4.31 (m, 3 H), 3.48 (s, 6 H), 2.81 (d, *J* = 6.1 Hz, 2 H), 1.32-2.03 (m, 9 H).


Example 108



2-(4-Bromo-2-trifluoromethoxy-phenyl)-1-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidin-1-yl}-ethanone hydrochloride

Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-1-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-piperidin-1-yl}-ethanone hydrochloride.


Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 566, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.48 (s, 1 H), 8.65 (t, *J* = 5.8 Hz, 1 H), 7.90 (d, *J* = 8.4 Hz, 1 H), 7.53-7.70 (m, 2 H), 7.37-7.44 (m, 2 H), 7.20-7.32 (m, 2 H), 4.59-4.72 (m, 1 H), 3.80-3.94 (m, 1 H), 3.68 (d, *J* = 6.1 Hz, 2 H), 3.25-3.58 (m, 8 H), 2.94-3.12 (m, 1 H), 2.50-2.68 (m, 1 H), 1.75-2.03 (m, 3 H), 1.06-1.32 (m, 2 H).

Example 109

***trans*-2-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide**

Step A: Synthesis of *trans*-2-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-acetamide.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 580, M (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.28 (d, J = 6.7 Hz, 1 H), 7.87-7.90 (d, J = 8.5 Hz, 1 H), 7.52-7.66 (m, 2 H), 7.39-7.44 (m, 2 H), 7.20-7.33 (m, 2 H), 5.85-5.98 (m, 1 H), 3.70-3.91 (m, 1 H), 3.58 (s, 2 H), 3.50 (s, 6 H), 3.16 (t, J = 6.5 Hz, 2 H), 2.03-2.20 (m, 2 H), 1.28-1.88 (m, 5 H), 0.96-1.18 (m, 2 H).

Example 110


***cis*-*N*-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide hydrochloride**

Step A: Synthesis of *cis*-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 448, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.01 (s, 1 H), 8.96 (d, J = 8.1 Hz, 1 H), 7.91 (d, J = 8.2 Hz, 1 H), 7.55-7.79 (m, 4 H), 7.49-7.54 (m, 1 H), 7.15-7.32 (m, 2 H), 6.76 (d, J = 8.4 Hz, 1 H), 4.30-4.41 (m, 1 H), 4.03-4.22 (m, 1 H), 3.52 (s, 6 H),

1.67-2.07 (m, 8 H).

Example 111




***cis*-3-(3,4-Difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-propionamide hydrochloride**

Step A: Synthesis of *cis*-3-(3,4-difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-propionamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 468, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.70 (s, 1 H), 9.00 (d, *J* = 8.3 Hz, 1 H), 7.90 (d, *J* = 8.3 Hz, 1 H), 7.66 (ddd, *J* = 8.3, 7.2, 1.0 Hz, 1 H), 7.48 (dd, *J* = 8.3, 1.0 Hz, 1 H), 7.11-7.31 (m, 2 H), 6.84-7.06 (m, 3 H), 4.32-4.44 (m, 1 H), 3.51 (s, 6 H), 3.26-3.33 (m, 2 H), 2.96 (t, *J* = 7.5 Hz, 2 H), 2.76 (t, *J* = 7.4 Hz, 2 H), 1.34-1.94 (m, 9 H).

Example 112



***cis*-*N*²-[4-(3,4-Difluoro-benzylamino)-cyclohexyl]-*N*²,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**


Step A: Synthesis of *cis*-*N*²-[4-(3,4-difluoro-benzylamino)-cyclohexyl]-*N*²,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained.

ESI MS *m/e* 434, M (free) + Na⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.03 (s, 1 H), 9.50

(brs, 2 H), 8.31-8.40 (m, 1 H), 8.19 (d, $J = 8.2$ Hz, 1 H), 7.73-7.90 (m, 2 H), 7.29-7.60 (m, 4 H), 4.04-4.28 (m, 3 H), 3.46 (s, 6 H), 3.06-3.22 (m, 1 H), 1.61-2.10 (m, 8 H).

Example 113



2HCl


cis- N^2 -(4-([3-(3,4-Difluoro-phenyl)-propylamino]-methyl)-cyclohexyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of *cis*- N^2 -(4-([3-(3,4-difluoro-phenyl)-propylamino]-methyl)-cyclohexyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained.

ESI MS m/e 454, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 12.50 (s, 1 H), 9.43 (brs, 2 H), 8.60 (d, $J = 7.93$ Hz, 1 H), 7.90 (d, $J = 8.2$ Hz, 1 H), 7.65 (ddd, $J = 8.2, 7.2, 1.1$ Hz, 1 H), 7.46 (d, $J = 8.6$ Hz, 1 H), 7.23-7.30 (m, 1 H), 6.91-7.08 (m, 3 H), 4.22-4.34 (m, 1 H), 3.51 (s, 6 H), 2.87-3.07 (m, 4 H), 2.68 (t, $J = 7.7$ Hz, 2 H), 1.53-2.43 (m, 11 H).

Example 114




HCl

2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-acetamide hydrochloride

Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-acetamide hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 588, M (free) + Na^+ ; ^1H NMR (300 MHz, CDCl_3) δ 13.32 (s, 1 H), 8.68 (d, $J = 8.4$ Hz, 1 H), 7.86 (d, $J = 7.4$ Hz, 1 H), 7.65 (ddd, $J = 8.4, 7.1, 1.2$ Hz, 1 H), 7.23-7.42 (m, 4 H), 6.59-6.69 (m, 1 H), 3.60 (s, 2 H), 3.48 (s, 7 H), 2.90-3.37 (m, 5 H), 1.78-2.08 (m, 3 H), 1.19-1.46 (m, 2 H).

Example 115




HCl

***trans*-2-(4-Bromo-2-trifluoromethoxy-phenyl)-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-acetamide hydrochloride**

Step A: Synthesis of *trans*-2-(4-bromo-2-trifluoromethoxy-phenyl)-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-acetamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS m/e 616, M (free) + Na^+ ; ^1H NMR (300 MHz, CDCl_3) δ 8.37-8.49 (m, 1 H), 7.89 (d, $J = 8.5$ Hz, 1 H), 7.53-7.68 (m, 2 H), 7.40-7.45 (m, 2 H), 7.20-7.32 (m, 2 H), 5.60-5.71 (m, 1 H), 3.55 (s, 2 H), 3.50 (s, 6 H), 3.35 (t, $J = 6.1$ Hz, 2 H), 3.08 (t, $J = 6.4$ Hz, 2 H), 0.77-2.00 (m, 10 H).

Example 116




HCl

***cis*-2-(3,4-Difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride**

Step A: Synthesis of *cis*-2-(3,4-difluoro-phenyl)-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 440, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.01 (s, 1 H), 8.85 (d, *J* = 8.2 Hz, 1 H), 7.89 (d, *J* = 8.2 Hz, 1 H), 7.65 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1 H), 7.52 (d, *J* = 8.2 Hz, 1 H), 6.95-7.33 (m, 4 H), 6.32 (d, *J* = 7.6 Hz, 1 H), 4.19-4.34 (m, 1 H), 3.82-4.01 (m, 1 H), 3.51 (s, 6 H), 3.47 (s, 2 H), 1.61-2.01 (m, 8 H).

Example 117




2HCl

***cis*-*N*²-{4-[2-(3,4-Difluoro-phenyl)-ethylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride**

Step A: Synthesis of *cis*-*N*²-{4-[2-(3,4-difluoro-phenyl)-ethylamino]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step A of example 72, the title compound was obtained. ESI MS *m/e* 426, M (free) + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 12.51 (s, 1 H), 9.70 (brs, 2 H), 8.67 (d, *J* = 7.5 Hz, 1 H), 7.92 (d, *J* = 8.0 Hz, 1 H), 7.68 (t, *J* = 8.0 Hz, 1 H), 7.52 (d, *J* = 8.4 Hz, 1 H), 7.30 (t, *J* = 7.8 Hz, 1 H), 6.97-7.22 (m, 3 H), 4.34 (brs, 1 H), 3.53 (s, 6 H), 3.12-3.41 (m, 5 H), 1.62-2.40 (m, 8 H).

Example 118**4-Bromo-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of [2-(4-amino-piperidin-1-yl)-quinazolin-4-yl]-dimethyl-amine.**


To a solution of 1-benzyl-piperidin-4-ylamine (2.00 g, 10.5 mmol) in THF (20 mL) was added (Boc)₂O (2.52 g, 11.5 mmol). The mixture was stirred at ambient temperature for 40 min, and concentrated. To a solution of the residue in MeOH (20 mL) was added 20% Pd(OH)₂ (400 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 20 hr. Additionally, 20% Pd(OH)₂ (400 mg) was added and the mixture was stirred at ambient temperature under hydrogen atmosphere for 7 hr, at 50 °C for 4.5 hr, and at ambient temperature for 12 hr, filtered through a pad of celite, and concentrated to give a white solid. A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (1.10 g, 5.30 mmol) and the above solid (1.27 g, 6.34 mmol) in 2-propanol (11 mL) was stirred at reflux for 20 hr. The precipitate was collected by filtration, washed with 2-propanol, dissolved in 50% MeOH in CHCl₃ (60 mL). The solution was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, EtOAc to CHCl₃) to give [2-(4-amino-piperidin-1-yl)-quinazolin-4-yl]-dimethyl-amine (864 mg, 68%) as a colorless oil. ESI MS m/e 272, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.79 (d, J = 8.2 Hz, 1 H), 7.45-7.55 (m, 2 H), 6.96-7.05 (m, 1 H), 4.83 (d, J = 13.4 Hz, 2 H), 3.26 (s, 6H), 2.84-3.03 (m, 3 H), 1.85-1.95 (m, 2 H), 1.20-1.50 (m, 4 H).

Step B: Synthesis of 4-bromo-N-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step A of example 20, the title compound was obtained.

ESI MS m/e 574, $M + H^+$; 1H NMR (300 MHz, $CDCl_3$) δ 7.94 (d, $J = 8.7$ Hz, 1 H), 7.80 (d, $J = 8.2$ Hz, 1 H), 7.39-7.61 (m, 4 H), 6.98-7.07 (m, 1 H), 4.60-4.81 (m, 3 H), 3.39-3.61 (m, 1 H), 3.25 (s, 6 H), 2.98-3.08 (m, 2 H), 1.73-1.92 (m, 2 H), 1.33-1.54 (m, 2 H).

Example 119




{2-[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-piperidin-1-yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride

Step A: Synthesis of {2-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-piperidin-1-yl]-quinazolin-4-yl}-dimethyl-amine dihydrochloride.

Using the procedure for the step B of example 37, the title compound was obtained.

ESI MS m/e 524, M (free) + H^+ ; 1H NMR (300 MHz, $CDCl_3$) δ 8.43 (d, $J = 8.1$ Hz, 1 H), 8.20 (d, $J = 8.4$ Hz, 1 H), 7.90 (d, $J = 8.4$ Hz, 1 H), 7.67 (t, $J = 7.5$ Hz, 1 H), 7.26-7.49 (m, 3 H), 5.13 (brs, 2 H), 4.27 (s, 2 H), 3.08-3.60 (s, 9 H), 2.08-2.78 (m, 4 H).

Example 120




4-Bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy-benzamide hydrochloride

Step A: Synthesis of 4-bromo-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-2-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 560, M (free) Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.68 (s, 1 H), 8.73 (d, *J* = 7.8 Hz, 1 H), 7.80-7.91 (m, 2 H), 7.68 (ddd, *J* = 8.4, 7.1, 1.3 Hz, 1 H), 7.55 (dd, *J* = 8.4, 1.9 Hz, 1 H), 7.42-7.46 (m, 1 H), 7.29 (ddd, *J* = 8.4, 7.1, 1.3 Hz, 1 H), 6.67 (d, *J* = 7.3 Hz, 1 H), 5.04 (brs, 2 H), 4.23-4.42 (m, 1 H), 3.27-3.61 (m, 8 H), 2.19-2.36 (m, 2 H), 1.57-1.81 (m, 2 H).

Example 121



2-(4-Bromo-2-trifluoromethoxy-phenyl)-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-acetamide hydrochloride

Step A: Synthesis of 2-(4-bromo-2-trifluoromethoxy-phenyl)-*N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-yl]-acetamide hydrochloride.

Using the procedure for the step A of example 47, the title compound was obtained. ESI MS *m/e* 574, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 13.08 (s, 1 H), 8.61 (d, *J* = 8.4 Hz, 1 H), 7.86 (d, *J* = 7.5 Hz, 1 H), 7.56-7.68 (m, 2 H), 7.21-7.39 (m, 4 H), 4.70-5.10 (m, 2 H), 4.04-4.22 (m, 1 H), 3.68 (s, 2 H), 3.34-3.61 (m, 8 H), 1.59-2.19 (m, 4 H).

Example 122 - 301.

To a solution of amine obtained in step A of example 15 (30 μmol) and pyridine (120 μmol) in CH₂Cl₂ (400 μL) was added an appropriate sulfonyl chloride (60 μmol) in

CH_2Cl_2 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N_2 . To the residue was partitioned between CHCl_3 and saturated aqueous NH_4Cl . The aqueous layer was extracted with CHCl_3 . The combined organic layers were dried over MgSO_4 . After concentration by a stream of dry N_2 , dry CH_2Cl_2 (600 μL) and PSA (300 μL) were added to the residue. After the stirring at 25 °C for 20 hr, the reaction mixture was filtrated and purified by flash chromatography (NH-silica gel, 33% MeOH in CHCl_3) to give the desired product.

Example 302 - 588.

To a solution of amine obtained in step C of example 9 or step A of example 64 (30 μmol) in CH_2Cl_2 (200 μL) were added poly(4-vinylpyridine) (75 μL) in CH_2Cl_2 (200 μL) and acid chloride (60 μmol) in CH_2Cl_2 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was filtered and concentrated by a stream of dry N_2 . To the residue were added dry CH_2Cl_2 (600 μL) and PSA (300 μL). After the stirring at 25 °C for 20 hr, the reaction mixture was filtrated and purified by flash chromatography (NH-silica gel, 33% MeOH in CHCl_3) to give the desired product.

Example 589 - 1136.

To a solution of carboxylic acid (200 μL , 60 μmol) in CH_2Cl_2 (200 μL) were added 1-cyclohexyl-3-methylpolystyrene-carbodiimide (150 μL , 126 μmol) in CH_2Cl_2 (200 μL) and amine obtained in step C of example 9 or step A of example 64 (30 μmol) in CH_2Cl_2 (200 μL) at 25 °C. After stirring at the same temperature for 20 hr, the reaction mixture was filtered through NH-silica gel, and concentrated by a stream of dry N_2 . To the residue were added dry CH_2Cl_2 (700 μL) and polystyrene linked benzaldehyde (75 μL , 60 μmol). After the stirring at 50 °C for 20 hr, the reaction mixture was filtrated, and concentrated by a stream of dry N_2 to give the desired product.

Example 1137 - 1745.

To a solution of the amide product in THF (200 μL) was added 1 M borane-THF

complex in THF (300 μ l, 300 μ mol). The mixture was stirred at 80 °C for 1 hr, and concentrated by a stream of dry N₂. To the residue were added 1 M aqueous HCl (300 μ l) and THF (300 μ l). The mixture was stirred at 80 °C for 1 hr, and concentrated by a stream of dry N₂. To the residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃. The combined organic layers were dried over MgSO₄. The mixture was concentrated by a stream of dry N₂, and the purified by flash chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product.






Example 1746 - 2184.






To a solution of amine obtained in step C of example 9 or step A of example 64 (36 μ mol) in MeOH (200 μ L) were added aldehyde (30 μ mol) in MeOH (200 μ L) and AcOH (90 μ mol) at 25 °C. The reaction mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBH₃CN (120 μ mol) in MeOH (200 μ L). After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N₂. To the residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃. The combined organic layers were dried over MgSO₄. The mixture was concentrated by a stream of dry N₂, and purified by flash chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product.






Example 2185 - 2328.






To a solution of alcohol (35 μ mol) in CH₂Cl₂ (200 μ L) was added Dess-Martin periodinane (63 μ mol) in CH₂Cl₂ (200 μ L) at 25 °C, and the reaction mixture was stirred at the same temperature for 20 hr. To the reaction mixture were added amine obtained in step C of example 9 or step A of example 64 (36 μ mol) in MeOH (200 μ L) and AcOH (90 μ L), and the mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBH₃CN (120 μ mol) in MeOH (200 μ L). After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N₂. To the residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was






extracted with CHCl_3 . The combined organic layers were dried over MgSO_4 . The mixture was concentrated by a stream of dry N_2 , and purified by flash chromatography (silica gel, 2% to 7% 2 M NH_3/MeOH in CHCl_3) to give the desired product.






Example No.	Structure	APCI-MS
122		472 (M + H)
123		532 (M + H)
124		511 (M + H)
125		496 (M + H)
126		616 (M + H)






Example No.	Structure	APCI-MS
127		532 (M + H)
128		526 (M + H)
129		510 (M + H)
130		538 (M + H)
131		631 (M + H)






Example No.	Structure	APCI-MS
132		488 (M + H)
133		650 (M + H)
134		494 (M + H)
135		479 (M + H)
136		479 (M + H)






Example No.	Structure	APCI-MS
137		558 (M + H)
138		502 (M + H)
139		516 (M + H)
140		536 (M + H)
141		646 (M + H)






Example No.	Structure	APCI-MS
142		601 (M + H)
143		522 (M + H)
144		528 (M + H)
145		514 (M + H)
146		482 (M + H)






Example No.	Structure	APCI-MS
147		527 (M + H)
148		496 (M + H)
149		484 (M + H)
150		513 (M + H)
151		529 (M + H)






Example No.	Structure	APCI-MS
152		532 (M + H)
153		557 (M + H)
154		532 (M + H)
155		458 (M + H)
156		499 (M + H)






Example No.	Structure	APCI-MS
157		499 (M + H)
158		499 (M + H)
159		567 (M + H)
160		490 (M + H)
161		544 (M + H)






Example No.	Structure	APCI-MS
162		580 (M + H)
163		558 (M + H)
164		505 (M + H)
165		460 (M + H)
166		556 (M + H)






Example No.	Structure	APCI-MS
167		580 (M + H)
168		522 (M + H)
169		468 (M + H)
170		480 (M + H)
171		468 (M + H)






Example No.	Structure	APCI-MS
172		595 (M + H)
173		605 (M + H)
174		522 (M + H)
175		482 (M + H)
176		622 (M + H)






Example No.	Structure	APCI-MS
177		653 (M + H)
178		544 (M + H)
179		606 (M + H)
180		600 (M + H)
181		600 (M + H)






Example No.	Structure	APCI-MS
182		567 (M + H)
183		572 (M + H)
184		572 (M + H)
185		506 (M + H)
186		473 (M + H)






Example No.	Structure	APCI-MS
187		472 (M + H)
188		518 (M + H)
189		627 (M + H)
190		548 (M + H)
191		608 (M + H)






Example No.	Structure	APCI-MS
192		472 (M + H)
193		514 (M + H)
194		681 (M + H)
195		640 (M + H)
196		715 (M + H)






Example No.	Structure	APCI-MS
197		662 (M + H)
198		530 (M + H)
199		502 (M + H)
200		516 (M + H)
201		515 (M + H)






Example No.	Structure	APCI-MS
202		486 (M + H)
203		545 (M + H)
204		512 (M + H)
205		530 (M + H)
206		496 (M + H)






Example No.	Structure	APCI-MS
207		556 (M + H)
208		510 (M + H)
209		522 (M + H)
210		502 (M + H)
211		498 (M + H)






Example No.	Structure	APCI-MS
212		502 (M + H)
213		506 (M + H)
214		484 (M + H)
215		568 (M + H)
216		526 (M + H)






Example No.	Structure	APCI-MS
217		524 (M + H)
218		562 (M + H)
219		486 (M + H)
220		524 (M + H)
221		649 (M + H)






Example No.	Structure	APCI-MS
222		601 (M + H)
223		490 (M + H)
224		610 (M + H)
225		498 (M + H)
226		522 (M + H)






Example No.	Structure	APCI-MS
227		538 (M + H)
228		479 (M + H)
229		546 (M + H)
230		556 (M + H)
231		522 (M + H)






Example No.	Structure	APCI-MS
232		506 (M + H)
233		496 (M + H)
234		580 (M + H)
235		520 (M + H)
236		693 (M + H)






Example No.	Structure	APCI-MS
237		560 (M + H)
238		546 (M + H)
239		524 (M + H)
240		527 (M + H)
241		513 (M + H)






Example No.	Structure	APCI-MS
242		508 (M + H)
243		490 (M + H)
244		590 (M + H)
245		524 (M + H)
246		490 (M + H)






Example No.	Structure	APCI-MS
247		550 (M + H)
248		524 (M + H)
249		568 (M + H)
250		524 (M + H)
251		530 (M + H)






Example No.	Structure	APCI-MS
252		513 (M + H)
253		530 (M + H)
254		513 (M + H)
255		532 (M + H)
256		480 (M + H)






Example No.	Structure	APCI-MS
257		468 (M + H)
258		536 (M + H)
259		536 (M + H)
260		502 (M + H)
261		486 (M + H)






Example No.	Structure	APCI-MS
262		482 (M + H)
263		536 (M + H)
264		604 (M + H)
265		536 (M + H)
266		592 (M + H)






Example No.	Structure	APCI-MS
267		626 (M + H)
268		558 (M + H)
269		434 (M + H)
270		518 (M + H)
271		454 (M + H)






Example No.	Structure	APCI-MS
272		556 (M + H)
273		528 (M + H)
274		528 (M + H)
275		406 (M + H)
276		602 (M + H)






Example No.	Structure	APCI-MS
277		420 (M + H)
278		392 (M + H)
279		490 (M + H)
280		420 (M + H)
281		446 (M + H)






Example No.	Structure	APCI-MS
282		538 (M + H)
283		460 (M + H)
284		454 (M + H)
285		532 (M + H)
286		510 (M + H)






Example No.	Structure	APCI-MS
287		532 (M + H)
288		616 (M + H)
289		488 (M + H)
290		522 (M + H)
291		528 (M + H)






Example No.	Structure	APCI-MS
292		547 (M + H)
293		472 (M + H)
294		504 (M + H)
295		504 (M + H)
296		468 (M + H)






Example No.	Structure	APCI-MS
297		538 (M + H)
298		522 (M + H)
299		488 (M + H)
300		590 (M + H)
301		522 (M + H)






Example No.	Structure	APCI-MS
302		520 (M + H)
303		390 (M + H)
304		446 (M + H)
305		468 (M + H)
306		468 (M + H)






Example No.	Structure	APCI-MS
307		432 (M + H)
308		505 (M + H)
309		536 (M + H)
310		469 (M + H)
311		504 (M + H)






Example No.	Structure	APCI-MS
312		430 (M + H)
313		433 (M + H)
314		408 (M + H)
315		451 (M + H)
316		380 (M + H)






Example No.	Structure	APCI-MS
317		476 (M + H)
318		391 (M + H)
319		437 (M + H)
320		448 (M + H)
321		471 (M + H)






Example No.	Structure	APCI-MS
322		470 (M + H)
323		412 (M + H)
324		557 (M + H)
325		391 (M + H)
326		435 (M + H)






Example No.	Structure	APCI-MS
327		425 (M + H)
328		569 (M + H)
329		391 (M + H)
330		524 (M + H)
331		498 (M + H)






Example No.	Structure	APCI-MS
332		442 (M + H)
333		396 (M + H)
334		516 (M + H)
335		474 (M + H)
336		474 (M + H)






Example No.	Structure	APCI-MS
337		444 (M + H)
338		482 (M + H)
339		516 (M + H)
340		458 (M + H)
341		498 (M + H)






Example No.	Structure	APCI-MS
342		442 (M + H)
343		440 (M + H)
344		442 (M + H)
345		442 (M + H)
346		460 (M + H)






Example No.	Structure	APCI-MS
347		476 (M + H)
348		476 (M + H)
349		462 (M + H)
350		516 (M + H)
351		480 (M + H)






Example No.	Structure	APCI-MS
352		432 (M + H)
353		408 (M + H)
354		442 (M + H)
355		434 (M + H)
356		442 (M + H)






Example No.	Structure	APCI-MS
357		422 (M + H)
358		406 (M + H)
359		490 (M + H)
360		440 (M + H)
361		510 (M + H)






Example No.	Structure	APCI-MS
362		456 (M + H)
363		456 (M + H)
364		422 (M + H)
365		460 (M + H)
366		472 (M + H)






Example No.	Structure	APCI-MS
367		498 (M + H)
368		464 (M + H)
369		418 (M + H)
370		539 (M + H)
371		465 (M + H)






Example No.	Structure	APCI-MS
372		499 (M + H)
373		497 (M + H)
374		558 (M + H)
375		526 (M + H)
376		450 (M + H)






Example No.	Structure	APCI-MS
377		395 (M + H)
378		553 (M + H)
379		500 (M + H)
380		469 (M + H)
381		532 (M + H)






Example No.	Structure	APCI-MS
382		450 (M + H)
383		529 (M + H)
384		515 (M + H)
385		594 (M + H)
386		553 (M + H)






Example No.	Structure	APCI-MS
387		473 (M + H)
388		428 (M + H)
389		450 (M + H)
390		502 (M + H)
391		508 (M + H)






Example No.	Structure	APCI-MS
392		472 (M + H)
393		476 (M + H)
394		479 (M + H)
395		446 (M + H)
396		462 (M + H)






Example No.	Structure	APCI-MS
397		510 (M + H)
398		454 (M + H)
399		416 (M + H)
400		438 (M + H)
401		492 (M + H)






Example No.	Structure	APCI-MS
402		457 (M + H)
403		420 (M + H)
404		404 (M + H)
405		430 (M + H)
406		448 (M + H)






Example No.	Structure	APCI-MS
407		465 (M + H)
408		434 (M + H)
409		410 (M + H)
410		587 (M + H)
411		420 (M + H)






Example No.	Structure	APCI-MS
412		465 (M + H)
413		525 (M + H)
414		448 (M + H)
415		510 (M + H)
416		464 (M + H)






Example No.	Structure	APCI-MS
417		432 (M + H)
418		422 (M + H)
419		434 (M + H)
420		476 (M + H)
421		418 (M + H)






Example No.	Structure	APCI-MS
422		623 (M + H)
423		618 (M + H)
424		484 (M + H)
425		461 (M + H)
426		482 (M + H)






Example No.	Structure	APCI-MS
427		450 (M + H)
428		454 (M + H)
429		430 (M + H)
430		482 (M + H)
431		454 (M + H)






Example No.	Structure	APCI-MS
432		500 (M + H)
433		478 (M + H)
434		543 (M + H)
435		502 (M + H)
436		473 (M + H)






Example No.	Structure	APCI-MS
437		489 (M + H)
438		328 (M + H)
439		354 (M + H)
440		396 (M + H)
441		384 (M + H)






Example No.	Structure	APCI-MS
442		356 (M + H)
443		399 (M + H)
444		396 (M + H)
445		384 (M + H)
446		439 (M + H)






Example No.	Structure	APCI-MS
447		534 (M + H)
448		404 (M + H)
449		460 (M + H)
450		482 (M + H)
451		482 (M + H)






Example No.	Structure	APCI-MS
452		446 (M + H)
453		519 (M + H)
454		550 (M + H)
455		483 (M + H)
456		518 (M + H)






Example No.	Structure	APCI-MS
457		444 (M + H)
458		447 (M + H)
459		422 (M + H)
460		465 (M + H)
461		394 (M + H)






Example No.	Structure	APCI-MS
462		490 (M + H)
463		405 (M + H)
464		451 (M + H)
465		462 (M + H)
466		485 (M + H)






Example No.	Structure	APCI-MS
467		484 (M + H)
468		426 (M + H)
469		571 (M + H)
470		405 (M + H)
471		449 (M + H)






Example No.	Structure	APCI-MS
472		439 (M + H)
473		583 (M + H)
474		405 (M + H)
475		538 (M + H)
476		512 (M + H)






Example No.	Structure	APCI-MS
477		456 (M + H)
478		410 (M + H)
479		530 (M + H)
480		488 (M + H)
481		488 (M + H)






Example No.	Structure	APCI-MS
482		458 (M + H)
483		496 (M + H)
484		530 (M + H)
485		472 (M + H)
486		512 (M + H)






Example No.	Structure	APCI-MS
487		456 (M + H)
488		454 (M + H)
489		456 (M + H)
490		456 (M + H)
491		474 (M + H)






Example No.	Structure	APCI-MS
492		490 (M + H)
493		490 (M + H)
494		476 (M + H)
495		530 (M + H)
496		494 (M + H)






Example No.	Structure	APCI-MS
497		446 (M + H)
498		422 (M + H)
499		456 (M + H)
500		448 (M + H)
501		456 (M + H)






Example No.	Structure	APCI-MS
502		436 (M + H)
503		420 (M + H)
504		504 (M + H)
505		454 (M + H)
506		524 (M + H)






Example No.	Structure	APCI-MS
507		470 (M + H)
508		470 (M + H)
509		436 (M + H)
510		474 (M + H)
511		486 (M + H)






Example No.	Structure	APCI-MS
512		512 (M + H)
513		478 (M + H)
514		432 (M + H)
515		553 (M + H)
516		479 (M + H)






Example No.	Structure	APCI-MS
517		513 (M + H)
518		511 (M + H)
519		572 (M + H)
520		540 (M + H)
521		464 (M + H)






Example No.	Structure	APCI-MS
522		409 (M + H)
523		567 (M + H)
524		514 (M + H)
525		483 (M + H)
526		546 (M + H)






Example No.	Structure	APCI-MS
527		464 (M + H)
528		543 (M + H)
529		529 (M + H)
530		608 (M + H)
531		567 (M + H)






Example No.	Structure	APCI-MS
532		487 (M + H)
533		442 (M + H)
534		464 (M + H)
535		516 (M + H)
536		522 (M + H)






Example No.	Structure	APCI-MS
537		486 (M + H)
538		490 (M + H)
539		493 (M + H)
540		460 (M + H)
541		476 (M + H)






Example No.	Structure	APCI-MS
542		524 (M + H)
543		468 (M + H)
544		430 (M + H)
545		452 (M + H)
546		506 (M + H)






Example No.	Structure	APCI-MS
547		471 (M + H)
548		434 (M + H)
549		418 (M + H)
550		444 (M + H)
551		462 (M + H)






Example No.	Structure	APCI-MS
552		479 (M + H)
553		448 (M + H)
554		424 (M + H)
555		601 (M + H)
556		462 (M + H)






Example No.	Structure	APCI-MS
557		524 (M + H)
558		478 (M + H)
559		446 (M + H)
560		436 (M + H)
561		448 (M + H)






Example No.	Structure	APCI-MS
562		490 (M + H)
563		432 (M + H)
564		637 (M + H)
565		632 (M + H)
566		498 (M + H)






Example No.	Structure	APCI-MS
567		475 (M + H)
568		496 (M + H)
569		464 (M + H)
570		468 (M + H)
571		444 (M + H)






Example No.	Structure	APCI-MS
572		496 (M + H)
573		468 (M + H)
574		514 (M + H)
575		492 (M + H)
576		557 (M + H)






Example No.	Structure	APCI-MS
577		516 (M + H)
578		487 (M + H)
579		503 (M + H)
580		342 (M + H)
581		368 (M + H)






Example No.	Structure	APCI-MS
582		410 (M + H)
583		398 (M + H)
584		370 (M + H)
585		413 (M + H)
586		410 (M + H)






Example No.	Structure	APCI-MS
587		398 (M + H)
588		453 (M + H)
589		432 (M + H)
590		432 (M + H)
591		474 (M + H)






Example No.	Structure	APCI-MS
592		458 (M + H)
593		490 (M + H)
594		535 (M + H)
595		430 (M + H)
596		552 (M + H)






Example No.	Structure	APCI-MS
597		433 (M + H)
598		503 (M + H)
599		536 (M + H)
600		506 (M + H)
601		429 (M + H)






Example No.	Structure	APCI-MS
602		486 (M + H)
603		459 (M + H)
604		443 (M + H)
605		636 (M + H)
606		601 (M + H)






Example No.	Structure	APCI-MS
607		705 (M + H)
608		623 (M + H)
609		559 (M + H)
610		583 (M + H)
611		596 (M + H)






Example No.	Structure	APCI-MS
612		512 (M + H)
613		480 (M + H)
614		494 (M + H)
615		494 (M + H)
616		537 (M + H)






Example No.	Structure	APCI-MS
617		492 (M + H)
618		523 (M + H)
619		534 (M + H)
620		556 (M + H)
621		587 (M + H)






Example No.	Structure	APCI-MS
622		587 (M + H)
623		523 (M + H)
624		641 (M + H)
625		641 (M + H)
626		523 (M + H)






Example No.	Structure	APCI-MS
627		544 (M + H)
628		526 (M + H)
629		548 (M + H)
630		405 (M + H)
631		564 (M + H)






Example No.	Structure	APCI-MS
632		524 (M + H)
633		630 (M + H)
634		564 (M + H)
635		518 (M + H)
636		647 (M + H)






Example No.	Structure	APCI-MS
637		545 (M + H)
638		671 (M + H)
639		490 (M + H)
640		482 (M + H)
641		466 (M + H)






Example No.	Structure	APCI-MS
642		494 (M + H)
643		528 (M + H)
644		482 (M + H)
645		517 (M + H)
646		537 (M + H)






Example No.	Structure	APCI-MS
647		496 (M + H)
648		508 (M + H)
649		508 (M + H)
650		496 (M + H)
651		559 (M + H)






Example No.	Structure	APCI-MS
652		490 (M + H)
653		564 (M + H)
654		550 (M + H)
655		602 (M + H)
656		522 (M + H)






Example No.	Structure	APCI-MS
657		533 (M + H)
658		468 (M + H)
659		502 (M + H)
660		449 (M + H)
661		493 (M + H)






Example No.	Structure	APCI-MS
662		468 (M + H)
663		501 (M + H)
664		515 (M + H)
665		501 (M + H)
666		438 (M + H)






Example No.	Structure	APCI-MS
667		508 (M + H)
668		582 (M + H)
669		674 (M + H)
670		474 (M + H)
671		457 (M + H)






Example No.	Structure	APCI-MS
672		441 (M + H)
673		550 (M + H)
674		438 (M + H)
675		569 (M + H)
676		424 (M + H)






Example No.	Structure	APCI-MS
677		436 (M + H)
678		415 (M + H)
679		441 (M + H)
680		458 (M + H)
681		451 (M + H)






Example No.	Structure	APCI-MS
682		449 (M + H)
683		435 (M + H)
684		465 (M + H)
685		476 (M + H)
686		526 (M + H)






Example No.	Structure	APCI-MS
687		465 (M + H)
688		476 (M + H)
689		494 (M + H)
690		453 (M + H)
691		463 (M + H)






Example No.	Structure	APCI-MS
697		515 (M + H)
698		458 (M + H)
699		500 (M + H)
700		504 (M + H)
701		579 (M + H)






Example No.	Structure	APCI-MS
702		438 (M + H)
703		506 (M + H)
704		456 (M + H)
705		452 (M + H)
706		530 (M + H)






Example No.	Structure	APCI-MS
707		493 (M + H)
708		486 (M + H)
709		472 (M + H)
710		563 (M + H)
711		480 (M + H)






Example No.	Structure	APCI-MS
712		464 (M + H)
713		494 (M + H)
714		532 (M + H)
715		546 (M + H)
716		533 (M + H)






Example No.	Structure	APCI-MS
717		622 (M + H)
718		472 (M + H)
719		438 (M + H)
720		464 (M + H)
721		512 (M + H)






Example No.	Structure	APCI-MS
722		437 (M + H)
723		577 (M + H)
724		465 (M + H)
725		488 (M + H)
726		435 (M + H)






Example No.	Structure	APCI-MS
727		434 (M + H)
728		613 (M + H)
729		408 (M + H)
730		394 (M + H)
731		542 (M + H)






Example No.	Structure	APCI-MS
732		549 (M + H)
733		530 (M + H)
734		668 (M + H)
735		490 (M + H)
736		486 (M + H)






Example No.	Structure	APCI-MS
737		501 (M + H)
738		488 (M + H)
739		562 (M + H)
740		502 (M + H)
741		524 (M + H)






Example No.	Structure	APCI-MS
742		588 (M + H)
743		487 (M + H)
744		436 (M + H)
745		660 (M + H)
746		605 (M + H)






Example No.	Structure	APCI-MS
747		662 (M + H)
748		696 (M + H)
749		603 (M + H)
750		561 (M + H)
751		639 (M + H)






Example No.	Structure	APCI-MS
752		657 (M + H)
753		559 (M + H)
754		645 (M + H)
755		631 (M + H)
756		589 (M + H)






Example No.	Structure	APCI-MS
757		557 (M + H)
758		591 (M + H)
759		565 (M + H)
760		568 (M + H)
761		601 (M + H)






Example No.	Structure	APCI-MS
762		607 (M + H)
763		477 (M + H)
764		477 (M + H)
765		482 (M + H)
766		461 (M + H)






Example No.	Structure	APCI-MS
767		461 (M + H)
768		444 (M + H)
769		496 (M + H)
770		496 (M + H)
771		519 (M + H)






Example No.	Structure	APCI-MS
772		530 (M + H)
773		460 (M + H)
774		602 (M + H)
775		437 (M + H)
776		419 (M + H)






Example No.	Structure	APCI-MS
777		548 (M + H)
778		672 (M + H)
779		540 (M + H)
780		540 (M + H)
781		522 (M + H)






Example No.	Structure	APCI-MS
782		512 (M + H)
783		632 (M + H)
784		644 (M + H)
785		680 (M + H)
786		646 (M + H)






Example No.	Structure	APCI-MS
787		646 (M + H)
788		582 (M + H)
789		602 (M + H)
790		630 (M + H)
791		670 (M + H)






Example No.	Structure	APCI-MS
792		710 (M + H)
793		684 (M + H)
794		650 (M + H)
795		624 (M + H)
796		636 (M + H)






Example No.	Structure	APCI-MS
797		602 (M + H)
798		616 (M + H)
799		612 (M + H)
800		622 (M + H)
801		650 (M + H)






Example No.	Structure	APCI-MS
802		606 (M + H)
803		586 (M + H)
804		624 (M + H)
805		528 (M + H)
806		452 (M + H)






Example No.	Structure	APCI-MS
807		438 (M + H)
808		424 (M + H)
809		522 (M + H)
810		488 (M + H)
811		488 (M + H)






Example No.	Structure	APCI-MS
812		488 (M + H)
813		504 (M + H)
814		504 (M + H)
815		458 (M + H)
816		452 (M + H)






Example No.	Structure	APCI-MS
817		497 (M + H)
818		547 (M + H)
819		549 (M + H)
820		522 (M + H)
821		629 (M + H)






Example No.	Structure	APCI-MS
822		510 (M + H)
823		538 (M + H)
824		512 (M + H)
825		583 (M + H)
826		535 (M + H)






Example No.	Structure	APCI-MS
827		556 (M + H)
828		480 (M + H)
829		494 (M + H)
830		597 (M + H)
831		570 (M + H)






Example No.	Structure	APCI-MS
832		478 (M + H)
833		448 (M + H)
834		446 (M + H)
835		450 (M + H)
836		432 (M + H)






Example No.	Structure	APCI-MS
837		452 (M + H)
838		460 (M + H)
839		478 (M + H)
840		444 (M + H)
841		492 (M + H)






Example No.	Structure	APCI-MS
842		522 (M + H)
843		603 (M + H)
844		518 (M + H)
845		490 (M + H)
846		563 (M + H)






Example No.	Structure	APCI-MS
847		457 (M + H)
848		471 (M + H)
849		418 (M + H)
850		463 (M + H)
851		460 (M + H)






Example No.	Structure	APCI-MS
852		444 (M + H)
853		576 (M + H)
854		490 (M + H)
855		550 (M + H)
856		439 (M + H)






Example No.	Structure	APCI-MS
857		408 (M + H)
858		410 (M + H)
859		424 (M + H)
860		394 (M + H)
861		424 (M + H)






Example No.	Structure	APCI-MS
862		424 (M + H)
863		411 (M + H)
864		425 (M + H)
865		384 (M + H)
866		424 (M + H)






Example No.	Structure	APCI-MS
867		446 (M + H)
868		446 (M + H)
869		488 (M + H)
870		549 (M + H)
871		444 (M + H)






Example No.	Structure	APCI-MS
872		566 (M + H)
873		447 (M + H)
874		517 (M + H)
875		550 (M + H)
876		520 (M + H)






Example No.	Structure	APCI-MS
877		443 (M + H)
878		500 (M + H)
879		473 (M + H)
880		457 (M + H)
881		650 (M + H)






Example No.	Structure	APCI-MS
882		615 (M + H)
883		719 (M + H)
884		637 (M + H)
885		573 (M + H)
886		597 (M + H)






Example No.	Structure	APCI-MS
887		610 (M + H)
888		526 (M + H)
889		494 (M + H)
890		508 (M + H)
891		508 (M + H)






Example No.	Structure	APCI-MS
892		551 (M + H)
893		506 (M + H)
894		537 (M + H)
895		548 (M + H)
896		570 (M + H)






Example No.	Structure	APCI-MS
897		601 (M + H)
898		601 (M + H)
899		537 (M + H)
900		655 (M + H)
901		655 (M + H)






Example No.	Structure	APCI-MS
902		558 (M + H)
903		540 (M + H)
904		562 (M + H)
905		419 (M + H)
906		578 (M + H)






Example No.	Structure	APCI-MS
907		538 (M + H)
908		644 (M + H)
909		578 (M + H)
910		532 (M + H)
911		661 (M + H)






Example No.	Structure	APCI-MS
912		559 (M + H)
913		685 (M + H)
914		506 (M + H)
915		504 (M + H)
916		496 (M + H)






Example No.	Structure	APCI-MS
917		480 (M + H)
918		508 (M + H)
919		542 (M + H)
920		496 (M + H)
921		531 (M + H)






Example No.	Structure	APCI-MS
922		551 (M + H)
923		510 (M + H)
924		522 (M + H)
925		522 (M + H)
926		510 (M + H)






Example No.	Structure	APCI-MS
927		504 (M + H)
928		504 (M + H)
929		578 (M + H)
930		564 (M + H)
931		616 (M + H)






Example No.	Structure	APCI-MS
932		536 (M + H)
933		547 (M + H)
934		482 (M + H)
935		516 (M + H)
936		463 (M + H)






Example No.	Structure	APCI-MS
937		507 (M + H)
938		482 (M + H)
939		515 (M + H)
940		529 (M + H)
941		515 (M + H)






Example No.	Structure	APCI-MS
942		452 (M + H)
943		522 (M + H)
944		596 (M + H)
945		688 (M + H)
946		488 (M + H)

Example No.	Structure	APCI-MS
947		471 (M + H)
948		455 (M + H)
949		564 (M + H)
950		452 (M + H)
951		583 (M + H)






Example No.	Structure	APCI-MS
952		438 (M + H)
953		450 (M + H)
954		429 (M + H)
955		455 (M + H)
956		472 (M + H)






Example No.	Structure	APCI-MS
957		463 (M + H)
958		449 (M + H)
959		479 (M + H)
960		490 (M + H)
961		540 (M + H)






Example No.	Structure	APCI-MS
962		479 (M + H)
963		490 (M + H)
964		508 (M + H)
965		467 (M + H)
966		477 (M + H)






Example No.	Structure	APCI-MS
967		533 (M + H)
968		479 (M + H)
969		476 (M + H)
970		599 (M + H)
971		567 (M + H)






Example No.	Structure	APCI-MS
972	 <chem>CN(C)c1nc(NC2CCCCC2CCNC(=O)C3CCCCC3NC(=O)c4ccccc4)n2ccccc12</chem>	529 (M + H)
973	 <chem>CN(C)c1nc(NC2CCCCC2CCNC(=O)CCCc3[nH]c4ccccc34)n2ccccc12</chem>	472 (M + H)
974	 <chem>CN(C)c1nc(NC2CCCCC2CCNC(=O)C3CCCCC3C(=O)c4ccccc4)n2ccccc12</chem>	514 (M + H)
975	 <chem>CN(C)c1nc(NC2CCCCC2CCNC(=O)CCNC(=O)CCNC(=O)c3ccccc3)n2ccccc12</chem>	518 (M + H)
976	 <chem>CC(C)(C)S(=O)(=O)N1CCCC1C(=O)NC2CCCCC2CCNC(=O)C3CCCCC3NC(=O)c4nc5ccccc45n6ccccc36</chem>	593 (M + H)






Example No.	Structure	APCI-MS
977		452 (M + H)
978		520 (M + H)
979		470 (M + H)
980		466 (M + H)
981		544 (M + H)






Example No.	Structure	APCI-MS
982		507 (M + H)
983		604 (M + H)
984		500 (M + H)
985		486 (M + H)
986		577 (M + H)






Example No.	Structure	APCI-MS
987		494 (M + H)
988		478 (M + H)
989		508 (M + H)
990		546 (M + H)
991		560 (M + H)






Example No.	Structure	APCI-MS
992		547 (M + H)
993		636 (M + H)
994		486 (M + H)
995		452 (M + H)
996		478 (M + H)






Example No.	Structure	APCI-MS
997		526 (M + H)
998		451 (M + H)
999		591 (M + H)
1000		479 (M + H)
1001		502 (M + H)






Example No.	Structure	APCI-MS
1002		448 (M + H)
1003		627 (M + H)
1004		422 (M + H)
1005		408 (M + H)
1006		556 (M + H)






Example No.	Structure	APCI-MS
1007		563 (M + H)
1008		544 (M + H)
1009		682 (M + H)
1010		504 (M + H)
1011		500 (M + H)






Example No.	Structure	APCI-MS
1012		515 (M + H)
1013		502 (M + H)
1014		576 (M + H)
1015		516 (M + H)
1016		538 (M + H)






Example No.	Structure	APCI-MS
1017		602 (M + H)
1018		501 (M + H)
1019		450 (M + H)
1020		674 (M + H)
1021		619 (M + H)






Example No.	Structure	APCI-MS
1022		676 (M + H)
1023		710 (M + H)
1024		617 (M + H)
1025		575 (M + H)
1026		653 (M + H)






Example No.	Structure	APCI-MS
1027		671 (M + H)
1028		659 (M + H)
1029		645 (M + H)
1030		603 (M + H)
1031		571 (M + H)






Example No.	Structure	APCI-MS
1032		605 (M + H)
1033		579 (M + H)
1034		582 (M + H)
1035		615 (M + H)
1036		621 (M + H)






Example No.	Structure	APCI-MS
1037		491 (M + H)
1038		491 (M + H)
1039		496 (M + H)
1040		475 (M + H)
1041		475 (M + H)






Example No.	Structure	APCI-MS
1042		458 (M + H)
1043		510 (M + H)
1044		510 (M + H)
1045		533 (M + H)
1046		544 (M + H)






Example No.	Structure	APCI-MS
1047		474 (M + H)
1048		616 (M + H)
1049		451 (M + H)
1050		433 (M + H)
1051		562 (M + H)






Example No.	Structure	APCI-MS
1052		686 (M + H)
1053		554 (M + H)
1054		554 (M + H)
1055		536 (M + H)
1056		526 (M + H)






Example No.	Structure	APCI-MS
1057		646 (M + H)
1058		658 (M + H)
1059		694 (M + H)
1060		660 (M + H)
1061		660 (M + H)






Example No.	Structure	APCI-MS
1062		596 (M + H)
1063		616 (M + H)
1064		644 (M + H)
1065		684 (M + H)
1066		724 (M + H)






Example No.	Structure	APCI-MS
1067		698 (M + H)
1068		664 (M + H)
1069		638 (M + H)
1070		650 (M + H)
1071		630 (M + H)






Example No.	Structure	APCI-MS
1072		626 (M + H)
1073		664 (M + H)
1074		620 (M + H)
1075		600 (M + H)
1076		638 (M + H)






Example No.	Structure	APCI-MS
1077		542 (M + H)
1078		466 (M + H)
1079		452 (M + H)
1080		438 (M + H)
1081		536 (M + H)






Example No.	Structure	APCI-MS
1082		502 (M + H)
1083		502 (M + H)
1084		502 (M + H)
1085		518 (M + H)
1086		518 (M + H)






Example No.	Structure	APCI-MS
1087		472 (M + H)
1088		466 (M + H)
1089		511 (M + H)
1090		561 (M + H)
1091		563 (M + H)






Example No.	Structure	APCI-MS
1092		536 (M + H)
1093		643 (M + H)
1094		524 (M + H)
1095		552 (M + H)
1096		526 (M + H)






Example No.	Structure	APCI-MS
1102		611 (M + H)
1103		584 (M + H)
1104		492 (M + H)
1105		462 (M + H)
1106		460 (M + H)






Example No.	Structure	APCI-MS
1107		464 (M + H)
1108		446 (M + H)
1109		466 (M + H)
1110		474 (M + H)
1111		492 (M + H)






Example No.	Structure	APCI-MS
1112		458 (M + H)
1113		506 (M + H)
1114		536 (M + H)
1115		617 (M + H)
1116		532 (M + H)






Example No.	Structure	APCI-MS
1117		504 (M + H)
1118		577 (M + H)
1119		471 (M + H)
1120		485 (M + H)
1121		432 (M + H)






Example No.	Structure	APCI-MS
1122		458 (M + H)
1123		590 (M + H)
1124		504 (M + H)
1125		564 (M + H)
1126		453 (M + H)






Example No.	Structure	APCI-MS
1127		422 (M + H)
1128		424 (M + H)
1129		438 (M + H)
1130		408 (M + H)
1131		438 (M + H)






Example No.	Structure	APCI-MS
1132		438 (M + H)
1133		425 (M + H)
1134		439 (M + H)
1135		398 (M + H)
1136		438 (M + H)






Example No.	Structure	APCI-MS
1137		506 (M + H)
1138		376 (M + H)
1139		432 (M + H)
1140		454 (M + H)
1141		454 (M + H)






Example No.	Structure	APCI-MS
1142		491 (M + H)
1143		522 (M + H)
1144		455 (M + H)
1145		416 (M + H)
1146		419 (M + H)






Example No.	Structure	APCI-MS
1147		394 (M + H)
1148		366 (M + H)
1149		462 (M + H)
1150		377 (M + H)
1151		457 (M + H)






Example No.	Structure	APCI-MS
1152		456 (M + H)
1153		398 (M + H)
1154		543 (M + H)
1155		421 (M + H)
1156		555 (M + H)






Example No.	Structure	APCI-MS
1157		377 (M + H)
1158		510 (M + H)
1159		484 (M + H)
1160		382 (M + H)
1161		460 (M + H)






Example No.	Structure	APCI-MS
1162		460 (M + H)
1163		430 (M + H)
1164		468 (M + H)
1165		502 (M + H)
1166		444 (M + H)






Example No.	Structure	APCI-MS
1167		484 (M + H)
1168		428 (M + H)
1169		426 (M + H)
1170		428 (M + H)
1171		428 (M + H)






Example No.	Structure	APCI-MS
1172		446 (M + H)
1173		462 (M + H)
1174		462 (M + H)
1175		448 (M + H)
1176		502 (M + H)






Example No.	Structure	APCI-MS
1177		466 (M + H)
1178		394 (M + H)
1179		428 (M + H)
1180		420 (M + H)
1181		428 (M + H)






Example No.	Structure	APCI-MS
1182		408 (M + H)
1183		392 (M + H)
1184		476 (M + H)
1185		426 (M + H)
1186		496 (M + H)






Example No.	Structure	APCI-MS
1187		442 (M + H)
1188		442 (M + H)
1189		408 (M + H)
1190		446 (M + H)
1191		458 (M + H)






Example.No.	Structure	APCI-MS
1192		484 (M + H)
1193		450 (M + H)
1194		404 (M + H)
1195		525 (M + H)
1196		483 (M + H)






Example No.	Structure	APCI-MS
1197		544 (M + H)
1198		512 (M + H)
1199		436 (M + H)
1200		381 (M + H)
1201		539 (M + H)






Example No.	Structure	APCI-MS
1202		486 (M + H)
1203		518 (M + H)
1204		436 (M + H)
1205		515 (M + H)
1206		501 (M + H)






Example No.	Structure	APCI-MS
1207		580 (M + H)
1208		539 (M + H)
1209		459 (M + H)
1210		414 (M + H)
1211		436 (M + H)






Example No.	Structure	APCI-MS
1212		488 (M + H)
1213		494 (M + H)
1214		458 (M + H)
1215		465 (M + H)
1216		432 (M + H)






Example No.	Structure	APCI-MS
1217		406 (M + H)
1218		496 (M + H)
1219		440 (M + H)
1220		424 (M + H)
1221		478 (M + H)






Example No.	Structure	APCI-MS
1222		406 (M + H)
1223		390 (M + H)
1224		416 (M + H)
1225		434 (M + H)
1226		451 (M + H)






Example No.	Structure	APCI-MS
1227		420 (M + H)
1228		396 (M + H)
1229		573 (M + H)
1230		434 (M + H)
1231		496 (M + H)






Example No.	Structure	APCI-MS
1232		450 (M + H)
1233		418 (M + H)
1234		408 (M + H)
1235		420 (M + H)
1236		462 (M + H)






Example No.	Structure	APCI-MS
1237		404 (M + H)
1238		609 (M + H)
1239		468 (M + H)
1240		436 (M + H)
1241		440 (M + H)






Example No.	Structure	APCI-MS
1242		418 (M + H)
1243		468 (M + H)
1244		440 (M + H)
1245		486 (M + H)
1246		475 (M + H)






Example No.	Structure	APCI-MS
1247		340 (M + H)
1248		382 (M + H)
1249		370 (M + H)
1250		342 (M + H)
1251		382 (M + H)






Example No.	Structure	APCI-MS
1252		370 (M + H)
1253		520 (M + H)
1254		390 (M + H)
1255		446 (M + H)
1256		468 (M + H)






Example No.	Structure	APCI-MS
1257		468 (M + H)
1258		505 (M + H)
1259		536 (M + H)
1260		469 (M + H)
1261		430 (M + H)






Example No.	Structure	APCI-MS
1262		433 (M + H)
1263		408 (M + H)
1264		380 (M + H)
1265		476 (M + H)
1266		391 (M + H)






Example No.	Structure	APCI-MS
1267		448 (M + H)
1268		471 (M + H)
1269		470 (M + H)
1270		412 (M + H)
1271		557 (M + H)






Example No.	Structure	APCI-MS
1272		435 (M + H)
1273		425 (M + H)
1274		569 (M + H)
1275		391 (M + H)
1276		524 (M + H)






Example No.	Structure	APCI-MS
1277		498 (M + H)
1278		396 (M + H)
1279		474 (M + H)
1280		474 (M + H)
1281		444 (M + H)






Example No.	Structure	APCI-MS
1282		482 (M + H)
1283		516 (M + H)
1284		458 (M + H)
1285		498 (M + H)
1286		442 (M + H)






Example No.	Structure	APCI-MS
1287		440 (M + H)
1288		442 (M + H)
1289		442 (M + H)
1290		460 (M + H)
1291		476 (M + H)






Example No.	Structure	APCI-MS
1292		476 (M + H)
1293		462 (M + H)
1294		516 (M + H)
1295		480 (M + H)
1296		408 (M + H)






Example No.	Structure	APCI-MS
1297		442 (M + H)
1298		434 (M + H)
1299		442 (M + H)
1300		422 (M + H)
1301		490 (M + H)






Example No.	Structure	APCI-MS
1302		440 (M + H)
1303		456 (M + H)
1304		422 (M + H)
1305		460 (M + H)
1306		472 (M + H)






Example No.	Structure	APCI-MS
1307		498 (M + H)
1308		464 (M + H)
1309		418 (M + H)
1310		539 (M + H)
1311		497 (M + H)






Example No.	Structure	APCI-MS
1312		558 (M + H)
1313		526 (M + H)
1314		450 (M + H)
1315		395 (M + H)
1316		553 (M + H)






Example No.	Structure	APCI-MS
1317		500 (M + H)
1318		532 (M + H)
1319		450 (M + H)
1320		529 (M + H)
1321		515 (M + H)






Example No.	Structure	APCI-MS
1322		594 (M + H)
1323		473 (M + H)
1324		428 (M + H)
1325		450 (M + H)
1326		502 (M + H)






Example No.	Structure	APCI-MS
1327		508 (M + H)
1328		472 (M + H)
1329		476 (M + H)
1330		479 (M + H)
1331		446 (M + H)






Example No.	Structure	APCI-MS
1332		420 (M + H)
1333		510 (M + H)
1334		454 (M + H)
1335		438 (M + H)
1336		492 (M + H)






Example No.	Structure	APCI-MS
1337		420 (M + H)
1338		404 (M + H)
1339		430 (M + H)
1340		448 (M + H)
1341		465 (M + H)






Example No.	Structure	APCI-MS
1342		434 (M + H)
1343		410 (M + H)
1344		587 (M + H)
1345		448 (M + H)
1346		510 (M + H)






Example No.	Structure	APCI-MS
1347		464 (M + H)
1348		432 (M + H)
1349		422 (M + H)
1350		434 (M + H)
1351		476 (M + H)






Example No.	Structure	APCI-MS
1352		418 (M + H)
1353		623 (M + H)
1354		618 (M + H)
1355		486 (M + H)
1356		463 (M + H)






Example No.	Structure	APCI-MS
1357		482 (M + H)
1358		452 (M + H)
1359		454 (M + H)
1360		432 (M + H)
1361		482 (M + H)






Example No.	Structure	APCI-MS
1362		454 (M + H)
1363		502 (M + H)
1364		489 (M + H)
1365		328 (M + H)
1366		354 (M + H)






Example No.	Structure	APCI-MS
1367		396 (M + H)
1368		384 (M + H)
1369		356 (M + H)
1370		396 (M + H)
1371		384 (M + H)






Example No.	Structure	APCI-MS
1372		418 (M + H)
1373		420 (M + H)
1374		460 (M + H)
1375		444 (M + H)
1376		476 (M + H)






Example No.	Structure	APCI-MS
1377		521 (M + H)
1378		416 (M + H)
1379		538 (M + H)
1380		419 (M + H)
1381		522 (M + H)






Example No.	Structure	APCI-MS
1382		492 (M + H)
1383		472 (M + H)
1384		429 (M + H)
1385		622 (M + H)
1386		545 (M + H)






Example No.	Structure	APCI-MS
1387		555 (M + H)
1388		466 (M + H)
1389		480 (M + H)
1390		482 (M + H)
1391		523 (M + H)






Example No.	Structure	APCI-MS
1392		480 (M + H)
1393		520 (M + H)
1394		573 (M + H)
1395		573 (M + H)
1396		627 (M + H)






Example No.	Structure	APCI-MS
1397		613 (M + H)
1398		532 (M + H)
1399		512 (M + H)
1400		391 (M + H)
1401		510 (M + H)






Example No.	Structure	APCI-MS
1402		633 (M + H)
1403		531 (M + H)
1404		468 (M + H)
1405		452 (M + H)
1406		468 (M + H)






Example No.	Structure	APCI-MS
1407		503 (M + H)
1408		523 (M + H)
1409		482 (M + H)
1410		494 (M + H)
1411		482 (M + H)






Example No.	Structure	APCI-MS
1412		531 (M + H)
1413		550 (M + H)
1414		536 (M + H)
1415		588 (M + H)
1416		508 (M + H)






Example No.	Structure	APCI-MS
1417		519 (M + H)
1418		488 (M + H)
1419		435 (M + H)
1420		479 (M + H)
1421		487 (M + H)






Example No.	Structure	APCI-MS
1422		501 (M + H)
1423		426 (M + H)
1424		494 (M + H)
1425		568 (M + H)
1426		660 (M + H)






Example No.	Structure	APCI-MS
1427		460 (M + H)
1428		424 (M + H)
1429		555 (M + H)
1430		427 (M + H)
1431		444 (M + H)






Example No.	Structure	APCI-MS
1432		435 (M + H)
1433		421 (M + H)
1434		451 (M + H)
1435		462 (M + H)
1436		512 (M + H)






Example No.	Structure	APCI-MS
1437		451 (M + H)
1438		462 (M + H)
1439		480 (M + H)
1440		439 (M + H)
1441		449 (M + H)






Example No.	Structure	APCI-MS
1442		505 (M + H)
1443		539 (M + H)
1444		487 (M + H)
1445		488 (M + H)
1446		565 (M + H)






Example No.	Structure	APCI-MS
1447		492 (M + H)
1448		442 (M + H)
1449		516 (M + H)
1450		465 (M + H)
1451		472 (M + H)






Example No.	Structure	APCI-MS
1452		458 (M + H)
1453		466 (M + H)
1454		450 (M + H)
1455		480 (M + H)
1456		518 (M + H)






Example No.	Structure	APCI-MS
1457		532 (M + H)
1458		580 (M + H)
1459		452 (M + H)
1460		498 (M + H)
1461		409 (M + H)






Example No.	Structure	APCI-MS
1462		563 (M + H)
1463		420 (M + H)
1464		535 (M + H)
1465		516 (M + H)
1466		476 (M + H)






Example No.	Structure	APCI-MS
1467		472 (M + H)
1468		487 (M + H)
1469		548 (M + H)
1470		512 (M + H)
1471		473 (M + H)






Example No.	Structure	APCI-MS
1472		648 (M + H)
1473		591 (M + H)
1474		645 (M + H)
1475		531 (M + H)
1476		619 (M + H)






Example No.	Structure	APCI-MS
1477		529 (M + H)
1478		563 (M + H)
1479		537 (M + H)
1480		540 (M + H)
1481		579 (M + H)






Example No.	Structure	APCI-MS
1482		463 (M + H)
1483		449 (M + H)
1484		432 (M + H)
1485		482 (M + H)
1486		482 (M + H)






Example No.	Structure	APCI-MS
1487		505 (M + H)
1488		516 (M + H)
1489		560 (M + H)
1490		423 (M + H)
1491		405 (M + H)






Example No.	Structure	APCI-MS
1492		534 (M + H)
1493		526 (M + H)
1494		526 (M + H)
1495		510 (M + H)
1496		498 (M + H)






Example No.	Structure	APCI-MS
1497		632 (M + H)
1498		570 (M + H)
1499		590 (M + H)
1500		618 (M + H)
1501		658 (M + H)






Example No.	Structure	APCI-MS
1502		672 (M + H)
1503		638 (M + H)
1504		612 (M + H)
1505		624 (M + H)
1506		590 (M + H)






Example No.	Structure	APCI-MS
1507		604 (M + H)
1508		598 (M + H)
1509		574 (M + H)
1510		424 (M + H)
1511		508 (M + H)






Example No.	Structure	APCI-MS
1512		474 (M + H)
1513		474 (M + H)
1514		474 (M + H)
1515		490 (M + H)
1516		490 (M + H)






Example No.	Structure	APCI-MS
1517		444 (M + H)
1518		438 (M + H)
1519		483 (M + H)
1520		535 (M + H)
1521		510 (M + H)






Example No.	Structure	APCI-MS
1522		601 (M + H)
1523		496 (M + H)
1524		420 (M + H)
1525		498 (M + H)
1526		521 (M + H)






Example No.	Structure	APCI-MS
1527		542 (M + H)
1528		466 (M + H)
1529		480 (M + H)
1530		583 (M + H)
1531		556 (M + H)






Example No.	Structure	APCI-MS
1532		464 (M + H)
1533		434 (M + H)
1534		434 (M + H)
1535		436 (M + H)
1536		418 (M + H)






Example No.	Structure	APCI-MS
1537		438 (M + H)
1538		446 (M + H)
1539		464 (M + H)
1540		430 (M + H)
1541		478 (M + H)






Example No.	Structure	APCI-MS
1542		575 (M + H)
1543		506 (M + H)
1544		476 (M + H)
1545		564 (M + H)
1546		478 (M + H)






Example No.	Structure	APCI-MS
1547		396 (M + H)
1548		410 (M + H)
1549		410 (M + H)
1550		410 (M + H)
1551		370 (M + H)






Example No.	Structure	APCI-MS
1552		410 (M + H)
1553		432 (M + H)
1554		474 (M + H)
1555		458 (M + H)
1556		490 (M + H)






Example No.	Structure	APCI-MS
1557		535 (M + H)
1558		430 (M + H)
1559		552 (M + H)
1560		433 (M + H)
1561		536 (M + H)






Example No.	Structure	APCI-MS
1562		506 (M + H)
1563		429 (M + H)
1564		486 (M + H)
1565		443 (M + H)
1566		636 (M + H)






Example No.	Structure	APCI-MS
1567		705 (M + H)
1568		559 (M + H)
1569		569 (M + H)
1570		480 (M + H)
1571		494 (M + H)






Example No.	Structure	APCI-MS
1572		496 (M + H)
1573		537 (M + H)
1574		494 (M + H)
1575		534 (M + H)
1576		587 (M + H)






Example No.	Structure	APCI-MS
1577		587 (M + H)
1578		523 (M + H)
1579		627 (M + H)
1580		627 (M + H)
1581		526 (M + H)






Example No.	Structure	APCI-MS
1582		524 (M + H)
1583		564 (M + H)
1584		647 (M + H)
1585		545 (M + H)
1586		671 (M + H)






Example No.	Structure	APCI-MS
1587		482 (M + H)
1588		466 (M + H)
1589		528 (M + H)
1590		482 (M + H)
1591		517 (M + H)






Example No.	Structure	APCI-MS
1592		537 (M + H)
1593		496 (M + H)
1594		508 (M + H)
1595		496 (M + H)
1596		564 (M + H)






Example No.	Structure	APCI-MS
1597		550 (M + H)
1598		602 (M + H)
1599		522 (M + H)
1600		533 (M + H)
1601		468 (M + H)






Example No.	Structure	APCI-MS
1602		502 (M + H)
1603		449 (M + H)
1604		493 (M + H)
1605		515 (M + H)
1606		440 (M + H)






Example No.	Structure	APCI-MS
1607		508 (M + H)
1608		582 (M + H)
1609		674 (M + H)
1610		474 (M + H)
1611		548 (M - H)






Example No.	Structure	APCI-MS
1612		438 (M + H)
1613		569 (M + H)
1614		441 (M + H)
1615		458 (M + H)
1616		449 (M + H)






Example No.	Structure	APCI-MS
1617		435 (M + H)
1618		465 (M + H)
1619		476 (M + H)
1620		526 (M + H)
1621		465 (M + H)






Example No.	Structure	APCI-MS
1622		476 (M + H)
1623		494 (M + H)
1624		453 (M + H)
1625		463 (M + H)
1626		519 (M + H)






Example No.	Structure	APCI-MS
1627		553 (M + H)
1628		501 (M + H)
1629		458 (M + H)
1630		502 (M + H)
1631		579 (M + H)






Example No.	Structure	APCI-MS
1632		506 (M + H)
1633		456 (M + H)
1634		530 (M + H)
1635		479 (M + H)
1636		590 (M + H)






Example No.	Structure	APCI-MS
1637		486 (M + H)
1638		472 (M + H)
1639		480 (M + H)
1640		464 (M + H)
1641		494 (M + H)






Example No.	Structure	APCI-MS
1642		532 (M + H)
1643		546 (M + H)
1644		608 (M + H)
1645		438 (M + H)
1646		466 (M + H)






Example No.	Structure	APCI-MS
1647		512 (M + H)
1648		423 (M + H)
1649		577 (M + H)
1650		434 (M + H)
1651		549 (M + H)






Example No.	Structure	APCI-MS
1652		530 (M + H)
1653		490 (M + H)
1654		486 (M + H)
1655		501 (M + H)
1656		562 (M + H)






Example No.	Structure	APCI-MS
1657		487 (M + H)
1658		660 (M + H)
1659		605 (M + H)
1660		662 (M + H)
1661		696 (M + H)






Example No.	Structure	APCI-MS
1662		639 (M + H)
1663		659 (M + H)
1664		647 (M + H)
1665		633 (M + H)
1666		543 (M + H)






Example No.	Structure	APCI-MS
1667		577 (M + H)
1668		551 (M + H)
1669		554 (M + H)
1670		477 (M + H)
1671		463 (M + H)






Example No.	Structure	APCI-MS
1672		446 (M + H)
1673		496 (M + H)
1674		496 (M + H)
1675		519 (M + H)
1676		530 (M + H)






Example No.	Structure	APCI-MS
1677		574 (M + H)
1678		437 (M + H)
1679		419 (M + H)
1680		548 (M + H)
1681		672 (M + H)






Example No.	Structure	APCI-MS
1682		540 (M + H)
1683		540 (M + H)
1684		524 (M + H)
1685		512 (M + H)
1686		632 (M + H)






Example No.	Structure	APCI-MS
1687		646 (M + H)
1688		648 (M + H)
1689		584 (M + H)
1690		632 (M + H)
1691		672 (M + H)






Example No.	Structure	APCI-MS
1692		686 (M + H)
1693		652 (M + H)
1694		626 (M + H)
1695		638 (M + H)
1696		618 (M + H)






Example No.	Structure	APCI-MS
1697		612 (M + H)
1698		588 (M + H)
1699		624 (M + H)
1700		438 (M + H)
1701		522 (M + H)






Example No.	Structure	APCI-MS
1702		488 (M + H)
1703		488 (M + H)
1704		488 (M + H)
1705		504 (M + H)
1706		504 (M + H)






Example No.	Structure	APCI-MS
1707		458 (M + H)
1708		452 (M + H)
1709		497 (M + H)
1710		549 (M + H)
1711		524 (M + H)






Example No.	Structure	APCI-MS
1712		615 (M + H)
1713		510 (M + H)
1714		434 (M + H)
1715		512 (M + H)
1716		535 (M + H)






Example No.	Structure	APCI-MS
1717		556 (M + H)
1718		480 (M + H)
1719		494 (M + H)
1720		597 (M + H)
1721		570 (M + H)






Example No.	Structure	APCI-MS
1722		478 (M + H)
1723		448 (M + H)
1724		448 (M + H)
1725		450 (M + H)
1726		432 (M + H)






Example No.	Structure	APCI-MS
1727		452 (M + H)
1728		460 (M + H)
1729		478 (M + H)
1730		444 (M + H)
1731		492 (M + H)






Example No.	Structure	APCI-MS
1732		524 (M + H)
1733		589 (M + H)
1734		520 (M + H)
1735		490 (M + H)
1736		563 (M + H)






Example No.	Structure	APCI-MS
1737		471 (M + H)
1738		578 (M + H)
1739		410 (M + H)
1740		424 (M + H)
1741		424 (M + H)






Example No.	Structure	APCI-MS
1742		424 (M + H)
1743		447 (M + Na)
1744		384 (M + H)
1745		424 (M + H)
1746		434 (M + H)






Example No.	Structure	APCI-MS
1747		472 (M + H)
1748		520 (M + H)
1749		514 (M + H)
1750		470 (M + H)
1751		500 (M + H)






Example No.	Structure	APCI-MS
1752		482 (M + H)
1753		502 (M + H)
1754		490 (M + H)
1755		426 (M + H)
1756		683 (M + H)






Example No.	Structure	APCI-MS
1757		537 (M + H)
1758		588 (M + H)
1759		460 (M + H)
1760		477 (M + H)
1761		447 (M + H)






Example No.	Structure	APCI-MS
1762		509 (M + H)
1763		438 (M + H)
1764		464 (M + H)
1765		450 (M + H)
1766		383 (M + H)






Example No.	Structure	APCI-MS
1767		476 (M + H)
1768		396 (M + H)
1769		434 (M + H)
1770		416 (M + H)
1771		470 (M + H)






Example No.	Structure	APCI-MS
1772		410 (M + H)
1773		442 (M + H)
1774		394 (M + H)
1775		461 (M + H)
1776		476 (M + H)






Example No.	Structure	APCI-MS
1777		510 (M + H)
1778		544 (M + H)
1779		380 (M + H)
1780		437 (M + H)
1781		464 (M + H)






Example No.	Structure	APCI-MS
1782		394 (M + H)
1783		546 (M + H)
1784		519 (M + H)
1785		542 (M + H)
1786		624 (M + H)






Example No.	Structure	APCI-MS
1787		366 (M + H)
1788		460 (M + H)
1789		469 (M + H)
1790		450 (M + H)
1791		456 (M + H)






Example No.	Structure	APCI-MS
1792		430 (M + H)
1793		456 (M + H)
1794		456 (M + H)
1795		500 (M + H)
1796		537 (M + Na)






Example No.	Structure	APCI-MS
1797		537 (M + Na)
1798		548 (M + H)
1799		504 (M + H)
1800		644 (M + H)
1801		436 (M + H)






Example No.	Structure	APCI-MS
1802		410 (M + H)
1803		422 (M + H)
1804		467 (M + H)
1805		406 (M + H)
1806		406 (M + H)






Example No.	Structure	APCI-MS
1807		440 (M - H)
1808		437 (M + H)
1809		408 (M + H)
1810		404 (M + H)
1811		404 (M + H)






Example No.	Structure	APCI-MS
1812		422 (M + H)
1813		453 (M + H)
1814		433 (M + H)
1815		429 (M + H)
1816		429 (M + H)






Example No.	Structure	APCI-MS
1817		415 (M + H)
1818		404 (M + H)
1819		471 (M + H)
1820		433 (M + H)
1821		569 (M + H)






Example No.	Structure	APCI-MS
1822		415 (M + H)
1823		408 (M + H)
1824		510 (M + H)
1825		525 (M + H)
1826		541 (M + H)






Example No.	Structure	APCI-MS
1827		555 (M + H)
1828		578 (M + H)
1829		548 (M + H)
1830		526 (M + H)
1831		544 (M + H)






Example No.	Structure	APCI-MS
1832		528 (M + H)
1833		476 (M + H)
1834		456 (M + H)
1835		498 (M + H)
1836		450 (M + H)






Example No.	Structure	APCI-MS
1837		451 (M + H)
1838		460 (M + H)
1839		464 (M + H)
1840		450 (M + H)
1841		562 (M + H)






Example No.	Structure	APCI-MS
1842		518 (M + H)
1843		512 (M + H)
1844		442 (M + H)
1845		542 (M + H)
1846		424 (M + H)






Example No.	Structure	APCI-MS
1847		530 (M + H)
1848		581 (M + H)
1849		581 (M + H)
1850		451 (M + H)
1851		508 (M + H)






Example No.	Structure	APCI-MS
1852		518 (M + H)
1853		512 (M + H)
1854		543 (M + H)
1855		569 (M + H)
1856		452 (M + H)






Example No.	Structure	APCI-MS
1857		433 (M + H)
1858		601 (M + H)
1859		481 (M + H)
1860		542 (M + H)
1861		534 (M + H)






Example No.	Structure	APCI-MS
1862		434 (M + H)
1863		502 (M + H)
1864		576 (M + H)
1865		466 (M + H)
1866		436 (M + H)






Example No.	Structure	APCI-MS
1867		436 (M + H)
1868		466 (M + H)
1869		432 (M + H)
1870		436 (M + H)
1871		429 (M + H)






Example No.	Structure	APCI-MS
1872		380 (M + H)
1873		391 (M + H)
1874		498 (M + H)
1875		446 (M + H)
1876		465 (M + H)






Example No.	Structure	APCI-MS
1877		518 (M + H)
1878		377 (M + H)
1879		377 (M + H)
1880		476 (M + H)
1881		491 (M + H)






Example No.	Structure	APCI-MS
1882		427 (M + H)
1883		536 (M + H)
1884		524 (M + H)
1885		448 (M + H)
1886		478 (M + H)






Example No.	Structure	APCI-MS
1887		510 (M + H)
1888		422 (M + H)
1889		464 (M + H)
1890		486 (M + H)
1891		462 (M + H)






Example No.	Structure	APCI-MS
1892		400 (M + H)
1893		478 (M + H)
1894		418 (M + H)
1895		448 (M + H)
1896		458 (M + H)






Example No.	Structure	APCI-MS
1897		522 (M + H)
1898		492 (M + H)
1899		600 (M + H)
1900		472 (M + H)
1901		472 (M + H)






Example No.	Structure	APCI-MS
1902		468 (M + H)
1903		460 (M + H)
1904		472 (M + H)
1905		406 (M + H)
1906		446 (M + H)






Example No.	Structure	APCI-MS
1907		480 (M + H)
1908		404 (M + H)
1909		472 (M + H)
1910		486 (M + H)
1911		437 (M + H)






Example No.	Structure	APCI-MS
1912		432 (M + H)
1913		460 (M + H)
1914		474 (M + H)
1915		420 (M + H)
1916		432 (M + H)






Example No.	Structure	APCI-MS
1917		480 (M + H)
1918		444 (M + H)
1919		478 (M + H)
1920		512 (M + H)
1921		392 (M + H)






Example No.	Structure	APCI-MS
1922		403 (M + H)
1923		476 (M + H)
1924		447 (M + H)
1925		446 (M + H)
1926		382 (M + H)






Example No.	Structure	APCI-MS
1927		342 (M + H)
1928		380 (M + H)
1929		370 (M + H)
1930		482 (M + H)
1931		442 (M + H)






Example No.	Structure	APCI-MS
1932		519 (M + H)
1933		505 (M + H)
1934		429 (M + H)
1935		432 (M + H)
1936		418 (M + H)






Example No.	Structure	APCI-MS
1937		588 (M + H)
1938		468 (M + H)
1939		443 (M + H)
1940		434 (M + H)
1941		500 (M + H)






Example No.	Structure	APCI-MS
1942		530 (M + H)
1943		506 (M + H)
1944		414 (M + H)
1945		442 (M + H)
1946		448 (M + H)






Example No.	Structure	APCI-MS
1947		474 (M + H)
1948		461 (M + H)
1949		509 (M + H)
1950		437 (M + H)
1951		427 (M + H)






Example No.	Structure	APCI-MS
1952		444 (M + H)
1953		460 (M + H)
1954		447 (M + H)
1955		456 (M + H)
1956		479 (M + H)






Example No.	Structure	APCI-MS
1957		469 (M + H)
1958		440 (M + H)
1959		476 (M + H)
1960		453 (M + H)
1961		552 (M + H)






Example No.	Structure	APCI-MS
1962		500 (M + H)
1963		554 (M + H)
1964		428 (M + H)
1965		538 (M + H)
1966		448 (M + H)






Example No.	Structure	APCI-MS
1967		486 (M + H)
1968		534 (M + H)
1969		528 (M + H)
1970		484 (M + H)
1971		514 (M + H)






Example No.	Structure	APCI-MS
1972		496 (M + H)
1973		592 (M + H)
1974		516 (M + H)
1975		504 (M + H)
1976		440 (M + H)






Example No.	Structure	APCI-MS
1977		697 (M + H)
1978		551 (M + H)
1979		602 (M + H)
1980		474 (M + H)
1981		491 (M + H)






Example No.	Structure	APCI-MS
1982		523 (M + H)
1983		452 (M + H)
1984		478 (M + H)
1985		464 (M + H)
1986		397 (M + H)






Example No.	Structure	APCI-MS
1987		454 (M - H)
1988		490 (M + H)
1989		410 (M + H)
1990		448 (M + H)
1991		430 (M + H)






Example No.	Structure	APCI-MS
1992		484 (M + H)
1993		424 (M + H)
1994		456 (M + H)
1995		408 (M + H)
1996		475 (M + H)






Example No.	Structure	APCI-MS
1997		490 (M + H)
1998		524 (M + H)
1999		558 (M + H)
2000		394 (M + H)
2001		451 (M + H)






Example No.	Structure	APCI-MS
2002		478 (M + H)
2003		408 (M + H)
2004		560 (M + H)
2005		533 (M + H)
2006		556 (M + H)






Example No.	Structure	APCI-MS
2007		638 (M + H)
2008		380 (M + H)
2009		474 (M + H)
2010		483 (M + H)
2011		464 (M + H)






Example No.	Structure	APCI-MS
2012		470 (M + H)
2013		444 (M + H)
2014		470 (M + H)
2015		487 (M + H)
2016		470 (M + H)






Example No.	Structure	APCI-MS
2017		514 (M + H)
2018		527 (M - H)
2019		562 (M + H)
2020		518 (M + H)
2021		658 (M + H)






Example No.	Structure	APCI-MS
2022		466 (M + H)
2023		450 (M + H)
2024		424 (M + H)
2025		436 (M + H)
2026		420 (M + H)






Example No.	Structure	APCI-MS
2027		420 (M + H)
2028		456 (M + H)
2029		451 (M + H)
2030		422 (M + H)
2031		418 (M + H)






Example No.	Structure	APCI-MS
2032		418 (M + H)
2033		436 (M + H)
2034		467 (M + H)
2035		443 (M + H)
2036		443 (M + H)






Example No.	Structure	APCI-MS
2037		429 (M + H)
2038		418 (M + H)
2039		485 (M + H)
2040		447 (M + H)
2041		583 (M + H)






Example No.	Structure	APCI-MS
2042		536 (M + H)
2043		429 (M + H)
2044		422 (M + H)
2045		507 (M + H)
2046		524 (M + H)






Example No.	Structure	APCI-MS
2047		539 (M + H)
2048		555 (M + H)
2049		569 (M + H)
2050		592 (M + H)
2051		562 (M + H)






Example No.	Structure	APCI-MS
2052		540 (M + H)
2053		558 (M + H)
2054		542 (M + H)
2055		490 (M + H)
2056		470 (M + H)






Example No.	Structure	APCI-MS
2057		512 (M + H)
2058		464 (M + H)
2059		465 (M + H)
2060		474 (M + H)
2061		478 (M + H)






Example No.	Structure	APCI-MS
2062		478 (M + H)
2063		464 (M + H)
2064		576 (M + H)
2065		532 (M + H)
2066		526 (M + H)






Example No.	Structure	APCI-MS
2067		456 (M + H)
2068		556 (M + H)
2069		438 (M + H)
2070		544 (M + H)
2071		595 (M + H)






Example No.	Structure	APCI-MS
2072		595 (M + H)
2073		465 (M + H)
2074		522 (M + H)
2075		532 (M + H)
2076		526 (M + H)






Example No.	Structure	APCI-MS
2077		557 (M + H)
2078		583 (M + H)
2079		466 (M + H)
2080		447 (M + H)
2081		615 (M + H)






Example No.	Structure	APCI-MS
2082		495 (M + H)
2083		556 (M + H)
2084		548 (M + H)
2085		448 (M + H)
2086		516 (M + H)






Example No.	Structure	APCI-MS
2087		590 (M + H)
2088		480 (M + H)
2089		450 (M + H)
2090		450 (M + H)
2091		480 (M + H)






Example No.	Structure	APCI-MS
2092		446 (M + H)
2093		450 (M + H)
2094		443 (M + H)
2095		394 (M + H)
2096		405 (M + H)






Example No.	Structure	APCI-MS
2097		512 (M + H)
2098		460 (M + H)
2099		479 (M + H)
2100		532 (M + H)
2101		391 (M + H)






Example No.	Structure	APCI-MS
2102		391 (M + H)
2103		490 (M + H)
2104		505 (M + H)
2105		441 (M + H)
2106		550 (M + H)






Example No.	Structure	APCI-MS
2107		538 (M + H)
2108		462 (M + H)
2109		492 (M + H)
2110		524 (M + H)
2111		436 (M + H)






Example No.	Structure	APCI-MS
2112		478 (M + H)
2113		500 (M + H)
2114		476 (M + H)
2115		414 (M + H)
2116		492 (M + H)






Example No.	Structure	APCI-MS
2117		432 (M + H)
2118		472 (M + H)
2119		536 (M + H)
2120		506 (M + H)
2121		614 (M + H)






Example No.	Structure	APCI-MS
2122		486 (M + H)
2123		486 (M + H)
2124		482 (M + H)
2125		474 (M + H)
2126		486 (M + H)






Example No.	Structure	APCI-MS
2127		420 (M + H)
2128		494 (M + H)
2129		418 (M + H)
2130		486 (M + H)
2131		500 (M + H)






Example No.	Structure	APCI-MS
2132		446 (M + H)
2133		474 (M + H)
2134		488 (M + H)
2135		434 (M + H)
2136		446 (M + H)






Example No.	Structure	APCI-MS
2137		492 (M + H)
2138		458 (M + H)
2139		492 (M + H)
2140		526 (M + H)
2141		406 (M + H)






Example No.	Structure	APCI-MS
2142		417 (M + H)
2143		490 (M + H)
2144		461 (M + H)
2145		460 (M + H)
2146		396 (M + H)






Example No.	Structure	APCI-MS
2147		356 (M + H)
2148		394 (M + H)
2149		384 (M + H)
2150		496 (M + H)
2151		456 (M + H)






Example No.	Structure	APCI-MS
2152		533 (M + H)
2153		519 (M + H)
2154		443 (M + H)
2155		446 (M + H)
2156		432 (M + H)






Example No.	Structure	APCI-MS
2157		602 (M + H)
2158		457 (M + H)
2159		448 (M + H)
2160		514 (M + H)
2161		544 (M + H)






Example No.	Structure	APCI-MS
2162		520 (M + H)
2163		428 (M + H)
2164		462 (M + H)
2165		488 (M + H)
2166		475 (M + H)






Example No.	Structure	APCI-MS
2167		523 (M + H)
2168		451 (M + H)
2169		441 (M + H)
2170		458 (M + H)
2171		474 (M + H)






Example No.	Structure	APCI-MS
2172		461 (M + H)
2173		470 (M + H)
2174		493 (M + H)
2175		483 (M + H)
2176		454 (M + H)






Example No.	Structure	APCI-MS
2177		490 (M + H)
2178		467 (M + H)
2179		566 (M + H)
2180		514 (M + H)
2181		568 (M + H)






Example No.	Structure	APCI-MS
2182		594 (M + H)
2183		442 (M + H)
2184		552 (M + H)
2185		435 (M + H)
2186		450 (M + H)






Example No.	Structure	APCI-MS
2187		448 (M + H)
2188		444 (M + H)
2189		478 (M + H)
2190		434 (M + H)
2191		446 (M + H)






Example No.	Structure	APCI-MS
2192		420 (M + H)
2193		440 (M + H)
2194		464 (M + H)
2195		448 (M + H)
2196		502 (M + H)






Example No.	Structure	APCI-MS
2197		462 (M + H)
2198		508 (M + H)
2199		440 (M + H)
2200		488 (M + H)
2201		516 (M + H)






Example No.	Structure	APCI-MS
2202		404 (M + H)
2203		478 (M + H)
2204		456 (M + H)
2205		464 (M + H)
2206		456 (M + H)






Example No.	Structure	APCI-MS
2207		450 (M + H)
2208		442 (M + H)
2209		408 (M + H)
2210		424 (M + H)
2211		424 (M + H)






Example No.	Structure	APCI-MS
2212		448 (M + H)
2213		458 (M + H)
2214		458 (M + H)
2215		420 (M + H)
2216		419 (M + H)






Example No.	Structure	APCI-MS
2217		440 (M + H)
2218		446 (M + H)
2219		434 (M + H)
2220		446 (M + H)
2221		404 (M + H)






Example No.	Structure	APCI-MS
2222		408 (M + H)
2223		420 (M + H)
2224		420 (M + H)
2225		463 (M + H)
2226		460 (M + H)






Example No.	Structure	APCI-MS
2227		462 (M + H)
2228		502 (M + H)
2229		434 (M + H)
2230		456 (M + H)
2231		432 (M + H)






Example No.	Structure	APCI-MS
2232		460 (M + H)
2233		488 (M + H)
2234		474 (M + H)
2235		446 (M + H)
2236		484 (M + H)






Example No.	Structure	APCI-MS
2237		420 (M + H)
2238		568 (M + H)
2239		428 (M + H)
2240		396 (M + H)
2241		420 (M + H)






Example No.	Structure	APCI-MS
2242		468 (M + H)
2243		432 (M + H)
2244		468 (M + H)
2245		458 (M + H)
2246		423 (M + H)






Example No.	Structure	APCI-MS
2247		420 (M + H)
2248		404 (M + H)
2249		448 (M + H)
2250		446 (M + H)
2251		540 (M + H)






Example No.	Structure	APCI-MS
2252		470 (M + H)
2253		472 (M + H)
2254		479 (M + H)
2255		433 (M + H)
2256		458 (M + H)






Example No.	Structure	APCI-MS
2257		515 (M + H)
2258		410 (M + H)
2259		394 (M + H)
2260		368 (M + H)
2261		372 (M + H)






Example No.	Structure	APCI-MS
2262		397 (M + H)
2263		464 (M + H)
2264		462 (M + H)
2265		458 (M + H)
2266		492 (M + H)






Example No.	Structure	APCI-MS
2267		448 (M + H)
2268		460 (M + H)
2269		434 (M + H)
2270		454 (M + H)
2271		478 (M + H)







Example No.	Structure	APCI-MS
2272		462 (M + H)
2273		516 (M + H)
2274		476 (M + H)
2275		522 (M + H)
2276		454 (M + H)






Example No.	Structure	APCI-MS
2277		502 (M + H)
2278		530 (M + H)
2279		418 (M + H)
2280		492 (M + H)
2281		470 (M + H)






Example No.	Structure	APCI-MS
2282		478 (M + H)
2283		470 (M + H)
2284		464 (M + H)
2285		456 (M + H)
2286		422 (M + H)






Example No.	Structure	APCI-MS
2287		438 (M + H)
2288		462 (M + H)
2289		472 (M + H)
2290		472 (M + H)
2291		434 (M + H)






Example No.	Structure	APCI-MS
2292		433 (M + H)
2293		454 (M + H)
2294		460 (M + H)
2295		448 (M + H)
2296		460 (M + H)






Example No.	Structure	ESI-MS	Retention Time (min)
3293	 <chem>CCOC1=CC=C(C=C1)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	3.05
3294	 <chem>CCOC1=CC(=CC=C1OC)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	3.21
3295	 <chem>COc1cc(F)ccc1CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	2.94
3296	 <chem>CN(C)Cc1ccc(cc1)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $3\text{CF}_3\text{CO}_2\text{H}$	419.4 (M + H)	2.51
3297	 <chem>c1cc[nH]c1CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $3\text{CF}_3\text{CO}_2\text{H}$	366.4 (M + H)	2.26
3298	 <chem>COc1cc(F)ccc1CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	2.93






Example No.	Structure	APCI-MS
2297		422 (M + H)
2298		474 (M + H)
2299		476 (M + H)
2300		516 (M + H)
2301		448 (M + H)



Example No.	Structure	APCI-MS
2302		470 (M + H)
2303		446 (M + H)
2304		488 (M + H)
2305		460 (M + H)
2306		434 (M + H)

Example No.	Structure	APCI-MS
2307		582 (M + H)
2308		442 (M + H)
2309		419 (M + H)
2310		434 (M + H)
2311		482 (M + H)


Example No.	Structure	APCI-MS
2312		418 (M + H)
2313		446 (M + H)
2314		482 (M + H)
2315		472 (M + H)
2316		437 (M + H)

Example No.	Structure	APCI-MS
2317		434 (M + H)
2318		418 (M + H)
2319		462 (M + H)
2320		460 (M + H)
2321		554 (M + H)

Example No.	Structure	APCI-MS
2322		470 (M + H)
2323		537 (M + H)
2324		529 (M + H)
2325		424 (M + H)
2326		408 (M + H)

Example No.	Structure	APCI-MS
2327	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCCC=C</chem>	382 (M + H)
2328	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCC4OCCO4</chem>	386 (M + H)

Example 2329



***trans*-4-Bromo-N-{4-[(4-methylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride**

Step A: Synthesis of *trans*-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid.

To a solution of *trans*-4-aminomethyl-cyclohexanecarboxylic acid (3.14 g, 20 mmol) in THF (20 mL) and 1 M aqueous sodium hydroxide (42 mL) was added a solution of 4-bromo-2-trifluoromethoxy benzenesulfonyl chloride (6.9 g, 20.4 mmol) in THF (20 mL) and the mixture was stirred for 2 hr at ambient temperature. The resulting mixture was concentrated and 1 M aqueous HCl (45 mL) was added. The resulting precipitate was filtered, washed with water and hexanes to give *trans*-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid (7.18 g, 78%) as a white powder.

ESI MS m/e 460/462 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 12.00 (brs, 1 H), 7.99 (brs, 1 H), 7.84-7.80 (m, 3 H), 2.72 (d, $J = 6.3$ Hz, 2 H), 2.10 (m, 1 H), 1.86 (m, 2 H), 1.71 (m, 2 H), 1.31 (m, 1 H), 1.23 (m, 2 H), 0.87 (m, 2 H).

Step B: Synthesis of *trans*-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid amide.

A solution of *trans*-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid (7.14 g, 15.5 mmol) and triethylamine (2.35 mL, 16.9 mmol) in THF (25 mL) was cooled to 0 °C. To the mixture was added ethyl chloroformate (1.62 mL, 17 mmol) in THF (5 mL) over 10 min. After stirring at 0 °C for 15 min, aqueous ammonia (27 mL) was added dropwise and the mixture was stirred at ambient temperature for 2 hr. The mixture was concentrated under reduced pressure and the concentrate was treated with water to give a solid. The solid was filtered and washed with water and hexanes to give *trans*-4-[(4-bromo-2-trifluoromethoxy-

benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid amide as a white solid (4.2 g, 59%).

ESI MS m/e 459/461 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 7.98 (brs, 1 H), 7.84-7.80 (m, 3 H), 7.13 (s, 1 H), 6.62 (s, 1 H), 2.72 (d, $J = 6.5$ Hz, 2 H), 1.98 (m, 1 H), 1.70 (m, 4 H), 1.29 (m, 1 H), 1.23 (m, 2 H), 0.83 (m, 2 H).

Step C: Synthesis of *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide.

To a solution of *trans*-4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexanecarboxylic acid amide (4.2 g, 9.2 mmol) in THF (40 mL) was added a solution of 1 M BH_3 in THF (32 mL, 32 mmol) over 40 min. The mixture was refluxed for 2 hr. After cooling to 0 °C, the mixture was quenched with water (7 mL). To the resulting mixture were added 4 M HCl in EtOAc (28 mL) and MeOH (28 mL) and the mixture was concentrated. To the residue was added MeOH (28 mL) and the mixture was once again concentrated. The resulting HCl-salt was recrystallized from Et_2O and subsequently neutralized with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH_2Cl_2 (twice), the organic layers combined, dried over sodium sulfate, and concentrated under reduced pressure to give *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide as a white solid (3.0 g, 74%).

ESI MS m/e 445/447 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 7.84-7.79 (m, 3 H), 3.42 (brs, 2 H), 2.72 (d, $J = 6.8$ Hz, 2 H), 2.33 (d, $J = 6.5$ Hz, 2 H), 1.73 (m, 4 H), 1.27 (m, 1 H), 1.09 (m, 1 H), 0.80 (m, 4 H).


Step D: Synthesis of *trans*-4-Bromo-*N*-{4-[(4-methylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride.

A mixture of (2-chloro-quinazolin-4-yl)-methylamine obtained in step A of example 50 (58 mg, 0.3 mmol) and *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide (133 mg, 0.3 mmol) in 2-propanol (0.5 mL) was stirred at reflux for 24 hr. The mixture was cooled and the resulting white solid was collected by filtration and washed with 2-propanol to give *trans*-4-Bromo-*N*-{4-[(4-methylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide hydrochloride as a white solid (121 mg, 67%).

ESI MS m/e 602/604 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 12.61 (brs, 1 H), 9.70

(brs, 1 H), 8.26 (d, $J = 8.1$ Hz, 1 H), 8.15 (brs, 1 H), 8.02 (t, $J = 5.7$ Hz, 1 H), 7.84-7.74 (m, 4 H), 7.41 (m, 1 H), 3.32 (m, 2 H), 3.07 (d, $J = 3.5$ Hz, 3 H), 2.73 (t, $J = 6.2$ Hz, 2 H), 1.77 (m, 4 H), 1.53 (m, 1 H), 1.32 (m, 1 H), 0.96 (m, 2 H), 0.82 (m, 2 H).

Example 2330



***trans*-N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride**

Step A: Synthesis of *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid.

To a solution of *trans*-4-aminomethyl-cyclohexanecarboxylic acid (1.5 g, 10 mmol) in THF (10 mL) and 1 M aqueous sodium hydroxide (27 mL) was added a solution of 2,5-bis(2,2,2-trifluoroethoxy) benzenesulfonyl chloride (3.8 g, 10.25 mmol) in THF (10 mL) dropwise and the mixture was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated and 1 M aqueous HCl (22.5 mL) was added. The resulting precipitate was filtered, washed with water and hexanes to give *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid as a white powder (2.8 g, 57%).

ESI MS m/e 494 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 7.36 (m, 3 H), 7.23 (brs, 1 H), 4.88 (m, 4 H), 2.73 (m, 2 H), 2.10 (m, 1 H), 1.87 (m, 2 H), 1.72 (m, 2 H), 1.30 (m, 1 H), 1.23 (m, 2 H), 0.87 (m, 2 H).

Step B: Synthesis of *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid amide.

A solution of *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid (2.78 g, 5.63 mmol) and triethylamine (1.9 mL,

13.6 mmol) in THF (25 mL) was cooled to 0 °C. To the mixture was added ethyl chloroformate (0.586 mL, 6.2 mmol) in THF (5 mL) over 10 min. After stirring at 0 °C for 15 min, 25% aqueous ammonia (10 mL) was added dropwise. The mixture was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated under reduced pressure and the concentrate was diluted with water to give a solid. The solid was filtered and washed with water and hexanes to give *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid amide as a white solid (2.7 g, 98%).

ESI MS m/e 493 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 7.36 (m, 3 H), 7.23 (t, $J = 6.1$ Hz, 1 H), 7.13 (s, 1 H), 6.62 (s, 1 H), 4.88 (m, 4 H), 2.74 (t, $J = 6.4$ Hz, 2 H), 1.99 (m, 1 H), 1.75 (m, 4 H), 1.28 (m, 1 H), 1.23 (m, 2 H), 0.83 (m, 2 H).

Step C: Synthesis of *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide.

To a solution of *trans*-4-{[2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonylamino]-methyl}-cyclohexanecarboxylic acid amide (2.7 g, 5.5 mmol) in THF (20 mL) was added a solution of 1 M BH_3 in THF (20 mL, 20 mmol) over 40 min. The mixture was stirred at reflux for 2 hr. After cooling to 0 °C, the mixture was quenched with water (7 mL). To the mixture were added 4 M HCl in EtOAc (28 mL) and MeOH (50 mL) and the mixture was concentrated. To the residue was added MeOH (50 mL) and the mixture was once again concentrated. The resulting HCl-salt was recrystallized from Et_2O and subsequently neutralized with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH_2Cl_2 (twice), the combined organic layers were dried over sodium sulfate, and concentrated under reduced pressure to give *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide as a white solid (1.5 g, 57%).


ESI MS m/e 479 $M + H^+$; 1H NMR (500 MHz, DMSO- d_6) δ 7.36-7.32 (m, 3 H), 6.62 (brs, 1 H), 4.88-4.78 (m, 4 H), 3.42 (b, 2 H), 2.73 (d, $J = 6.6$ Hz, 2 H), 2.34 (d, $J = 6.3$ Hz, 2 H), 1.73 (m, 4 H), 1.27 (m, 1 H), 1.10 (m, 1 H), 0.77 (m, 4 H).

Step D: Synthesis of *trans*-*N*-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride.

A mixture of (2-chloro-quinazoline-4-yl)-dimethyl-amine obtained in step B of example 1 (41.4 mg, 0.2 mmol) and *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide (95.6 mg, 0.2 mmol) in 2-propanol was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was purified by column chromatography (silica gel) to give the product as a white foam. The product was dissolved in CH₂Cl₂ and treated with 1 M HCl in Et₂O. The mixture was concentrated to give *trans*-*N*-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2,5-bis-(2,2,2-trifluoro-ethoxy)-benzenesulfonamide hydrochloride as a white foam (101 mg, 78%).

ESI MS *m/e* 650 *M* + *H*⁺; ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.16 (d, *J* = 8.2 Hz, 1 H), 8.00 (brs, 1 H), 7.78 (t, *J* = 7.9, 1 H), 7.44 (brs, 1 H), 7.34 (m, 4 H), 7.24 (t, *J* = 5.9 Hz, 1 H), 4.88 (m, 4 H), 3.32 (s, 6 H), 3.29 (m, 2 H), 2.75 (t, *J* = 6.2 Hz, 2 H), 1.74 (m, 4 H), 1.52 (m, 1 H), 1.32 (m, 1 H), 0.94 (m, 2 H), 0.83 (m, 2 H).

Example 2331



***trans*-4-Bromo-*N*-(4-guanidinomethyl-cyclohexylmethyl)-2-trifluoromethoxy-benzenesulfonamide dihydrochloride**

Step A: Synthesis of *trans*-[({4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexylmethyl}-amino)-*tert*-butoxycarbonylamino-methyl]-carbamic acid *tert*-butyl ester.

To a solution of *trans*-*N*-(4-aminomethyl-cyclohexylmethyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide obtained in step C of example 2329 (45 mg, 0.1 mmol) and triethylamine (14 μL, 0.1 mmol) in CH₂Cl₂ (5 mL) was added (*tert*-butoxycarbonylamino-trifluoromethanesulfonylimino-methyl)-carbamic acid *tert*-butyl ester (39.1 mg, 0.1 mmol). The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was purified by column chromatography (silica gel,

CH_2Cl_2 to 10% MeOH in CH_2Cl_2) to give *trans*-[({4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-

cyclohexylmethyl}-amino)-*tert*-butoxycarbonylamino-methyl]-carbamic acid

tert-butyl ester as a white solid (63 mg, 92%).


ESI MS m/e 687/689 $M + H^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.45 (s, 1 H), 8.22 (t, $J = 5.6$ Hz, 1 H), 7.97 (t, $J = 5.6$ Hz, 1 H), 7.99-7.79 (m, 3 H), 3.13 (t, $J = 6.4$ Hz, 2 H), 2.72 (t, $J = 6$ Hz, 2 H), 1.70 (m, 4 H), 1.46 (s, 9 H), 1.38 (s, 9 H), 1.31 (m, 2 H), 0.83 (m, 4 H).

Step B: Synthesis of *trans*-4-bromo-*N*-(4-guanidinomethyl-cyclohexylmethyl)-2-trifluoromethoxy-benzenesulfonamide dihydrochloride.

A solution of *trans*-[({4-[(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-methyl]-cyclohexylmethyl}-amino)-*tert*-butoxycarbonylamino-methyl]-carbamic acid *tert*-butyl ester (53 mg, 0.077 mmol) in 50% TFA in CH_2Cl_2 (2 mL) was stirred at ambient temperature for 3 hr and the reaction mixture was concentrated. To the residue was added a solution of 1 M HCl in Et_2O (0.5 mL) and the mixture was concentrated to give *trans*-4-Bromo-*N*-(4-guanidinomethyl-cyclohexylmethyl)-2-trifluoromethoxy-benzenesulfonamide dihydrochloride as a white solid (29 mg, 68%).

ESI MS m/e 487/489 $M + H^+$; ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.01 (t, $J = 5.5$ Hz, 1 H), 7.84 (m, 3 H), 7.68 (m, 1 H), 7.30 (m, 2 H), 6.85 (m, 2 H), 2.94 (t, $J = 6.1$ Hz, 2 H), 2.74 (t, $J = 6.1$ Hz, 2 H), 1.71 (m, 2 H), 1.31 (m, 4 H), 0.86 (m, 4 H).

Example 2332



cis-*N*¹,*N*¹-Dimethyl-*N*²-{4-[(2-trifluoromethyl-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine ditrifluoro-acetic acid

Step A: Synthesis of *cis*-4-*tert*-butoxycarbonylamino-cyclohexanecarboxylic acid.

To a solution of *cis*-4-amino-cyclohexanecarboxylic acid (50 g, 350 mmol) in THF

(200 mL) and 1 M aqueous sodium hydroxide (380 mL, 380 mmol) was added (Boc)₂O (83.5 g, 360 mmol). The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was cooled to 0 °C followed by acidification with 1 M HCl (pH = 3). The resulting white solid was filtered, washed with water and hexanes to give *cis*-4-*tert*-butoxycarbonylamino-cyclohexanecarboxylic acid (71g, 83%) as a white solid. ESI MS *m/e* 244 *M* + *H*⁺ ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.00 (brs, 1 H), 6.74 (d, *J* = 4.25, 1 H), 3.30 (brs, 1 H), 2.35 (m, 1 H), 1.87 (m, 2 H), 1.55-1.37 (m, 15 H).

Step B: Synthesis of *cis*-(4-carbamoyl-cyclohexyl)-carbamic acid *tert*-butyl ester.

To a solution cooled at 0°C of *cis*-4-*tert*-butoxycarbonylamino-cyclohexanecarboxylic acid (68.0 g, 280 mmol) and triethylamine (31.1 g, 307 mmol) in THF (300 mL) was added ethyl chloroformate (29.3 mL, 308 mmol) dropwise. After stirring at 0 °C for 30 min, 25% aqueous ammonia (168 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was extracted with EtOAc (three times). The combined organic layer was washed with saturated aqueous NaHCO₃, 1 M HCl, brine, and water, dried over Na₂SO₄, filtered, and concentrated to give *cis*-(4-carbamoyl-cyclohexyl)-carbamic acid *tert*-butyl ester (62.0 g, 88%) as a white solid.

ESI MS *m/e* 243 *M* + *H*⁺ ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.10 (brs, 1 H), 6.69 (b, 2 H), 3.41 (brs, 1 H), 2.14 (m, 1 H), 1.79 (m, 2 H), 1.59 (m, 2 H), 1.45-1.37 (m, 13 H).

Step C: Synthesis of *cis*-4-amino-cyclohexanecarboxylic acid amide hydrochloride.

To a solution of *cis*-(4-carbamoyl-cyclohexyl)-carbamic acid *tert*-butyl ester (62 g, 256 mmol) in CH₂Cl₂ (250 mL) was added TFA (250 mL) and the mixture was stirred at ambient temperature for 1 hr. The mixture was concentrated and 2 M HCl in Et₂O (150 mL) was added to give a white precipitate. The mixture was concentrated to give *cis*-4-amino-cyclohexanecarboxylic acid amide hydrochloride (45 g, 98%) as a white solid.

ESI MS *m/e* 143 *M* + *H*⁺ ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.08 (m, 3 H), 7.28 (s, 1 H), 6.78 (s, 1 H), 3.10 (m, 1 H), 2.24 (m, 1 H), 1.90 (m, 2 H), 1.66 (m, 4 H), 1.50 (m, 2 H).

Step D: Synthesis of *cis*-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide.

A solution of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of

example 1 (31.05 g, 150 mmol) and *cis*-4-amino-cyclohexanecarboxylic acid amide hydrochloride (26.7 g, 150 mmol) in pyridine (150 mL) was stirred at reflux for overnight. The reaction mixture was concentrated and residue was dissolve in CH₂Cl₂. The organic layer was washed with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (silica gel, 2% to 10% 2 M NH₃/MeOH in CH₂Cl₂) to give a slightly brown solid and the solid was recrystallized from CH₂Cl₂ to give *cis*-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide (20.6 g, 44%) as yellow crystals.

ESI MS *m/e* 314 M + H⁺ ; ¹H NMR (400 MHz, DMSO-d₆) δ 8.19 (brs, 1 H), 8.15 (d, *J* = 8.4 Hz, 1 H), 7.77 (t, *J* = 8.0 Hz, 1 H), 7.42 (d, *J* = 7.2 Hz, 1 H), 7.35 (t, *J* = 8.4 Hz, 1 H), 7.21 (s, 1 H), 6.74 (s, 1 H), 4.12 (m, 1 H), 3.46 (m, 6 H), 2.24 (m, 1 H), 1.79-1.61 (m, 8 H).

Step E: Synthesis of *cis*-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine.

To a solution of *cis*-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide (18.78 g, 60 mmol) in THF (200 mL) was added a solution of 1 M BH₃ in THF (300 mL, 300 mmol). The mixture was stirred at reflux for 2 hr. After cooling the reaction mixture to 0 °C, 4 M HCl in EtOAc (100 mL) and MeOH (200 mL) were added. The mixture was concentrated. The mixture was treated with 1 M aqueous sodium hydroxide and the aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over sodium sulfate, concentrated, and purified by column chromatography (silica gel, 10% 2 M NH₃/MeOH in CH₂Cl₂) to give *cis*-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine as a white solid (10.6 g, 59%).


ESI MS *m/e* 300 M + H⁺ ; ¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (d, *J* = 8.4 Hz, 1 H), 7.46 (t, *J* = 6.8 Hz, 1 H), 7.26 (d, *J* = 8.4 Hz, 1 H), 6.99 (t, *J* = 6.8 Hz, 1 H), 6.28 (brs, 1 H), 4.02 (m, 1 H), 3.19 (m, 6 H), 2.47 (d, *J* = 6.8 Hz, 2 H), 2.73 (m 2 H), 1.68-1.33 (m, 9 H).

Step F: Synthesis of *cis*-N⁴,N⁴-dimethyl-N²-{4-[(2-trifluoromethyl-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine ditrifluoro-acetic acid.

A solution of *cis*-*N*²-(4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (33 mg, 0.11 mmol) and 2-trifluoromethyl benzaldehyde (17.41 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature for 3 hr. To the mixture was added NaBH(OAc)₃ (85 mg, 0.4 mmol) and the mixture was stirred at ambient temperature for overnight. This resulting mixture was quenched with 50% DMSO in water (2 mL) and the solution was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*-*N*⁴,*N*⁴-dimethyl-*N*²-{4-[(2-trifluoromethyl-benzylamino)-methyl]-cyclohexyl}-quinazoline-2,4-diamine ditrifluoro-acetic acid (41.4 mg, 60%) as a white solid.

ESI MS *m/e* 458 M + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.12 (brs, 1 H), 8.94 (b, 2 H), 8.65 (d, *J* = 6.8 Hz, 1 H), 8.16 (d, *J* = 8.8 Hz, 1 H), 7.77-7.66 (m, 5 H), 7.41 (d, *J* = 8.4 Hz, 1 H), 7.35 (t, *J* = 8 Hz, 1 H), 4.22 (s, 2 H), 4.17 (m, 1 H), 3.46 (b, 6 H), 2.94 (m, 2 H), 1.87-1.44 (m, 9 H).

Example 2333



***cis*-5-(4-Chloro-phenyl)-2-trifluoromethyl-furan-3-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-amide trifluoro-acetic acid**


Step A: Synthesis of *cis*-5-(4-chloro-phenyl)-2-trifluoromethyl-furan-3-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-amide trifluoro-acetic acid.

A solution of *cis*-*N*²-(4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine obtained in step E of example 2332 (30 mg, 0.1 mmol), 5-(4-chloro-phenyl)-2-trifluoromethyl-furan-3-acid chloride (37 mg, 0.12 mmol), and pyridine (12 μL, 0.15 mmol) in DMF (0.5 mL) was stirred at ambient temperature for overnight. The resulting mixture was diluted with DMSO (0.8 mL) and the mixture was purified by preparative

HPLC. The pure fractions were combined and lyophilized to give *cis*-5-(4-chloro-phenyl)-2-trifluoromethyl-furan-3-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-amide trifluoro-acetic acid (17.5 mg, 26%) as a white solid.

ESI MS m/e 572 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.30 (brs, 1 H), 8.65 (t, $J = 6.8$ Hz, 1 H), 8.19 (brs, 1 H), 8.14 (d, $J = 8.0$ Hz, 1 H), 7.83-7.30 (m, 8 H), 4.1 (m, 1 H), 3.46 (b, 6 H), 3.09 (m, 2 H), 1.77-1.38 (m, 9 H).

Example 2334



***cis*-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4,5-trimethoxy-benzamide trifluoro-acetic acid**


Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4,5-trimethoxy-benzamide trifluoro-acetic acid.

To HOBt-6-carboxamidomethyl polystyrene 200-400 mesh (77 mg, 0.1 mmol) were added a solution of 0.3 M PyBroP in DMF (1 mL, 0.3 mmol), 3,4,5-trimethoxybenzoic acid (63 mg, 0.3 mmol), and diisopropylethylamine (85 μ L, 0.5 mmol). The mixture was stirred at ambient temperature for 5 hr. The resin was washed with DMF (3 times), CH_2Cl_2 (3 times), MeOH (3 times), CH_2Cl_2 (2 times), and DMF (2 times). To the resin was added *cis*- N^2 -(4-aminomethyl-cyclohexyl)- N^4 , N^4 -dimethyl-quinazoline-2,4-diamine obtained in step E of example 2332 (28 mg, 0.09 mmol) in DMF (0.5 mL) and the mixture was stirred at ambient temperature for overnight. The resin was filtered and washed with 0.5 mL DMSO (2 times). The combined filtrates were purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis* N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4,5-trimethoxy-benzamide trifluoro-acetic acid (7.4 mg, 12%) as a white solid.

ESI MS m/e 494 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.25 (brs, 1 H), 8.45 (t, $J = 5.6$ Hz, 1 H), 8.17 (brs, 1 H), 8.14 (d, $J = 8.0$ Hz, 1 H), 7.76 (t, $J = 8.4$ Hz, 1 H), 7.42 (d, J

= 7.2 Hz, 1 H), 7.34 (t, J = 7.6 Hz, 1 H), 7.15 (s, 2 H), 4.13 (m, 1 H), 3.44 (s, 3 H), 3.39 (s, 3 H), 3.20 (m, 2 H), 1.77-1.37 (m, 9 H).

Example 2335



Biphenyl-4-carboxylic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-amide

Step A: Synthesis of (4-amino-benzyl)-carbamic acid *tert*-butyl ester.

A solution of 4-aminomethyl-phenylamine (12.2 g, 100 mmol) and (Boc)₂O (21.8 g, 100 mmol) in CH₂Cl₂ (100 mL) was stirred at ambient temperature for overnight. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH₂Cl₂ to 10% MeOH in CH₂Cl₂) to give (4-amino-benzyl)-carbamic acid *tert*-butyl ester (11.6 g, 52%) as a slightly yellow solid.

ESI MS m/e 223 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.27 (t, J = 6.0 Hz, 1 H), 6.86 (d, J = 8.0 Hz, 2 H), 6.47 (d, J = 6.4 Hz, 2 H), 4.89 (s, 2 H), 3.91 (d, J = 6.0 Hz, 2 H), 1.39 (s, 9 H).

Step B: Synthesis of biphenyl-4-carboxylic acid (4-aminomethyl-phenyl)-amide hydrochloride.

To a solution of (4-amino-benzyl)-carbamic acid *tert*-butyl ester (1.11 g, 5 mmol), biphenyl carboxylic acid (0.99 g, 5 mmol), EDC (1.2 g, 6.25 mmol), and HOAt (0.82 g, 6 mmol) in CH₂Cl₂ (10 mL) was added triethylamine (pH = 10) and the mixture was stirred at ambient temperature for overnight. The organic layer was washed with saturated aqueous NaHCO₃, 1 M aqueous HCl, water, dried over Na₂SO₄, filtered, and concentrated. The residue was dissolved in 50% TFA in CH₂Cl₂ (10 mL) and the mixture was stirred at ambient temperature. After 30 minutes, the mixture was concentrated and diluted with 1 M HCl in Et₂O (5 mL). The mixture was concentrated to give biphenyl-4-carboxylic acid (4-aminomethyl-phenyl)-amide hydrochloride (828 mg, 49%).


ESI MS m/e 303 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 10.40 (s, 1 H), 8.34 (b, 3 H), 8.07 (d, $J = 8.0$ Hz, 2 H), 7.83-7.73 (m, 6 H), 7.51-7.38 (m, 5 H), 4.0 (q, $J = 5.6$ Hz, 2 H).

Step C: Synthesis of biphenyl-4-carboxylic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-amide.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (42 mg, 0.2 mmol) and biphenyl-4-carboxylic acid (4-aminomethyl-phenyl)-amide hydrochloride (49 mg, 0.14 mmol) in 2-propanol (1 mL) and triethylamine (200 μ L) was stirred at reflux for 2 days. The resulting mixture was concentrated and purified by column chromatography (silica gel, CH_2Cl_2 to 10% 2 M $NH_3/MeOH$ in CH_2Cl_2) to give biphenyl-4-carboxylic acid {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-phenyl}-amide (10 mg, 15%) as a white solid.

ESI MS m/e 474 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 10.19 (s, 1 H), 8.02 (d, $J = 7.2$ Hz, 2 H), 7.86 (d, $J = 8.4$ Hz, 1 H), 7.80 (d, $J = 8.4$ Hz, 2 H), 7.73 (d, $J = 7.2$ Hz, 2 H), 7.68 (d, $J = 7.6$ Hz, 2 H), 7.50-7.15 (m, 8 H), 7.01 (t, $J = 8.4$ Hz, 1 H), 4.51 (d, $J = 6.4$ Hz, 2 H), 3.30 (s, 3 H), 3.2 (s, 3 H).

Example 2336



***cis*-N²-{4-[2-(4-Bromo-2-trifluoromethoxy-benzylamino)-ethyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid**

Step A: Synthesis of *cis*-[4-(2-benzoyloxycarbonylamino-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of *cis*-[4-(2-amino-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (4.84 g, 20 mmol) in CH_2Cl_2 (50 mL) and triethylamine (3.06 mL, 22 mmol) was added benzyl chloroformate (3.13 mL, 22 mmol) and the mixture was stirred for 4 hr. The resulting mixture was washed with water, 1 M aqueous HCl, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by column chromatography (silica gel,

CH₂Cl₂ to 10% MeOH in CH₂Cl₂) to give *cis*-[4-(2-benzyloxycarbonylamino-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (5.46 g, 73%) as a colorless oil.

ESI MS *m/e* 377 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.36-7.24 (m, 5 H), 7.19 (t, *J* = 5.6 Hz, 1 H), 6.76 (d, *J* = 6.8 Hz, 1 H), 4.91 (s, 2 H), 3.40 (m, 1 H), 2.99 (m, 2 H), 1.44-1.33 (m, 20H).

Step B: Synthesis of *cis*-[2-(4-amino-cyclohexyl)-ethyl]-carbamic acid benzyl ester.

A solution of *cis*-[4-(2-benzyloxycarbonylamino-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (5.26 g, 14 mmol) in 50% TFA in CH₂Cl₂ (60 mL) was stirred at ambient temperature for 1 hr. The mixture was concentrated and the residue was diluted with saturated aqueous NaHCO₃. The aqueous layer was extracted with CH₂Cl₂ (three times). The organic layer was dried over Na₂SO₄ and concentrated to give *cis*-[2-(4-amino-cyclohexyl)-ethyl]-carbamic acid benzyl ester (3.5 g, 91%) as a colorless oil.

ESI MS *m/e* 277 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (b, 2 H), 7.34-7.27 (m, 5 H), 7.21 (t, *J* = 5.2 Hz, 1 H), 4.97 (s, 2 H), 3.14 (m, 1 H), 2.99 (q, *J* = 6.4 Hz, 2 H), 1.58-1.34 (m, 11 H).

Step C: Synthesis of *cis*{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}-carbamic acid benzyl ester.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (2.45 g, 10.2 mmol) and *cis*-[2-(4-amino-cyclohexyl)-ethyl]-carbamic acid benzyl ester (3.3 g, 10.2 mmol) and triethylamine (1.65 mL, 10.2 mmol) in 2-propanol (15 mL) was heated at 170 °C for 45 min using a Smith Microwave Synthesizer. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH₂Cl₂ to 10% 2 M NH₃/MeOH in CH₂Cl₂) to give *cis*{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}-carbamic acid benzyl ester (4.48g, 85%) as a yellow oil.

ESI MS *m/e* 448 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.07-7.20 (m, 11 H), 4.98 (s, 2 H), 4.08 (m, 1 H), 3.39 (b, 6 H), 3.04 (m, 2 H), 1.7-1.3 (m, 11 H).

Step D: Synthesis of *cis*-N²-[4-(2-amino-ethyl)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine.

To a solution of *cis*-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-


ethyl}-carbamic acid benzyl ester (4.47 g, 10 mmol) in EtOH (20 mL) was added 1,4-cyclohexadiene (20 mL) and 200 mg of 10% Pd/C. The reaction mixture was stirred at ambient temperature for 18 hr, filtered through pad of celite, and concentrated. The residue was purified by column chromatography (silica gel, 5% to 15% 2 M NH₃/MeOH in CH₂Cl₂) to give *cis*-N²-[4-(2-amino-ethyl)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (2.41g, 77%) as a yellow oil.

ESI MS m/e 314 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (d, *J* = 8.0 Hz, 1 H), 7.44 (t, *J* = 6.8 Hz, 1 H), 7.27 (d, *J* = 8.0 Hz, 1 H), 6.97 (t, *J* = 6.8 Hz, 1 H), 6.31 (brs, 1 H), 3.97 (m, 1 H), 3.37 (b, 2 H), 3.17 (s, 3), 3.14 (s, 3 H), 2.62 (t, *J* = 7.6 Hz, 2 H), 1.68-1.31 (m, 11 H).

Step E: Synthesis of *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-benzylamino)-ethyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.

A solution of *cis*-N²-[4-(2-amino-ethyl)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (31.4 mg, 0.1 mmol) and 4-bromo-2-trifluoromethoxy benzaldehyde (26.9 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature. After 3 hr, NaBH(OAc)₃ (85 mg, 0.4 mmol) was added and the resulting mixture was stirred at ambient temperature for overnight. The reaction mixture was quenched with 50% DMSO in water (2 mL). The mixture was concentrated and purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*-N²-{4-[2-(4-bromo-2-trifluoromethoxy-benzylamino)-ethyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (32.2 mg, 41%) as a white solid.

ESI MS m/e 566/568 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.76 (brs, 1 H), 8.81 (b, 2 H), 8.43 (m, 1 H), 8.09 (d, *J* = 8.4 Hz, 1 H), 7.71-7.56 (m, 4 H), 7.35 (d, *J* = 8.0 Hz, 1 H), 7.29 (t, *J* = 8.0 Hz, 1 H), 4.15 (m, 3 H), 3.39 (m, 6 H), 2.97 (m, 2 H), 1.67-1.30 (m, 11 H).


Example 2337

***cis*-2,6-Dichloro-*N*-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}-benzamide trifluoro-acetic acid**

Step A: Synthesis of *cis*-2,6-dichloro-*N*-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}-benzamide trifluoro-acetic acid.

To a solution of *cis*-*N*²-[4-(2-amino-ethyl)-cyclohexyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine (31.4 mg, 0.1 mmol) and 2,6-dichlorobenzoyl chloride (20.7 mg, 0.1 mmol) in DMF (0.5 mL) was added triethylamine (20 uL, 0.14 mmol). After stirring the mixture at ambient temperature for 6 hr, DMSO (0.5 mL) was added and the mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*-2,6-dichloro-*N*-{2-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-ethyl}-benzamide trifluoro-acetic acid (17.6 mg, 29%) as a white solid.

ESI MS *m/e* 486 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.93 (brs, 1 H), 8.26 (t, *J* = 5.2 Hz, 1 H), 8.14 (d, *J* = 8.0 Hz, 1 H), 7.95 (brs, 1 H), 7.76 (t, *J* = 8.4 Hz, 1 H), 7.52-7.31 (m, 5 H), 4.15 (m, 1 H), 3.45 (b, 6 H), 3.29 (m, 2 H), 1.76-1.31 (m, 11 H).

Example 2338

***cis*-*N*²-[4-(2-Ethoxy-benzylamino)-cyclohexylmethyl]-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid**

Step A: Synthesis of *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester.

To a solution of *cis*-(4-carbamoyl-cyclohexyl)-carbamic acid *tert*-butyl ester obtained in step B of example 2332 (9.68 g, 40 mmol) in THF (100 mL) was added a solution of 1 M BH₃ in THF (80 mL, 80 mmol) over 30 min. The mixture was stirred at reflux for 2 hr. After cooling the reaction mixture to ambient temperature, 1 M aqueous sodium hydroxide was carefully added. The solvents were removed under reduced pressure and the aqueous layer was extracted with CH₂Cl₂ (twice). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester as colorless oil (5.16 g, 57%). ESI MS *m/e* 229 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 6.67 (d, *J* = 6.8 Hz, 1 H), 3.43 (m, 1 H), 2.41 (d, *J* = 6.4 Hz, 2 H) 1.49-1.22 (m, 18 H).

Step B: Synthesis of *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester.

A mixture of *cis*-(4-aminomethyl-cyclohexyl)-carbamic acid *tert*-butyl ester (1.14 g, 5 mmol), (2-chloro-quinazoline-4-yl)-dimethyl-amine obtained in step B of example 1 (1.035 g, 5 mmol), and triethylamine (1.5 mL, 11 mmol) in 2-propanol (2.5 mL) was heated at 170 °C for 35 min using a Smith Microwave Synthesizer. The mixture was concentrated and the residue was purified by column chromatography (silica gel, CH₂Cl₂ to 10% 2 M NH₃/MeOH in CH₂Cl₂) to give *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (1.28 g, 80%) as a white solid.

ESI MS *m/e* 400 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.04-7.06 (m, 4 H), 6.77 (d, *J* = 6.0 Hz, 1 H), 3.40-3.16 (m, 9 H), 1.70-1.37 (m, 18 H).

Step C: Synthesis of *cis*-N²-(4-amino-cyclohexylmethyl)-N²,N²-dimethyl-quinazoline-2,4-diamine.

A solution of *cis*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (1.2 g, 3 mmol) in 50% TFA in CH₂Cl₂ (20 mL) was stirred at ambient temperature. After 30 minutes, the mixture was concentrated and the residue was diluted with 1 M aqueous sodium hydroxide. The aqueous layer was extracted with CH₂Cl₂ (twice). The combined organic layer was dried over Na₂SO₄, filtered and concentrated to give *cis*-N²-(4-amino-cyclohexylmethyl)-N²,N²-dimethyl-quinazoline-2,4-diamine (0.88 g, 98%) as a white solid.


ESI MS m/e 300 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 7.85 (d, $J = 7.6$ Hz, 1 H), 7.47 (t, $J = 6.8$ Hz, 1 H), 7.27 (brs, 1 H), 7.0 (t, $J = 7.2$ Hz, 1 H), 6.66 (brs, 1 H), 3.33-3.14 (m, 9 H), 1.69-1.48 (m, 9 H).

Step D: Synthesis of *cis*- N^2 -[4-(2-ethoxy-benzylamino)-cyclohexylmethyl]- N^4 , N^4 -dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.

A solution of *cis*- N^2 -(4-amino-cyclohexylmethyl)- N^4 , N^4 -dimethyl-quinazoline-2,4-diamine (30 mg, 0.1 mmol) and 2-ethoxy benzaldehyde (15 mg, 0.1 mmol) in MeOH (1 mL) was stirred at ambient temperature. After 3 hr, $NaBH(OAc)_3$ (85 mg, 0.4 mmol) was added and the mixture was stirred at ambient temperature for overnight. The resulting mixture was quenched with 50% DMSO in water (2 mL) and the solution was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*- N^2 -[4-(2-ethoxy-benzylamino)-cyclohexylmethyl]- N^4 , N^4 -dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (33 mg, 50%) as a white solid.

ESI MS m/e 434 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 13.03 (brs, 1 H), 8.79 (brs, 1 H), 8.49 (m, 2 H), 8.15 (d, $J = 8.4$ Hz, 1 H), 7.77 (t, $J = 7.6$ Hz, 1 H), 7.40-7.33 (m, 4 H), 7.07 (d, $J = 7.6$ Hz, 1 H), 6.99 (t, $J = 7.2$ Hz, 1 H), 4.11-4.06 (m, 4 H), 3.47-3.41 (m, 8 H), 3.15 (m, 1 H), 1.90-1.60 (m, 9 H), 1.37 (t, $J = 7.2$ Hz, 3 H).

Example 2339



***cis*-3,5-Dichloro- N -{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-benzamide trifluoro-acetic acid**


Step A: Synthesis of *cis*-3,5-dichloro- N -{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-benzamide trifluoro-acetic acid.

A solution of *cis*- N^2 -(4-amino-cyclohexylmethyl)- N^4 , N^4 -dimethyl-quinazoline-2,4-

diamine (30 mg, 0.1 mmol) and 3,5-dichlorobenzoylchloride (20.9 mg, 0.1 mmol) and pyridine (12 μ L, 0.25 mmol) in DMSO (1 mL) was stirred at ambient temperature for overnight. The mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*-3,5-dichloro-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexyl}-benzamide trifluoro-acetic acid. (18 mg, 31%) as a white solid.

ESI MS m/e 472 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.13 (brs, 1 H), 8.34 (d, J = 7.2 Hz, 1 H), 8.15 (d, J = 8.8 Hz, 1 H), 8.06 (brs, 1 H), 7.82-7.73 (m, 4 H), 7.45 (d, J = 7.6 Hz, 1 H), 7.36 (t, J = 7.6 Hz, 1 H), 3.9 (m, 1 H), 3.47-3.25 (m, 8 H), 1.83-1.56 (m, 9 H).

Example 2340



trans-*N*²-{4-[(2,3-Dimethoxy-benzylamino)-methyl]-cyclohexyl}-*N*[′],*N*[′]-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid

Step A: Synthesis of *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid.

To a solution of *trans*-4-amino-cyclohexanecarboxylic acid (37.7 g, 0.24 mol) in a mixture of dioxane (250 ml) and water (200 ml) cooled in an ice bath were added 1 M aqueous sodium hydroxide (10.07 g, 0.25 mol) and (Boc)₂O (57.6 g, 0.26 mol). The reaction mixture was stirred at ambient temperature. After 3 hr, the mixture was concentrated and the residue was dissolved in water. The aqueous layer was washed with Et₂O (3 times). The aqueous layer was cooled in an ice bath and acidified with 1 M aqueous HCl (pH = 2) and the resulting white precipitate was dried to give *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid (47.4 g, 76.8%) as a white solid.

ESI MS m/e 258 $M + H^+$; 1H NMR (400 MHz, CDCl₃) δ 11.95 (brs, 1 H), 6.79 (t, J = 6.0 Hz, 1 H), 2.76 (t, J = 6.0 Hz, 2 H), 2.11 (m, 1 H), 1.87 (m, 2 H), 1.69 (m, 2 H), 1.36 (s,

9 H), 1.27 (m, 3 H), 0.9 (m, 2 H).

Step B: Synthesis of *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester.

To a solution of *trans*-4-(*tert*-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid (46.9 g, 0.18 mol) in benzene (300 mL) were added triethylamine (24.2 g, 0.24 mol) and diphenylphosphoryl azide (55.9 g, 0.20 mol). The reaction mixture was stirred at 80 °C for 1 hr. To the mixture was added benzyl alcohol (25.9 g, 0.24 mol) and stirred at 100 °C for 4 hr. The mixture was subsequently cooled to ambient temperature for overnight, concentrated, and the resulting pale orange solid dissolved in EtOAc. The organic layer was washed with water (three times), concentrated, and the residue was purified by column chromatography (silica gel, 50% EtOAc in hexane) to give *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (66.7g, 100%) as a white solid.

ESI MS m/e 363 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 7.24-7.23 (m, 5 H), 5.06 (s, 2 H), 4.57 (m, 2 H), 3.44 (brs, 1 H), 2.97 (t, $J = 6.4$ Hz, 2 H), 2.04 (m, 2 H), 1.79 (m, 2 H), 1.43 (s, 9 H), 1.08-0.76 (m, 5 H).

Step C: Synthesis of *trans*-(4-amino-cyclohexylmethyl)-carbamic acid *tert*-butyl ester.

To a solution of *trans*-[4-(*tert*-butoxycarbonylamino-methyl)-cyclohexyl]-carbamic acid benzyl ester (5.32 g, 0.015 mol) in EtOH (200 mL) was added 10% Pd/C (50 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 4 hr. The resulting mixture was filtered through a pad of celite and concentrated. The residue was purified by column chromatography (silica gel, 3% 2 M $NH_3/MeOH$ in CH_2Cl_2) to give *trans*-(4-amino-cyclohexylmethyl)-carbamic acid *tert*-butyl ester as a colorless solid (3.197 g, 95.4%).

ESI MS m/e 229 $M + H^+$; 1H NMR (400 MHz, $CDCl_3$) δ 8.44 (brs, 1 H), 4.59 (b, 1 H), 2.96 (m, 2 H), 2.08 (m, 2 H), 1.83 (m, 2 H), 1.43 (s, 9 H), 1.08 (m, 5 H).

Step D: Synthesis of *trans*- N^2 -(4-aminomethyl-cyclohexyl)- N^4,N^4 -dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid

A mixture of *trans*-(4-amino-cyclohexylmethyl)-carbamic acid *tert*-butyl ester


(0.24 g, 1 mmol) and (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.32 g, 1.4 mmol) in 2-propanol (5 mL) was heated to 170 °C for 30 min using a Smith Microwave Synthesizer. This procedure was repeated 19 times. The reaction mixtures were combined and purified by column chromatography (silica gel) to give 1.13 g of a yellow solid. The yellow solid was dissolved in 50% TFA in CH₂Cl₂ (20 mL) and the mixture was stirred at ambient temperature. After 10 hours, the mixture was concentrated and the residue was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *trans*-*N*²-(4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (0.49 g, 5%) as a white solid.

ESI MS *m/e* 300 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.16 (d, *J* = 5.6 Hz, 1 H), 8.11 (m, 2 H), 7.86 (d, *J* = 8.0 Hz, 1 H), 7.51 (t, *J* = 7.6 Hz, 1 H), 7.41 (d, *J* = 8.0 Hz, 1 H), 7.18 (t, *J* = 6.8 Hz, 1 H), 3.8 (brs, 1 H), 3.47 (s, 6 H), 2.10 (m, 2 H), 1.92 (m, 2 H), 1.42-1.12 (m, 5 H).

Step E: Synthesis of *trans*-*N*²-{4-[(2,3-dimethoxy-benzylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.

A mixture of 2,3-dimethoxy benzaldehyde (15 mg, 0.09 mmol), *trans*-*N*²-(4-aminomethyl-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (28 mg, 0.053 mmol), NaBH(OAc)₃ (76 mg, 0.36 mmol), and MeOH (2 mL) was heated at 100 °C for 40 seconds using a Smith Microwave Synthesizer. The resulting mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *trans*-*N*²-{4-[(2,3-dimethoxy-benzylamino)-methyl]-cyclohexyl}-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (10.2 mg, 28 %).

ESI MS *m/e* 450 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.68 (d, *J* = 6.0 Hz, 1 H), 9.41 (brs, 1 H), 7.85 (d, *J* = 7.6 Hz, 1 H), 7.52 (t, *J* = 7.2 Hz, 1 H), 7.46 (d, *J* = 8.0 Hz, 1 H), 7.19 (t, *J* = 7.2 Hz, 1 H), 7.09 (t, *J* = 8.0 Hz, 1 H), 6.98 (d, *J* = 7.2 Hz, 1 H), 6.90 (d, *J* = 7.6 Hz, 1 H), 4.16 (s, 2 H), 3.96 (s, 3 H), 3.87 (s, 3 H), 3.75 (m, 1 H), 3.47 (m, 6 H), 2.80 (m, 2 H), 2.11 (m, 2 H), 1.86 (m, 2 H), 1.48-1.50 (m, 5 H).

Example 2341***cis*-N²-[4-(3,5-Dichloro-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid****Step A: Synthesis of *cis*-(4-*tert*-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.**

To a suspension of *cis*-4-*tert*-butoxycarbonylamino-cyclohexanecarboxylic acid (50.0 g, 206 mmol) in benzene were added triethylamine (26.9 g, 266 mmol) and phosphorazidic acid diphenyl ester (62.2 g, 226 mmol). The reaction mixture was stirred at 80°C for 1 hr. Benzyl alcohol (31.4 g, 290 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 30% EtOAc in hexane) to give *cis*-(4-*tert*-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (54.1 g, 76%) as a colorless oil.

ESI MS *m/e* 349 M + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.34-7.28 (m, 5 H), 7.12 (d, *J* = 5.6 Hz, 1 H), 6.62 (brs, 1 H), 4.98 (s, 2 H), 3.39-3.37 (m, 2 H), 1.60-1.45 (m, 8 H), 1.37 (s, 9 H).

Step B: Synthesis of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester.

Using the procedure for the step C of example 2340, the title compound was obtained.

ESI MS *m/e* 215 M + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.60 (d, *J* = 6.0 Hz, 1 H), 3.30-3.28 (m, 1 H), 2.74 (s, 1 H), 1.59-1.51 (m, 2 H), 1.45-1.37 (m, 15 H).

Step C: Synthesis of *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-

carbamic acid *tert*-butyl ester.

A solution of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (0.5 g, 2.3 mmol), (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B in example 1 (0.53, 2.6 mmol), diisopropylethylamine (1.22 mL, 7.0 mmol) and 2-propanol (1.0 mL) was heated using a Smith Microwave Synthesizer at 170 °C for 1 hour. This reaction procedure was repeated 39 more times and the resulting reaction mixtures were combined. The mixture was concentrated and the residue was purified by column chromatography (silica gel, 2% to 4% 2 M NH₃/MeOH in CH₂Cl₂) to give *cis*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (22.1 g, 0.057 mol, 61%) as a colorless oil.

ESI MS *m/e* 386 M + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.85 (d, *J* = 8.0 Hz, 1 H), 7.47 (t, *J* = 8.4 Hz, 1 H), 7.27 (d, *J* = 8.0 Hz, 1 H), 7.00 (t, *J* = 7.6 Hz, 1 H), 6.60 (brs, 1 H), 6.18 (brs, 1 H), 3.89-3.88 (m, 1 H), 3.39 (brs, 1 H), 3.19 (s, 6 H), 1.77-1.71 (m, 2 H), 1.68-1.52 (m, 6 H), 1.38 (s, 9 H).

Step D: Synthesis of *cis*-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine.

Using the procedure for the step C of example 2338, the title compound was obtained.

ESI MS *m/e* 286 M + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.84 (d, *J* = 8.4 Hz, 1 H), 7.45 (t, *J* = 6.8 Hz, 1 H), 7.26 (d, *J* = 8.4 Hz, 1 H), 6.99 (t, *J* = 7.6 Hz, 1 H), 6.20 (brs, 1 H), 3.90-3.89 (m, 1 H), 3.18 (s, 6 H), 2.79 (s, 1 H), 1.74-1.71 (m, 2 H), 1.57-1.41 (m, 8 H).


Step E: Synthesis of *cis*-N²-[4-(3,5-dichloro-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.

To a solution of *cis*-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (31.4 mg, 0.11 mmol) in MeOH (0.5 mL) was added 3,5-dichlorobenzaldehyde (17.5 mg, 0.10 mmol). The mixture was stirred at ambient temperature for 0.5 hr and sodium triacetoxyborohydride (85 mg, 0.40 mmol) was added. The mixture was stirred for overnight and the reaction was quenched with 50% DMSO in water (1.0 mL). The mixture was purified by preparative HPLC. The pure fractions were combined and lyophilized to give *cis*-N²-[4-(3,5-dichloro-benzylamino)-cyclohexyl]-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine ditrifluoro-acetic acid (23 mg, 0.041 mmol, 37%) as a white

solid.

ESI MS m/e 444 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 13.55 (s, 1 H), 8.90 (brs, 3 H), 8.17 (d, $J = 8.0$ Hz, 1 H), 7.79 (t, 7.6 Hz, 1 H), 7.68 (s, 1 H), 7.61 (s, 2 H), 7.41 (d, $J = 7.6$ Hz, 1 H), 7.36 (t, $J = 7.6$ Hz, 1 H), 4.23 (s, 2 H), 4.07 (s, 1 H), 3.48 (s, 6 H), 2.00-1.92 (m, 4 H), 1.82-1.74 (m, 4 H).

Example 2342




***cis*-N-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide trifluoro-acetic acid.**

Step A: Synthesis of *cis*-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide trifluoro-acetic acid.

Using the procedure for the step A of example 2333, the title compound was obtained.

ESI MS m/e 426 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 12.46 (brs, 1 H), 8.36 (s, 1 H), 8.15 (d, $J = 8.0$ Hz, 1 H), 7.97 (brs, 1 H), 7.94-7.89 (m, 1 H), 7.77-7.73 (m, 2 H), 7.56-7.49 (m, 1 H), 7.41 (brs, 1 H), 7.36 (t, $J = 7.6$ Hz, 1 H), 4.07 (m, 1 H), 3.87 (m, 1 H), 3.47 (brs, 6 H), 1.89 (m, 2 H), 1.74 (m, 6 H).

Example 2343




***cis*-4-Dimethylamino-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide ditrifluoro-acetic acid**

Step A: Synthesis of *cis*-4-dimethylamino-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide ditrifluoro-acetic acid.

To a solution of 4-dimethylaminobenzoic acid (16.5 mg, 0.10 mmol) in DMF (0.5 mL) were added HATU (45.6 mg, 0.12 mmol), diisopropylethylamine (34.8 μ L, 0.20 mmol), and *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴,*N*⁴-dimethyl-quinazolin-2,4-diamine obtained in step D of example 2341 (28.5 mg, 0.10 mmol) and stirred at ambient temperature for overnight. The resulting mixture was diluted with DMSO (0.5 mL) and purified by preparative HPLC. The pure fractions combined and lyophilized to give *cis*-4-dimethylamino-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide ditrifluoro-acetic acid (34.1 mg, 0.052mmol, 52%) as a white solid.

ESI MS m/e 433 $M + H^+$; ¹H NMR (400 MHz, DMSO- d_6) δ 12.73 (s, 1 H), 8.34 (s, 1 H), 8.16 (d, $J = 8.0$ Hz, 1 H), 7.78-7.70 (m, 4 H), 7.43 (d, $J = 7.6$ Hz, 1 H), 7.35 (t, $J = 8.0$ Hz, 1 H), 6.67 (d, $J = 8.8$ Hz, 2 H), 4.05 (m, 1 H), 3.86 (m, 1 H), 3.47 (s, 6 H), 2.95 (s, 3 H), 2.53 (s, 3 H), 1.91 (m, 2 H), 1.75-1.72 (m, 6 H).

Example 2344



***trans*-4-Bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide**

Step A: Synthesis of *trans*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester.

To a solution of *trans*-1,4-diamino-cyclohexane (10 g, 0.088 mol) in 1,4-dioxane (400 mL) was added a solution of (Boc)₂O (4.78 g, 0.022 mol) in 1,4-dioxane (100 mL) over 30 min. The mixture was stirred at ambient temperature for overnight and then the dioxane was removed in vacuo. The resulting precipitate was dissolved in H₂O (500 mL) and left to sit for 1 hour. During this time, the di-Boc-protected diamino-cyclohexane fell out as a white crystalline precipitate. This was subsequently filtered from the aqueous solvent. The aqueous layer was extracted with EtOAc (three times). The organic layers were combined and washed with H₂O. The organic layer was dried over MgSO₄ and concentrated to give *trans*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (4 g, 0.019 mol, 85%).

ESI MS *m/e* 215 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 6.63 (d, *J* = 8.0 Hz, 1 H), 3.11-3.09 (m, 1 H), 2.44-2.37 (m, 1 H), 1.70-1.67 (m, 4 H), 1.41-1.31 (m, 11 H), 1.20-0.95 (m, 4 H).

Step B: Synthesis of *trans*-[4-(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

To a solution of *trans*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (1 g, 0.0047 mol) in CH₂Cl₂ were added diisopropylethylamine (1.63 mL, 0.0093 mol) and 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (1.03 mL, 0.0051 mol). The reaction mixture was stirred at ambient temperature for 1 hr and then washed with water. The aqueous layer was extracted with CH₂Cl₂ (twice), the organic layers were combined, dried over MgSO₄, and concentrated. The resulting precipitate was recrystallized with CH₂Cl₂ and hexanes to give *trans*-[4-(4-bromo-2-trifluoromethoxy-benzenesulfonylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (2.39 g, 0.0046 mol, 99%).

ESI MS *m/e* 517 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.99 (d, *J* = 7.6 Hz, 1 H), 7.85 (d, *J* = 8.0 Hz, 1 H), 7.79-7.77 (m, 1 H), 6.67 (d, *J* = 8.0 Hz, 1 H), 3.14-2.94 (m, 2 H), 1.70-1.60 (m, 4 H), 1.34 (s, 9 H), 1.30-1.18 (m, 2 H), 1.14-1.03 (m, 2 H).

Step C: Synthesis of *trans*-*N*-(4-amino-cyclohexyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step C of example 2338, the title compound was obtained.


ESI MS m/e 417/419 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 7.85 (d, $J = 8.4$ Hz, 1 H), 7.79-7.76 (m, 3 H), 3.32 (brs, 2 H), 3.03-2.95 (m, 1 H), 2.41-2.36 (m, 1 H), 1.67-1.57 (m, 4 H), 1.28-1.18 (m, 2 H), 0.99-0.89 (m, 2 H).

Step D: Synthesis of *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide.

To a solution of *trans*-*N*-(4-amino-cyclohexyl)-4-bromo-2-trifluoromethoxy-benzenesulfonamide (100 mg, 0.24 mmol) in 2-propanol (0.5 mL) was added (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (54.7 mg, 0.26 mmol). The mixture was heated using a Smith Microwave Synthesizer at 170 °C for 15 min. The mixture was concentrated and the residue was purified by chromatography (2% to 4% 2 M $NH_3/MeOH$ in CH_2Cl_2) to give *trans*-4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-2-trifluoromethoxy-benzenesulfonamide (42 mg, 0.71 mmol, 30%) as a white solid.

ESI MS m/e 588/590 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 8.02 (d, $J = 7.6$ Hz, 1 H), 7.88 (d, $J = 8.4$ Hz, 1 H), 7.82-7.77 (m, 3 H), 7.45-7.41 (m, 1 H), 7.25-7.41 (m, 1 H), 6.99 (t, $J = 7.2$ Hz, 1 H), 6.37 (brs, 1 H), 3.68-3.67 (m, 1 H), 3.16 (s, 6 H), 3.09-3.02 (m, 1 H), 1.89-1.86 (m, 2 H), 1.69-1.67 (m, 2 H), 1.40-1.17 (m, 4 H).

Example 2345



***trans*-4'-Fluoro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide.**

Step A: Synthesis of 4'-fluoro-biphenyl-4-carboxylic acid.

To a solution of 4-bromobenzoic acid (5 g, 0.025 mol) in THF (150 mL) under an

atmosphere of argon were added tetrakis(triphenylphosphine) palladium(0) (862 mg, 0.75 mmol), 2 M aqueous Na_2CO_3 (30 mL), and a solution 4-fluorophenylboronic acid (3.48 g, 0.025 mol) in a minimal amount of ethanol (~10 mL). The resulting reaction mixture was stirred at reflux under an argon atmosphere for overnight. The reaction mixture was cooled to ambient temperature and acidified with addition of 1 M HCl aqueous. The aqueous layer was extracted with Et_2O (three times). The organic layers were combined, dried over MgSO_4 , filtered and concentrated. The resulting precipitate was crystallized in Et_2O and hexane to give 4'-fluoro-biphenyl-4-carboxylic acid (4.4 g, 0.020 mol, 82%) as a white solid.

^1H NMR (400 MHz, DMSO-d_6) δ 12.96 (s, 1 H), 8.00-7.98 (m, 2 H), 7.78-7.75 (m, 4 H), 7.34-7.31 (m, 2 H).

Step B: Synthesis of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester.

Using the procedure for the step D of example 2344, the title compound was obtained.

ESI MS m/e 386 $\text{M} + \text{H}^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.83 (d, $J = 8.0$ Hz, 1 H), 7.46 (t, $J = 6.8$ Hz, 1 H), 7.27-7.25 (m, 1 H), 6.99 (t, $J = 7.2$ Hz, 1 H), 6.71 (d, $J = 8.4$ Hz, 1 H), 6.38 (brs, 1 H), 3.72 (m, 1 H), 3.17 (s, 6 H), 1.92-1.90 (m, 2 H), 1.79-1.76 (m, 2 H), 1.37 (s, 9 H), 1.34-1.23 (m, 4 H).


Step C: Synthesis of *trans*-4'-fluoro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide.

To a solution of *trans*-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (0.76 g, 0.20 mmol) in CH_2Cl_2 (20 mL) was added TFA (304 μL , 0.39 mmol). The solution was stirred at ambient temperature for 4 hr. The resulting mixture was concentrated and the residue was dissolved in CH_2Cl_2 . The organic layer was washed with a dilute aqueous NaOH and aqueous NaHCO_3 solution. The aqueous layer was extracted with CH_2Cl_2 (twice) and the organic layers combined, dried over MgSO_4 , and concentrated. To a solution of the residue (0.1 g) and 4'-fluoro-biphenyl-4-carboxylic acid (76 mg, 0.35 mmol) in CH_2Cl_2 were added HOAt (62 mg, 0.46 mmol), WSC•HCl (87 mg, 0.46 mmol), and diisopropylethylamine (31 μL , 0.18 mmol). The mixture was stirred for 1 hr at ambient temperature and the reaction was quenched with

water. The aqueous layer was extracted with CH_2Cl_2 (twice). The organic layers were combined, dried over MgSO_4 , concentrated and the residue purified by column chromatography (silica gel, 2% to 4% 2 M NH_3/MeOH in CH_2Cl_2) to give *trans*-4'-fluoro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-amide (35 mg, 0.072, 21%) as a white solid.

ESI MS m/e 484 $M + H^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.30 (brs, 1 H), 8.12 (brs, 2 H), 7.92 (d, $J = 8.4$ Hz, 2 H), 7.77-7.72 (m, 5 H), 7.44 (brs, 1 H), 7.34-7.28 (m, 3 H), 3.82 (brs, 2 H), 3.47 (brs, 6 H), 2.04 (m, 2 H), 1.94 (m, 2 H), 1.54-1.48 (m, 4 H).

Example 2346



cis- N^2 -[4-(4-Bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]- N^4 -*tert*-butyl-quinazoline-2,4-diamine ditrifluoro-acetic acid

Step A: Synthesis of *tert*-butyl-(2-chloro-quinazolin-4-yl)-amine.

To a solution of 2,4-dichloro-quinazoline obtained in step B of example 1 (4 g, 20 mmol) in THF (50 mL) were added *tert*-butyl amine (2.15 mL, 20.5 mmol) and diisopropylethylamine (3.5 mL, 21 mmol). The mixture was stirred at ambient temperature for 2 hr. The mixture was concentrated and the residue was dissolved in EtOAc. The organic layer was washed with water, dried over Na_2SO_4 , and filtered. The mixture was concentrated to give *tert*-butyl-(2-chloro-quinazolin-4-yl)-amine as a white solid (3 g, 64%).

ESI MS m/e 236 $M + H^+$; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.40 (d, $J = 8.4$ Hz, 1 H), 7.75-7.36 (m, 2 H), 7.58 (d, $J = 8.4$ Hz, 1 H), 7.48 (t, $J = 7.2$ Hz, 1 H), 1.52 (s, 9 H).

Step B: Synthesis of *cis*- N^2 -(4-amino-cyclohexyl)- N^4 -*tert*-butyl-quinazoline-2,4-diamine.

To a suspension of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (122


mg, 0.57 mmol) in 2-propanol (2 mL) were added *tert*-butyl-(2-chloro-quinazolin-4-yl)-amine (100 mg, 0.42 mmol) and diisopropylethylamine (180 μ L, 1 mmol) and the mixture was heated at 170 °C for 1 hr using a Smith Microwave Synthesizer. The resulting solution was concentrated and purified by column chromatography (silica gel, 3% MeOH in CH_2Cl_2) to give [4-(4-*tert*-butylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (112 mg, 65%) as a yellow solid. To a suspension of *cis*-[4-(4-*tert*-butylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid *tert*-butyl ester (95 mg, 0.23 mmol) in CH_2Cl_2 (3 mL) was added trifluoroacetic acid (2 mL) dropwise. The reaction mixture was stirred at ambient temperature for 2 hr. The solution was concentrated, alkalized with saturated aqueous NaHCO_3 and 1 M aqueous sodium hydroxide (pH = 9), and the aqueous layer was extracted with CH_2Cl_2 (three times). The combined organic layer was dried over MgSO_4 , filtered, and concentrated. The solid was collected by filtration to give *cis*-*N*²-(4-amino-cyclohexyl)-*N*⁴-*tert*-butyl-quinazoline-2,4-diamine (44.6 mg, 53%) as a yellow solid.

ESI MS *m/e* 314 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl_3) δ 7.48 (t, *J* = 6.8 Hz, 1 H), 7.38 (m, 2 H), 7.04 (t, *J* = 8.0 Hz, 1 H), 5.42 (brs, 1 H), 4.15 (m, 1 H), 2.85 (m, 1 H), 1.2-1.9 (m, 17 H).

Step C: Synthesis of *cis*-*N*²-[4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-*N*⁴-*tert*-butyl-quinazoline-2,4-diamine ditrifluoro-acetic acid.

Using the procedure for the step C of example 2341, the title compound was obtained.

ESI MS *m/e* 566 *M* + *H*⁺; ¹H NMR (400 MHz, CDCl_3) δ 9.36 (d, *J* = 8.0 Hz, 1 H), 7.67-7.64 (m, 2 H), 7.53-7.48 (m, 3 H), 7.43 (s, 1 H), 7.33 (m, 1 H), 6.17 (s, 1 H), 4.45 (m, 1 H), 4.28 (s, 2 H), 3.35 (m, 1 H), 2.14-1.6 (m, 17 H).

Example 2347**4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide****Step A: Synthesis of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester.**

Using the procedure for the step D of example 2330, the title compound was obtained.

ESI MS m/e 377 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 8.38 (brs, 1 H), 8.08 (brs, 1 H), 7.70 (brs, 1 H), 7.47 (brs, 1 H), 7.36 (t, $J = 6.2$ Hz, 1 H), 7.30 (d, $J = 8.0$ Hz, 3 H), 7.16 (d, $J = 7.6$ Hz, 2 H), 4.60 (d, $J = 6.4$ Hz, 2 H), 4.07 (d, $J = 6.0$ Hz, 2 H), 3.39 (s, 6 H), 1.37 (s, 9 H).

Step B: Synthesis of N^2 -(4-aminomethyl-benzyl)- N' , N' -dimethyl-quinazoline-2,4-diamine hydrochloride.

To a cooled solution of {4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester (3.90 g, 9.57 mmol) in MeOH was added 1 M HCl in Et₂O (67.0 ml, 67.0 mmol) and the solution was stirred for overnight. The resulting mixture was concentrated to give N^2 -(4-aminomethyl-benzyl)- N' , N' -dimethyl-quinazoline-2,4-diamine hydrochloride as a white crystalline solid (3.48 g, 95.6%).

ESI MS m/e 308.2 $M + H^+$; 1H NMR (400 MHz, CD₃OD) δ 8.16 (d, $J = 7.2$ Hz, 1 H), 7.75 (brs, 1 H), 7.48 (m, 5 H), 7.39 (brs, 1 H), 4.76 (s, 2 H), 4.12 (s, 2 H), 3.51 (m, 6 H).


Step C: Synthesis of 4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide.

A solution of N^2 -(4-aminomethyl-benzyl)- N' , N' -dimethyl-quinazoline-2,4-diamine hydrochloride (50.0 mg, 0.131 mmol), 4-bromo-2-trifluoromethoxy-benzenesulfonyl chloride (53.3 mg, 0.157 mmol) and diisopropylethylamine (91 μ l, 0.524 mmol) in 2-

propanol (1.5 mL) was stirred at ambient temperature for 2 hr. The resulting mixture was concentrated, and the residue was purified by column chromatography (silica gel, 10% MeOH in CH₂Cl₂) to give 4-bromo-*N*-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-benzyl}-2-trifluoromethoxy-benzenesulfonamide as a white crystalline compound (40 mg, 50%).

ESI MS *m/e* 612 *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.51 (t, *J* = 6.4 Hz, 1 H), 8.06 (brs, 1 H), 7.76-7.67 (m, 4 H), 7.54-7.41 (m, 2 H), 7.24 (d, *J* = 7.6 Hz, 3 H), 7.14 (d, *J* = 8.0 Hz, 2 H), 4.56 (d, *J* = 6.0 Hz, 2 H), 4.08 (d, *J* = 6.0 Hz, 2 H), 3.36 (s, 6 H).

Example 2348



4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy-benzenesulfonamide

Step A: Synthesis of (4-amino-phenyl)-carbamic acid *tert*-butyl ester.

Using the procedure for the step A of example 2344, the title compound was obtained.

ESI MS *m/e* 209 *M* + H⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.75 (s, 1 H), 7.03 (d, *J* = 7.6 Hz, 2 H), 6.43 (dt, *J* = 9.5, 2.7 Hz, 2 H), 4.71 (s, 2 H), 1.43 (s, 9 H).

Step B: Synthesis of *N*²-(4-amino-phenyl)-*N*⁴,*N*⁴-dimethyl-quinazoline-2,4-diamine hydrochloride.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.5 g, 2.6 mmol) and (4-amino-phenyl)-carbamic acid *tert*-butyl ester (0.5 g, 2.6 mmol) in CH₂Cl₂ (2 mL) was heated by Smith Synthesizer at 130 °C for 20 min. The mixture was concentrated to give [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-carbamic acid *tert*-butyl ester as a pale yellow solid (0.86 g, 87%). The reaction was repeated six times, and the total product combined was 8.5 g. To a solution of above product (8.5 g, 22.4 mmol) in MeOH (250 mL) was added 4 M HCl in dioxane (8.4 mL,

33.6 mmol) dropwise, and the mixture was stirred at ambient temperature for overnight. The mixture was concentrated to give *N*²-(4-amino-phenyl)-*N*¹,*N*¹-dimethyl-quinazoline-2,4-diamine hydrochloride as a pale pink solid (6.2 g, 87.5%).


ESI MS *m/e* 280 *M* + *H*⁺; ¹H NMR (400 MHz, D₂O) δ 7.84 (d, *J* = 8.8 Hz, 1 H), 7.54 (td, *J* = 7.8, 1.2 Hz, 1 H), 7.46 (dt, *J* = 9.5, 2.7 Hz, 2 H), 7.27-7.16 (m, 4 H), 3.35 (b, 3 H), 3.12 (b, 3 H).

Step C: Synthesis of 4-bromo-*N*-[4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-2-trifluoromethoxy-benzenesulfonamide.

Using the procedure for the step C of example 2347, the title compound was obtained.

ESI MS *m/e* 584 *M* + *H*⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.27 (brs, 1 H), 9.14 (brs, 1 H), 7.98 (d, *J* = 8.4 Hz, 1 H), 7.80-7.71 (m, 5 H), 7.60-7.56 (m, 1 H), 7.44 (d, *J* = 8.4 Hz, 1 H), 7.15 (t, *J* = 7.4 Hz, 1 H), 6.95 (d, *J* = 16.8 Hz, 2 H), 9.29 (s, 6 H).

Example 2349




4'-Chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-amide trifluoro-acetic acid

Synthesis of 4'-chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-amide trifluoro-acetic acid.

A solution of *N*²-(4-amino-phenyl)-*N*¹,*N*¹-dimethyl-quinazoline-2,4-diamine hydrochloride obtained in step B of example 2348 (81.6 mg, 0.258 mmol), 4'-chloro-biphenyl-4-carboxylic acid (50.0 mg, 0.215 mmol), HATU (106 mg, 0.280 mmol), and diisopropylethylamine (150 μL, 0.860 mmol), in CH₂Cl₂ (2 mL) was stirred at ambient temperature for overnight, and the mixture was concentrated. The residue was purified by HPLC to give 4'-chloro-biphenyl-4-carboxylic acid [4-(4-dimethylamino-quinazolin-2-ylamino)-phenyl]-amide trifluoro-acetic acid as a white solid (10 mg, 9 %).

ESI MS m/e 494 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 10.33 (s, 1 H), 8.17 (d, $J = 8.0$ Hz, 1 H), 8.80 (d, $J = 8.8$ Hz, 2 H), 7.85-7.75 (m, 7 H), 7.63-7.53 (m, 6 H), 7.36 (t, $J = 7.6$ Hz, 1 H), 3.46 (s, 6 H).

Example 2350



N-[1-(4-Dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-fluorobenzenesulfonamide

Step A: Synthesis of *N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-fluorobenzenesulfonamide.

To a solution of 4-aminomethyl-piperidine-1-carboxylic acid *tert*-butyl ester (60 mg, 0.28 mmol) and diisopropylethylamine (49 mL, 0.28 mmol) in CH_2Cl_2 (2 mL) was added 2-fluorobenzenesulfonyl chloride (54 mg, 0.28 mmol) and the mixture was stirred at ambient temperature for 18 hr. To the resulting mixture was added trifluoroacetic acid (0.70 mL) and stirred at ambient temperature for 18 hr. The reaction mixture was concentrated and neutralized with saturated aqueous $NaHCO_3$. The aqueous layer was extracted with EtOAc, and the organic layer was concentrated to give 2-fluoro-*N*-piperidin-4-ylmethyl-benzenesulfonamide as a pale yellow solid. To a solution of above solid (0.076 g, 0.28 mmol) and diisopropylethylamine (0.072 mL, 0.42 mmol) in 2-propanol (3 mL) was added (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (0.044 g, 0.21 mmol) and the resulting mixture was stirred at 100 °C for 18 hr. The mixture was concentrated, and the residue was purified by column chromatography (silica gel, 5% MeOH in CH_2Cl_2) to give *N*-[1-(4-dimethylamino-quinazolin-2-yl)-piperidin-4-ylmethyl]-2-fluorobenzenesulfonamide as a pale yellow solid (0.024 g, 26%).

ESI MS m/e 444 $M + H^+$; 1H NMR (400 MHz, DMSO- d_6) δ 7.98 (m, 1 H), 7.86 (m, 1 H), 7.77 (m, 1 H), 7.67 (m, 1 H), 7.47-7.29 (m, 4 H), 7.02 (m, 1 H), 4.69 (m, 2 H), 3.21 (s, 6 H), 2.76 (m, 4 H), 1.66 (m, 3 H), 1.00 (m, 2 H).

Using the procedure for example 2329 and purification by preparative HPLC, the compounds of example 2351 - 2819 were obtained.

Using the procedure for example 2331 and purification by preparative HPLC, the compounds of example 2820 - 2842 were obtained.

Using the procedure for example 2332, the compounds of example 2843 - 3003 were obtained.

Using the procedure for example 2333, the compounds of example 3004 - 3090 were obtained.

Using the procedure for example 2334, the compounds of example 3091 - 3161 were obtained.

Using the procedure for example 2335 and purification by preparative HPLC, the compounds of example 3162 - 3178 were obtained.

Using the procedure for example 2336, the compounds of example 3179 - 3208 were obtained.

Using the procedure for example 2337, the compounds of example 3209 was obtained.

Using the procedure for example 2338, the compounds of example 3210 - 3225 were obtained.

Using the procedure for example 2339, the compounds of example 3226 - 3228 were obtained.

Using the procedure for example 2340, the compounds of example 3229 - 3231 were obtained.

Using the procedure for example 2341, the compounds of example 3232 - 3393 were obtained.

Using the procedure for example 2342, the compounds of example 3394 - 3472 were obtained.

Using the procedure for example 2343, the compounds of example 3473 - 3527 were obtained.







Using the procedure for example 2346, the compounds of example 3528 - 3535 were obtained.







Using the procedure for example 2347 and purification by preparative HPLC, the compounds of example 3536 - 3545 were obtained.







Using the procedure for example 2348 and purification by preparative HPLC, the compounds of example 3546 - 3548 were obtained.







Using the procedure for example 2349, the compounds of example 3549 - 3567 were obtained.







Using the procedure for example 2350 and purification by preparative HPLC, the compounds of example 3568 - 3579 were obtained.







Example No.	Structure	ESI-MS	Retention Time (min)
2351	 <p>CF₃CO₂H</p>	454.0 (M + H)	3.60
2352	 <p>CF₃CO₂H</p>	530.2 (M + H)	4.02
2353	 <p>2CF₃CO₂H</p>	545.4 (M + H)	3.05
2354	 <p>CF₃CO₂H</p>	496.4 (M + H)	3.49
2355	 <p>CF₃CO₂H</p>	537.4 (M + H)	3.24
2356	 <p>CF₃CO₂H</p>	440.0 (M + H)	3.47







Example No.	Structure	ESI-MS	Retention Time (min)
2357	 <p>CF₃CO₂H</p>	484.4 (M + H)	3.49
2358	 <p>CF₃CO₂H</p>	470.2 (M + H)	3.20
2359	 <p>2CF₃CO₂H</p>	539.4 (M + H)	3.12
2360	 <p>CF₃CO₂H</p>	522.2 (M + H)	4.22
2361	 <p>2CF₃CO₂H</p>	599.0 (M + H)	3.48
2362	 <p>CF₃CO₂H</p>	560.2 (M + H)	3.99







Example No.	Structure	ESI-MS	Retention Time (min)
2363		548.4 (M + H)	4.06
2364	 $2\text{CF}_3\text{CO}_2\text{H}$	534.0 (M + H)	3.11
2365	 $\text{CF}_3\text{CO}_2\text{H}$	502.4 (M + H)	3.81
2366	 $\text{CF}_3\text{CO}_2\text{H}$	530.2 (M + H)	4.04
2367	 $\text{CF}_3\text{CO}_2\text{H}$	532.4 (M + H)	3.85
2368	 $\text{CF}_3\text{CO}_2\text{H}$	520.2 (M + H)	3.86







Example No.	Structure	ESI-MS	Retention Time (min)
2369	 $\text{CF}_3\text{CO}_2\text{H}$	474.2 (M + H)	3.72
2370	 $\text{CF}_3\text{CO}_2\text{H}$	518.2 (M + H)	3.71
2371	 $2\text{CF}_3\text{CO}_2\text{H}$	573.2 (M + H)	3.15
2372	 $\text{CF}_3\text{CO}_2\text{H}$	556.2 (M + H)	4.38
2373	 $2\text{CF}_3\text{CO}_2\text{H}$	633.4 (M + H)	3.48
2374	 $\text{CF}_3\text{CO}_2\text{H}$	594.2 (M + H)	4.23







Example No.	Structure	ESI-MS	Retention Time (min)
2375	 <chem>CC1(CCN2C(=N1)N(CN2CC3=CC=C(C=C3)F)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	582.4 (M + H)	4.26
2376	 <chem>CC1(CCN2C(=N1)N(CN2C3=CC=CC=C3)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	536.2 (M + H)	4.06
2377	 <chem>CC1(CCN2C(=N1)N(CN2CC3=CC=C(C=C3)CC)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	564.2 (M + H)	4.32
2378	 <chem>CC1(CCN2C(=N1)N(CN2CC3=CC=C(C=C3)OC)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	566.4 (M + H)	4.11
2379	 <chem>CC1(CCN2C(=N1)N(CN2CC3=CC=C(C=C3)F)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	554.2 (M + H)	4.10
2380	 <chem>CC1(CCN2C(=N1)N(CN2CC3=CC=C(C=C3)OC(F)(F)F)CC4=CC=C(C=C4)S(=O)(=O)N5CCCCC5)C6=CC=C(C=C6)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	614.2 (M + H)	4.26







Example No.	Structure	ESI-MS	Retention Time (min)
2381	 <chem>COc1nc2c(ncn2C1CC2CCCCC2NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	524.4 (M + H)	3.87
2382	 <chem>COCCNc1nc2c(ncn2C1CC2CCCCC2NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	568.2 (M + H)	3.87
2383	 <chem>c1ccc(Nc2nc3c(ncn3C1CC2CCCCC2NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc2)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	586.2 (M + H)	4.18
2384	 <chem>CCc1ccc(Nc2nc3c(ncn3C1CC2CCCCC2NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc2)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	614.2 (M + H)	4.45
2385	 <chem>Clc1ccc(Nc2nc3c(ncn3C1CC2CCCCC2NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc2)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	620.4 (M + H)	4.32
2386	 <chem>CN1C=NC2=C1N=CN2C1CC2CCCCC2NS(=O)(=O)c3ccc(C)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	468.2 (M + H)	3.20







Example No.	Structure	ESI-MS	Retention Time (min)
2387	 $\text{CF}_3\text{CO}_2\text{H}$	551.6 (M + H)	2.82
2388	 $\text{CF}_3\text{CO}_2\text{H}$	454.0 (M + H)	3.06
2389	 $\text{CF}_3\text{CO}_2\text{H}$	498.6 (M + H)	3.10
2390	 $\text{CF}_3\text{CO}_2\text{H}$	484.2 (M + H)	2.76
2391	 $2\text{CF}_3\text{CO}_2\text{H}$	553.6 (M + H)	2.40
2392	 $\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	3.77







Example No.	Structure	ESI-MS	Retention Time (min)
2393	 $2\text{CF}_3\text{CO}_2\text{H}$	613.4 (M + H)	2.74
2394	 $\text{CF}_3\text{CO}_2\text{H}$	623.4 (M + H)	3.06
2395	 $\text{CF}_3\text{CO}_2\text{H}$	574.4 (M + H)	3.51
2396	 $\text{CF}_3\text{CO}_2\text{H}$	562.2 (M + H)	3.59
2397	 $2\text{CF}_3\text{CO}_2\text{H}$	548.6 (M + H)	2.48
2398	 $\text{CF}_3\text{CO}_2\text{H}$	516.4 (M + H)	3.39







Example No.	Structure	ESI-MS	Retention Time (min)
2399	 <p>CF₃CO₂H</p>	550.4 (M + H)	3.56
2400	 <p>CF₃CO₂H</p>	546.2 (M + H)	3.38
2401	 <p>CF₃CO₂H</p>	534.0 (M + H)	3.43
2402	 <p>CF₃CO₂H</p>	608.2 (M + H)	3.75
2403	 <p>CF₃CO₂H</p>	518 (M + H)	3.22
2404	 <p>CF₃CO₂H</p>	562.2 (M + H)	3.20







Example No.	Structure	ESI-MS	Retention Time (min)
2405	 <p>CF₃CO₂H</p>	626.0 (M + H)	3.76
2406	 <p>CF₃CO₂H</p>	614.0 (M + H)	3.72
2407	 <p>CF₃CO₂H</p>	610.0 (M + H)	3.57
2408	 <p>CF₃CO₂H</p>	598.2 (M + H)	3.97
2409	 <p>CF₃CO₂H</p>	564.2 (M + H)	3.46
2410	 <p>CF₃CO₂H</p>	508.0 (M + H)	3.44







Example No.	Structure	ESI-MS	Retention Time (min)
2411	 <chem>CF3CO2H</chem>	616.2 (M + H)	3.94
2412	 <chem>CF3CO2H</chem>	604.2 (M + H)	4.51
2413	 <chem>CF3CO2H</chem>	600.2 (M + H)	4.32
2414	 <chem>CF3CO2H</chem>	588.0 (M + H)	4.38
2415	 <chem>CF3CO2H</chem>	650.2 (M + H)	4.20
2416	 <chem>CF3CO2H</chem>	726.4 (M + H)	4.52







Example No.	Structure	ESI-MS	Retention Time (min)
2417	 $2\text{CF}_3\text{CO}_2\text{H}$	741.6 (M + H)	3.59
2418	 $\text{CF}_3\text{CO}_2\text{H}$	692.2 (M + H)	4.12
2419	 $2\text{CF}_3\text{CO}_2\text{H}$	767.6 (M + H)	4.59
2420	 $\text{CF}_3\text{CO}_2\text{H}$	733.4 (M + H)	3.87
2421	 $\text{CF}_3\text{CO}_2\text{H}$	636.2 (M + H)	4.08
2422	 $\text{CF}_3\text{CO}_2\text{H}$	680.2 (M + H)	4.07







Example No.	Structure	ESI-MS	Retention Time (min)
2423	 <chem>CF3CO2H</chem>	666.0 (M + H)	3.86
2424	 <chem>2CF3CO2H</chem>	735.4 (M + H)	3.50
2425	 <chem>CF3CO2H</chem>	718.4 (M + H)	4.64
2426	 <chem>2CF3CO2H</chem>	795.6 (M + H)	3.70
2427	 <chem>CF3CO2H</chem>	744.2 (M + H)	4.43
2428	 <chem>CF3CO2H</chem>	698.0 (M + H)	4.26







Example No.	Structure	ESI-MS	Retention Time (min)
2429	 <chem>Clc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	732.4 (M + H)	4.37
2430	 <chem>CCc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	726.4 (M + H)	4.52
2431	 <chem>COc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	728.4 (M + H)	4.36
2432	 <chem>Fc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	716.4 (M + H)	4.32
2433	 <chem>Cc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	616.0 (M + H)	4.22
2434	 <chem>Cc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5OC(F)(F)F)cc1</chem> <chem>CF3CO2H</chem>	692.0 (M + H)	4.57







Example No.	Structure	ESI-MS	Retention Time (min)
2435	 $2\text{CF}_3\text{CO}_2\text{H}$	707.2 (M + H)	3.64
2436	 $\text{CF}_3\text{CO}_2\text{H}$	658.2 (M + H)	4.15
2437	 $\text{CF}_3\text{CO}_2\text{H}$	733.2 (M + H)	4.68
2438	 $\text{CF}_3\text{CO}_2\text{H}$	699.2 (M + H)	3.88
2439	 $\text{CF}_3\text{CO}_2\text{H}$	646.4 (M + H)	4.08
2440	 $\text{CF}_3\text{CO}_2\text{H}$	632.4 (M + H)	3.86







Example No.	Structure	ESI-MS	Retention Time (min)
2441	 $2\text{CF}_3\text{CO}_2\text{H}$	701.4 (M + H)	3.51
2442	 $\text{CF}_3\text{CO}_2\text{H}$	684.2 (M + H)	4.75
2443	 $2\text{CF}_3\text{CO}_2\text{H}$	761.2 (M + H)	3.74
2444	 $\text{CF}_3\text{CO}_2\text{H}$	722.2 (M + H)	4.59
2445	 $\text{CF}_3\text{CO}_2\text{H}$	710.2 (M + H)	4.60
2446	 $2\text{CF}_3\text{CO}_2\text{H}$	696.2 (M + H)	3.53







Example No.	Structure	ESI-MS	Retention Time (min)
2447	 <chem>CC1(CCN2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)OC(F)(F)F)C7=CC(=CC=C7)Br</chem> <chem>CC(F)(F)C(=O)O</chem>	664.2 (M + H)	4.39
2448	 <chem>CC1(CCN2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)OC(F)(F)F)C7=CC=C(C=C7)CC</chem> <chem>CC(F)(F)C(=O)O</chem>	692.0 (M + H)	4.65
2449	 <chem>ClC1=CC=C(N2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)OC(F)(F)F)C7=CC(=CC=C7)Br</chem> <chem>CC(F)(F)C(=O)O</chem>	698.0 (M + H)	4.59
2450	 <chem>COc1ccc(N2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)OC(F)(F)F)cc1</chem> <chem>CC(F)(F)C(=O)O</chem>	694.2 (M + H)	4.42
2451	 <chem>Fc1ccc(N2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)OC(F)(F)F)cc1</chem> <chem>CC(F)(F)C(=O)O</chem>	682.2 (M + H)	4.42
2452	 <chem>CN(C)c1ccc(N2C(=N1)N(C2)C3=CC=CC=C3N4CCCCC4C5=CC(=CC=C5)S(=O)(=O)N4C6=CC(=CC=C6)C(F)(F)F)cc1</chem> <chem>CC(F)(F)C(=O)O</chem>	590.2 (M + H)	4.28







Example No.	Structure	ESI-MS	Retention Time (min)
2453	 $\text{CF}_3\text{CO}_2\text{H}$	666.2 (M + H)	4.61
2454	 $2\text{CF}_3\text{CO}_2\text{H}$	681.2 (M + H)	3.72
2455	 $\text{CF}_3\text{CO}_2\text{H}$	632.4 (M + H)	4.21
2456	 $2\text{CF}_3\text{CO}_2\text{H}$	707.2 (M + H)	4.70
2457	 $\text{CF}_3\text{CO}_2\text{H}$	673.2 (M + H)	3.94
2458	 $\text{CF}_3\text{CO}_2\text{H}$	576.2 (M + H)	4.16







Example No.	Structure	ESI-MS	Retention Time (min)
2459	 $\text{CF}_3\text{CO}_2\text{H}$	620.4 (M + H)	4.19
2460	 $\text{CF}_3\text{CO}_2\text{H}$	606.6 (M + H)	3.94
2461	 $2\text{CF}_3\text{CO}_2\text{H}$	675.4 (M + H)	3.59
2462	 $\text{CF}_3\text{CO}_2\text{H}$	658.6 (M + H)	4.82
2463	 $2\text{CF}_3\text{CO}_2\text{H}$	735.4 (M + H)	3.82
2464	 $\text{CF}_3\text{CO}_2\text{H}$	696.0 (M + H)	4.56







Example No.	Structure	ESI-MS	Retention Time (min)
2465	 <p>CF₃CO₂H</p>	684.4 (M + H)	4.61
2466	 <p>2CF₃CO₂H</p>	670.2 (M + H)	3.56
2467	 <p>CF₃CO₂H</p>	638.2 (M + H)	4.43
2468	 <p>CF₃CO₂H</p>	666.2 (M + H)	4.68
2469	 <p>CF₃CO₂H</p>	672.2 (M + H)	4.60
2470	 <p>CF₃CO₂H</p>	668.2 (M + H)	4.44







Example No.	Structure	ESI-MS	Retention Time (min)
2471	 <p>CF₃CO₂H</p>	656.4 (M + H)	4.47
2472	 <p>2CF₃CO₂H</p>	595.4 (M + H)	3.32
2473	 <p>CF₃CO₂H</p>	534.0 (M + H)	3.81
2474	 <p>CF₃CO₂H</p>	520.4 (M + H)	3.56
2475	 <p>2CF₃CO₂H</p>	589.2 (M + H)	3.25
2476	 <p>CF₃CO₂H</p>	572.4 (M + H)	4.47







Example No.	Structure	ESI-MS	Retention Time (min)
2477	 <chem>2CF3CO2H</chem>	649.4 (M + H)	3.50
2478	 <chem>CF3CO2H</chem>	610.4 (M + H)	4.26
2479	 <chem>CF3CO2H</chem>	598.2 (M + H)	4.30
2480	 <chem>2CF3CO2H</chem>	584.4 (M + H)	3.29
2481	 <chem>CF3CO2H</chem>	552.6 (M + H)	4.11
2482	 <chem>CF3CO2H</chem>	580.6 (M + H)	4.40







Example No.	Structure	ESI-MS	Retention Time (min)
2483	 <chem>Clc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc6ccccc65)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	586.2 (M + H)	4.30
2484	 <chem>COc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc6ccccc65)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	582.4 (M + H)	4.14
2485	 <chem>Fc1ccc(Nc2nc3ccccc3n2CNC4CCCCC4NS(=O)(=O)c5ccc6ccccc65)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	570.2 (M + H)	4.14
2486	 <chem>CN1C=NC2=C(N1)C(=NC2)CNC3CCCCC3NS(=O)(=O)c4ccc5ccccc54</chem> $\text{CF}_3\text{CO}_2\text{H}$	504.2 (M + H)	3.94
2487	 <chem>CN1C=NC2=C(N1)C(=NC2)CNC3CCCCC3NS(=O)(=O)c4ccc5ccccc54C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C7</chem> $\text{CF}_3\text{CO}_2\text{H}$	580.6 (M + H)	4.34
2488	 <chem>CN1C=NC2=C(N1)C(=NC2)CNC3CCCCC3NS(=O)(=O)c4ccc5ccccc54Cc6ccncc6C7=CC=CC=C7C8=CC=CC=C8C7</chem> $2\text{CF}_3\text{CO}_2\text{H}$	595.2 (M + H)	3.41







Example No.	Structure	ESI-MS	Retention Time (min)
2489	 <chem>CCNc1nc2c(nc1)ccc2C[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccc5ccccc45</chem> $\text{CF}_3\text{CO}_2\text{H}$	490.2 (M + H)	3.84
2490	 <chem>COCNc1nc2c(nc1)ccc2C[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccc5ccccc45</chem> $\text{CF}_3\text{CO}_2\text{H}$	534.2 (M + H)	3.84
2491	 <chem>ONc1nc2c(nc1)ccc2C[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccc5ccccc45</chem> $\text{CF}_3\text{CO}_2\text{H}$	520.4 (M + H)	3.60
2492	 <chem>CN1CCOC1Cc2nc3c(nc2)ccc3C[C@H]4CCCC[C@H]4NS(=O)(=O)c5ccc6ccccc56</chem> $2\text{CF}_3\text{CO}_2\text{H}$	589.2 (M + H)	3.29
2493	 <chem>C1CCCCC1Cc2nc3c(nc2)ccc3C[C@H]4CCCC[C@H]4NS(=O)(=O)c5ccc6ccccc56</chem> $\text{CF}_3\text{CO}_2\text{H}$	572.4 (M + H)	4.51
2494	 <chem>C1CCN(CC1Cc2ccccc2)Cc3nc4c(nc3)ccc4C[C@H]5CCCC[C@H]5NS(=O)(=O)c6ccc7ccccc67</chem> $2\text{CF}_3\text{CO}_2\text{H}$	649.4 (M + H)	3.52







Example No.	Structure	ESI-MS	Retention Time (min)
2495	 CF ₃ CO ₂ H	610.2 (M + H)	4.29
2496	 CF ₃ CO ₂ H	598.2 (M + H)	4.34
2497	 CF ₃ CO ₂ H	552.6 (M + H)	4.13
2498	 CF ₃ CO ₂ H	580.6 (M + H)	4.37
2499	 CF ₃ CO ₂ H	586.2 (M + H)	4.30
2500	 CF ₃ CO ₂ H	570.2 (M + H)	4.18







Example No.	Structure	ESI-MS	Retention Time (min)
2501	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	547.4 (M + H)	3.69
2502	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	623.4 (M + H)	4.10
2503	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	638.2 (M + H)	3.20
2504	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	589.2 (M + H)	3.62
2505	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	664.4 (M + H)	4.25
2506	 <chem>CN(C)CC1=NC2=CC=CC=C2N=C(NC1CC3=CC=CC=C3S(=O)(=O)N(C)C)C4=CC=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	630.4 (M + H)	3.35







Example No.	Structure	ESI-MS	Retention Time (min)
2507	 $2\text{CF}_3\text{CO}_2\text{H}$	533.2 (M + H)	3.57
2508	 $2\text{CF}_3\text{CO}_2\text{H}$	577.6 (M + H)	3.58
2509	 $2\text{CF}_3\text{CO}_2\text{H}$	563.2 (M + H)	3.28
2510	 $3\text{CF}_3\text{CO}_2\text{H}$	632.6 (M + H)	3.06
2511	 $2\text{CF}_3\text{CO}_2\text{H}$	615.4 (M + H)	4.30
2512	 $3\text{CF}_3\text{CO}_2\text{H}$	692.2 (M + H)	3.38







Example No.	Structure	ESI-MS	Retention Time (min)
2513	 2CF ₃ CO ₂ H	641.4 (M + H)	4.13
2514	 2CF ₃ CO ₂ H	595.4 (M + H)	3.89
2515	 2CF ₃ CO ₂ H	623.4 (M + H)	4.20
2516	 2CF ₃ CO ₂ H	629.2 (M + H)	4.15
2517	 2CF ₃ CO ₂ H	613.2 (M + H)	4.02
2518	 CF ₃ CO ₂ H	528.2 (M + H)	4.03







Example No.	Structure	ESI-MS	Retention Time (min)
2519	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	570.2 (M + H)	3.96
2520	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	611.0 (M + H)	3.69
2521	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	514.2 (M + H)	3.94
2522	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	625.4 (M + H)	3.94
2523	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	558.2 (M + H)	3.96
2524	 <chem>CC1(CCN(C1)c2cc3ccccc3n2)CCN(C1)CC1</chem> <chem>Clc1cc(S(=O)(=O)NCC2(CCN(C2)c3cc4ccccc4n3)CCN(C4)CC4)cc(Cl)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	544.2 (M + H)	3.67







Example No.	Structure	ESI-MS	Retention Time (min)
2525	 <chem>2CF3CO2H</chem>	613.2 (M + H)	3.31
2526	 <chem>CF3CO2H</chem>	596.2 (M + H)	4.69
2527	 <chem>2CF3CO2H</chem>	673.4 (M + H)	3.57
2528	 <chem>CF3CO2H</chem>	634.4 (M + H)	4.41
2529	 <chem>CF3CO2H</chem>	622.2 (M + H)	4.45
2530	 <chem>CF3CO2H</chem>	576 (M + H)	4.25

Example No.	Structure	ESI-MS	Retention Time (min)
2531	 <p>CF₃CO₂H</p>	604.4 (M + H)	4.52
2532	 <p>CF₃CO₂H</p>	610.2 (M + H)	4.40
2533	 <p>CF₃CO₂H</p>	606.4 (M + H)	4.29
2534	 <p>CF₃CO₂H</p>	594.2 (M + H)	4.27
2535	 <p>2CF₃CO₂H</p>	571.8 (M + H)	4.99
2536	 <p>CF₃CO₂H</p>	609.8 (M + H)	4.43







Example No.	Structure	ESI-MS	Retention Time (min)
2537	 $\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	4.86
2538	 $\text{CF}_3\text{CO}_2\text{H}$	564.6 (M + H)	5.13
2539	 $\text{CF}_3\text{CO}_2\text{H}$	530.6 (M + H)	4.65
2540	 $2\text{CF}_3\text{CO}_2\text{H}$	605.6 (M + H)	5.21
2541	 $\text{CF}_3\text{CO}_2\text{H}$	571.6 (M + H)	4.45
2542	 $2\text{CF}_3\text{CO}_2\text{H}$	568.8 (M + H)	4.09







Example No.	Structure	ESI-MS	Retention Time (min)
2543	 $\text{CF}_3\text{CO}_2\text{H}$	570.6 (M + H)	5.11
2544	 $2\text{CF}_3\text{CO}_2\text{H}$	629.6 (M + H)	4.37
2545	 $2\text{CF}_3\text{CO}_2\text{H}$	655.6 (M + H)	5.35
2546	 $\text{CF}_3\text{CO}_2\text{H}$	621.8 (M + H)	4.63
2547	 $\text{CF}_3\text{CO}_2\text{H}$	606.8 (M + H)	5.45
2548	 $\text{CF}_3\text{CO}_2\text{H}$	644.6 (M + H)	5.21







Example No.	Structure	ESI-MS	Retention Time (min)
2549	 $\text{CF}_3\text{CO}_2\text{H}$	632.6 (M + H)	5.25
2550	 $2\text{CF}_3\text{CO}_2\text{H}$	618.6 (M + H)	4.29
2551	 $\text{CF}_3\text{CO}_2\text{H}$	616.6 (M + H)	5.14
2552	 $\text{CF}_3\text{CO}_2\text{H}$	604.6 (M + H)	5.13
2553	 $\text{CF}_3\text{CO}_2\text{H}$	544.6 (M + H)	5.03
2554	 $2\text{CF}_3\text{CO}_2\text{H}$	585.6 (M + H)	5.13







Example No.	Structure	ESI-MS	Retention Time (min)
2555	 2CF ₃ CO ₂ H	623.6 (M + H)	4.25
2556	 CF ₃ CO ₂ H	574.6 (M + H)	4.73
2557	 2CF ₃ CO ₂ H	649.0 (M + H)	5.25
2558	 CF ₃ CO ₂ H	615.0 (M + H)	4.51
2559	 2CF ₃ CO ₂ H	617.4 (M + H)	4.15
2560	 CF ₃ CO ₂ H	600.6 (M + H)	5.37







Example No.	Structure	ESI-MS	Retention Time (min)
2561	 <chem>BrC1=CC=C(S(=O)(=O)N[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	677.0 (M + H)	4.45
2562	 <chem>COc1ccc(cc1)CN[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C(=O)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	638.6 (M + H)	5.18
2563	 <chem>BrC1=CC=C(S(=O)(=O)N[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	612.6 (M + H)	4.16
2564	 <chem>BrC1=CC=C(S(=O)(=O)N[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	580.0 (M + H)	5.01
2565	 <chem>BrC1=CC=C(S(=O)(=O)N[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	608.0 (M + H)	5.26
2566	 <chem>ClC1=CC(=C(C(=C1)Cl)S(=O)(=O)N[C@H]2C[C@@H](CN2C3=NC4=C(N=CN3C5=CC=CC=C5)C6=CC=CC=C6)C2)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	613.6 (M + H)	4.44







Example No.	Structure	ESI-MS	Retention Time (min)
2567	 2CF ₃ CO ₂ H	639.6 (M + H)	5.48
2568	 CF ₃ CO ₂ H	552.6 (M + H)	4.92
2569	 2CF ₃ CO ₂ H	607.8 (M + H)	4.33
2570	 2CF ₃ CO ₂ H	667.4 (M + H)	4.67
2571	 CF ₃ CO ₂ H	628.6 (M + H)	5.29
2572	 2CF ₃ CO ₂ H	602.6 (M + H)	4.35







Example No.	Structure	ESI-MS	Retention Time (min)
2573	 <p>CF₃CO₂H</p>	570.6 (M + H)	5.23
2574	 <p>CF₃CO₂H</p>	805.4 (M + H)	4.91
2575	 <p>2CF₃CO₂H</p>	730.8 (M + H)	4.47
2576	 <p>CF₃CO₂H</p>	771.6 (M + H)	4.93
2577	 <p>CF₃CO₂H</p>	745.6 (M + H)	5.01
2578	 <p>CF₃CO₂H</p>	580.8 (M + H)	5.18







Example No.	Structure	ESI-MS	Retention Time (min)
2579	 2CF ₃ CO ₂ H	621.8 (M + H)	5.27
2580	 CF ₃ CO ₂ H	587.6 (M + H)	4.51
2581	 2CF ₃ CO ₂ H	584.6 (M + H)	4.21
2582	 CF ₃ CO ₂ H	582.8 (M + H)	5.03
2583	 CF ₃ CO ₂ H	653.8 (M + H)	4.90
2584	 CF ₃ CO ₂ H	604.6 (M + H)	5.33







Example No.	Structure	ESI-MS	Retention Time (min)
2585	 <chem>2CF3CO2H</chem>	645.6 (M + H)	5.41
2586	 <chem>CF3CO2H</chem>	458.6 (M + H)	4.39
2587	 <chem>CF3CO2H</chem>	458.6 (M + H)	4.40
2588	 <chem>CF3CO2H</chem>	474.6 (M + H)	4.39
2589	 <chem>CF3CO2H</chem>	474.6 (M + H)	4.58
2590	 <chem>CF3CO2H</chem>	542.6 (M + H)	4.79

Example No.	Structure	ESI-MS	Retention Time (min)
2591	 <chem>CC1=NC2=C(N1)N=CN=C2NCC3CCCCC3NS(=O)(=O)c4cc(Br)ccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.51
2592	 <chem>COc1cc(OC)cc(S(=O)(=O)NCC2CCCCC2NCC3=NC4=CC=CC=C4N=C3N)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	500.8 (M + H)	4.33
2593	 <chem>FC(F)(F)c1ccccc1S(=O)(=O)NCC2CCCCC2NCC3=NC4=CC=CC=C4N=C3N</chem> $\text{CF}_3\text{CO}_2\text{H}$	524.6 (M + H)	4.61
2594	 <chem>FC(F)(F)c1ccccc1S(=O)(=O)NCC2CCCCC2NCC3=NC4=CC=CC=C4N=C3N</chem> $\text{CF}_3\text{CO}_2\text{H}$	508.6 (M + H)	4.57
2595	 <chem>CC(C)(C)c1ccc(S(=O)(=O)NCC2CCCCC2NCC3=NC4=CC=CC=C4N=C3N)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	496.8 (M + H)	4.87
2596	 <chem>Cc1nc2ccccc2n1NCC3CCCCC3NS(=O)(=O)c4ccsc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	446.8 (M + H)	4.29







Example No.	Structure	ESI-MS	Retention Time (min)
2597	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5ccc(F)cc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.8 (M + H)	4.47
2598	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5cccc(F)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.8 (M + H)	4.53
2599	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5cccc(Cl)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.6 (M + H)	4.55
2600	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5ccccc5Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	487.6 (M + H)	4.65
2601	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5cc(C(F)(F)F)ccc5Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	556.6 (M + H)	4.91
2602	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NS(=O)(=O)c5cccc(Br)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	532.4 (M + H)	4.61







Example No.	Structure	ESI-MS	Retention Time (min)
2603	 <chem>COc1ccc(S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)N3)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	514.8 (M + H)	4.43
2604	 <chem>FC(F)(F)c1ccccc1S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)N3</chem> $\text{CF}_3\text{CO}_2\text{H}$	538.6 (M + H)	4.80
2605	 <chem>CC(C)(C)c1ccc(S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)N3)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	510.6 (M + H)	5.00
2606	 <chem>c1ccsc1S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)N3</chem> $\text{CF}_3\text{CO}_2\text{H}$	460.6 (M + H)	4.40
2607	 <chem>FC1=CC=CC=C1S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)CC3</chem> $\text{CF}_3\text{CO}_2\text{H}$	486.6 (M + H)	4.60
2608	 <chem>FC1=CC=C(C=C1)S(=O)(=O)NCC2CCCCC2C3=NC4=CC=CC=C4N(C)CC3</chem> $\text{CF}_3\text{CO}_2\text{H}$	484.6 (M + H)	4.64







Example No.	Structure	ESI-MS	Retention Time (min)
2609	 CF ₃ CO ₂ H	503.6 (M + H)	4.74
2610	 CF ₃ CO ₂ H	502.6 (M + H)	4.86
2611	 CF ₃ CO ₂ H	570.8 (M + H)	5.00
2612	 CF ₃ CO ₂ H	546.0 (M + H)	4.80
2613	 CF ₃ CO ₂ H	528.8 (M + H)	4.63
2614	 CF ₃ CO ₂ H	552.8 (M + H)	4.90







Example No.	Structure	ESI-MS	Retention Time (min)
2615	 CF ₃ CO ₂ H	536.6 (M + H)	4.82
2616	 CF ₃ CO ₂ H	524.8 (M + H)	5.07
2617	 CF ₃ CO ₂ H	474.6 (M + H)	4.55
2618	 CF ₃ CO ₂ H	468.4 (M + H)	4.59
2619	 CF ₃ CO ₂ H	502.6 (M + H)	4.81
2620	 CF ₃ CO ₂ H	552.8 (M + H)	4.94







Example No.	Structure	ESI-MS	Retention Time (min)
2621	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(C)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	482.6 (M + H)	4.73
2622	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(Br)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	546.6 (M + H)	4.85
2623	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4cc(Cl)cc(Cl)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	5.08
2624	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4cc(Br)cc(OC(F)(F)F)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	630.4 (M + H)	5.11
2625	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4cc(C(F)(F)F)cc(C(F)(F)F)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	604.6 (M + H)	5.16
2626	 <chem>CCN(C)c1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4c5ccccc5cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.75







Example No.	Structure	ESI-MS	Retention Time (min)
2627	 $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.91
2628	 $2\text{CF}_3\text{CO}_2\text{H}$	561.6 (M + H)	4.61
2629	 $\text{CF}_3\text{CO}_2\text{H}$	500.8 (M + H)	4.75
2630	 $\text{CF}_3\text{CO}_2\text{H}$	500.2 (M + H)	4.85
2631	 $\text{CF}_3\text{CO}_2\text{H}$	516.6 (M + H)	4.81
2632	 $\text{CF}_3\text{CO}_2\text{H}$	516.6 (M + H)	4.95







Example No.	Structure	ESI-MS	Retention Time (min)
2633	 CF ₃ CO ₂ H	584.6 (M + H)	5.18
2634	 CF ₃ CO ₂ H	560.6 (M + H)	4.87
2635	 CF ₃ CO ₂ H	542.8 (M + H)	4.80
2636	 CF ₃ CO ₂ H	566.6 (M + H)	5.01
2637	 CF ₃ CO ₂ H	550.8 (M + H)	4.95
2638	 CF ₃ CO ₂ H	538.6 (M + H)	5.20

Example No.	Structure	ESI-MS	Retention Time (min)
2639	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccsc4)C5CCCCC5SS(=O)(=O)c6ccsc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.6 (M + H)	4.65
2640	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccccc4)C5CCCCC5SS(=O)(=O)c6ccccc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	482.6 (M + H)	4.73
2641	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccc(Cl)cc4)C5CCCCC5SS(=O)(=O)c6ccccc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	516.8 (M + H)	4.97
2642	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccc(OC(F)(F)F)cc4)C5CCCCC5SS(=O)(=O)c6ccccc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	566.6 (M + H)	5.12
2643	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccc(C)cc4)C5CCCCC5SS(=O)(=O)c6ccccc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	496.8 (M + H)	4.89
2644	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3SS(=O)(=O)c4ccc(Br)cc4)C5CCCCC5SS(=O)(=O)c6ccccc6</chem> $\text{CF}_3\text{CO}_2\text{H}$	560.0 (M + H)	4.98







Example No.	Structure	ESI-MS	Retention Time (min)
2645	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4ccc(Cl)cc4)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	550.6 (M + H)	5.21
2646	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4c5ccccc5cc4)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	532.6 (M + H)	4.99
2647	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4c5ccccc5cc4)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	532.6 (M + H)	5.03
2648	 <chem>CCN(CC)c1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4c5ccccc5cc4N(C)C)C5=CC=CC=C5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	575.8 (M + H)	4.80
2649	 <chem>CC(C)Nc1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4ccccc4F)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	486.6 (M + H)	4.64
2650	 <chem>CC(C)Nc1nc2c(ncn2C1CCN3CCCCC3S(=O)(=O)c4ccc(F)cc4)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	486.6 (M + H)	4.66







Example No.	Structure	ESI-MS	Retention Time (min)
2651	 CF ₃ CO ₂ H	502.6 (M + H)	4.72
2652	 CF ₃ CO ₂ H	502.6 (M + H)	4.87
2653	 CF ₃ CO ₂ H	570.6 (M + H)	5.03
2654	 CF ₃ CO ₂ H	546.6 (M + H)	4.77
2655	 CF ₃ CO ₂ H	528.8 (M + H)	4.68
2656	 CF ₃ CO ₂ H	552.8 (M + H)	4.89







Example No.	Structure	ESI-MS	Retention Time (min)
2657	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)C(F)Fc4ccccc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	536.6 (M + H)	4.85
2658	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(C(C)(C)C)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	524.8 (M + H)	5.15
2659	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccsc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	474.8 (M + H)	4.63
2660	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccccc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	4.61
2661	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(Cl)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	502.6 (M + H)	4.86
2662	 <chem>CC(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(Br)cc4)cc3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	546.6 (M + H)	4.64







Example No.	Structure	ESI-MS	Retention Time (min)
2663	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cc(Cl)cc(Cl)c3)cc3ccccc33</chem> $\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	4.81
2664	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cc(Br)cc(OC(F)(F)F)c3)cc3ccccc33</chem> $\text{CF}_3\text{CO}_2\text{H}$	630.4 (M + H)	4.85
2665	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc3ccccc33</chem> $\text{CF}_3\text{CO}_2\text{H}$	604.6 (M + H)	4.87
2666	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cccc4ccccc34)cc3ccccc33</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.67
2667	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cccc4ccccc34)cc3ccccc33</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.90
2668	 <chem>CC(C)Nc1nc2c(ncn2C1CCN(C1)S(=O)(=O)c3cccc4c(C)cccc34)cc3ccccc33</chem> $2\text{CF}_3\text{CO}_2\text{H}$	561.6 (M + H)	4.64







Example No.	Structure	ESI-MS	Retention Time (min)
2669	 CF ₃ CO ₂ H	500.8 (M + H)	4.73
2670	 CF ₃ CO ₂ H	500.8 (M + H)	4.74
2671	 CF ₃ CO ₂ H	516.6 (M + H)	4.89
2672	 CF ₃ CO ₂ H	516.6 (M + H)	4.93
2673	 CF ₃ CO ₂ H	560.0 (M + H)	4.89
2674	 CF ₃ CO ₂ H	542.8 (M + H)	4.76







Example No.	Structure	ESI-MS	Retention Time (min)
2675	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)OC(F)(F)F)c3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	566.6 (M + H)	5.03
2676	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)OC(F)(F)F)c3ccccc13</chem> $\text{CF}_3\text{CO}_2\text{H}$	550.8 (M + H)	4.96
2677	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(C(C)(C)C)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	538.8 (M + H)	5.25
2678	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccsc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.6 (M + H)	4.67
2679	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	482.4 (M + H)	4.71
2680	 <chem>CC(C)(C)Nc1nc2c(ncn2C1CCNCC3CCCCC3NS(=O)(=O)c4ccc(Cl)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	516.6 (M + H)	4.95







Example No.	Structure	ESI-MS	Retention Time (min)
2681	 CF ₃ CO ₂ H	566.8 (M + H)	5.07
2682	 CF ₃ CO ₂ H	496.8 (M + H)	4.83
2683	 CF ₃ CO ₂ H	560.6 (M + H)	5.01
2684	 CF ₃ CO ₂ H	550.6 (M + H)	5.07
2685	 CF ₃ CO ₂ H	644.6 (M + H)	5.29
2686	 CF ₃ CO ₂ H	618.6 (M + H)	5.25







Example No.	Structure	ESI-MS	Retention Time (min)
2687	 <p>CF₃CO₂H</p>	532.6 (M + H)	5.01
2688	 <p>CF₃CO₂H</p>	532.6 (M + H)	5.04
2689	 <p>2CF₃CO₂H</p>	575.8 (M + H)	4.75
2690	 <p>CF₃CO₂H</p>	484.6 (M + H)	4.51
2691	 <p>CF₃CO₂H</p>	500.8 (M + H)	4.59
2692	 <p>CF₃CO₂H</p>	500.8 (M + H)	4.71







Example No.	Structure	ESI-MS	Retention Time (min)
2693	 <chem>BrC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)C7C7</chem> $\text{CF}_3\text{CO}_2\text{H}$	544.6 (M + H)	4.63
2694	 <chem>COc1cc(OC)cc(S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	526.8 (M + H)	4.55
2695	 <chem>FC(F)(F)c1ccccc1S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	550.6 (M + H)	4.79
2696	 <chem>FC(F)(F)c1ccccc1S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	534.6 (M + H)	4.69
2697	 <chem>CC(C)(C)c1ccc(S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	522.4 (M + H)	5.03
2698	 <chem>c1ccsc1S(=O)(=O)N[C@H]2CCCC[C@H]2CN3C(=N4C=CC=CC=C4N5C(=N3)C(=C5)NC6CC6)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.8 (M + H)	4.43







Example No.	Structure	ESI-MS	Retention Time (min)
2699	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5ccccc5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	466.6 (M + H)	4.50
2700	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5ccc(OC(F)(F)F)cc5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	550.6 (M + H)	4.87
2701	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5ccc(C)cc5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.6 (M + H)	4.65
2702	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5ccc(Br)cc5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	544.6 (M + H)	4.75
2703	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5cc(Cl)cc(Cl)c5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	534.6 (M + H)	4.90
2704	 <chem>CC1(C)Nc2nc3c(ncn3c2CNC4CCCCC4NS(=O)(=O)c5cc(OC(F)(F)F)cc(Br)c5)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	628.6 (M + H)	5.08







Example No.	Structure	ESI-MS	Retention Time (min)
2705	 $\text{CF}_3\text{CO}_2\text{H}$	602.6 (M + H)	5.10
2706	 $\text{CF}_3\text{CO}_2\text{H}$	516.8 (M + H)	4.71
2707	 $\text{CF}_3\text{CO}_2\text{H}$	516.8 (M + H)	4.81
2708	 $2\text{CF}_3\text{CO}_2\text{H}$	559.6 (M + H)	4.50
2709	 $\text{CF}_3\text{CO}_2\text{H}$	498.8 (M + H)	4.64
2710	 $\text{CF}_3\text{CO}_2\text{H}$	498.8 (M + H)	4.73

Example No.	Structure	ESI-MS	Retention Time (min)
2711	 <chem>CC1(C)CC1CN2C=NC3C(=N2)N(C3CC4CCCCC4NS(=O)(=O)c5ccc(Cl)cc5)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	514.8 (M + H)	4.87
2712	 <chem>CC1(C)CC1CN2C=NC3C(=N2)N(C3CC4CCCCC4NS(=O)(=O)c5cc(F)(F)Fcc5)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	564.6 (M + H)	4.93
2713	 <chem>CC1(C)CC1CN2C=NC3C(=N2)N(C3CC4CCCCC4NS(=O)(=O)c5cc(F)(F)Fcc5)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	548.6 (M + H)	4.87
2714	 <chem>CC1(C)CC1CN2C=NC3C(=N2)N(C3CC4CCCCC4NS(=O)(=O)c5ccc(C(C)(C)C)cc5)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	536.6 (M + H)	5.19
2715	 <chem>CC(C)(C)OC(=O)NCCN1C=NC2C(=N1)N(C2CC3CCCCC3NS(=O)(=O)c4cc(Cl)cc4)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	603.8 (M + H)	4.76
2716	 <chem>CC(C)(C)OC(=O)NCCN1C=NC2C(=N1)N(C2CC3CCCCC3NS(=O)(=O)c4cc(Cl)cc4)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	603.4 (M + H)	4.87







Example No.	Structure	ESI-MS	Retention Time (min)
2717	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4cc(Cl)cc(F)(F)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	671.6 (M + H)	5.05
2718	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4ccc(Br)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	647.6 (M + H)	4.79
2719	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4ccc(OC)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	629.8 (M + H)	4.67
2720	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4ccc(OC(F)(F)F)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	653.8 (M + H)	4.91
2721	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4cc(F)(F)c(F)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	637.8 (M + H)	4.85
2722	 <chem>CC(C)(C)OC(=O)NCCNc1nc2ccccc2n1CNC3CCCCC3NS(=O)(=O)c4ccc(C(C)(C)C)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	625.8 (M + H)	5.14







Example No.	Structure	ESI-MS	Retention Time (min)
2723	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=CC=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	575.6 (M + H)	4.63
2724	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=CC=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	569.8 (M + H)	4.66
2725	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=C(C=C4)C5=CC=CC=C5Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	603.8 (M + H)	4.88
2726	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(F)(F)F</chem> $\text{CF}_3\text{CO}_2\text{H}$	653.8 (M + H)	5.01
2727	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=C(C=C4)C5=CC=CC=C5C</chem> $\text{CF}_3\text{CO}_2\text{H}$	583.8 (M + H)	4.77
2728	 <chem>CC(C)(C)OC(=O)NCCNC1=NC2=CC=CC=C2N=C1NCC3=CC=CC=C3S(=O)(=O)C4=CC=C(C=C4)C5=CC=CC=C5Br</chem> $\text{CF}_3\text{CO}_2\text{H}$	647 (M + H)	4.92







Example No.	Structure	ESI-MS	Retention Time (min)
2729	 $\text{CF}_3\text{CO}_2\text{H}$	637.8 (M + H)	5.13
2730	 $\text{CF}_3\text{CO}_2\text{H}$	731.6 (M + H)	5.19
2731	 $\text{CF}_3\text{CO}_2\text{H}$	705.8 (M + H)	5.22
2732	 $\text{CF}_3\text{CO}_2\text{H}$	619.8 (M + H)	4.91
2733	 $\text{CF}_3\text{CO}_2\text{H}$	619.8 (M + H)	4.93
2734	 $2\text{CF}_3\text{CO}_2\text{H}$	663.0 (M + H)	4.67







Example No.	Structure	ESI-MS	Retention Time (min)
2735	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4ccc(Cl)cc4)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	631.8 (M + H)	5.01
2736	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4cc(Cl)c(C(F)(F)F)cc4)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	699.0 (M + H)	5.19
2737	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4ccccc4Br)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	675.8 (M + H)	4.95
2738	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4cc(OC)c(OC)cc4)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	657.8 (M + H)	4.81
2739	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4ccccc4C(F)(F)F)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	665.8 (M + H)	4.97
2740	 <chem>CC(C)(C)OC(=O)Nc1ccc2nc(NC(C3CCCCC3CNC(=O)c4ccc(C(C)(C)C)cc4)CC2)c3ccccc32</chem> $\text{CF}_3\text{CO}_2\text{H}$	653.8 (M + H)	5.27

Example No.	Structure	ESI-MS	Retention Time (min)
2741	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	603.4 (M + H)	4.77
2742	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	597.8 (M + H)	4.79
2743	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	631.8 (M + H)	5.02
2744	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	681.8 (M + H)	5.14
2745	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	611.8 (M + H)	4.93
2746	<p style="text-align: center;">$\text{CF}_3\text{CO}_2\text{H}$</p>	675.0 (M + H)	5.05







Example No.	Structure	ESI-MS	Retention Time (min)
2747	 $\text{CF}_3\text{CO}_2\text{H}$	665.8 (M + H)	5.29
2748	 $\text{CF}_3\text{CO}_2\text{H}$	759.6 (M + H)	5.31
2749	 $\text{CF}_3\text{CO}_2\text{H}$	733.8 (M + H)	5.36
2750	 $\text{CF}_3\text{CO}_2\text{H}$	647.8 (M + H)	5.05
2751	 $\text{CF}_3\text{CO}_2\text{H}$	647.8 (M + H)	5.08
2752	 $2\text{CF}_3\text{CO}_2\text{H}$	691.0 (M + H)	4.89







Example No.	Structure	ESI-MS	Retention Time (min)
2753	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccc(F)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	559.6 (M + H)	4.51
2754	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccccc4Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	575.6 (M + H)	4.57
2755	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4cccc(Cl)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	575.6 (M + H)	4.69
2756	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4ccccc4Br</chem> $\text{CF}_3\text{CO}_2\text{H}$	619.6 (M + H)	4.63
2757	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4cc(OC(F)(F)F)ccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	625.8 (M + H)	4.72
2758	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CN[C@H]3CCCC[C@H]3NS(=O)(=O)c4cccc(C(F)(F)F)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	609.8 (M + H)	4.67







Example No.	Structure	ESI-MS	Retention Time (min)
2759	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4ccc(S(=O)(=O)c5ccccc5)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	541.8 (M + H)	4.45
2760	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4ccc(OC(F)(F)F)cc4S(=O)(=O)c5ccccc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	625.8 (M + H)	4.38
2761	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4ccc(C)cc4S(=O)(=O)c5ccccc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	555.8 (M + H)	4.57
2762	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4cc(Cl)cc(Cl)cc4S(=O)(=O)c5ccccc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	609.8 (M + H)	4.94
2763	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4cc(C(F)(F)F)cc(C(F)(F)F)cc4S(=O)(=O)c5ccccc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	677.8 (M + H)	5.05
2764	 <chem>CC(C)(C)OC(=O)NNc1nc2ccccc2n1CNCC3CCCCC3CNc4c5ccccc5c6ccccc46S(=O)(=O)c7ccccc7</chem> $\text{CF}_3\text{CO}_2\text{H}$	591.6 (M + H)	4.73







Example No.	Structure	ESI-MS	Retention Time (min)
2765	 $\text{CF}_3\text{CO}_2\text{H}$	591.6 (M + H)	4.75
2766	 $2\text{CF}_3\text{CO}_2\text{H}$	635.0 (M + H)	4.47
2767	 $2\text{CF}_3\text{CO}_2\text{H}$	503.6 (M + H)	3.83
2768	 $2\text{CF}_3\text{CO}_2\text{H}$	503.6 (M + H)	3.99
2769	 $2\text{CF}_3\text{CO}_2\text{H}$	571.6 (M + H)	4.16
2770	 $2\text{CF}_3\text{CO}_2\text{H}$	547.6 (M + H)	3.85







Example No.	Structure	ESI-MS	Retention Time (min)
2771	 <chem>2CF3CO2H</chem>	529.6 (M + H)	3.75
2772	 <chem>2CF3CO2H</chem>	553.8 (M + H)	3.99
2773	 <chem>2CF3CO2H</chem>	537.6 (M + H)	3.93
2774	 <chem>2CF3CO2H</chem>	525.8 (M + H)	4.22
2775	 <chem>2CF3CO2H</chem>	475.6 (M + H)	3.64
2776	 <chem>2CF3CO2H</chem>	469.6 (M + H)	3.71







Example No.	Structure	ESI-MS	Retention Time (min)
2777	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4ccc(Cl)cc4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	503.6 (M + H)	3.97
2778	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4ccc(OC(F)(F)F)cc4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	553.8 (M + H)	4.17
2779	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4ccc(C)cc4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	483.4 (M + H)	3.87
2780	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4ccc(Br)cc4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	547.6 (M + H)	4.04
2781	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4cc(Cl)cc(Cl)c4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	537.4 (M + H)	4.23
2782	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CC3CCCCC3NS(=O)(=O)c4cc(Br)cc(OC(F)(F)F)c4)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	631.6 (M + H)	4.23







Example No.	Structure	ESI-MS	Retention Time (min)
2783	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C3=CC=CC=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	605.8 (M + H)	4.41
2784	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3cccc4ccccc34)C3=CC=CC=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	519.6 (M + H)	4.01
2785	 <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3cccc4ccccc34)C3=CC=CC=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	519.6 (M + H)	4.07
2786	 <chem>CN1C=CC2=C(C1)S(=O)(=O)NC2CCC3=CC=CC=C3</chem> <chem>NCCNC1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3cccc4ccccc34)C3=CC=CC=C3</chem> $3\text{CF}_3\text{CO}_2\text{H}$	562.6 (M + H)	3.77
2787	 <chem>NCCCN1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3ccccc3Cl)C3=CC=CC=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	531.6 (M + H)	3.90
2788	 <chem>NCCCN1=NC2=CC=CC=C2N=C(NC1CCC(CC1)CNS(=O)(=O)c3ccccc3Cl)C3=CC=CC=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	531.6 (M + H)	4.04







Example No.	Structure	ESI-MS	Retention Time (min)
2789	 2CF ₃ CO ₂ H	599.6 (M + H)	4.24
2790	 2CF ₃ CO ₂ H	575.0 (M + H)	3.95
2791	 2CF ₃ CO ₂ H	557.6 (M + H)	3.86
2792	 2CF ₃ CO ₂ H	565.6 (M + H)	4.03
2793	 2CF ₃ CO ₂ H	554 (M + H)	4.29
2794	 2CF ₃ CO ₂ H	503.6 (M + H)	3.78

Example No.	Structure	ESI-MS	Retention Time (min)
2795	 2CF ₃ CO ₂ H	497.6 (M + H)	3.83
2796	 2CF ₃ CO ₂ H	531.6 (M + H)	4.05
2797	 2CF ₃ CO ₂ H	582.0 (M + H)	4.23
2798	 2CF ₃ CO ₂ H	511 (M + H)	3.95
2799	 2CF ₃ CO ₂ H	575.6 (M + H)	4.10
2800	 2CF ₃ CO ₂ H	565.0 (M + H)	4.32







Example No.	Structure	ESI-MS	Retention Time (min)
2801	 2CF ₃ CO ₂ H	659.6 (M + H)	4.35
2802	 2CF ₃ CO ₂ H	634.0 (M + H)	4.43
2803	 2CF ₃ CO ₂ H	547.6 (M + H)	4.09
2804	 2CF ₃ CO ₂ H	547.6 (M + H)	4.15
2805	 3CF ₃ CO ₂ H	590.6 (M + H)	3.93
2806	 2CF ₃ CO ₂ H	459.6 (M + H)	4.07







Example No.	Structure	ESI-MS	Retention Time (min)
2807	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3cc(F)cc(F)c3)cc3ccccc33</chem> $2\text{CF}_3\text{CO}_2\text{H}$	477.6 (M + H)	4.07
2808	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3ccccc3Cl</chem> $2\text{CF}_3\text{CO}_2\text{H}$	475.6 (M + H)	4.07
2809	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3cccc(Cl)c3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	475.6 (M + H)	4.23
2810	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3cc(OC)cc(OC)c3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	501.8 (M + H)	4.15
2811	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3ccccc3C(F)(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	509.4 (M + H)	4.27
2812	 <chem>Nc1nc2c(ncn2C1CCN(CCC1)NS(=O)(=O)c3ccc(OC(F)(F)F)cc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	525.6 (M + H)	4.37







Example No.	Structure	ESI-MS	Retention Time (min)
2813	 <p>2CF₃CO₂H</p>	519.6 (M + H)	4.25
2814	 <p>2CF₃CO₂H</p>	509.4 (M + H)	4.49
2815	 <p>2CF₃CO₂H</p>	603.0 (M + H)	4.60
2816	 <p>2CF₃CO₂H</p>	577.6 (M + H)	4.72
2817	 <p>2CF₃CO₂H</p>	491 (M + H)	4.31
2818	 <p>2CF₃CO₂H</p>	491.6 (M + H)	4.33







Example No.	Structure	ESI-MS	Retention Time (min)
2819	 <chem>CC1=CC=C(C=C1C(=O)N1C=NC2=CC=CC=C2N1N)NS(=O)(=O)C3=CC=CC=C3C</chem> 3CF ₃ CO ₂ H	534.6 (M + H)	4.01
2820	 <chem>NC(=N)NC1CCC(CC1)CNS(=O)(=O)C2=CC=CC=C2</chem> 2HCl	325.4 (M + H)	3.91
2821	 <chem>NC(=N)NC1CCC(CC1)CNS(=O)(=O)C2=CC=C(Cl)C=C2</chem> 2HCl	359.4 (M + H)	4.24
2822	 <chem>NC(=N)NC1CCC(CC1)CNS(=O)(=O)C2=CC=C(OC(F)(F)F)C=C2</chem> 2HCl	409.4 (M + H)	4.51
2823	 <chem>NC(=N)NC1CCC(CC1)CNS(=O)(=O)C2=CC=C(C)C=C2</chem> 2HCl	339.6 (M + H)	4.09
2824	 <chem>NC(=N)NC1CCC(CC1)CNS(=O)(=O)C2=CC=C(Br)C=C2</chem> 2HCl	403.4 (M + H)	4.28







Example No.	Structure	ESI-MS	Retention Time (min)
2825	 <chem>Nc1ccccc1NS(=O)(=O)c2cc(Cl)cc(Cl)c2</chem> 2HCl	393.0 (M + H)	4.57
2826	 <chem>Nc1ccccc1NS(=O)(=O)c2cc(OC(F)(F)F)cc(OC(F)(F)F)c2</chem> 2HCl	521.6 (M + H)	4.69
2827	 <chem>Nc1ccccc1NS(=O)(=O)c2cc(F)c(F)c(F)c2</chem> 2HCl	461.6 (M + H)	4.77
2828	 <chem>Nc1ccccc1NS(=O)(=O)c2c3ccccc3ccc2</chem> 2HCl	375.4 (M + H)	4.33
2829	 <chem>Nc1ccccc1NS(=O)(=O)c2c3ccccc3cc2</chem> 2HCl	375.4 (M + H)	4.39
2830	 <chem>CN1Cc2ccccc2S(=O)(=O)c3c4ccccc4cc31</chem> 2HCl	418.8 (M + H)	4.33







Example No.	Structure	ESI-MS	Retention Time (min)
2831	 2HCl	343.4 (M + H)	3.96
2832	 2HCl	343.4 (M + H)	4.03
2833	 2HCl	359.4 (M + H)	4.05
2834	 2HCl	359.4 (M + H)	4.24
2835	 2HCl	403.4 (M + H)	4.07
2836	 2HCl	385.4 (M + H)	4.00







Example No.	Structure	ESI-MS	Retention Time (min)
2837	 2HCl	409.4 (M + H)	4.32
2838	 2HCl	393.6 (M + H)	4.23
2839	 2HCl	381.6 (M + H)	4.62
2840	 2HCl	330.8 (M + H)	3.83
2841	 2HCl	361.4 (M + H)	4.05
2842	 2HCl	427.4 (M + H)	4.51







Example No.	Structure	ESI-MS	Retention Time (min)
2843	 2CF ₃ CO ₂ H	458.4 (M + H)	3.22
2844	 2CF ₃ CO ₂ H	415.4 (M + H)	3.01
2845	 2CF ₃ CO ₂ H	432.6 (M + H)	3.26
2846	 2CF ₃ CO ₂ H	396.2 (M + H)	2.81
2847	 2CF ₃ CO ₂ H	450.0 (M + H)	3.09
2848	 2CF ₃ CO ₂ H	408.4 (M + H)	2.85







Example No.	Structure	ESI-MS	Retention Time (min)
2849	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4cc5ccccc45O</chem> $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	2.89
2850	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4ccc5ccccc45</chem> $2\text{CF}_3\text{CO}_2\text{H}$	440.0 (M + H)	3.20
2851	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4ccc(Oc5ccccc5)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	482.4 (M + H)	3.43
2852	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4cc(OC)c(O)c(OC)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	466.4 (M + H)	2.71
2853	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4ccoc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	380.2 (M + H)	2.72
2854	 <chem>CN(C)c1nc2c(ncn2C1)N[C@H]3CCCC[C@H]3NCCc4cc(F)c(F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	2.91







Example No.	Structure	ESI-MS	Retention Time (min)
2855	 <chem>CCOC1=CC=C(C=C1C(=O)O)CNCC2(C)CCN(C2)C3=NC4=CC=CC=C4N(C)C3=NC5=CC=CC=C5N5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.0 (M + H)	2.82
2856	 <chem>OC(=O)C1=CC=C(C=C1)CNCC2(C)CCN(C2)C3=NC4=CC=CC=C4N(C)C3=NC5=CC=CC=C5N5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	2.69
2857	 <chem>OC1=CC=C(C=C1C(=O)O)C(=O)ClCNCC2(C)CCN(C2)C3=NC4=CC=CC=C4N(C)C3=NC5=CC=CC=C5N5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	440.0 (M + H)	2.85
2858	 <chem>ClC1=CC(=C(C=C1)OC2=CC=C(C=C2)CNCC3(C)CCN(C3)C4=NC5=CC=CC=C5N(C)C4=NC6=CC=CC=C6N6)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	550.6 (M + H)	3.80
2859	 <chem>C1=CC=C2C(=C1)N=CN2CNCC3(C)CCN(C3)C4=NC5=CC=CC=C5N(C)C4=NC6=CC=CC=C6N6</chem> $3\text{CF}_3\text{CO}_2\text{H}$	441.4 (M + H)	3.03
2860	 <chem>CC(C)(C)C1=CC=C(C=C1)CNCC2(C)CCN(C2)C3=NC4=CC=CC=C4N(C)C3=NC5=CC=CC=C5N5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	446.6 (M + H)	3.41







Example No.	Structure	ESI-MS	Retention Time (min)
2861	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC5C=C(C=C4)OCC5)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	2.91
2862	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC=C(C=C4)Cl)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	3.05
2863	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC5=CC=CC=C5N=C4)N</chem> $3\text{CF}_3\text{CO}_2\text{H}$	441.4 (M + H)	2.68
2864	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC(=C(C=C4)OC)N(C)C)N</chem> $3\text{CF}_3\text{CO}_2\text{H}$	463.4 (M + H)	2.76
2865	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC=C(C=C4)F)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	408.4 (M + H)	2.91
2866	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NC4C=CC(=C(C=C4)Cl)Cl)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	492.2 (M + H)	3.30







Example No.	Structure	ESI-MS	Retention Time (min)
2867	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC(OC)OC4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	2.93
2868	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC(OC(F)(F)F)C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	3.27
2869	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	390.6 (M + H)	2.88
2870	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC(OC5=CC=CC=C5)C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	482.2 (M + H)	3.43
2871	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC(F)C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	408.4 (M + H)	2.91
2872	 <chem>CC1=NC2=CC=CC=C2N1CNC3CCCCC3CN4C=CC(OC)C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.91







Example No.	Structure	ESI-MS	Retention Time (min)
2873	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(Br)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	468.2 (M + H)	3.09
2874	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(O)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	406.4 (M + H)	2.80
2875	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(OCC)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	2.97
2876	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(C(F)(F)F)cc4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	524.6 (M + H)	3.12
2877	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4cc(F)c(Cl)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	442.4 (M + H)	3.10
2878	 <chem>CN(C)c1nc2ccccc2n1C(=O)N[C@H]3CCCC[C@H]3CNCCc4cc(F)c(F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	2.90







Example No.	Structure	ESI-MS	Retention Time (min)
2879	 <chem>COc1cc(OC)c(OC)cc1NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	480.2 (M + H)	2.89
2880	 <chem>BrC1=CC=C(C=C1)NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	468.2 (M + H)	3.07
2881	 <chem>Oc1cc(O)ccc1NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	422.4 (M + H)	2.61
2882	 <chem>COc1cc(OC)ccc1NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.0 (M + H)	2.93
2883	 <chem>CC1=CC=C(C=C1)NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	404.6 (M + H)	3.01
2884	 <chem>Ic1ccc(cc1)NCC2CCCCC2Nc3nc4c(ncn3C)ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	436.4 (M + H)	3.08







Example No.	Structure	ESI-MS	Retention Time (min)
2885	 2CF ₃ CO ₂ H	440.0 (M + H)	3.18
2886	 2CF ₃ CO ₂ H	470.4 (M + H)	3.25
2887	 2CF ₃ CO ₂ H	450.0 (M + H)	3.01
2888	 2CF ₃ CO ₂ H	466.4 (M + H)	3.40
2889	 2CF ₃ CO ₂ H	415.4 (M + H)	2.83
2890	 2CF ₃ CO ₂ H	458.4 (M + H)	3.25







Example No.	Structure	ESI-MS	Retention Time (min)
2891	 2CF ₃ CO ₂ H	468.2 (M + H)	3.00
2892	 2CF ₃ CO ₂ H	406.4 (M + H)	2.66
2893	 2CF ₃ CO ₂ H	420.4 (M + H)	2.92
2894	 3CF ₃ CO ₂ H	379.4 (M + H)	2.71
2895	 2CF ₃ CO ₂ H	434.4 (M + H)	2.87
2896	 2CF ₃ CO ₂ H	480.2 (M + H)	3.17







Example No.	Structure	ESI-MS	Retention Time (min)
2897	 2CF ₃ CO ₂ H	426.2 (M + H)	2.98
2898	 2CF ₃ CO ₂ H	480.2 (M + H)	2.99
2899	 2CF ₃ CO ₂ H	528.4 (M + H)	3.15
2900	 2CF ₃ CO ₂ H	458.4 (M + H)	3.19
2901	 2CF ₃ CO ₂ H	480.2 (M + H)	2.92
2902	 2CF ₃ CO ₂ H	470.4 (M + H)	3.27







Example No.	Structure	ESI-MS	Retention Time (min)
2903	 $2\text{CF}_3\text{CO}_2\text{H}$	404.6 (M + H)	2.87
2904	 $2\text{CF}_3\text{CO}_2\text{H}$	460.4 (M + H)	3.48
2905	 $2\text{CF}_3\text{CO}_2\text{H}$	410.4 (M + H)	2.96
2906	 $2\text{CF}_3\text{CO}_2\text{H}$	450.0 (M + H)	3.03
2907	 $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.08
2908	 $2\text{CF}_3\text{CO}_2\text{H}$	452.2 (M + H)	2.79







Example No.	Structure	ESI-MS	Retention Time (min)
2909	 $2\text{CF}_3\text{CO}_2\text{H}$	396.2 (M + H)	2.81
2910	 $3\text{CF}_3\text{CO}_2\text{H}$	459.4 (M + H)	3.21
2911	 $2\text{CF}_3\text{CO}_2\text{H}$	458.2 (M + H)	3.08
2912	 $2\text{CF}_3\text{CO}_2\text{H}$	410.4 (M + H)	2.88
2913	 $2\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	3.01
2914	 $3\text{CF}_3\text{CO}_2\text{H}$	429.4 (M + H)	2.97







Example No.	Structure	ESI-MS	Retention Time (min)
2915	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4ccc5c(c4)c(c6ccccc65)NCC6</chem> $3\text{CF}_3\text{CO}_2\text{H}$	507.2 (M + H)	3.53
2916	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4oc(cc4)Scc5ccc(Cl)cc5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	522.4 (M + H)	3.56
2917	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4ccc(N(C)C)cc4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	483.2 (M + H)	2.80
2918	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4c[nH]c5cc(Br)ccc45</chem> $3\text{CF}_3\text{CO}_2\text{H}$	507.2 (M + H)	3.27
2919	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4ccsc4Br</chem> $2\text{CF}_3\text{CO}_2\text{H}$	474.2 (M + H)	3.10
2920	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3CNCCc4cc(OC)cc(OC)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.0 (M + H)	3.00







Example No.	Structure	ESI-MS	Retention Time (min)
2921	 $2\text{CF}_3\text{CO}_2\text{H}$	498.4 (M + H)	3.15
2922	 $3\text{CF}_3\text{CO}_2\text{H}$	459.4 (M + H)	2.99
2923	 $2\text{CF}_3\text{CO}_2\text{H}$	476.0 (M + H)	3.10
2924	 $2\text{CF}_3\text{CO}_2\text{H}$	518.2 (M + H)	3.10
2925	 $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.12
2926	 $2\text{CF}_3\text{CO}_2\text{H}$	490.4 (M + H)	3.35







Example No.	Structure	ESI-MS	Retention Time (min)
2927	 2CF ₃ CO ₂ H	434.4 (M + H)	3.11
2928	 2CF ₃ CO ₂ H	478.4 (M + H)	3.29
2929	 2CF ₃ CO ₂ H	438.2 (M + H)	3.01
2930	 3CF ₃ CO ₂ H	433.4 (M + H)	2.59
2931	 2CF ₃ CO ₂ H	438.2 (M + H)	2.90
2932	 2CF ₃ CO ₂ H	456.2 (M + H)	3.10







Example No.	Structure	ESI-MS	Retention Time (min)
2933	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccc(C(F)(F)F)c(Cl)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	492.2 (M + H)	3.25
2934	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(F)c(C(F)(F)F)c(F)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.11
2935	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(OC(F)(F)F)c(O)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	490.4 (M + H)	3.20
2936	 <chem>CC(C)Oc1ccc(CNc2ccccc2NC3CCCCC3NC4C=NC5=CC=CC=C5N4C)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	3.17
2937	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccc(SC(F)(F)F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	489.6 (M + H)	3.31
2938	 <chem>COc1cc(OC)c(Br)cc1NC2CCCCC2NC3C=NC4=CC=CC=C4N3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	528.2 (M + H)	3.03







Example No.	Structure	ESI-MS	Retention Time (min)
2939	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC(=CC=C4)C(F)(F)F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	2.99
2940	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC(=CC=C4)NC(=O)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	447.4 (M + H)	2.66
2941	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC(=CC=C4)SC5=CC=C(C=C5)Cl</chem> $2\text{CF}_3\text{CO}_2\text{H}$	532.4 (M + H)	3.66
2942	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC(=CC=C4)C(O)C(OC)Br</chem> $2\text{CF}_3\text{CO}_2\text{H}$	514.4 (M + H)	3.08
2943	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC=C(C=C4)N5C=CC=C5</chem> $3\text{CF}_3\text{CO}_2\text{H}$	393.4 (M + H)	2.79
2944	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3CNCC4=CC(=CC=C4)C(OC(F)(F)F)</chem> $2\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	3.24







Example No.	Structure	ESI-MS	Retention Time (min)
2945	 $2\text{CF}_3\text{CO}_2\text{H}$	526.6 (M + H)	3.44
2946	 $2\text{CF}_3\text{CO}_2\text{H}$	526.6 (M + H)	3.42
2947	 $2\text{CF}_3\text{CO}_2\text{H}$	490.4 (M + H)	3.35
2948	 $2\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	3.43
2949	 $2\text{CF}_3\text{CO}_2\text{H}$	418.6 (M + H)	3.13
2950	 $2\text{CF}_3\text{CO}_2\text{H}$	458.4 (M + H)	3.10







Example No.	Structure	ESI-MS	Retention Time (min)
2951	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC=C(C(F)(F)F)C=C4</chem> $2CF_3CO_2H$	476.4 (M + H)	3.19
2952	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC=C(F)C=C4</chem> $2CF_3CO_2H$	438.2 (M + H)	2.95
2953	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC(=C(O)C(O)=C4</chem> $2CF_3CO_2H$	422.4 (M + H)	2.61
2954	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC(=C(Cl)C(Cl)=C4</chem> $2CF_3CO_2H$	458.2 (M + H)	3.07
2955	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC5=C(C4)OC(=C5)C6=CC=CC=C6</chem> $2CF_3CO_2H$	470.4 (M + H)	3.45
2956	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC4=CC5=C(C4)ON=C5C6=CC=CC=C6</chem> $2CF_3CO_2H$	471.6 (M + H)	2.88







Example No.	Structure	ESI-MS	Retention Time (min)
2957	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccccc4S)c5ccccc15</chem> $2\text{CF}_3\text{CO}_2\text{H}$	472.4 (M + H)	3.36
2958	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4cc(OC)c(OC)c(OC)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450 (M + H)	2.75
2959	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(OCC)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	3.20
2960	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4cc(OC)c(OC)c(OC)c4C(=O)OC</chem> $2\text{CF}_3\text{CO}_2\text{H}$	508.4 (M + H)	3.00
2961	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4cc(C)c(O)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.80
2962	 <chem>CN(C)c1nc2c(ncn2C(=O)N[C@H]3CCCC[C@H]3CNCCc4ccc(OC(F)(F)F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	3.20







Example No.	Structure	ESI-MS	Retention Time (min)
2963	 2CF ₃ CO ₂ H	404.4 (M + H)	2.87
2964	 2CF ₃ CO ₂ H	458.2 (M + H)	3.00
2965	 3CF ₃ CO ₂ H	394.4 (M + H)	2.30
2966	 2CF ₃ CO ₂ H	505.4 (M + H)	2.60
2967	 2CF ₃ CO ₂ H	424.2 (M + H)	3.00
2968	 2CF ₃ CO ₂ H	436.4 (M + H)	2.71







Example No.	Structure	ESI-MS	Retention Time (min)
2969	 <chem>CC(C)c1ccc(cc1)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	432.4 (M + H)	3.30
2970	 <chem>Clc1ccc(cc1)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	2.95
2971	 <chem>N#Cc1ccc(cc1)CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	415.4 (M + H)	2.79
2972	 <chem>Fc1cc(F)c(F)c(F)c1CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	480.2 (M + H)	3.00
2973	 <chem>c1ccc(cc1)Oc2ccc(cc2)CN[C@H]3CCCC[C@H]3Nc4nc5ccccc5n4C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	496.2 (M + H)	3.46
2974	 <chem>COc1cc(O)ccc1CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	562.2 (M + H)	2.99







Example No.	Structure	ESI-MS	Retention Time (min)
2975	 2CF ₃ CO ₂ H	492.4 (M + H)	3.64
2976	 2CF ₃ CO ₂ H	492.2 (M + H)	3.25
2977	 2CF ₃ CO ₂ H	448.4 (M + H)	3.22
2978	 2CF ₃ CO ₂ H	456.2 (M + H)	3.09
2979	 2CF ₃ CO ₂ H	434.4 (M + H)	2.89
2980	 2CF ₃ CO ₂ H	436.4 (M + H)	2.79







Example No.	Structure	ESI-MS	Retention Time (min)
2981	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccc(OC)c(F)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	438.2 (M + H)	2.91
2982	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccc5ccccc5n4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	441.4 (M + H)	2.55
2983	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4c5ccccc5s4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	446.4 (M + H)	3.13
2984	 <chem>CCN(CC)c1ccc(CNc2ccccc2NC3CCCCC3NC4=NC5=CC=CC=C5N4C(C)N)cc1</chem> $3\text{CF}_3\text{CO}_2\text{H}$	461.4 (M + H)	2.46
2985	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccccc4F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	422.2 (M + H)	3.01
2986	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc5oc(cc5n4)S6=NN=C(S6)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	510.2 (M + H)	2.85







Example No.	Structure	ESI-MS	Retention Time (min)
2987	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4cc(Cl)oc4)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	414.4 (M + H)	2.86
2988	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4cc(F)cc(I)c4)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	534.2 (M + H)	3.13
2989	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4ccsc4CC)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	3.08
2990	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4cc(F)c(Cl)c(C(F)(F)F)c4)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	510.4 (M + H)	3.32
2991	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4cc(F)c(C(F)(F)F)c(Cl)c4)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	510.4 (M + H)	3.17
2992	 <chem>CN(C)c1nc2c(ncn2C3CCCCC3NCc4cc(F)c(C(F)(F)F)cc4)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.4 (M + H)	3.17







Example No.	Structure	ESI-MS	Retention Time (min)
2993	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(F)c(C(F)(F)F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.21
2994	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(OC)c(F)c(O)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	454.2 (M + H)	2.77
2995	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(F)c(OC)c(OC)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	2.89
2996	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccccc4CC</chem> $2\text{CF}_3\text{CO}_2\text{H}$	418.6 (M + H)	3.12
2997	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4cc(Cl)c(F)c5ccoc5c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	496.4 (M + H)	3.29
2998	 <chem>CN(C)c1nc2ccccc2n1NC3CCCCC3CNc4ccc(NC(C)C)cc4</chem> $3\text{CF}_3\text{CO}_2\text{H}$	472.6 (M + H)	2.99







Example No.	Structure	ESI-MS	Retention Time (min)
2999	 2CF ₃ CO ₂ H	466.4 (M + H)	3.37
3000	 2CF ₃ CO ₂ H	574.2 (M + H)	3.64
3001	 2CF ₃ CO ₂ H	430.4 (M + H)	3.05
3002	 2CF ₃ CO ₂ H	532.4 (M + H)	4.05
3003	 2CF ₃ CO ₂ H	552.0 (M + H)	3.37
3004	 CF ₃ CO ₂ H	448.4 (M + H)	3.51







Example No.	Structure	ESI-MS	Retention Time (min)
3005	 CF ₃ CO ₂ H	454.2 (M + H)	3.91
3006	 CF ₃ CO ₂ H	472.4 (M + H)	4.02
3007	 CF ₃ CO ₂ H	494.4 (M + H)	4.01
3008	 CF ₃ CO ₂ H	537.4 (M + H)	3.77
3009	 CF ₃ CO ₂ H	418.6 (M + H)	3.63
3010	 CF ₃ CO ₂ H	418.6 (M + H)	3.51







Example No.	Structure	ESI-MS	Retention Time (min)
3011	 CF ₃ CO ₂ H	396.2 (M + H)	3.47
3012	 CF ₃ CO ₂ H	434.4 (M + H)	3.52
3013	 CF ₃ CO ₂ H	395.4 (M + H)	3.15
3014	 CF ₃ CO ₂ H	460.2 (M + H)	4.03
3015	 CF ₃ CO ₂ H	418.6 (M + H)	3.65
3016	 CF ₃ CO ₂ H	462.2 (M + H)	4.09







Example No.	Structure	ESI-MS	Retention Time (min)
3017	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)c4ccc(Br)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	484.2 (M + H)	3.79
3018	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)c4cc5ccccc5c(OC)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	498.6 (M + H)	3.88
3019	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)c4cc([N+](=O)[O-])cc(Cl)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	483.2 (M + H)	3.80
3020	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)c4cc(OC)cc(OC)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	478.2 (M + H)	3.49
3021	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)CSc4ccccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	450.0 (M + H)	3.61
3022	 <chem>CC1=NC2=CC=CC=C2N1N(C)C(C)N2C3CCCCC3CCNC(=O)COc4ccccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	448.2 (M + H)	3.70







Example No.	Structure	ESI-MS	Retention Time (min)
3023	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3cc(Cl)cc(Cl)c3</chem> $\text{CF}_3\text{CO}_2\text{H}$	554.4 (M + H)	4.41
3024	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3cc(C)s(c3)S(=O)(=O)c4ccc(Cl)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	598.2 (M + H)	4.03
3025	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3ccc([N+](=O)[O-])cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	499.2 (M + H)	3.59
3026	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3cc(OC)c(Cl)c(OC)c3</chem> $\text{CF}_3\text{CO}_2\text{H}$	524.6 (M + H)	3.84
3027	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3ccncc3Oc4ccccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	497.4 (M + H)	3.80
3028	 <chem>CC1=CN(C)C(=N1)N[C@H]2CCCC[C@H]2C(=O)Nc3ccsc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	410.2 (M + H)	3.43







Example No.	Structure	ESI-MS	Retention Time (min)
3029	 CF ₃ CO ₂ H	468.2 (M + H)	3.77
3030	 CF ₃ CO ₂ H	463.2 (M + H)	3.73
3031	 CF ₃ CO ₂ H	490.4 (M + H)	3.91
3032	 CF ₃ CO ₂ H	490.4 (M + H)	3.94
3033	 CF ₃ CO ₂ H	490.4 (M + H)	3.85
3034	 CF ₃ CO ₂ H	490.4 (M + H)	3.87







Example No.	Structure	ESI-MS	Retention Time (min)
3035	 <p>CF₃CO₂H</p>	490.4 (M + H)	3.63
3036	 <p>CF₃CO₂H</p>	490.2 (M + H)	3.54
3037	 <p>CF₃CO₂H</p>	540.4 (M + H)	3.95
3038	 <p>CF₃CO₂H</p>	440.4 (M + H)	3.58
3039	 <p>CF₃CO₂H</p>	458.4 (M + H)	3.56
3040	 <p>CF₃CO₂H</p>	476.4 (M + H)	3.83







Example No.	Structure	ESI-MS	Retention Time (min)
3041	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4cc(Cl)cc(F)c4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	490.4 (M + H)	3.82
3042	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4cc(Cl)cc(Cl)c4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	508.0 (M + H)	3.85
3043	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4ccc(Cl)cc4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	438.2 (M + H)	3.71
3044	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4cc(OC)cc(OC)c4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	3.65
3045	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4c5ccccc5oc4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	3.47
3046	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)c4cc(F)cc(F)c4)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	440.4 (M + H)	3.59







Example No.	Structure	ESI-MS	Retention Time (min)
3047	 <chem>COc1ccc(cc1)C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	3.36
3048	 <chem>COc1cc(OC)ccc1C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	464.4 (M + H)	3.39
3049	 <chem>CCc1ccc(cc1)C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	432.4 (M + H)	3.81
3050	 <chem>CCOC1=CC=C(C=C1)C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	3.69
3051	 <chem>Clc1ccc(cc1)C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	438.2 (M + H)	3.69
3052	 <chem>Clc1cc(Cl)ccc1C(=O)N[C@H]2CCCC[C@H]2Nc3nc(NC(C)=C)c4ccccc34</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.4 (M + H)	4.03







Example No.	Structure	ESI-MS	Retention Time (min)
3053	 CF ₃ CO ₂ H	429.2 (M + H)	3.47
3054	 CF ₃ CO ₂ H	488.4 (M + H)	4.60
3055	 CF ₃ CO ₂ H	424.2 (M + H)	3.41
3056	 CF ₃ CO ₂ H	530.2 (M + H)	3.83
3057	 CF ₃ CO ₂ H	446.4 (M + H)	4.02
3058	 CF ₃ CO ₂ H	438.2 (M + H)	3.70







Example No.	Structure	ESI-MS	Retention Time (min)
3059	 CF ₃ CO ₂ H	472.4 (M + H)	3.55
3060	 CF ₃ CO ₂ H	506.4 (M + H)	3.71
3061	 CF ₃ CO ₂ H	530.2 (M + H)	3.61
3062	 CF ₃ CO ₂ H	474.4 (M + H)	4.41
3063	 CF ₃ CO ₂ H	476.4 (M + H)	4.14
3064	 CF ₃ CO ₂ H	502.4 (M + H)	4.83







Example No.	Structure	ESI-MS	Retention Time (min)
3065	 CF ₃ CO ₂ H	480.4 (M + H)	4.09
3066	 CF ₃ CO ₂ H	486.4 (M + H)	3.84
3067	 CF ₃ CO ₂ H	440.4 (M + H)	3.46
3068	 CF ₃ CO ₂ H	494.4 (M + H)	3.79
3069	 CF ₃ CO ₂ H	472.4 (M + H)	3.55
3070	 CF ₃ CO ₂ H	464.4 (M + H)	3.63







Example No.	Structure	ESI-MS	Retention Time (min)
3071	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C(F)=CC(F)=C5</chem> <chem>CC(F)(F)C(=O)O</chem>	458.2 (M + H)	3.69
3072	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C(F)=CC(F)=C5</chem> <chem>CC(F)(F)C(=O)O</chem>	440.4 (M + H)	3.69
3073	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C(F)=CC(F)=C5</chem> <chem>CC(F)(F)C(=O)O</chem>	440.4 (M + H)	3.66
3074	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C(F)=CC=C5</chem> <chem>CC(F)(F)C(=O)O</chem>	422.4 (M + H)	3.55
3075	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C1=CC=C(C=C1)CCC</chem> <chem>CC(F)(F)C(=O)O</chem>	460.4 (M + H)	4.24
3076	 <chem>CC1=CN2C(=N1)N(C)C2c3ccccc3N[C@H]4CCCC[C@H]4CN5C(=O)C1=CC=C(C=C1)C#N</chem> <chem>CC(F)(F)C(=O)O</chem>	429.2 (M + H)	3.42







Example No.	Structure	ESI-MS	Retention Time (min)
3077	 <chem>COc1ccc(cc1)NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.61
3078	 <chem>COc1ccc(cc1)NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.4 (M + H)	3.86
3079	 <chem>CCCCCOc1ccc(cc1)NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.6 (M + H)	4.74
3080	 <chem>Fc1cc(F)c(F)cc1NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	458.2 (M + H)	3.68
3081	 <chem>C1CCCCC1NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	410.4 (M + H)	3.58
3082	 <chem>Cc1ccc(C(F)(F)F)cc1NC(=O)CC2CCCCC2Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	540.4 (M + H)	4.19







Example No.	Structure	ESI-MS	Retention Time (min)
3083	 CF ₃ CO ₂ H	422.2 (M + H)	3.50
3084	 CF ₃ CO ₂ H	494.4 (M + H)	3.39
3085	 CF ₃ CO ₂ H	440.0 (M + H)	3.55
3086	 CF ₃ CO ₂ H	438.2 (M + H)	3.48
3087	 CF ₃ CO ₂ H	454.2 (M + H)	3.75
3088	 CF ₃ CO ₂ H	472.4 (M + H)	3.83







Example No.	Structure	ESI-MS	Retention Time (min)
3089	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4ccc(F)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	422.2 (M + H)	3.51
3090	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4ccc(C(F)(F)F)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.4 (M + H)	3.87
3091	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4cc(F)cc(Br)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	500.4 (M + H)	3.03
3092	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4ccc(N(C)C)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	447.4 (M + H)	2.59
3093	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4ccc(c5ccsc5)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	486.4 (M + H)	3.25
3094	 <chem>CC1=CN(C)C2=CC=CC=C2N1C3CCCCC3CNC(=O)c4ccc(c5nn[nH]5)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.4 (M + H)	2.81







Example No.	Structure	ESI-MS	Retention Time (min)
3095	 CF ₃ CO ₂ H	452.4 (M + H)	2.98
3096	 CF ₃ CO ₂ H	496.4 (M + H)	3.29
3097	 CF ₃ CO ₂ H	448.4 (M + H)	2.77
3098	 CF ₃ CO ₂ H	458.4 (M + H)	3.06
3099	 CF ₃ CO ₂ H	484.4 (M + H)	3.40
3100	 CF ₃ CO ₂ H	418.6 (M + H)	2.69







Example No.	Structure	ESI-MS	Retention Time (min)
3101	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4=NC(=C(C5=CC=CC=C5)N=CN4)C(=O)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	496.4 (M + H)	3.01
3102	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4=CC(=CC=C4C(=O)N)Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	483.4 (M + H)	2.79
3103	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4C=CC5CC4C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.76
3104	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4=CC(=CC=C4C(=O)N)Br</chem> $\text{CF}_3\text{CO}_2\text{H}$	516.2 (M + H)	3.03
3105	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4=CC(=CC=C4C(=O)N)OC</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.4 (M + H)	2.41
3106	 <chem>CC1=NC2=CC=CC=C2N(C)C(=N1)NC3CCCCC3CNC(=O)C4=CC(=CC=C4C(=O)N)Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	483.2 (M + H)	2.84







Example No.	Structure	ESI-MS	Retention Time (min)
3107	 $2\text{CF}_3\text{CO}_2\text{H}$	455 (M + H)	2.45
3108	 $2\text{CF}_3\text{CO}_2\text{H}$	455.2 (M + H)	3.19
3109	 $\text{CF}_3\text{CO}_2\text{H}$	461.4 (M + H)	2.60
3110	 $2\text{CF}_3\text{CO}_2\text{H}$	470.4 (M + H)	2.74
3111	 $\text{CF}_3\text{CO}_2\text{H}$	446.6 (M + H)	2.61
3112	 $\text{CF}_3\text{CO}_2\text{H}$	464.4 (M + H)	2.35







Example No.	Structure	ESI-MS	Retention Time (min)
3113	 $\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	3.04
3114	 $2\text{CF}_3\text{CO}_2\text{H}$	456.2 (M + H)	2.44
3115	 $2\text{CF}_3\text{CO}_2\text{H}$	455.2 (M + H)	2.11
3116	 $\text{CF}_3\text{CO}_2\text{H}$	454.2 (M + H)	3.21
3117	 $2\text{CF}_3\text{CO}_2\text{H}$	433.6 (M + H)	2.34
3118	 $2\text{CF}_3\text{CO}_2\text{H}$	444.6 (M+)	2.93







Example No.	Structure	ESI-MS	Retention Time (min)
3119	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=N4O3</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=N4O3</chem> <chem>2CF3CO2H</chem>	421.4 (M + H)	2.23
3120	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC5=CC=CC=C5C3=CC=C4</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC5=CC=CC=C5C3=CC=C4</chem> <chem>CF3CO2H</chem>	506.4 (M + H)	3.31
3121	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>2CF3CO2H</chem>	511.6 (M + H)	3.21
3122	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CF3CO2H</chem>	479.4 (M + H)	3.60
3123	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CF3CO2H</chem>	434.4 (M + H)	2.37
3124	 <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CC1=NC2=CC=CC=C2N1N=C3C(=O)NCC4=CC=CC=C4C(=O)N5C=CC(OC)=CC=C5</chem> <chem>CF3CO2H</chem>	516.4 (M + H)	3.02







Example No.	Structure	ESI-MS	Retention Time (min)
3125	 CF ₃ CO ₂ H	394.4 (M + H)	2.45
3126	 CF ₃ CO ₂ H	450.2 (M + H)	2.41
3127	 2CF ₃ CO ₂ H	477.0 (M + H)	2.88
3128	 2CF ₃ CO ₂ H	405.6 (M + H)	2.61
3129	 CF ₃ CO ₂ H	472.6 (M + H)	3.17
3130	 CF ₃ CO ₂ H	464.4 (M + H)	2.59







Example No.	Structure	ESI-MS	Retention Time (min)
3131	 $\text{CF}_3\text{CO}_2\text{H}$	484.2 (M + H)	2.99
3132	 $2\text{CF}_3\text{CO}_2\text{H}$	453.0 (M + H)	2.45
3133	 $\text{CF}_3\text{CO}_2\text{H}$	488.4 (M + H)	3.59
3134	 $\text{CF}_3\text{CO}_2\text{H}$	454.2 (M + H)	2.81
3135	 $2\text{CF}_3\text{CO}_2\text{H}$	421.4 (M + H)	2.89
3136	 $\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	2.53







Example No.	Structure	ESI-MS	Retention Time (min)
3137	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4=CC=C(C=C4)C(=C)C=C4N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	483.2 (M + H)	2.83
3138	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4=CC=C5C=C(C4)SC5</chem> $\text{CF}_3\text{CO}_2\text{H}$	487.4 (M+2H+)	3.40
3139	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4SCC(S4)N</chem> $\text{CF}_3\text{CO}_2\text{H}$	445.6 (M + H)	2.36
3140	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4=CC=C(C=C4)C(=C)C=C4N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	453.2 (M + H)	2.46
3141	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4=CC(OC)=CC(OC)=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	2.77
3142	 <chem>CC1=NC2=CC=CC=C2N1NC3CCCCC3NC(=O)C4=CC=C(C=C4)C(=C)C=C4O</chem> $\text{CF}_3\text{CO}_2\text{H}$	672.2 (M + H)	3.92







Example No.	Structure	ESI-MS	Retention Time (min)
3143	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)c4cc(Br)cc(Br)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	576.2 (M + H)	3.71
3144	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)c4cc(O)ncn4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	421.2 (M + H)	2.01
3145	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)c4cc([N+](=O)[O-])cc([N+](=O)[O-])c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	494.4 (M + H)	2.77
3146	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)c4ccncc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	405.6 (M + H)	1.99
3147	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)c4ccc(OC(F)(F)F)cc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.4 (M + H)	3.13
3148	 <chem>CC1=NC2=CC=CC=C2N1N[C@H]3CCCC[C@H]3NC(=O)/C=C/c4ccccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	430.4 (M + H)	2.91







Example No.	Structure	ESI-MS	Retention Time (min)
3149	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)c4c[nH]c5ccc(O)cc45</chem> $2\text{CF}_3\text{CO}_2\text{H}$	459.4 (M + H)	2.47
3150	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)c4c5cc(=O)ccc5oc4=O</chem> $\text{CF}_3\text{CO}_2\text{H}$	486.6 (M + H)	2.93
3151	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)c4c5cc(OC)ccc5oc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	3.03
3152	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)c4cc([N+](=O)[O-])ccc4O</chem> $\text{CF}_3\text{CO}_2\text{H}$	465.2 (M + H)	3.13
3153	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)c4ccncc4Br</chem> $2\text{CF}_3\text{CO}_2\text{H}$	483.4 (M + H)	2.67
3154	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3CCNC(=O)Cc4cc(OC)c(Br)cc4OC</chem> $\text{CF}_3\text{CO}_2\text{H}$	556.4 (M + H)	2.84







Example No.	Structure	ESI-MS	Retention Time (min)
3155	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)c4c[nH]c5ccccc45</chem> $2\text{CF}_3\text{CO}_2\text{H}$	443.4 (M + H)	2.94
3156	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)C(c4ccccc4)c5ccccc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	508.2 (M + H)	3.20
3157	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)CC4CCCCC4</chem> $\text{CF}_3\text{CO}_2\text{H}$	440.0 (M + H)	2.72
3158	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)c4c(O)c(C)(C)c(C)c4</chem> $\text{CF}_3\text{CO}_2\text{H}$	532.4 (M + H)	3.58
3159	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)c4nc(C)s4-c5ccc(Cl)cc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	535.4 (M + H)	3.51
3160	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3CNC(=O)c4cc5cc(Cl)ccc5o4</chem> $\text{CF}_3\text{CO}_2\text{H}$	504.4 (M + H)	3.49







Example No.	Structure	ESI-MS	Retention Time (min)
3161	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	572.4 (M + H)	3.71
3162	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	460.2 (M + H)	3.80
3163	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	589.2 (M + H)	4.00
3164	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	492.2 (M + H)	3.90
3165	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	478.2 (M + H)	3.80
3166	 <chem>CC1=CN2C(=NC(=N2)N1C3=CC=CC=C3)N[C@H]4CCCC[C@H]4CNC(=O)c5cc(oc5C(F)(F)F)c6ccc(Cl)cc6</chem> <chem>CC(F)(F)C(=O)O</chem>	607.6 (M + H)	4.00







Example No.	Structure	ESI-MS	Retention Time (min)
3167	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3ccc(cc3)CO)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	504.2 (M + H)	3.40
3168	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3ccc(cc3)S)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	506.2 (M + H)	3.90
3169	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3ccc(cc3)c4ccsc4)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.2 (M + H)	3.80
3170	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3ccc(cc3)c4ccsc4)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	466.2 (M + H)	3.70
3171	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3nc(s3)c4ccc(Cl)cc4)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	515.2 (M + H)	3.90
3172	 <chem>CC1=NC2=CC=CC=C2N=C(NC(=O)c3nc(s3)c4ccc(Cl)cc4)C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	644.2 (M + H)	4.10







Example No.	Structure	ESI-MS	Retention Time (min)
3173	 <p>CF₃CO₂H</p>	488.2 (M + H)	3.90
3174	 <p>CF₃CO₂H</p>	474.4 (M + H)	3.80
3175	 <p>CF₃CO₂H</p>	525.4 (M + H)	3.70
3176	 <p>CF₃CO₂H</p>	654.2 (M + H)	3.90
3177	 <p>CF₃CO₂H</p>	428.2 (M + H)	3.10
3178	 <p>CF₃CO₂H</p>	414.4 (M + H)	2.90







Example No.	Structure	ESI-MS	Retention Time (min)
3179	 <chem>CC1=CC(OC)=C(CN1CC2=CN(C)C(=N2)N3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5)CC4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	506.4 (M + H)	3.04
3180	 <chem>CC1=CC(OC)=C(OC)C(N1CC2=CN(C)C(=N2)N3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5)CC4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	578.8 (M + H)	3.50
3181	 <chem>CC1=CC(OC)=CC(N1CC2=CN(C)C(=N2)N3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5)CC4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	520.6 (M + H)	3.19
3182	 <chem>CC1=CC=C2C(=C1)N(C3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5)C2</chem> $2\text{CF}_3\text{CO}_2\text{H}$	448.4 (M + H)	2.80
3183	 <chem>COc1cc(OC)c(OC)c(CN1CC2=CN(C)C(=N2)N3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5)c1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	494.6 (M + H)	2.66
3184	 <chem>COc1cc2c(c1)OCO2CCN3CCCCC3CC4=CC=C5C(=N4)N(C)C=C5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	2.66







Example No.	Structure	ESI-MS	Retention Time (min)
3185	 2CF ₃ CO ₂ H	492.6 (M + H)	2.94
3186	 2CF ₃ CO ₂ H	464.4 (M + H)	2.65
3187	 2CF ₃ CO ₂ H	464.4 (M + H)	2.68
3188	 2CF ₃ CO ₂ H	566.4 (M + H)	3.03
3189	 2CF ₃ CO ₂ H	512.6 (M + H)	2.85
3190	 2CF ₃ CO ₂ H	474.4 (M + H)	3.09







Example No.	Structure	ESI-MS	Retention Time (min)
3191	 $3\text{CF}_3\text{CO}_2\text{H}$	477.4 (M + H)	2.51
3192	 $2\text{CF}_3\text{CO}_2\text{H}$	464.4 (M + H)	2.67
3193	 $2\text{CF}_3\text{CO}_2\text{H}$	494.6 (M + H)	2.78
3194	 $2\text{CF}_3\text{CO}_2\text{H}$	494.6 (M + H)	2.60
3195	 $2\text{CF}_3\text{CO}_2\text{H}$	434.6 (M + H)	2.67
3196	 $2\text{CF}_3\text{CO}_2\text{H}$	546.4 (M + H)	4.30







Example No.	Structure	ESI-MS	Retention Time (min)
3197	 $2\text{CF}_3\text{CO}_2\text{H}$	606.6 (M + H)	3.95
3198	 $2\text{CF}_3\text{CO}_2\text{H}$	536.6 (M + H)	3.83
3199	 $2\text{CF}_3\text{CO}_2\text{H}$	492.4 (M + H)	2.97
3200	 $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	2.79
3201	 $2\text{CF}_3\text{CO}_2\text{H}$	542.0 (M + H)	2.85
3202	 $2\text{CF}_3\text{CO}_2\text{H}$	492.6 (M + H)	2.81







Example No.	Structure	ESI-MS	Retention Time (min)
3203	 $2\text{CF}_3\text{CO}_2\text{H}$	590.4 (M + H)	3.02
3204	 $2\text{CF}_3\text{CO}_2\text{H}$	502.2 (M + H)	2.91
3205	 $2\text{CF}_3\text{CO}_2\text{H}$	480.4 (M + H)	2.51
3206	 $2\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	3.21
3207	 $3\text{CF}_3\text{CO}_2\text{H}$	443.6 (M + H)	2.66
3208	 $2\text{CF}_3\text{CO}_2\text{H}$	536.4 (M + H)	3.08







Example No.	Structure	ESI-MS	Retention Time (min)
3209	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	520.0 (M + H)	3.51
3210	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	480.4 (M + H)	2.58
3211	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	552.0 (M + H)	3.11
3212	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	464.4 (M + H)	3.22
3213	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	2.70
3214	 <chem>CN(C)c1nc2c(ncn2C1CCNCCNC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	2.58







Example No.	Structure	ESI-MS	Retention Time (min)
3215	 <p>2CF₃CO₂H</p>	480.4 (M + H)	2.73
3216	 <p>3CF₃CO₂H</p>	429.4 (M + H)	3.29
3217	 <p>2CF₃CO₂H</p>	480.2 (M + H)	2.78
3218	 <p>2CF₃CO₂H</p>	522.4 (M + H)	3.77
3219	 <p>2CF₃CO₂H</p>	450.2 (M + H)	2.57
3220	 <p>2CF₃CO₂H</p>	498.0 (M + H)	2.97







Example No.	Structure	ESI-MS	Retention Time (min)
3221	 $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	3.17
3222	 $2\text{CF}_3\text{CO}_2\text{H}$	480.0 (M + H)	3.08
3223	 $2\text{CF}_3\text{CO}_2\text{H}$	590.2 (M + H)	4.20
3224	 $2\text{CF}_3\text{CO}_2\text{H}$	576.4 (M + H)	3.95
3225	 $2\text{CF}_3\text{CO}_2\text{H}$	512.4 (M + H)	3.86
3226	 $\text{CF}_3\text{CO}_2\text{H}$	472.4 (M + H)	3.07







Example No.	Structure	ESI-MS	Retention Time (min)
3227	 $\text{CF}_3\text{CO}_2\text{H}$	540.6 (M + H)	3.75
3228	 $\text{CF}_3\text{CO}_2\text{H}$	464.4 (M + H)	3.07
3229	 $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	3.40
3230	 $2\text{CF}_3\text{CO}_2\text{H}$	552.6 (M + H)	3.50
3231	 $2\text{CF}_3\text{CO}_2\text{H}$	590.2 (M + H)	3.60
3232	 $2\text{CF}_3\text{CO}_2\text{H}$	418.6 (M + H)	3.25







Example No.	Structure	ESI-MS	Retention Time (min)
3233	 $2\text{CF}_3\text{CO}_2\text{H}$	382.2 (M + H)	2.67
3234	 $2\text{CF}_3\text{CO}_2\text{H}$	436.4 (M + H)	3.05
3235	 $2\text{CF}_3\text{CO}_2\text{H}$	394.4 (M + H)	2.75
3236	 $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.82
3237	 $2\text{CF}_3\text{CO}_2\text{H}$	426.4 (M + H)	3.17
3238	 $2\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	3.44







Example No.	Structure	ESI-MS	Retention Time (min)
3239	 2CF ₃ CO ₂ H	452.2 (M + H)	2.69
3240	 2CF ₃ CO ₂ H	436.4 (M + H)	2.80
3241	 2CF ₃ CO ₂ H	426.2 (M + H)	2.79
3242	 2CF ₃ CO ₂ H	536.4 (M + H)	3.75
3243	 3CF ₃ CO ₂ H	427.2 (M + H)	2.95
3244	 2CF ₃ CO ₂ H	432.4 (M + H)	3.41







Example No.	Structure	ESI-MS	Retention Time (min)
3245	 $2\text{CF}_3\text{CO}_2\text{H}$	434.2 (M + H)	2.84
3246	 $2\text{CF}_3\text{CO}_2\text{H}$	410.2 (M + H)	3.02
3247	 $3\text{CF}_3\text{CO}_2\text{H}$	427.4 (M + H)	2.61
3248	 $2\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	2.91
3249	 $2\text{CF}_3\text{CO}_2\text{H}$	460.4 (M + H)	3.19
3250	 $2\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	2.79







Example No.	Structure	ESI-MS	Retention Time (min)
3251	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4ccc(F)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	394.4 (M + H)	2.83
3252	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4ccc(Br)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	454.2 (M + H)	3.08
3253	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4cc(O)ccc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	392.4 (M + H)	2.73
3254	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4cc(OC)c(OC)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	2.92
3255	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4nn[nH]c4Cc5ccc(C(F)(F)F)cc5</chem> $3\text{CF}_3\text{CO}_2\text{H}$	510.4 (M + H)	3.17
3256	 <chem>CN(C)C1=NC2=CC=CC=C2N(C1)N[C@H]3CCCC[C@H]3NCCc4cc(F)c(Cl)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	428.2 (M + H)	3.08







Example No.	Structure	ESI-MS	Retention Time (min)
3257	 2CF ₃ CO ₂ H	392.4 (M + H)	2.63
3258	 2CF ₃ CO ₂ H	412.2 (M + H)	2.83
3259	 2CF ₃ CO ₂ H	466.4 (M + H)	2.89
3260	 2CF ₃ CO ₂ H	454.0 (M + H)	3.05
3261	 2CF ₃ CO ₂ H	408.2 (M + H)	2.53
3262	 2CF ₃ CO ₂ H	390.4 (M + H)	2.92







Example No.	Structure	ESI-MS	Retention Time (min)
3263	 2CF ₃ CO ₂ H	422.2 (M + H)	3.05
3264	 2CF ₃ CO ₂ H	456.4 (M + H)	3.25
3265	 2CF ₃ CO ₂ H	452.2 (M + H)	3.37
3266	 2CF ₃ CO ₂ H	401.2 (M + H)	2.76
3267	 2CF ₃ CO ₂ H	444.4 (M + H)	3.17
3268	 2CF ₃ CO ₂ H	392.4 (M + H)	2.61







Example No.	Structure	ESI-MS	Retention Time (min)
3269	 2CF ₃ CO ₂ H	406.4 (M + H)	2.86
3270	 3CF ₃ CO ₂ H	365.4 (M + H)	2.61
3271	 2CF ₃ CO ₂ H	420.4 (M + H)	2.83
3272	 2CF ₃ CO ₂ H	466.4 (M + H)	3.10
3273	 2CF ₃ CO ₂ H	514.4 (M + H)	3.13
3274	 2CF ₃ CO ₂ H	444.4 (M + H)	3.17

Example No.	Structure	ESI-MS	Retention Time (min)
3275	 2CF ₃ CO ₂ H	466.4 (M + H)	2.86
3276	 2CF ₃ CO ₂ H	456.2 (M + H)	3.22
3277	 2CF ₃ CO ₂ H	446.6 (M + H)	3.45
3278	 2CF ₃ CO ₂ H	436.4 (M + H)	2.95
3279	 2CF ₃ CO ₂ H	420.2 (M + H)	3.03
3280	 2CF ₃ CO ₂ H	382.4 (M + H)	2.72







Example No.	Structure	ESI-MS	Retention Time (min)
3281	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4cc(Cl)cc(Cl)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	444.4 (M + H)	3.07
3282	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4cc(C)s4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	396.2 (M + H)	2.79
3283	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4cc(F)cc(F)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	412.4 (M + H)	2.95
3284	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4c5ccccc4c6ccccc5N(C)c6</chem> $32\text{CF}_3\text{CO}_2\text{H}$	493.4 (M + H)	3.57
3285	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4oc(C5=CC=C(C=C5)S4)C6=CC=C(Cl)C=C6</chem> $2\text{CF}_3\text{CO}_2\text{H}$	508.2 (M + H)	3.52
3286	 <chem>CN(C)c1nc2c(ncn2C1)C3CCCCC3NCc4c5ccccc4c6ccccc5N(C)c6</chem> $2\text{CF}_3\text{CO}_2\text{H}$	469.6 (M + H)	2.76







Example No.	Structure	ESI-MS	Retention Time (min)
3287	 $3\text{CF}_3\text{CO}_2\text{H}$	493.2 (M + H)	3.17
3288	 $2\text{CF}_3\text{CO}_2\text{H}$	460.2 (M + H)	2.95
3289	 $2\text{CF}_3\text{CO}_2\text{H}$	484.2 (M + H)	3.14
3290	 $2\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	3.11
3291	 $2\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	3.11
3292	 $2\text{CF}_3\text{CO}_2\text{H}$	476.4 (M + H)	3.39

Example No.	Structure	ESI-MS	Retention Time (min)
3299	 2CF ₃ CO ₂ H	442.4 (M + H)	2.97
3300	 2CF ₃ CO ₂ H	478.2 (M + H)	3.19
3301	 2CF ₃ CO ₂ H	462.2 (M + H)	3.05
3302	 2CF ₃ CO ₂ H	476.4 (M + H)	3.20
3303	 2CF ₃ CO ₂ H	366.4 (M + H)	2.64
3304	 2CF ₃ CO ₂ H	412.4 (M + H)	2.85







Example No.	Structure	ESI-MS	Retention Time (min)
3305	 $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.67
3306	 $3\text{CF}_3\text{CO}_2\text{H}$	449.4 (M + H)	2.74
3307	 $2\text{CF}_3\text{CO}_2\text{H}$	394.4 (M + H)	2.86
3308	 $2\text{CF}_3\text{CO}_2\text{H}$	478.2 (M + H)	3.38
3309	 $2\text{CF}_3\text{CO}_2\text{H}$	444.4 (M + H)	3.09
3310	 $2\text{CF}_3\text{CO}_2\text{H}$	376.4 (M + H)	2.82

Example No.	Structure	ESI-MS	Retention Time (min)
3311	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4ccc(OC)cc4)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	406.4 (M + H)	2.87
3312	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4cc(OC)c(OC)cc4)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	436.4 (M + H)	2.91
3313	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4c5ccccc5cc4)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	3.13
3314	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4cc(OC)c(Oc)cc4)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	436.4 (M + H)	2.99
3315	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4ccccc4Br)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	454.0 (M + H)	2.97
3316	 <chem>CN(C)c1nc2c(ncn2C1N[C@H]3CCCC[C@H]3NCc4cc(F)c(F)cc4)cc3ccccc13</chem> $2\text{CF}_3\text{CO}_2\text{H}$	412.4 (M + H)	2.92







Example No.	Structure	ESI-MS	Retention Time (min)
3317	 2CF ₃ CO ₂ H	466.4 (M + H)	2.95
3318	 2CF ₃ CO ₂ H	390.4 (M + H)	2.95
3319	 2CF ₃ CO ₂ H	396.2 (M + H)	2.89
3320	 2CF ₃ CO ₂ H	438.2 (M + H)	2.76
3321	 3CF ₃ CO ₂ H	445.4 (M + H)	3.16
3322	 3CF ₃ CO ₂ H	415.4 (M + H)	2.96







Example No.	Structure	ESI-MS	Retention Time (min)
3323	 <chem>COc1ccc2c(c1)cnc2CNC3CCCCC3Nc4nc5ccccc5n4C</chem> $3\text{CF}_3\text{CO}_2\text{H}$	445.4 (M + H)	2.96
3324	 <chem>Clc1cc(Br)cc(O)cc1CNC2CCCCC2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	504.2 (M + H)	3.11
3325	 <chem>CC(C)Oc1ccc(CNC2CCCCC2Nc3nc4ccccc4n3C)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.17
3326	 <chem>Cc1ccccc1SC(C2CCCCC2Nc3nc4ccccc4n3C)C(F)(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.27
3327	 <chem>COc1cc(Br)cc(OC)cc1CNC2CCCCC2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	514.4 (M + H)	3.07
3328	 <chem>Fc1cc(C(F)(F)F)ccc1CNC2CCCCC2Nc3nc4ccccc4n3C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	2.99







Example No.	Structure	ESI-MS	Retention Time (min)
3329	<p>2CF₃CO₂H</p>	433.2 (M + H)	2.63
3330	<p>2CF₃CO₂H</p>	518.4 (M + H)	3.63
3331	<p>2CF₃CO₂H</p>	500.4 (M + H)	3.09
3332	<p>3CF₃CO₂H</p>	379.4 (M + H)	2.77
3333	<p>2CF₃CO₂H</p>	460.2 (M + H)	3.31
3334	<p>2CF₃CO₂H</p>	512.4 (M + H)	3.51







Example No.	Structure	ESI-MS	Retention Time (min)
3335	 2CF ₃ CO ₂ H	512.6 (M + H)	3.51
3336	 2CF ₃ CO ₂ H	476.2 (M + H)	3.39
3337	 2CF ₃ CO ₂ H	448.4 (M + H)	3.42
3338	 2CF ₃ CO ₂ H	404.4 (M + H)	3.17
3339	 2CF ₃ CO ₂ H	444.4 (M + H)	3.13
3340	 2CF ₃ CO ₂ H	462.2 (M + H)	3.21







Example No.	Structure	ESI-MS	Retention Time (min)
3341	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4ccc(OC)cc4)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	2.97
3342	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4cc(Cl)cc(Cl)c4)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	444.6 (M + H)	3.16
3343	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4c(C)c(C)n(Cc5ccccc5)c4)C</chem> $3\text{CF}_3\text{CO}_2\text{H}$	469.4 (M + H)	3.47
3344	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4c(C)c(C)oc(Cc5ccccc5)c4)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	456.4 (M + H)	3.47
3345	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4c(C)c(C)n(Cc5ccccc5)c4)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	457.4 (M + H)	3.09
3346	 <chem>CN(C)c1nc2c(ncnc12)N[C@H]3CC[C@H](C[C@H]3NCCc4c(C)c(C)s(Cc5ccccc5)c4)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	458.2 (M + H)	3.37







Example No.	Structure	ESI-MS	Retention Time (min)
3347	 <chem>CN(C)c1nc2c(ncn2C1NCC3CCCC[C@H]3NCc4ccc(OC)c(OC)c4)C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	436.4 (M + H)	2.83
3348	 <chem>CCOCc1ccc(CNCC2CCCC[C@H]2NCc3nc4c(ncn4C1N)C3)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.30
3349	 <chem>CC(=O)Oc1cc(OC)c(CNCC2CCCC[C@H]2NCc3nc4c(ncn4C1N)C3)cc1OC</chem> $2\text{CF}_3\text{CO}_2\text{H}$	494.4 (M + H)	2.98
3350	 <chem>Cc1cc(CNCC2CCCC[C@H]2NCc3nc4c(ncn4C1N)C3)cc(O)c1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	406.4 (M + H)	2.80
3351	 <chem>FC(F)(F)c1ccccc1OCc2nc3c(ncn3C1NCC4CCCC[C@H]4NCc5ccccc52)C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	460.4 (M + H)	3.20
3352	 <chem>Cc1ccccc1CNCC2CCCC[C@H]2NCc3nc4c(ncn4C1N)C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	390.4 (M + H)	2.97







Example No.	Structure	ESI-MS	Retention Time (min)
3353	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3NCc4cc(Cl)ccc4Cl</chem> $2\text{CF}_3\text{CO}_2\text{H}$	444.2 (M + H)	3.01
3354	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3NCc4c[nH]c5c4[nH]5</chem> $3\text{CF}_3\text{CO}_2\text{H}$	380.2 (M + H)	2.27
3355	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3NCc4ccc(OCCN(CC)CC)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	491.4 (M + H)	2.55
3356	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3NCc4ccc(Cl)cc4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	410.4 (M + H)	3.05
3357	 <chem>CN(C)c1nc2ccccc2n1N[C@H]3CCCC[C@H]3NCc4cc(OC)cc(O)c4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	422.2 (M + H)	2.69
3358	 <chem>CC(C)Cc1ccc(CN[C@H]2CCCC[C@H]2Nc3nc4ccccc4n3C)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	418.6 (M + H)	3.36







Example No.	Structure	ESI-MS	Retention Time (min)
3359	 2CF ₃ CO ₂ H	410.4 (M + H)	2.97
3360	 2CF ₃ CO ₂ H	401.2 (M + H)	2.81
3361	 2CF ₃ CO ₂ H	466.2 (M + H)	3.01
3362	 2CF ₃ CO ₂ H	482.4 (M + H)	3.43
3363	 2CF ₃ CO ₂ H	548.4 (M + H)	3.03
3364	 3CF ₃ CO ₂ H	543.6 (M + H)	3.95

Example No.	Structure	ESI-MS	Retention Time (min)
3365	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC=C/C=C/C6=CC=CC=C6</chem> $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	3.64
3366	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC(=CC=C5)C(F)(F)FCl</chem> $2\text{CF}_3\text{CO}_2\text{H}$	478.4 (M + H)	3.29
3367	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC(=CC(=C5)OC)OC</chem> $2\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.20
3368	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC=C(C=C5)OC(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	442.4 (M + H)	3.09
3369	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC(=CC(=C5)O)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.87
3370	 <chem>CN(C)c1nc2c(ncn2C1)C3=CC=CC=C3N[C@H]4CCCC[C@H]4CNCC5=CC(=CC(=C5)O)OC</chem> $2\text{CF}_3\text{CO}_2\text{H}$	422.2 (M + H)	2.79







Example No.	Structure	ESI-MS	Retention Time (min)
3371	 $2\text{CF}_3\text{CO}_2\text{H}$	424.2 (M + H)	2.96
3372	 $3\text{CF}_3\text{CO}_2\text{H}$	427.2 (M + H)	2.53
3373	 $2\text{CF}_3\text{CO}_2\text{H}$	432.4 (M + H)	3.12
3374	 $3\text{CF}_3\text{CO}_2\text{H}$	447.4 (M + H)	2.45
3375	 $2\text{CF}_3\text{CO}_2\text{H}$	408.2 (M + H)	3.02
3376	 $2\text{CF}_3\text{CO}_2\text{H}$	496.4 (M + H)	2.81







Example No.	Structure	ESI-MS	Retention Time (min)
3377	 2CF ₃ CO ₂ H	400.2 (M + H)	2.81
3378	 2CF ₃ CO ₂ H	520.2 (M + H)	3.14
3379	 2CF ₃ CO ₂ H	410.4 (M + H)	3.12
3380	 2CF ₃ CO ₂ H	496.4 (M + H)	3.40
3381	 2CF ₃ CO ₂ H	496.4 (M + H)	3.17
3382	 2CF ₃ CO ₂ H	462.2 (M + H)	3.19







Example No.	Structure	ESI-MS	Retention Time (min)
3383	 $2\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	3.28
3384	 $2\text{CF}_3\text{CO}_2\text{H}$	440.4 (M + H)	2.74
3385	 $2\text{CF}_3\text{CO}_2\text{H}$	454.2 (M + H)	2.89
3386	 $2\text{CF}_3\text{CO}_2\text{H}$	404.4 (M + H)	3.09
3387	 $2\text{CF}_3\text{CO}_2\text{H}$	482.2 (M + H)	3.29
3388	 $3\text{CF}_3\text{CO}_2\text{H}$	458.4 (M + H)	2.99







Example No.	Structure	ESI-MS	Retention Time (min)
3389	 2CF ₃ CO ₂ H	452.2 (M + H)	3.40
3390	 2CF ₃ CO ₂ H	560.2 (M + H)	3.73
3391	 2CF ₃ CO ₂ H	416.4 (M + H)	2.99
3392	 2CF ₃ CO ₂ H	518.6 (M + H)	4.08
3393	 2CF ₃ CO ₂ H	436.4 (M + H)	2.95
3394	 CF ₃ CO ₂ H	434.4 (M + H)	3.30







Example No.	Structure	ESI-MS	Retention Time (min)
3395	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C4=CC=CC=C4C(=O)N[C@H]5CCCC[C@H]5C6=CC=CC=C6C(=O)N7C=NC8=CC=CC=C8N7C</chem> $\text{CF}_3\text{CO}_2\text{H}$	440.4 (M + H)	4.26
3396	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C(=O)N[C@H]4CCCC[C@H]4C5=CC=C(C(=O)N6C=NC7=CC=CC=C7N6C)C=C5Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	458.2 (M + H)	4.39
3397	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C(=O)N[C@H]4CCCC[C@H]4C5=CC=CC=C5C(=O)N6C=NC7=CC=CC=C7N6C</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.4 (M + H)	4.37
3398	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C(=O)N[C@H]4CCCC[C@H]4C5=CC=C(C(=O)N6C=NC7=CC=CC=C7N6C)C=C5F</chem> $\text{CF}_3\text{CO}_2\text{H}$	523.6 (M + H)	4.15
3399	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C(=O)N[C@H]4CCCC[C@H]4C5=CC=C(C(=O)N6C=NC7=CC=CC=C7N6C)C=C5C</chem> $\text{CF}_3\text{CO}_2\text{H}$	404.4 (M + H)	3.46
3400	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=CC=C3C(=O)N[C@H]4CCCC[C@H]4C5=CC=C(C(=O)N6C=NC7=CC=CC=C7N6C)C=C5C</chem> $\text{CF}_3\text{CO}_2\text{H}$	404.4 (M + H)	3.75







Example No.	Structure	ESI-MS	Retention Time (min)
3401	 CF ₃ CO ₂ H	382.4 (M + H)	3.65
3402	 CF ₃ CO ₂ H	420.4 (M + H)	3.81
3403	 CF ₃ CO ₂ H	381.2 (M + H)	3.33
3404	 CF ₃ CO ₂ H	404.4 (M + H)	3.93
3405	 CF ₃ CO ₂ H	435.2 (M + H)	3.40
3406	 CF ₃ CO ₂ H	484.4 (M + H)	4.15

Example No.	Structure	ESI-MS	Retention Time (min)
3407	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)C5=CC(=CC=C5)[N+](=O)[O-]C6=CC=C(C=C6)Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	469.4 (M + H)	4.20
3408	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)CCSC5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	436.2 (M + H)	3.88
3409	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)CCOC5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	3.91
3410	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)CC(F)(F)Fc5ccc(Cl)cc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	558.4 (M + H)	4.92
3411	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)c5cccnc5C(=O)Nc6ccccc6</chem> $2\text{CF}_3\text{CO}_2\text{H}$	483.4 (M + H)	4.08
3412	 <chem>CC1=NC2=CC=CC=C2N1C(C)=NC3=CC=CC=C3C4(CCC(C)CC4)NC(=O)c5ccsc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	396.2 (M + H)	3.68







Example No.	Structure	ESI-MS	Retention Time (min)
3413	 CF ₃ CO ₂ H	454.2 (M + H)	3.70
3414	 CF ₃ CO ₂ H	449.4 (M + H)	4.09
3415	 CF ₃ CO ₂ H	476.2 (M + H)	4.33
3416	 CF ₃ CO ₂ H	476.4 (M + H)	3.60
3417	 CF ₃ CO ₂ H	476.4 (M + H)	4.23
3418	 CF ₃ CO ₂ H	476.4 (M + H)	4.38







Example No.	Structure	ESI-MS	Retention Time (min)
3419	 CF ₃ CO ₂ H	426.2 (M + H)	3.87
3420	 CF ₃ CO ₂ H	444.4 (M + H)	3.86
3421	 CF ₃ CO ₂ H	462.2 (M + H)	4.15
3422	 CF ₃ CO ₂ H	424.2 (M + H)	4.06
3423	 CF ₃ CO ₂ H	450.4 (M + H)	4.03
3424	 CF ₃ CO ₂ H	434.2 (M + H)	3.75







Example No.	Structure	ESI-MS	Retention Time (min)
3425	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5cc(F)cc(F)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	3.88
3426	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5cc(OC)c(OC)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	3.64
3427	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5cc(OC)c(O)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	3.55
3428	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5ccc(CC)cc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	418.6 (M + H)	4.17
3429	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5ccc(OCC)cc5</chem> $\text{CF}_3\text{CO}_2\text{H}$	434.4 (M + H)	4.03
3430	 <chem>CC1=CN2C(=N1)c3ccccc3N2C4CCCCC4NC(=O)c5cc(Cl)cc(Cl)c5</chem> $\text{CF}_3\text{CO}_2\text{H}$	458.2 (M + H)	4.45







Example No.	Structure	ESI-MS	Retention Time (min)
3431	 CF ₃ CO ₂ H	415.4 (M + H)	3.76
3432	 CF ₃ CO ₂ H	474.4 (M + H)	5.06
3433	 CF ₃ CO ₂ H	410.2 (M + H)	3.64
3434	 CF ₃ CO ₂ H	516.2 (M + H)	4.24
3435	 CF ₃ CO ₂ H	424.2 (M + H)	4.09
3436	 CF ₃ CO ₂ H	458.2 (M + H)	3.89







Example No.	Structure	ESI-MS	Retention Time (min)
3437	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC=CC=C4I</chem> $\text{CF}_3\text{CO}_2\text{H}$	516.2 (M + H)	3.88
3438	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC=CC=C4CCCC</chem> $\text{CF}_3\text{CO}_2\text{H}$	460.4 (M + H)	4.86
3439	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC=CC=C4CCCCCC</chem> $\text{CF}_3\text{CO}_2\text{H}$	488.4 (M + H)	4.70
3440	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC=CC=C4C(Cl)Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	472.4 (M + H)	4.29
3441	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC(=CC=C4)F(F)</chem> $\text{CF}_3\text{CO}_2\text{H}$	426.2 (M + H)	3.69
3442	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=C(F)C(F)=C(F)C(F)=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.2 (M + H)	4.16

Example No.	Structure	ESI-MS	Retention Time (min)
3443	 CF ₃ CO ₂ H	458.2 (M + H)	3.91
3444	 CF ₃ CO ₂ H	450.4 (M + H)	3.95
3445	 CF ₃ CO ₂ H	444.4 (M + H)	4.01
3446	 CF ₃ CO ₂ H	426.2 (M + H)	4.00
3447	 CF ₃ CO ₂ H	408.4 (M + H)	3.75
3448	 CF ₃ CO ₂ H	446.6 (M + H)	4.65







Example No.	Structure	ESI-MS	Retention Time (min)
3449	 CF ₃ CO ₂ H	415.2 (M + H)	3.75
3450	 CF ₃ CO ₂ H	420.4 (M + H)	3.91
3451	 CF ₃ CO ₂ H	490.4 (M + H)	4.99
3452	 CF ₃ CO ₂ H	504.4 (M + H)	5.16
3453	 CF ₃ CO ₂ H	444.4 (M + H)	4.00
3454	 CF ₃ CO ₂ H	396.2 (M + H)	3.85







Example No.	Structure	ESI-MS	Retention Time (min)
3455	 CF ₃ CO ₂ H	526.6 (M + H)	4.69
3456	 CF ₃ CO ₂ H	408.4 (M + H)	3.30
3457	 CF ₃ CO ₂ H	480.4 (M + H)	3.76
3458	 CF ₃ CO ₂ H	426.2 (M + H)	3.86
3459	 CF ₃ CO ₂ H	424.2 (M + H)	3.76
3460	 CF ₃ CO ₂ H	440.4 (M + H)	4.05







Example No.	Structure	ESI-MS	Retention Time (min)
3461	 CF ₃ CO ₂ H	458.4 (M + H)	4.25
3462	 CF ₃ CO ₂ H	408.2 (M + H)	3.84
3463	 CF ₃ CO ₂ H	458.2 (M + H)	4.25
3464	 CF ₃ CO ₂ H	446.6 (M + H)	4.44
3465	 CF ₃ CO ₂ H	470.2 (M + H)	4.13
3466	 CF ₃ CO ₂ H	476.2 (M + H)	4.25







Example No.	Structure	ESI-MS	Retention Time (min)
3467	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1cc(F)c(F)c(F)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.92
3468	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1cc(F)c(F)c(F)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	526.4 (M + H)	4.31
3469	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1cc(Cl)c(F)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	4.15
3470	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1ccc(OCC)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	462.2 (M + H)	4.48
3471	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1ccc(cc1)-c2ccccc2</chem> $\text{CF}_3\text{CO}_2\text{H}$	466.4 (M + H)	4.45
3472	 <chem>CC1=NC2=CC=CC=C2N(C)N=C1N[C@H]3CCCC[C@H]3NC(=O)c1ccc(OC(F)(F)F)cc1</chem> $\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	4.29







Example No.	Structure	ESI-MS	Retention Time (min)
3473	 CF ₃ CO ₂ H	486.2 (M + H)	4.32
3474	 CF ₃ CO ₂ H	438.4 (M + H)	4.31
3475	 2CF ₃ CO ₂ H	441.4 (M + H)	3.75
3476	 CF ₃ CO ₂ H	434.4 (M + H)	4.10
3477	 CF ₃ CO ₂ H	469.4 (M + H)	4.19
3478	 CF ₃ CO ₂ H	444.4 (M + H)	4.36







Example No.	Structure	ESI-MS	Retention Time (min)
3479	 3CF ₃ CO ₂ H	482.4 (M + H)	4.35
3480	 CF ₃ CO ₂ H	482.4 (M + H)	4.64
3481	 CF ₃ CO ₂ H	502.2 (M + H)	4.37
3482	 CF ₃ CO ₂ H	458.2 (M + H)	4.08
3483	 2CF ₃ CO ₂ H	465.4 (M + H)	3.66
3484	 CF ₃ CO ₂ H	404.4 (M + H)	4.03

Example No.	Structure	ESI-MS	Retention Time (min)
3485	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC(=CC=C4)C(=O)N5C=CC(=C5)[N+](=O)[O-]</chem> $\text{CF}_3\text{CO}_2\text{H}$	469.4 (M + H)	4.23
3486	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC=C5C(=C4)SC=N5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	447.4 (M + H)	3.94
3487	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC=C(N5C=CC=N5)C=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	456.2 (M + H)	4.07
3488	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC(=CC=C4)C(=O)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	432.4 (M + H)	3.99
3489	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC=C5C(=C4)N=CN=C5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	441.3 (M + H)	1.70
3490	 <chem>CC1=CN(C)C2=CC=CC=C2N1N=C3CCCCC3NC(=O)C4=CC(=CC=C4)C(=O)N5C=CC(=C5)O</chem> $\text{CF}_3\text{CO}_2\text{H}$	440.2 (M + H)	4.57







Example No.	Structure	ESI-MS	Retention Time (min)
3491	 $2\text{CF}_3\text{CO}_2\text{H}$	393.4 (M + H)	4.01
3492	 $2\text{CF}_3\text{CO}_2\text{H}$	497.4 (M + H)	4.45
3493	 $\text{CF}_3\text{CO}_2\text{H}$	470.2 (M + H)	2.40
3494	 $2\text{CF}_3\text{CO}_2\text{H}$	439.4 (M + H)	1.92
3495	 $2\text{CF}_3\text{CO}_2\text{H}$	407.4 (M + H)	2.30
3496	 $2\text{CF}_3\text{CO}_2\text{H}$	469.5 (M + H)	2.27







Example No.	Structure	ESI-MS	Retention Time (min)
3497	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC=C(C=C4)C(=C)N</chem> $2\text{CF}_3\text{CO}_2\text{H}$	439.4 (M + H)	1.93
3498	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC(=O)N=CC=C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	407.4 (M + H)	1.62
3499	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)/C=C/C4=CC=CC=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	416.3 (M + H)	2.34
3500	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC(OC)=CC=C4O</chem> $\text{CF}_3\text{CO}_2\text{H}$	460.4 (M + H)	2.46
3501	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC(OC)=CC(=C4)[N+](=O)[O-]</chem> $\text{CF}_3\text{CO}_2\text{H}$	465.4 (M + H)	4.13
3502	 <chem>CN1C=NC2=CC=CC=C2N1C3CCCCC3NC(=O)C4=CC(=C(C=C4)N)C</chem> $2\text{CF}_3\text{CO}_2\text{H}$	419.4 (M + H)	3.87







Example No.	Structure	ESI-MS	Retention Time (min)
3503	 $\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	3.97
3504	 $\text{CF}_3\text{CO}_2\text{H}$	406.2 (M + H)	2.18
3505	 $\text{CF}_3\text{CO}_2\text{H}$	470.4 (M + H)	4.74
3506	 $\text{CF}_3\text{CO}_2\text{H}$	466.4 (M + H)	3.83
3507	 $2\text{CF}_3\text{CO}_2\text{H}$	441.2 (M + H)	4.38
3508	 $2\text{CF}_3\text{CO}_2\text{H}$	441.2 (M + H)	3.62







Example No.	Structure	ESI-MS	Retention Time (min)
3509	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4=CC=CC=C4</chem> $\text{CF}_3\text{CO}_2\text{H}$	454.5 (M + H)	2.44
3510	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4OCCC4</chem> $\text{CF}_3\text{CO}_2\text{H}$	384.4 (M + H)	3.67
3511	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4=CC(=C(C=C4)Br)C(=C)C4=CC=C4Cl</chem> $\text{CF}_3\text{CO}_2\text{H}$	502.2 (M + H)	4.37
3512	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4=CC(=C(C=C4)OC)OC</chem> $\text{CF}_3\text{CO}_2\text{H}$	480.5 (M + H)	2.18
3513	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4=CC=CC=C4O</chem> $\text{CF}_3\text{CO}_2\text{H}$	380.2 (M + H)	3.81
3514	 <chem>CC1(C)N2C(=N1)N=CN=C2C3CCCCC3NC(=O)CC4=CC=CC=C4N=C5C=CC=C5S4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	463.2 (M + H)	4.23







Example No.	Structure	ESI-MS	Retention Time (min)
3515	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3CNC=C3)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	443.4 (M + H)	2.12
3516	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3CNC=S3)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	431.1 (M + H)	1.90
3517	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3C(NC(=O)C4=CC(=C(C=C4)Cl)Cl)C=C3)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	5.05
3518	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3C(NC(=O)C4=CC(=C(C=C4)F)F)C=C3)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	440.5 (M + H)	2.33
3519	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3C(NC(=O)C4=CC(=C(C=C4)OC)OC)C=C3)C=C1</chem> $\text{CF}_3\text{CO}_2\text{H}$	464.5 (M + H)	2.20
3520	 <chem>CN1C=NC(NC2CCCCC2NC(=O)C3C(NC(=O)C4=CC=CC=C4N)C=C3)C=C1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	391.1 (M + H)	1.59







Example No.	Structure	ESI-MS	Retention Time (min)
3521	 <chem>CC1=NC2=CC=CC=C2N=C(NC3CCCCC3NC(=O)C4=CC=C(C=C4)OC(F)(F)F)N1</chem> $\text{CF}_3\text{CO}_2\text{H}$	474.4 (M + H)	4.53
3522	 <chem>COc1cc(Br)ccc1C(=O)NC2CCCCC2NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	542.2 (M + H)	2.26
3523	 <chem>Cc1ccc2c(c1)c(c[nH]2)C(=O)NC3CCCCC3NC4=NC5=CC=CC=C5N(C)C4</chem> $2\text{CF}_3\text{CO}_2\text{H}$	429.3 (M + H)	2.41
3524	 <chem>Cc1ccccc1C(=O)NC2CCCCC2NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	494.6 (M + H)	2.59
3525	 <chem>CC1=CC(=C(C=C1)C(=O)NC2CCCCC2NC3=NC4=CC=CC=C4N(C)C3)C(C)(C)C</chem> $\text{CF}_3\text{CO}_2\text{H}$	518.5 (M + H)	2.96
3526	 <chem>CC1=CC(=C(C=C1)C(=O)NC2CCCCC2NC3=NC4=CC=CC=C4N(C)C3)C(O)C5=CC=CC=C5</chem> $\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.19







Example No.	Structure	ESI-MS	Retention Time (min)
3527	 <chem>CC1(C)Nc2nc3ccccc3nc2N[C@H]1CNC(=O)C(O)c4ccccc4</chem> $\text{CF}_3\text{CO}_2\text{H}$	420.4 (M + H)	2.19
3528	 <chem>CC(C)Nc1nc2ccccc2nc1N[C@H]1CNC(=O)Cc2ccc(Br)cc2OC(F)(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	552.0 (M + H)	2.45
3529	 <chem>C1CC1Nc2nc3ccccc3nc2N[C@H]1CNC(=O)Cc2ccc(Br)cc2OC(F)(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	564.2 (M + H)	2.48
3530	 <chem>C1CCCCC1Nc2nc3ccccc3nc2N[C@H]1CNC(=O)Cc2ccc(Br)cc2OC(F)(F)F</chem> $2\text{CF}_3\text{CO}_2\text{H}$	606.0 (M + H)	2.86
3531	 <chem>c1ccc(Nc2nc3ccccc3nc2N[C@H]1CNC(=O)Cc2ccc(Br)cc2OC(F)(F)F)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	586.2 (M + H)	3.20
3532	 <chem>CCc1ccc(Nc2nc3ccccc3nc2N[C@H]1CNC(=O)Cc2ccc(Br)cc2OC(F)(F)F)cc1</chem> $2\text{CF}_3\text{CO}_2\text{H}$	614.4 (M + H)	2.76







Example No.	Structure	ESI-MS	Retention Time (min)
3533	 2CF ₃ CO ₂ H	620.0 (M + H)	2.68
3534	 2CF ₃ CO ₂ H	616.0 (M + H)	2.56
3535	 2CF ₃ CO ₂ H	566.0 (M + H)	2.54
3536	 CF ₃ CO ₂ H	532.2 (M + H)	3.35
3537	 2CF ₃ CO ₂ H	541.4 (M + H)	3.11
3538	 CF ₃ CO ₂ H	505.2 (M + H)	2.98







Example No.	Structure	ESI-MS	Retention Time (min)
3539	 <chem>COc1cc(Br)cc(S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	556 (M + H)	3.37
3540	 <chem>Fc1ccccc1S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	516.4 (M + H)	3.39
3541	 <chem>Cc1cc(C)cc(C)S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	504.4 (M + H)	3.61
3542	 <chem>Cc1cc(C)cc(C)S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	574.4 (M + H)	4.27
3543	 <chem>COc1cc(OC)cc(S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3)c1</chem> $\text{CF}_3\text{CO}_2\text{H}$	508.2 (M + H)	3.17
3544	 <chem>COc1ccc(C(F)(F)F)cc1S(=O)(=O)NCc2ccc(cc2)NC3=NC4=CC=CC=C4N(C)C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	644.2 (M + H)	3.63






Example No.	Structure	ESI-MS	Retention Time (min)
3545	 $\text{CF}_3\text{CO}_2\text{H}$	520.4 (M + H)	3.56
3546	 $\text{CF}_3\text{CO}_2\text{H}$	504.2 (M + H)	3.25
3547	 $2\text{CF}_3\text{CO}_2\text{H}$	513.4 (M + H)	2.86
3548	 $\text{CF}_3\text{CO}_2\text{H}$	616.2 (M + H)	3.73
3549	 $2\text{CF}_3\text{CO}_2\text{H}$	450.4 (M + H)	2.79
3550	 $\text{CF}_3\text{CO}_2\text{H}$	466.2 (M + H)	3.35

Example No.	Structure	ESI-MS	Retention Time (min)
3551	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CN=CN(C4)C5=CC=CC=C5)C=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	465.2 (M + H)	3.34
3552	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CC=C(C=C4)C5=CC=NC=O5)C=C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	451.2 (M + H)	3.83
3553	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CC=CC=C4C5=CC=CC=C5N=O5)C=C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	451.2 (M + H)	4.10
3554	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CC=CC=C4N5C(=O)N(C5)C6=CC=CC=C6)C=C3</chem> $\text{CF}_3\text{CO}_2\text{H}$	563.2 (M + H)	4.33
3555	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CC=CC=C4S5=CC=CC=C5N=C45)C=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	468.4 (M + H)	3.66
3556	 <chem>CN1C=NC2=CC=CC=C2N1C3=CC=C(NC(=O)C4=CC=CC=C4S5=CC=CC=C5N=C45)C=C3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	467.4 (M + H)	2.85

Example No.	Structure	ESI-MS	Retention Time (min)
3557	 <chem>CC1=NC2=CC=CC=C2N(C)N1Nc3ccc(NC(=O)c4cc(Cl)ccn4)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	515.4 (M + H)	3.52
3558	 <chem>CC1=NC2=CC=CC=C2N(C)N1Nc3ccc(NC(=O)c4cc(Cl)ccn5c4nc=O5)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	485.2 (M + H)	3.40
3559	 <chem>CC1=NC2=CC=CC=C2N(C)N1Nc3ccc(NC(=O)c4cc5ccsc5cn4)cc3</chem> $2\text{CF}_3\text{CO}_2\text{H}$	467.4 (M + H)	3.90
3560	 <chem>CC1=NC2=CC=CC=C2N(C)N1Nc3ccc(NC(=O)c4cc5ccsc5n4)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	473.4 (M + H)	4.17
3561	 <chem>CC1=NC2=CC=CC=C2N(C)N1Nc3ccc(NC(=O)c4cc5ccccc5s4)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	467.4 (M + H)	3.57
3562	 <chem>COc1ccc(cc1)-c2ccc(cc2)C(=O)Nc3ccc(Nc4nc5ccccc5n4C(C)C)cc3</chem> $\text{CF}_3\text{CO}_2\text{H}$	490.2 (M + H)	4.00

Example No.	Structure	ESI-MS	Retention Time (min)
3563	 <chem>COc1ccc(cc1)C(=O)Nc2ccc(cc2)Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	490.2 (M + H)	3.99
3564	 <chem>c1ccc(cc1)c2nc3ccccc3n2C(=O)Nc4ccc(cc4)Nc5nc6ccccc6n5</chem> $2\text{CF}_3\text{CO}_2\text{H}$	476.2 (M + H)	3.76
3565	 <chem>c1ccc(cc1)c2sc(C(=O)Nc3ccc(cc3)Nc4nc5ccccc5n4)cc2</chem> $\text{CF}_3\text{CO}_2\text{H}$	467.2 (M + H)	4.07
3566	 <chem>Clc1cc(Cl)ccc1C(=O)Nc2ccc(cc2)Nc3nc4ccccc4n3C</chem> $\text{CF}_3\text{CO}_2\text{H}$	528.2 (M + H)	4.53
3567	 <chem>c1ccc(cc1)c2oc(C(=O)Nc3ccc(cc3)Nc4nc5ccccc5n4)c(C)c2</chem> $\text{CF}_3\text{CO}_2\text{H}$	464.2 (M + H)	4.11
3568	 <chem>Clc1cc(Cl)ccc1S(=O)(=O)NCc2ccccc2N3CCCCC3c4nc5ccccc5n4C</chem> $\text{CF}_3\text{CO}_2\text{H}$	494.0 (M + H)	3.43

Example No.	Structure	ESI-MS	Retention Time (min)
3569	 <p>CF₃CO₂H</p>	444.0 (M + H)	3.03
3570	 <p>CF₃CO₂H</p>	552.0 (M + H)	3.30
3571	 <p>CF₃CO₂H</p>	510.0 (M + H)	3.37
3572	 <p>CF₃CO₂H</p>	562.0 (M + H)	3.66
3573	 <p>CF₃CO₂H</p>	622.0 (M + H)	3.61
3574	 <p>CF₃CO₂H</p>	588.0 (M + H)	3.59

Example No.	Structure	ESI-MS	Retention Time (min)
3575	 CF ₃ CO ₂ H	510.0 (M + H)	3.31
3576	 CF ₃ CO ₂ H	562.0 (M + H)	3.61
3577	 CF ₃ CO ₂ H	510.0 (M + H)	3.35
3578	 CF ₃ CO ₂ H	597.0 (M + H)	3.55
3579	 CF ₃ CO ₂ H	665.0 (M + H)	4.02

Assay Procedures

Compounds identified and disclosed throughout this patent document were assayed according to the protocols found in co-pending patent application having U.S. Serial Number 09/826,509, which is incorporated herein by reference.

Example 3580

Preparation of Endogenous MCH Receptor.

The endogenous human MCH receptor was obtained by PCR using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 56°C for 1min and 72 °C for 1 min and 20 sec. The 5' PCR primer contained a HindIII site with the sequence:

5'-GTGAAGCTTGCCTCTGGTGCCTGCAGGAGG-3' (SEQ.ID.NO.:1)

and the 3' primer contained an EcoRI site with the sequence:

5'-GCAGAAATCCCGGTGGCGTGTGTGGTGCCC-3' (SEQ.ID.NO.:2).

The 1.3 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of CMVp expression vector. Later the cloning work by Lakaye et al showed that there is an intron the coding region of the gene. Thus the 5' end of the cDNA was obtained by 5' RACE PCR using Clontech's marathon-ready hypothalamus cDNA as template and the manufacturer's recommended protocol for cycling condition. The 5' RACE PCR for the first and second round PCR were as follows:

5'-CATGAGCTGGTGGATCATGAAGGG-3' (SEQ.ID.NO.:3) and

5'-ATGAAGGGCATGCCAGGAGAAAG-3' (SEQ.ID.NO.:4).

Nucleic acid and amino acid sequences were thereafter determined and verified with the published sequences found on GenBank having Accession Number U71092.

Example 3581

Preparation of Non-Endogenous, Constitutively Active MCH Receptor.

Preparation of a non-endogenous version of the human MCH receptor was accomplished by creating a MCH-IC3-SST2 mutation (*see*; SEQ.ID.NO.:7 for nucleic acid sequence, and SEQ.ID.NO.:8 for amino acid sequence). Blast result showed that MCH receptor had the highest sequence homology to known SST2 receptor. Thus the third intracellular loop ("IC3") of MCH receptor was replaced with that of the IC3 of SST2

receptor to see if the chimera would show constitutive activity.

The BamHI-BstEII fragment containing IC3 of MCH receptor was replaced with synthetic oligonucleotides that contained the IC3 of SST2. The PCR sense mutagenesis primer used had the following sequence:

5'-GATCCTGCAGAAGGTGAAGTCCTCTGGAATCCGAGTGGGCTCCTCTAAGAG
GAAGAAGTCTGAGAAGAAG-3' (SEQ.ID.NO.:9)

and the antisense primer had the following sequence:

5'-GTGACCTTCTTCTCAGACTTCTTCCTCTTAGAGGAGCCCACTCGGATTCCAG
AGGACTTCACCTTCTGCAG-3' (SEQ.ID.NO.:10).

The endogenous MCH receptor cDNA was used as a template.

Example 3582

GPCR Fusion Protein Preparation.

MCH Receptor-Gi α Fusion Protein construct was made as follows: primers were designed for endogenous MCH receptor was as follows:

5'-GTGAAGCTTGCCCGGCAGGATGGACCTGG-3' (SEQ.ID.NO.:11; sense)

5'-ATCTAGAGGTGCCTTTGCTTTCTG-3' (SEQ.ID.NO.:12; antisense).

The sense and anti-sense primers included the restriction sites for KB4 and XbaI, respectively.

PCR was utilized to secure the respective receptor sequences for fusion within the Gi α universal vector disclosed above, using the following protocol for each: 100ng cDNA for MCH receptor was added to separate tubes containing 2ul of each primer (sense and anti-sense), 3uL of 10mM dNTPs, 10uL of 10XTaqPlus™ Precision buffer, 1uL of TaqPlus™ Precision polymerase (Stratagene: #600211), and 80uL of water. Reaction temperatures and cycle times for MCH receptor were as follows: the initial denaturing step was done at 94°C for five minutes, and a cycle of 94°C for 30 seconds; 55°C for 30 seconds; 72°C for two minutes. A final extension time was done at 72°C for ten minutes. PCR product was run on a 1% agarose gel and then purified (data not shown). The purified product was digested with KB4 and XbaI (New England Biolabs) and the desired inserts will be isolated, purified and ligated into the Gi universal vector at the respective restriction site. The positive clones were isolated following transformation and determined by restriction enzyme digest; expression using 293 cells was accomplished

following the protocol set forth *infra*. Each positive clone for MCH receptor: Gi-Fusion Protein was sequenced and made available for the direct identification of candidate compounds. (See, SEQ.ID.NO.:13 for nucleic acid sequence and SEQ.ID.NO.:14 for amino acid sequence).

Endogenous version of MCH receptor was fused upstream from the G protein Gi and is located at nucleotide 1 through 1,059 (see, SEQ.ID.NO.:13) and amino acid residue 1 through 353 (see, SEQ.ID.NO.:14). With respect to the MCH receptor, 2 amino acid residues (an equivalent of 6 nucleotides) were placed in between the endogenous (or non-endogenous) GPCR and the start codon for the G protein $G_{i\alpha}$. Therefore, the Gi protein is located at nucleotide 1,066 through 2,133 (see, SEQ.ID.NO.:13) and at amino acid residue 356 through 711 (see, SEQ.ID.NO.:14). Those skilled in the art are credited with the ability to select techniques for constructing a GPCR Fusion Protein where the G protein is fused to the 3' end of the GPCR of interest.

Example 3583

ASSAY FOR DETERMINATION OF CONSTITUTIVE ACTIVITY OF NON-ENDOGENOUS GPCRS

A. Intracellular IP_3 Accumulation Assay

On day 1, cells comprising the receptors (endogenous and/or non-endogenous) can be plated onto 24 well plates, usually 1×10^5 cells/well (although this number can be optimized). On day 2 cells can be transfected by firstly mixing 0.25 μ g DNA in 50 μ l serum free DMEM/well and 2 μ l lipofectamine in 50 μ l serum-free DMEM/well. The solutions are gently mixed and incubated for 15-30 min at room temperature. Cells are washed with 0.5 ml PBS and 400 μ l of serum free media is mixed with the transfection media and added to the cells. The cells are then incubated for 3-4 hrs at $37^\circ\text{C}/5\%\text{CO}_2$ and then the transfection media is removed and replaced with 1ml/well of regular growth media. On day 3 the cells are labeled with ^3H -myo-inositol. Briefly, the media is removed and the cells are washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serum free media (GIBCO BRL) is added/well with 0.25 μCi of ^3H -myo-inositol/ well and the cells are incubated for 16-18 hrs o/n at $37^\circ\text{C}/5\%\text{CO}_2$. On Day 4 the cells are washed with 0.5 ml PBS and 0.45 ml of assay medium is added containing inositol-free/serum free media 10 μM pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 μ l of $10\times$

ketanserin (ket) to final concentration of 10 μ M. The cells are then incubated for 30 min at 37°C. The cells are then washed with 0.5 ml PBS and 200 μ l of fresh/ice cold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) is added/well. The solution is kept on ice for 5-10 min or until cells were lysed and then neutralized by 200 μ l of fresh/ice cold neutralization sol. (7.5 % HCL). The lysate is then transferred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1:2) is added/tube. The solution is vortexed for 15 sec and the upper phase is applied to a Biorad AG1-X8™ anion exchange resin (100-200 mesh). Firstly, the resin is washed with water at 1:1.25 W/V and 0.9 ml of upper phase is loaded onto the column. The column is washed with 10 mls of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates are eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/ 1 M ammonium formate. The columns are regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with H₂O and stored at 4°C in water.

Reference is made to Figure 1. Figure 1 provides an illustration of IP₃ production from several non-endogenous, constitutively activated version of MCH receptor as compared with the endogenous version of this receptor. When compared to the endogenous version of MCH receptor ("MCH-R wt"), MCH-IC3-SST2 evidenced about a 27% increase in IP₃ accumulation.

Example 3584

Determination of Compound Using [³⁵S]GTP γ S ASSAY

Direct identification of candidate compounds was initially screened using [³⁵S]GTP γ S Assay (see, Example 6 of co-pending patent application 09/826,509). Preferably, an MCH receptor: Gi Fusion Protein was utilized, according to Example 6(2) of co-pending patent application 09/826,509. Several lead hits were identified utilizing [³⁵S]GTP γ S Assay.

Example 3585

High Throughput Functional Screening: FLIPR™

Subsequently, a functional based assay was used to confirm the lead hits, referred to as FLIPR™ (the Fluorometric Imaging Plate Reader) and FDSS6000™ (Functional

Drug Screening System). This assay utilized a non-endogenous version of the MCH receptor, which was created by swapping the third intracellular loop of the MCH receptor with that of the SST2 receptor (see Example 2(B)(2) of patent application serial number 09/826,509).

The FLIPR and FDSS assays are able to detect intracellular Ca^{2+} concentration in cells, which can be utilized to assess receptor activation and determine whether a candidate compound is an, for example, antagonist, inverse agonist or agonist to a Gq-coupled receptor. The concentration of free Ca^{2+} in the cytosol of any cell is extremely low, whereas its concentration in the extracellular fluid and endoplasmic reticulum (ER) is very high. Thus, there is a large gradient tending to drive Ca^{2+} into the cytosol across both the plasma membrane and ER. The FLIPRTM and FDSS6000TM systems (Molecular Devices Corporation, HAMAMATSU Photonics K.K.) are designed to perform functional cell-based assays, such as the measurement of intracellular calcium for high-throughput screening. The measurement of fluorescent is associated with calcium release upon activation of the Gq-coupled receptors. Gi or Go coupled receptors are not as easily monitored through the FLIPRTM and FDSS6000TM systems because these G proteins do not couple with calcium signal pathways.

To confirm the lead hits identified using the [³⁵S]GTPγS assay, Fluorometric Imaging Plate Reader system was used to allow for rapid, kinetic measurements of intracellular fluorescence in 96 well microplates (or 384 well microplates). Simultaneous measurements of fluorescence in all wells can be made by FLIPR or FDSS6000TM every second with high sensitivity and precision. These systems are ideal for measuring cell-based functional assays such as monitoring the intracellular calcium fluxes that occur within seconds after activation of the Gq coupled receptor.

Briefly, the cells are seeded into 96 well at 5.5×10^4 cells/well with complete culture media (Dulbecco's Modified Eagle Medium with 10 % fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 0.5 mg/ml G418, pH 7.4) for the assay next day. On the day of assay, the media is removed and the cells are incubated with 100 μl of loading buffer (4 μM Fluo4-AM in complete culture media containing 2.5 mM Probenicid, 0.5 mg/ml and 0.2% bovine serum albumin) in 5% CO₂ incubator at 37°C for 1 hr. The loading buffer is removed, and the cells are washed with wash buffer (Hank's Balanced Salt Solution containing 2.5 mM Probenicid, 20 mM HEPES, 0.5 mg/ml and 0.2% bovine

serum albumin, pH 7.4)). One hundred fifty μ l of wash buffer containing various concentrations of test compound are added to the cells, and the cells are incubated in 5% CO₂ incubator at 37°C for 30 min. Fifty μ l of wash buffer containing various concentration of MCH are added to each well, and transient changes in [Ca²⁺]_i evoked by MCH are monitored using the FLIPR or FDSS in 96 well plates at Ex. 488 nm and Em. 530 nm for 290 second. When antagonist activity of compound is tested, 50 nM of MCH is used.

Use of FLIPR™ and FDSS6000™ can be accomplished by following manufacturer's instruction (Molecular Device Corporation and HAMAMATSU Photonics K.K.).

The results were shpwn below.


Compound No.	IC ₅₀ value (nM)
Example 41	6
Example 42	19

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.


Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

What is claimed is:

1. A compound of Formula I:




wherein Q is



II

or



III

R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

•halogen,

•hydroxy,

•oxo,

•C₁-C₃ alkoxy,

•C₁-C₃ alkoxy substituted by substituent(s) independently selected from

••carbocyclic aryl,

••heterocyclyl,

••heterocyclyl substituted by C₁-C₃ alkyl,

•C₁-C₃ alkylcarbonyloxy,

•carbocyclyloxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

••halogen,

••nitro,

••carbocyclic aryl,

••carbocyclic aryl substituted by C₁-C₃ alkoxy,

- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by C₁-C₃ alkyl,
 - substituted heterocyclyl-ethylideneaminooxy,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkoxycarbonyl substituted by carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from
 - cyano,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
- hydroxy,
- C₁-C₃ alkyl,
- C₁-C₃ alkylcarbonylamino,
- C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - C₁-C₄ alkoxycarbonylamino,
 - heterocyclyl carbonylamino,
 - carbocyclic arylsulfonylamino,

- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylaminocarbonyl,
 - halogenated mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- heterocyclylthio substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - C₃-C₆ cycloalkenyl,
 - carbocyclyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,

- C₂-C₃ alkenyl,
- C₂-C₃ alkenyl substituted by carbocyclic aryl,
- C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkylcarbonyloxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-carbocyclic arylamino,

- halogenated mono- or di-carbocyclic arylamino,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
- mercapto,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- C₁-C₃ alkylsulfonyl,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- heterocyclyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
 - C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,

- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl,
- (v) C₃-C₆ cycloalkenyl,
C₃-C₆ cycloalkenyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,
carbocyclyl substituted by substituent(s) independently selected from
 - hydroxy,

- nitro,
- (vii) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - carbocyclic aryloxy,
 - mono- or di-C₁-C₃ alkylamino-N-oxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - carbocyclylimino,
 - carbocyclylimino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,

- C₂-C₃ alkenyl substituted by carbocyclic aryl,
- C₁-C₉ alkoxy,
- C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - hydroxy,
 - halogen,
 - carboxy,
 - mono- or di-C₁-C₃ alkylamino,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- C₂-C₃ alkenyloxy,
- C₁-C₃ alkylcarbonyloxy,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - halogenated C₁-C₄ alkyl,
 - C₁-C₃ alkoxy,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
- (carbocyclic aryl)S(O)₂O,

- carboxy,
- C₁-C₃ alkoxycarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl,
- mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
- mono- or di-carbocyclic arylaminocarbonyl,
- mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
- amino,
- mono- or di-C₁-C₄ alkylamino,
- mono- or di-C₁-C₄ alkylamino substituted by cyano,
- mono- or di-carbocyclic arylamino,
- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- carbocyclic aryl diazo,
- carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - cyano,
 - C₁-C₃ alkyl,
 - heterocyclylthio,
 - C₁-C₃ alkylsulfonyl,
 - mono- or di-C₁-C₃ alkylaminosulfonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,

- halogenated C₁-C₇ alkyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (viii) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - C₁-C₃ alkoxycarbonyl,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by carbocyclic aryl,
 - C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,

- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₄ alkylcarbonylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkenylthio,
 - carbocyclic arylthio,
 - halogenated carbocyclic arylthio,
 - carbocyclic arylthio substituted by C₁-C₃ alkoxy carbonyl,
 - heterocyclylthio,
 - heterocyclylthio substituted by C₁-C₃ alkyl,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - C₁-C₃ alkoxy carbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,

- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxycarbonyl;

R₂ is -NHNH₂, -NHNHBoc, -N(R_{2a})(R_{2b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl;

wherein R_{2a} is H or C₁-C₃ alkyl;


R_{2b} is C₁-C₄ alkyl, C₁-C₄ alkyl substituted by substituent(s) independently selected from

- hydroxy,
- C₁-C₃ alkoxy,
- amino,
- NHBoc,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- SO₂NH₂,
- heterocyclyl,

C₃-C₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,

or a group of Formula IV;























wherein Boc is carbamic acid *tert*-butyl ester and R₃ is C₁-C₃ alkyl or C₁-C₃ alkyl

substituted by substituent(s) independently selected from


- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by C₁-C₃ alkoxy;

L is selected from Formula V - XIX;







XIV




XV




XVI



XVII



XVIII



XIX

wherein R_4 is H or C_1 - C_3 alkyl;

R_5 is H, C_1 - C_3 alkyl, or C_1 - C_3 alkyl substituted by a substituted carbocyclic aryl;

Y is $-S(O)_2-$, $-C(O)-$, or $-(CH_2)_m$;

m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, biphenyl, or phenanthryl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1H-indolyl, 1H-pyrrolo[2,3-c]pyridyl, 1H-pyrrolyl, 1-oxo-3H-isobenzofuranyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, 4H-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-carbazolyl, 9H-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-

dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

2. A compound according to claim 1, wherein Q is Formula II;

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•halogen,

•oxo,

•C₁-C₃ alkoxy,

•C₁-C₃ alkoxy substituted by carbocyclic aryl,

•C₁-C₃ alkylcarbonyloxy,

•carbocyclyloxy,

•carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from

••halogen,

••nitro,

••C₁-C₄ alkyl,

••C₁-C₄ alkyl substituted by substituent(s) independently selected from

•••oxo,

•••carbocyclic arylcarbonylamino,

•••halogenated carbocyclic arylcarbonylamino,

•heterocyclyloxy,

•heterocyclyloxy substituted by C₁-C₃ alkyl,

•substituted heterocyclyl-ethylideneaminoxy,

•C₁-C₃ alkoxycarbonyl,

•C₁-C₃ alkoxycarbonyl substituted by carbocyclic aryl,

•mono- or di-C₁-C₃ alkylaminocarbonyl,

•mono- or di-carbocyclic arylamino,

•mono- or di-carbocyclic arylamino substituted by hydroxy,

•C₁-C₃ alkylcarbonylamino,

- C₁-C₃ alkylcarbonylamino substituted by substituent(s) independently selected from
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - C₁-C₄ alkoxy carbonylamino,
 - heterocyclyl carbonylamino,
 - carbocyclic arylsulfonylamino,
 - carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylaminocarbonyl,
 - halogenated mono- or di-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - heterocyclylthio,
 - heterocyclylthio substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - C₃-C₆ cycloalkyl,
 - C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
 - C₃-C₆ cycloalkenyl,

- carbocyclyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkylcarbonyloxy,
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,

- C₁-C₃ alkoxy,
- halogenated C₁-C₃ alkoxy,
- mercapto,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- C₁-C₃ alkylsulfonyl,
- C₃-C₆ cycloalkyl,
- carbocyclic aryl,
- heterocyclyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₆ alkenyl,
 - C₂-C₆ alkenyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - hydroxy,

- C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- (iii) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - carbocyclic arylcarbonylamino,
 - carbocyclic aryl,
 - (iv) carbocyclyl,
carbocyclyl substituted by nitro,
 - (v) carbocyclic aryl,
carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryloxy,
 - carbocyclylimino,
 - carbocyclylimino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkoxy,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,

- heterocyclyl,
- heterocyclyl substituted by C₁-C₃ alkyl,
- C₁-C₇ alkoxy,
- C₁-C₇ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by C₁-C₃ alkoxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylaminocarbonyl,
 - mono- or di-carbocyclic arylaminocarbonyl substituted by C₁-C₃ alkyl,
- amino,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₃ alkynylcarbonylamino,
- C₁-C₃ alkynylcarbonylamino substituted by carbocyclic aryl,
- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- carbocyclic arylthio substituted by cyano,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,

- halogenated C₁-C₇ alkyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (vi) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by carbocyclic aryl,
 - C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₃ alkoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - halogenated carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,

- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl;

Y is -C(O)-;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isoindolyl, 1H-indolyl, 1H-pyrrolyl, 1-oxo-3H-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, cinnolyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

3. A compound according to claim 2, wherein

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminoxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
- carbocyclic arylthio,
- heterocyclylthio substituted by nitro,
- heterocyclylthio substituted by methyl,
- C₅-C₆ cycloalkyl,
- C₅-C₆ cycloalkenyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from

- oxo,
- carbocyclic aryl,
- heterocyclyl,
- C₁-C₄ alkoxy,
- halogenated C₁-C₄ alkoxy,
- C₁-C₄ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- halogenated mono-carbocyclic arylaminocarbonyl,
- carbocyclic aryl,
- heterocyclyl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- C₁-C₂ alkyl,
- C₁-C₂ substituted by carbocyclic aryl,
- methoxy,
- methoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl,
- C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
- methyl substituted by oxo,
- methyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
- hydroxy,

- cyano,
- nitro,
- C₁-C₉ alkyl,
- C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₇ alkoxy,
 - halogenated C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,
 - amino,
 - di-methylamino,
 - propargynylcarbonylamino substituted by carbocyclic aryl,
 - carbocyclic arylsulfonylamino substituted by methyl,
 - (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
 - halogenated methylthio,
 - carbocyclic arylthio substituted by cyano,
 - di-propylamino sulfonyl,
 - mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - heterocyclyl substituted by methyl,
 - heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) heterocyclyl,
or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,

- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryl substituted by nitro,
 - heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein R₄ and R₅ are independently selected from H or C₁-C₃ alkyl;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren-9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxo-isindolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, azetidyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl,

quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, cinnolyl, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

4. A compound according to claim 3, wherein

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from




- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminoxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,
 - C₅-C₆ cycloalkenyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,

- ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₄ alkoxy,
 - halogenated C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,

- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
- halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₇ alkoxy,
 - halogenated C₁-C₇ alkoxy,
 - C₁-C₇ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,
 - amino,
 - di-methylamino,
 - propargynylcarbonylamino substituted by carbocyclic aryl,
 - carbocyclic arylsulfonylamino substituted by methyl,
 - (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
 - halogenated methylthio,
 - carbocyclic arylthio substituted by cyano,
 - di-propylamino sulfonyl,
 - mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - heterocyclyl substituted by methyl,
 - heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from

- halogen,
- nitro,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryl substituted by nitro,
 - heterocyclyl;

L is selected from Formula XX - XXII;



wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, 9-oxo-fluorenyl, indenyl, anthraquinonyl, C-fluoren-

9-ylidene, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 4-oxo-benzopyranyl, azetidiny, benzo[b]thienyl, furyl, isoxazolyl, morpholinyl, piperidyl, piridyl, pyrazolyl, pyridyl, quinolyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9*H*-xanthenyl, cinnolyl, imidazolyl, morpholino, pyrimidyl, pyrrolidyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

5. A compound according to claim 4, wherein

R₁ represents

(i) C₁-C₅ alkyl substituted by substituent(s) independently selected from

- oxo,
- di-propylaminocarbonyl,
- methoxy substituted by carbocyclic aryl,
- methylcarbonyloxy,
- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- carbocyclic aryloxy substituted by nitro,
- heterocyclyloxy substituted by methyl,
- substituted heterocyclyl-ethylideneaminooxy,
- tert*-butoxycarbonylamino,
- carbocyclic arylcarbonylamino,
- C₁-C₂ alkylthio,
- C₁-C₂ alkylthio substituted by substituent(s) independently selected from
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
 - carbocyclic arylthio,
 - heterocyclylthio substituted by nitro,
 - heterocyclylthio substituted by methyl,

- cyclohexenyl,
 - carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - methyl,
 - methoxy,
 - ethenyl substituted by carbocyclic aryl substituted methylsulfinyl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - oxo,
 - carbocyclic aryl,
 - heterocyclyl,
 - C₁-C₂ alkoxy,
 - halogenated C₁-C₂ alkoxy,
 - C₁-C₂ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated mono-carbocyclic arylaminocarbonyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₂ alkyl,
 - C₁-C₂ substituted by carbocyclic aryl,
 - methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (ii) C₂-C₃ alkenyl substituted by substituent(s) independently selected from
- carbocyclic aryl,
 - halogenated carbocyclic aryl,

- carbocyclic aryl substituted by nitro,
- (iii) C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - methyl substituted by oxo,
 - methyl substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (iv) carbocyclyl,
- (v) carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₂ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryloxy,
 - C₁-C₂ alkoxy,
 - halogenated C₁-C₂ alkoxy,
 - C₁-C₂ alkoxy substituted by carbocyclic aryl,
 - methylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methoxy,
 - amino,
 - di-methylamino,
 - propargynylcarbonylamino substituted by carbocyclic aryl,
 - carbocyclic arylsulfonylamino substituted by methyl,
 - (carbocyclic aryl)NHC(O)NH substituted by halogenated methoxy,
 - halogenated methylthio,
 - carbocyclic arylthio substituted by cyano,
 - di-propylamino sulfonyl,

- mono- or di- ethylaminocarbonyl substituted by carbocyclic aryl,
- carbocyclic aryl,
- heterocyclyl substituted by methyl,
- heterocyclyl substituted by halogenated carbocyclic aryl,
- (vi) or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - methylthio substituted by halogenated carbocyclic aryl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - methoxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by methyl,
 - C₁-C₃ alkylthio,
 - propenylthio,
 - carbocyclic arylthio,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic arylsulfonyl,
 - carbocyclic arylsulfonyl substituted by methyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - carbocyclic aryl substituted by methyl,
 - carbocyclic aryl substituted by nitro,
 - heterocyclyl;

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl;

carbocyclyl is 1-oxo-indanyl, indenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]hepteny;


heterocyclyl is 1*H*-indolyl, 2,4-dihydro-3-oxo-pyrazolyl, furyl, pyrazolyl, pyridyl,


thienyl, 1,2,3-triazolyl, 1*H*-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2*H*-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, pyrazolyl, pyrimidyl, quinolyl, thiazolyl, tetrahydro-thienyl, benzofuranyl, or benzothiazolyl;













halogen is fluoro, chloro, bromo, or iodo;













or a salt thereof.













6. A compound according to claim 5 of Formua I selected from the group consisting of





































































































,




,




,




,




,




,




,




,




,















,



























,



























,





















































































































































; or, in case of, a salt thereof.

7. A compound according to claim 3, wherein

R₁ represents

(i) C₁-C₁₀ alkyl,

C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

•C₅-C₆ cycloalkyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) C₃-C₆ cycloalkyl,

(iii) carbocyclic aryl,

(iv) or heterocyclyl;

L is selected from Formula XX - XXII;

wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;

heterocyclyl is 1,3-dioxo-isoindolyl, 1*H*-indolyl, 1-oxo-3*H*-isobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4-oxo-3,4-dihydro-phthalazinyl, 9,10,10-trioxo-thioxanthenyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, furyl, imidazolyl, isoxazolyl, morpholino, oxolanyl, piperidyl, pyridyl, quinoxalyl, thienyl, quinolyl, or benzothiazolyl; or a salt thereof.

8. A compound according to claim 7, wherein

R₁ represents

(i) C₁-C₄ alkyl,

C₁-C₄ alkyl substituted by substituent(s) independently selected from

•cyclopentyl,

•carbocyclic aryl,

•heterocyclyl,

(ii) carbocyclic aryl,













(iii) or heterocyclyl;


wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, or biphenyl;


heterocyclyl is 9*H*-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[b]thienyl, thienyl, 1*H*-indolyl, quinoxalyl, quinolyl, or benzothiazolyl; or a salt thereof.

9. A compound according to claim 8 of Formua I thereof selected from the group consisting of









; or, in case of, a salt thereof.

10. A compound according to claim 1, wherein Q is Formula II;

R₁ represents

- (i) C₁-C₁₀ alkyl,
- C₁-C₁₀ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by C₁-C₃ alkoxy,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino substituted by halogenated carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by substituent(s) independently selected from
 - cyano,
 - carbocyclic aryl,
 - heterocyclyl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkyl,
 - C₁-C₃ alkylcarbonylamino,
 - C₁-C₄ alkoxycarbonylamino,

- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from
 - nitro,
 - C₁-C₃ alkyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - C₁-C₃ alkylthio substituted by substituent(s) independently selected from
 - mono- or di-carbocyclic arylamino,
 - halogenated mono- or di-carbocyclic arylamino,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - carbocyclic arylthio,
 - carbocyclic arylthio substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
- carbocyclic arylsulfonyl,
- halogenated carbocyclic arylsulfonyl,
- heterocyclylthio,
- C₃-C₆ cycloalkyl,
- C₃-C₆ cycloalkyl substituted by C₁-C₃ alkyl,
- carbocyclyl,
- carbocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl substituted C₁-C₃ alkylsulfinyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,

- hydroxy,
- nitro,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - carbocyclic aryl,
 - carbocyclic aryloxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylamino,
 - C₁-C₃ alkylthio,
 - halogenated C₁-C₃ alkylthio,
 - C₁-C₃ alkylsulfonyl,
 - C₃-C₆ cycloalkyl,
 - carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,

- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- (ii) C₂-C₈ alkenyl,
C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,
 - heterocyclyl,
 - heterocyclyl substituted by nitro,
- (iii) C₂-C₄ alkynyl,
C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) C₃-C₆ cycloalkyl,
C₃-C₆ cycloalkyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - hydroxy,
 - oxo,
 - carbocyclic aryl,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - carbocyclic aryl,
- (v) C₃-C₆ cycloalkenyl,
C₃-C₆ cycloalkenyl substituted by C₁-C₃ alkyl,
- (vi) carbocyclyl,
carbocyclyl substituted by substituent(s) independently selected from

- hydroxy,
- nitro,
- (vii) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₉ alkyl,
 - C₁-C₉ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - oxo,
 - C₁-C₃ alkoxy,
 - carbocyclic aryloxy,
 - mono- or di-C₁-C₃ alkylamino-N-oxy,
 - mono- or di-C₁-C₃ alkylamino,
 - mono- or di-C₁-C₃ alkylamino substituted by carbocyclic aryl,
 - mono- or di-carbocyclic arylamino,
 - mono- or di-carbocyclic arylamino substituted by C₁-C₃ alkoxy,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
 - heterocyclyl,
 - heterocyclyl substituted by C₁-C₃ alkyl,
 - C₂-C₃ alkenyl,
 - C₂-C₃ alkenyl substituted by carbocyclic aryl,
 - C₁-C₉ alkoxy,
 - C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - hydroxy,
 - halogen,
 - carboxy,
 - mono- or di-C₁-C₃ alkylamino,

- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₂-C₃ alkenyloxy,
 - C₁-C₃ alkylcarbonyloxy,
 - carbocyclic aryloxy,
 - carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₄ alkyl,
 - halogenated C₁-C₄ alkyl,
 - C₁-C₃ alkoxy,
 - heterocyclyloxy,
 - heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - (carbocyclic aryl)S(O)₂O,
 - carboxy,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl,
 - mono- or di-C₁-C₃ alkylaminocarbonyl substituted by carbocyclic aryl,
 - amino,
 - mono- or di-C₁-C₄ alkylamino,
 - mono- or di-C₁-C₄ alkylamino substituted by cyano,
 - mono- or di-carbocyclic arylamino,
 - C₁-C₃ alkylcarbonylamino,

- carbocyclic arylsulfonylamino,
- carbocyclic arylsulfonylamino substituted by C₁-C₃ alkyl,
- (carbocyclic aryl)NHC(O)NH,
- (carbocyclic aryl)NHC(O)NH substituted by C₁-C₃ alkoxy,
- (carbocyclic aryl)NHC(O)NH substituted by halogenated C₁-C₃ alkoxy,
- C₁-C₃ alkylthio,
- halogenated C₁-C₃ alkylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkyl,
- heterocyclylthio,
- C₁-C₃ alkylsulfonyl,
- mono- or di-C₁-C₃ alkylaminosulfonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - C₁-C₇ alkyl,
 - halogenated C₁-C₇ alkyl,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - C₁-C₃ alkyl,
 - carbocyclic aryl,
 - halogenated carbocyclic aryl,
- (viii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,

- oxo,
- C₁-C₃ alkylcarbonyloxy,
- C₁-C₃ alkoxycarbonyl,
- C₁-C₃ alkylthio,
- C₁-C₃ alkylthio substituted by carbocyclic aryl,
- C₁-C₃ alkylthio substituted by halogenated carbocyclic aryl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - heterocyclyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxy substituted by carbocyclic aryl,
- carbocyclic aryloxy,
- carbocyclic aryloxy substituted by C₁-C₃ alkyl,
- mono- or di-C₁-C₃ alkylamino,
- C₁-C₄ alkylcarbonylamino,
- C₁-C₃ alkylthio,
- carbocyclic arylthio,
- halogenated carbocyclic arylthio,
- carbocyclic arylthio substituted by C₁-C₃ alkoxycarbonyl,
- heterocyclylthio,
- heterocyclylthio substituted by C₁-C₃ alkyl,
- C₁-C₃ alkylsulfonyl,
- carbocyclic arylsulfonyl,
- carbocyclic arylsulfonyl substituted by C₁-C₄ alkyl,
- C₁-C₃ alkoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,

- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- halogenated C₁-C₃ alkoxy,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
- C₁-C₃ alkyl,
- halogenated C₁-C₃ alkyl,
- C₁-C₃ alkoxy,
- C₁-C₃ alkoxycarbonyl;

Y is -(CH₂)_m, m is 0 or 1;

wherein carbocyclic aryl is phenyl, naphthyl, biphenyl, or phenanthryl;

carbocyclyl is 9*H*-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, indanyl, or indenyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolo[2,3-*c*]pyridyl, 1*H*-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2*H*-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 3,4-dihydro-2*H*-benzo[*b*][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, 4*H*-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, azetidiny, benzimidazolyl, benzo[1,3]dioxolyl, benzo[*b*]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-*b*]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxolanyl, piperazyl, piperidyl, pyrazolo[5,1-*b*]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, or thiolanyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

11. A compound according to claim 10, wherein

R₁ represents

(i) C₁-C₁₀ alkyl substituted by substituent(s) independently selected from

- methoxy,
- methoxy substituted by carbocyclic aryl,

- carbocyclic aryloxy,
- halogenated carbocyclic aryloxy,
- mono-C₁-C₂ alkylamino substituted by cyano,
- mono- or di-C₁-C₂ alkylamino substituted by carbocyclic aryl,
- mono-carbocyclic arylamino,
- mono-carbocyclic arylamino substituted by methyl,
- carbocyclic arylsulfonylamino substituted by methyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - C₁-C₂ alkoxy,
 - halogenated C₁-C₂ alkoxy,
 - heterocyclyl substituted by carbocyclic aryl,
- (ii) C₂-C₈ alkenyl substituted by substituent(s) independently selected from
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by methoxy,
- (iii) C₂-C₄ alkynyl substituted by carbocyclic aryl,
- (iv) cyclohexyl substituted by carbocyclic arylmethyl,
- (v) carbocyclyl,
- (vi) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - amino,
 - C₁-C₉ alkyl,
 - halogenated C₁-C₉ alkyl,

- C₁-C₉ alkoxy,
- C₁-C₉ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - halogenated carbocyclic aryl,
- propenyloxy,
- methylamino,
- di-C₁-C₂ alkylamino,
- di-C₁-C₂ alkylamino substituted by cyano,
- methylthio,
- halogenated methylthio,

(vii) heterocyclyl,

or heterocyclyl substituted by substituent(s) independently selected from

- halogen,
- C₁-C₄ alkyl,
- C₁-C₄ alkyl substituted by hydroxy,
- C₁-C₄ alkyl substituted by carbocyclic aryl,
- methoxy,
- C₁-C₂ alkoxycarbonyl,
- carbocyclic arylthio substituted by methoxycarbonyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - halogenated methyl,
- heterocyclyl;

R₂ is methylamino or dimethylamino;

L is selected from Formula Va, VIIIa, or IXa;

wherein carbocyclic aryl is phenyl, naphthyl, biphenyl, or phenanthryl;

carbocyclyl is 9*H*-fluorenyl, acenaphthyl, or anthraquinonyl;

heterocyclyl is 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3-dioxolanyl, 1*H*-indolyl, 1*H*-pyrrolyl, 2,2',5',2"-terthiophenyl, 2,2'-bithiophenyl, 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[1,4]oxazinyl, 4-oxo-benzopyranyl, 9*H*-carbazolyl, 9*H*-xanthenyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[b]thienyl, benzofuryl,

benzothiazolyl, furyl, imidazolyl, isoxazolyl, oxolanyl, pyrazolo[5,1-b]thiazolyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, 2*H*-benzopyranyl, 4*H*-benzo[1,3]dioxinyl, azetidiny, imidazo[2,1-b]thiazolyl, morpholinyl, or 2,3-dihydro-benzofuryl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

12. A compound according to claim 11, wherein

R₁ represents

(i) C₁-C₇ alkyl substituted by substituent(s) independently selected from

- methoxy,
 - methoxy substituted by carbocyclic aryl,
 - carbocyclic aryloxy,
 - halogenated carbocyclic aryloxy,
 - mono-ethylamino substituted by cyano,
 - di-methylamino substituted by carbocyclic aryl,
 - mono-carbocyclic arylamino,
 - mono-carbocyclic arylamino substituted by methyl,
 - carbocyclic arylsulfonylamino substituted by methyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₄ alkyl,
 - C₁-C₄ alkyl substituted by carbocyclic aryl,
 - C₁-C₄ alkyl substituted by hydroxy,
 - methoxy,
 - halogenated methoxy,
 - heterocyclyl substituted by carbocyclic aryl,
- (ii) C₂-C₇ alkenyl substituted by substituent(s) independently selected from
- methoxy substituted by carbocyclic aryl,
 - carbocyclic aryl,

- carbocyclic aryl substituted by methoxy,
- (iii) butynyl substituted by carbocyclic aryl,
- (iv) cyclohexyl substituted by carbocyclic arylmethyl,
- (v) carbocyclyl,
- (vi) carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - hydroxy,
 - cyano,
 - amino,
 - C₁-C₂ alkyl,
 - halogenated methyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - halogenated carbocyclic aryl,
 - propenyloxy,
 - di-C₁-C₂ alkylamino,
 - di-C₁-C₂ alkylamino substituted by cyano,
 - methylthio,
 - halogenated methylthio,
- (vii) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by hydroxy,
 - C₁-C₃ alkyl substituted by carbocyclic aryl,
 - methoxy,
 - ethoxycarbonyl,
 - carbocyclic arylthio substituted by methoxycarbonyl,
 - carbocyclic aryl,
 - carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- halogenated methyl,
- heterocyclyl;

L is selected from Formula XX - XXII;

wherein carbocyclic aryl is phenyl, **naphthyl**, or biphenyl;













carbocyclyl is acenaphthyl;













heterocyclyl is 1*H*-indolyl, 1*H*-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 9*H*-carbazolyl, benzo[1,3]dioxolyl, furyl, pyrazolyl, thienyl, 4-oxo-benzopyranyl, azetidiny, imidazo[2,1-*b*]thiazolyl, pyridyl, imidazolyl, 2,3-dihydro-benzofuryl, or benzo[*b*]thienyl;













halogen is fluoro, chloro, bromo, or iodo;


or a salt thereof.

13. A compound according to claim 12 of Formua I selected from the group consisting of












,




,




,




,




,




,




,




,




,



,





,




,









,




,




,




,




,




,




,




,




,















,




,




,







,




,




,




,




,




,




,




,




,















,




,




,







,




,




,




,




,




,




,




,




,




,



























,
















,














; or, in case of, a salt thereof.

14. A compound according to claim 1, wherein Q is Formula II;

R₁ represents

(i) C₁-C₁₆ alkyl,

C₁-C₁₆ alkyl substituted by substituent(s) independently selected from

- halogen,
- carbocyclyl,
- carbocyclic aryl,
- carbocyclic aryl substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - halogenated C₁-C₃ alkoxy,

(ii) C₂-C₃ alkenyl,

C₂-C₃ alkenyl substituted by carbocyclic aryl,

(iii) carbocyclic aryl,

carbocyclic aryl substituted by substituent(s) independently selected from

- halogen,
- cyano,
- nitro,
- C₁-C₅ alkyl,
- C₁-C₅ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - C₂-C₃ alkenyl,
 - C₁-C₄ alkoxy,
 - C₁-C₄ alkoxy substituted by substituent(s) independently selected from
 - halogen,
 - heterocyclyl,
 - halogenated heterocyclyl,
 - carbocyclic aryloxy,

- carbocyclic aryloxy substituted by substituent(s) independently selected from
 - halogen,
 - nitro,
- heterocyclyloxy,
- heterocyclyloxy substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxycarbonyl,
 - mono- or di-C₁-C₄ alkylamino,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic aryl diazo,
 - carbocyclic aryl diazo substituted by mono- or di- C₁-C₃ alkylamino,
 - C₁-C₃ alkylsulfonyl,
 - carbocyclic aryl,
- (iv) heterocyclyl,
- or heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - C₁-C₃ alkyl substituted by substituent(s) independently selected from
 - halogen,
 - oxo,
 - carbocyclic arylcarbonylamino,
 - halogenated carbocyclic arylcarbonylamino,
 - heterocyclyl,
 - heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl,
 - C₁-C₃ alkoxy,
 - C₁-C₃ alkylcarbonylamino,
 - carbocyclic arylsulfonyl,

- C₁-C₃ alkoxy carbonyl,
- carbocyclic aryl,
- halogenated carbocyclic aryl,
- heterocyclyl,
- heterocyclyl substituted by substituent(s) independently selected from
 - halogen,
 - C₁-C₃ alkyl,
 - halogenated C₁-C₃ alkyl;

Y is -S(O)₂-;

wherein carbocyclic aryl is phenyl, biphenyl, or naphthyl;






carbocyclyl is 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl;

heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1*H*-pyrrolyl, benzo[2,1,3]oxadiazolyl, benzo[*b*]thienyl, furyl, imidazolyl, isoxazolyl, pyrazolyl, pyridyl, quinolyl, thiazolyl, or thienyl;

halogen is fluoro, chloro, bromo, or iodo;

or a salt thereof.

15. A compound according to claim 14 of Formula I selected from the group consisting of



; or, in case of, a salt thereof.

16. A compound according to claim 1, wherein Q is Formula II;
R₁ is selected from H, -CO₂tBu, or -CO₂Bn (Bn is a benzyl group);
R₂ is methylamino or dimethylamino;
L is selected from Formula XX - XXII;
Y is a single bond;
or a salt thereof.


17. A method for modulating the G-protein receptor, SLC-1, comprising the step of contacting said SLC-1 with a MCH receptor antagonist.

18. A method for modulating the G-protein receptor, SLC-1, comprising the step of contacting said SLC-1 with a compound of claims 1-16.

19. The method of prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression in mammals in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound having the composition of any of claims 1-16.

20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the composition of any of claims 1-16.

Fig. 1



SEQUENCE LISTING

<110> Arena Pharmaceuticals, Inc.

<120> MCH Receptor Antagonists

<130> AREN-0238

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 30

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 1

gtgaagcttg cctctggtgc ctgcaggagg

30

<210> 2

<211> 31

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 2

gcagaattcc cggtggcgtg ttgtggtgcc c

31

<210> 3

<211> 24

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 3

catgagctgg tggatcatga aggg

24

<210> 4

<211> 24

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 4

atgaagggca tgcccaggag aaag

24

<210> 5

<211> 1349

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 5

atggacctgg aagcctcgct gctgcccact ggtcccaatg ccagcaacac ctctgatggc

60

cccgataacc tcaattcggc aggatcacct cctcgcacgg ggagcatctc ctacatcaac

120

atcatcatgc cttcggtggt cggcaccatc tgcctcctgg gcatcatcgg gaactccacg 180
gtcatcttcg cggtcgtgaa gaagtccaag ctgcactggg gcaacaacgt ccccgacatc 240
ttcatcatca acctctcggg agtagatctc ctctttctcc tgggcatgcc cttcatgac 300
caccagctca tgggcaatgg ggtgtggcac tttggggaga ccatgtgcac cctcatcacg 360
gccatggatg ccaatagtca gttcaccagc acctacatcc tgaccgcat ggccattgac 420
cgctacctgg cactgtcca ccccatctct tccacgaagt tccggaagcc ctctgtggcc 480
accctggtga tctgcctcct gtgggccctc tccttcatca gcatcaccct tgtgtggctg 540
tatgccagac tcatccccct cccaggaggt gcagtgggct gcggcatacg cctgccccaac 600
ccagacactg acctctactg gttcaccctg taccagtttt tcctggcctt tgccctgcct 660
tttgtggtca tcacagccgc atacgtgagg atcctgcaga aggtgaagtc ctctggaatc 720
cgagtgggct cctctaagag gaagaagtct gagaagaagg tccccgcac agccatcgcc 780
atctgtctgg tcttctttgt gtgctgggca ccctactatg tgctacagct gaccagttg 840
tccatcagcc gcccgacct cacctttgtc taactataca atgcggccat cagcttgggc 900
tatgccaaca gctgcctcaa cccctttgtg tacatcgtgc tctgtgagac gttccgcaa 960
cgcttggtcc tgtcggtgaa gcctgcagcc caggggcagc ttcgcgctgt cagcaacgct 1020
cagacggctg acgaggagag gacagaaagc aaaggcacct gatacttccc ctgccacct 1080
gcacacctcc aagtcagggc accacaacac gccaccggga gagatgctga gaaaaacca 1140
agaccgctcg ggaaatgcag gaaggccggg ttgtgagggg ttgttgcaat gaaataaata 1200
cattccatgg gctcacacgt tgctggggag gcctggagtc aggtttgggg ttttcagata 1260
tcagaaatcc cttgggggag caggatgaga cctttggata gaacagaagc tgagcaagag 1320
aacatgttgg tttggataac cggttgcac 1349

<210> 6

<211> 446

<212> PRT

<213> Homo Sapien

<220>

<223> Novel Sequence

<400> 6

Met Asp Leu Glu Ala Ser Leu Leu Pro Thr Gly Pro Asn Ala Ser Asn
 1 5 10 15

Thr Ser Asp Gly Pro Asp Asn Leu Thr Ser Ala Gly Ser Pro Pro Arg
 20 25 30

Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly
 35 40 45

Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser Thr Val Ile Phe Ala
 50 55 60

Val Val Lys Lys Ser Lys Leu His Trp Cys Asn Asn Val Pro Asp Ile
 65 70 75 80

Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met
 85 90 95

Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly
 100 105 110

Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
 115 120 125

Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu Ala
 130 135 140

Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Val Ala
 145 150 155 160

Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
 165 170 175

Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val
 180 185 190

Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe
 195 200 205

Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile
 210 215 220

Thr Ala Ala Tyr Val Arg Ile Leu Gln Lys Val Lys Ser Ser Gly Ile
 225 230 235 240

Arg Val Gly Ser Ser Lys Arg Lys Lys Ser Glu Lys Lys Val Thr Arg
 245 250 255

Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro Tyr
 260 265 270

Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu Thr
 275 280 285

Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn Ser

290	295	300
Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg Lys		
305	310	315 320
Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg Ala		
	325	330 335
Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys Gly		
	340	345 350
Thr Tyr Phe Pro Cys His Pro Ala His Leu Gln Val Arg Ala Pro Gln		
	355	360 365
His Ala Thr Gly Arg Asp Ala Glu Lys Asn Pro Arg Pro Leu Gly Lys		
	370	375 380
Cys Arg Lys Ala Gly Leu Gly Val Val Ala Met Lys Ile His Ser Met		
	385	390 395 400
Gly Ser His Val Ala Gly Glu Ala Trp Ser Gln Val Trp Gly Phe Gln		
	405	410 415
Ile Ser Glu Ile Pro Trp Gly Ser Arg Met Arg Pro Leu Asp Arg Thr		
	420	425 430
Glu Ala Glu Gln Glu Asn Met Leu Val Trp Ile Thr Gly Cys		
	435	440 445

<210> 7

<211> 70

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 7

gatcctgcag aaggtgaagt cctctggaat ccgagtgggc tcctctaaga ggaagaagtc 60

tgagaagaag 70

<210> 8

<211> 71

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 8
gtgaccttct tctcagactt cttcctctta gaggagccca ctcggattcc agaggacttc 60
accttctgca g 71

<210> 9

<211> 30

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 9
gtgaagcttg cccgggcagg atggacctgg 30

<210> 10

<211> 24

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 10
atctagaggt gcctttgctt tctg 24

<210> 11

<211> 2133

<212> DNA

<213> Homo Sapien

<400> 11
atggacctgg aagcctcgt gctgcccact ggtcccaatg ccagcaacac ctctgatggc 60
cccgataacc tcaactcggc aggatcacct cctcgcacgg ggagcatctc ctacatcaac 120

atcatcatgc cttcgggtgtt cggcaccatc tgcctcctgg gcatcatcgg gaactccacg 180
gtcatcttcg cggtcgtgaa gaagtccaag ctgcactggg gcaacaacgt ccccgacatc 240
ttcatcatca acctctcggg agtagatctc ctctttctcc tgggcatgcc cttcatgata 300
caccagctca tgggcaatgg ggtgtggcac tttggggaga ccatgtgcac cctcatcaag 360
gccatggatg ccaatagtca gttcaccagc acctacatcc tgaccgccat ggccattgac 420
cgctacctgg ccaactgtcca ccccatctct tccacgaagt tccggaagcc ctctgtggcc 480
accctgggtga tctgcctcct gtggggccctc tccttcatca gcatcacccc tgtgtggctg 540
tatgccagac tcatcccctt ccaggagggt gcagtggggt gcggcatacg cctgcccac 600
ccagacactg acctctactg gttcacctg taccagtttt tcttggcctt tgccctgcct 660
tttgtgggtca tcacagccgc atacgtgagg atcctgcagc gcatgacgtc ctcagtggcc 720
cccgctccc agcgcagcat ccggctgcgg acaaagaggg tgaccgcac agccatcgcc 780
atctgtctgg tcttctttgt gtgctgggca ccctactatg tgctacagct gaccagttg 840
tccatcagcc gcccgacct cacctttgtc tacttataca atgcggccat cagcttgggc 900
tatgccaaca gctgcctcaa cccctttgtg tacatcgtgc tctgtgagac gttccgcaaa 960
cgcttgggtcc tgcctgggtgaa gcctgcagcc caggggcagc ttcgcgctgt cagcaacgct 1020
cagacggctg acgaggagag gacagaaagc aaaggcacct ctagaatggg ctgcacactg 1080
agcgtgagg acaaggcggc cgtggagcgc agcaagatga tcgaccgcaa cctccgggag 1140
gacggagaga aggcagcgc cgaggtcaag ctgctgctgc tgggtgctgg tgaatccggg 1200
aagagcacia ttgtgaagca gatgaaaatt atccacgagg ctggctactc agaggaagag 1260
tgtaagcagt acaaagcagt ggtctacagc aacaccatcc agtccatcat tgccatcatt 1320
agagccatgg ggagattgaa aatcgacttt ggagacgctg ctctgctgga tgatgctgc 1380
caactcttcg tgcttgcctg ggctgcagag gaaggcttta tgaccgcgga gctcgccggc 1440
gtcataaaga gactgtggaa ggacagcggg gtgcaagcct gcttcaacag atcccgggag 1500
taccagctga acgattcggc ggcgtactac ctgaatgact tggacagaat agcacaacca 1560
aattacatcc caaccagca ggatgttctc agaactagag tgaaaacgac gggaaattgtg 1620
gaaaccact ttactttcaa agatcttcat tttaaaatgt ttgacgtggg aggccagaga 1680
tcagagcgga agaagtggat tcaactgctt gaaggcgtga ctgccatcat cttctgtgtg 1740
gccctgagtg actatgacct ggttcttgct gaggatgaag aaatgaaccg gatgcatgaa 1800
agcatgaagc tggtcgatag catatgtaac aacaagtggg ttacggacac atccatcatc 1860

cttttctga acaagaagga cctcttcgaa gagaagatca aaaagagtcc cctcacgata 1920
 tgctatccag aatatgcagg ctcaaacaca tatgaagagg cggctgcgta tatccagtgt 1980
 cagtttgaag acctcaataa aaggaaggac acaaaggaaa tttacaccca cttcacttgc 2040
 gccacggata cgaagaatgt gcagtttgtg ttcgatgctg taacggacgt catcataaag 2100
 aataacctaa aagactgtgg tctcttctaa tct 2133

<210> 12
 <211> 709
 <212> PRT
 <213> Homo Sapien

<400> 12
 Met Asp Leu Glu Ala Ser Leu Leu Pro Thr Gly Pro Asn Ala Ser Asn
 1 5 10 15
 Thr Ser Asp Gly Pro Asp Asn Leu Thr Ser Ala Gly Ser Pro Pro Arg
 20 25 30
 Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly
 35 40 45
 Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser Thr Val Ile Phe Ala
 50 55 60
 Val Val Lys Lys Ser Lys Leu His Trp Cys Asn Asn Val Pro Asp Ile
 65 70 75 80
 Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met
 85 90 95
 Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly
 100 105 110
 Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
 115 120 125
 Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu Ala
 130 135 140
 Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Val Ala
 145 150 155 160
 Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
 165 170 175
 Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val
 180 185 190
 Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe
 195 200 205

Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile
 210 215 220
 Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met Thr Ser Ser Val Ala
 225 230 235 240
 Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Thr Arg
 245 250 255
 Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro Tyr
 260 265 270
 Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu Thr
 275 280 285
 Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn Ser
 290 295 300
 Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg Lys
 305 310 315 320
 Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg Ala
 325 330 335
 Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys Gly
 340 345 350
 Thr Ser Arg Met Gly Cys Thr Leu Ser Ala Glu Asp Lys Ala Ala Val
 355 360 365
 Glu Arg Ser Lys Met Ile Asp Arg Asn Leu Arg Glu Asp Gly Glu Lys
 370 375 380
 Ala Ala Arg Glu Val Lys Leu Leu Leu Leu Gly Ala Gly Glu Ser Gly
 385 390 395 400
 Lys Ser Thr Ile Val Lys Gln Met Lys Ile Ile His Glu Ala Gly Tyr
 405 410 415
 Ser Glu Glu Glu Cys Lys Gln Tyr Lys Ala Val Val Tyr Ser Asn Thr
 420 425 430
 Ile Gln Ser Ile Ile Ala Ile Ile Arg Ala Met Gly Arg Leu Lys Ile
 435 440 445
 Asp Phe Gly Asp Ala Ala Arg Ala Asp Asp Ala Arg Gln Leu Phe Val
 450 455 460
 Leu Ala Gly Ala Ala Glu Glu Gly Phe Met Thr Ala Glu Leu Ala Gly
 465 470 475 480
 Val Ile Lys Arg Leu Trp Lys Asp Ser Gly Val Gln Ala Cys Phe Asn
 485 490 495
 Arg Ser Arg Glu Tyr Gln Leu Asn Asp Ser Ala Ala Tyr Tyr Leu Asn
 500 505 510

Asp Leu Asp Arg Ile Ala Gln Pro Asn Tyr Ile Pro Thr Gln Gln Asp
 515 520 525
 Val Leu Arg Thr Arg Val Lys Thr Thr Gly Ile Val Glu Thr His Phe
 530 535 540
 Thr Phe Lys Asp Leu His Phe Lys Met Phe Asp Val Gly Gly Gln Arg
 545 550 555 560
 Ser Glu Arg Lys Lys Trp Ile His Cys Phe Glu Gly Val Thr Ala Ile
 565 570 575
 Ile Phe Cys Val Ala Leu Ser Asp Tyr Asp Leu Val Leu Ala Glu Asp
 580 585 590
 Glu Glu Met Asn Arg Met His Glu Ser Met Lys Leu Phe Asp Ser Ile
 595 600 605
 Cys Asn Asn Lys Trp Phe Thr Asp Thr Ser Ile Ile Leu Phe Leu Asn
 610 615 620
 Lys Lys Asp Leu Phe Glu Glu Lys Ile Lys Lys Ser Pro Leu Thr Ile
 625 630 635 640
 Cys Tyr Pro Glu Tyr Ala Gly Ser Asn Thr Tyr Glu Glu Ala Ala Ala
 645 650 655
 Tyr Ile Gln Cys Gln Phe Glu Asp Leu Asn Lys Arg Lys Asp Thr Lys
 660 665 670
 Glu Ile Tyr Thr His Phe Thr Cys Ala Thr Asp Thr Lys Asn Val Gln
 675 680 685
 Phe Val Phe Asp Ala Val Thr Asp Val Ile Ile Lys Asn Asn Leu Lys
 690 695 700
 Asp Cys Gly Leu Phe
 705